<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD006629.pub2" GROUP_ID="SCHIZ" ID="403206051911390099" MERGED_FROM="" MODIFIED="2013-01-24 12:58:49 +0000" MODIFIED_BY="Claire Irving" REVIEW_NO="" REVMAN_SUB_VERSION="5.2.3 " REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="4.0">
<COVER_SHEET MODIFIED="2013-01-24 12:58:49 +0000" MODIFIED_BY="Claire Irving">
<TITLE>Antipsychotic switching for people with schizophrenia who have neuroleptic-induced weight or metabolic problems</TITLE>
<CONTACT MODIFIED="2013-01-24 12:58:49 +0000" MODIFIED_BY="Claire Irving"><PERSON ID="1FAB457D82E26AA2004A583D5CD2BC3A" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Anitha</FIRST_NAME><LAST_NAME>Mukundan</LAST_NAME><POSITION>Consultant Psychiatrist</POSITION><EMAIL_1>Anitha.Mukundan@bdct.nhs.uk</EMAIL_1><EMAIL_2>an5mu@yahoo.co.uk</EMAIL_2><ADDRESS><DEPARTMENT>City Mental Health Team</DEPARTMENT><ORGANISATION>Horton Park Centre</ORGANISATION><ADDRESS_1>Horton Park Avenue</ADDRESS_1><CITY>Bradford</CITY><ZIP>BD7 3EG</ZIP><COUNTRY CODE="GB">UK</COUNTRY></ADDRESS></PERSON></CONTACT>
<CREATORS MODIFIED="2013-01-24 12:58:49 +0000" MODIFIED_BY="Claire Irving"><PERSON ID="1FAB457D82E26AA2004A583D5CD2BC3A" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Anitha</FIRST_NAME><LAST_NAME>Mukundan</LAST_NAME><POSITION>Consultant Psychiatrist</POSITION><EMAIL_1>Anitha.Mukundan@bdct.nhs.uk</EMAIL_1><EMAIL_2>an5mu@yahoo.co.uk</EMAIL_2><ADDRESS><DEPARTMENT>City Mental Health Team</DEPARTMENT><ORGANISATION>Horton Park Centre</ORGANISATION><ADDRESS_1>Horton Park Avenue</ADDRESS_1><CITY>Bradford</CITY><ZIP>BD7 3EG</ZIP><COUNTRY CODE="GB">UK</COUNTRY></ADDRESS></PERSON><PERSON ID="D3501D7982E26AA20080535F3969BCCC" ROLE="AUTHOR"><FIRST_NAME>Guy</FIRST_NAME><LAST_NAME>Faulkner</LAST_NAME><POSITION>Assistant Professor (Exercise and Health Psychology)</POSITION><EMAIL_1>guy.faulkner@utoronto.ca</EMAIL_1><ADDRESS><DEPARTMENT>Faculty of Kinesiology and Physical Education</DEPARTMENT><ORGANISATION>University of Toronto</ORGANISATION><ADDRESS_1>55 Harbord St</ADDRESS_1><CITY>Toronto</CITY><ZIP>On M5S 2W6</ZIP><COUNTRY CODE="CA">Canada</COUNTRY></ADDRESS></PERSON><PERSON ID="1184E6AB82E26AA201DC7B3EFFD89F66" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Tony</FIRST_NAME><LAST_NAME>Cohn</LAST_NAME><POSITION>Staff Psychiatrist</POSITION><EMAIL_1>Tony_Cohn@camh.net</EMAIL_1><ADDRESS><DEPARTMENT>Schizophrenia Program and MAPS</DEPARTMENT><ORGANISATION>Centre for Addiction and Mental Health</ORGANISATION><ADDRESS_1>1001 Queen Street West</ADDRESS_1><CITY>Toronto</CITY><ZIP>M6J1H4</ZIP><REGION>Ontario</REGION><COUNTRY CODE="CA">Canada</COUNTRY><PHONE_1>416 535-8501  2573</PHONE_1><FAX_1>416 944-9679</FAX_1></ADDRESS></PERSON><PERSON ID="1185277D82E26AA201DC7B3E697E007E" ROLE="AUTHOR"><PREFIX>A/Prof</PREFIX><FIRST_NAME>Gary</FIRST_NAME><LAST_NAME>Remington</LAST_NAME><POSITION>Professor of Psychiatry</POSITION><EMAIL_1>Gary_Remington@camh.net</EMAIL_1><ADDRESS><DEPARTMENT>Centre for Addiction and Mental Health</DEPARTMENT><ORGANISATION>University of Toronto</ORGANISATION><ADDRESS_1>250 College St</ADDRESS_1><CITY>Toronto</CITY><ZIP>M5T 1R8</ZIP><REGION>Ontario</REGION><COUNTRY CODE="CA">Canada</COUNTRY><PHONE_1>416 535-8501  4750</PHONE_1><FAX_1>416 979-6849</FAX_1></ADDRESS></PERSON></CREATORS>
<DATES MODIFIED="2013-01-24 12:56:41 +0000" MODIFIED_BY="Samantha Roberts">
<UP_TO_DATE>
<DATE DAY="26" MONTH="2" YEAR="2008"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="26" MONTH="2" YEAR="2008"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="25" MONTH="8" YEAR="2013"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="3" YEAR="2007"/>
<REVIEW_PUBLISHED ISSUE="12" YEAR="2010"/>
<LAST_CITATION_ISSUE ISSUE="12" YEAR="2010"/>
</DATES>
<WHATS_NEW MODIFIED="2013-01-24 12:54:25 +0000" MODIFIED_BY="[Empty name]">
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2013-01-24 12:54:25 +0000" MODIFIED_BY="[Empty name]">
<DATE DAY="27" MONTH="11" YEAR="2012"/>
<DESCRIPTION>
<P>Update search of Cochrane Schizophrenia Group's Trial Register (see <A HREF="http://archie.cochrane.org/sections/documents/view?version=44705070754671417758120516110605&amp;format=REVMAN#SEARCH_METHODS">Search methods for identification of studies</A>), 167 studies added to awaiting classification.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY>
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_NEW_CONCLUSIONS">
<DATE DAY="26" MONTH="2" YEAR="2008"/>
<DESCRIPTION>
<P>Substantive amendment</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</HISTORY>
<SOURCES_OF_SUPPORT>
<INTERNAL_SOURCES>
<SOURCE>
<NAME>Yorkshire Deanery</NAME>
<COUNTRY CODE="GB">UK</COUNTRY>
<DESCRIPTION/>
</SOURCE>
<SOURCE>
<NAME>University of Toronto</NAME>
<COUNTRY CODE="CA">Canada</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</INTERNAL_SOURCES>
<EXTERNAL_SOURCES/>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2013-01-24 12:54:38 +0000" MODIFIED_BY="[Empty name]">
<SUMMARY MODIFIED="2010-10-28 17:44:11 +0100" MODIFIED_BY="[Empty name]">
<TITLE MODIFIED="2010-10-15 08:43:09 +0100" MODIFIED_BY="[Empty name]">Can changing antipsychotic medication improve side effects like increases in weight, blood sugar and cholesterol?</TITLE>
<SUMMARY_BODY MODIFIED="2010-10-28 17:44:11 +0100" MODIFIED_BY="[Empty name]">
<P>Weight gain is common among people with schizophrenia. The medication commonly used to treat schizophrenia may cause substantial weight gain. This weight gain could be treated through lifestyle interventions that increase physical activity or change diet; or through using other forms of medication that might help with weight loss. However, an easier alternative might be changing the antipsychotic medication to one that causes less weight gain. This review examines evidence for this possibility. Switching antipsychotic medication did show some reduction in weight and also contributed broader health benefits such as reducing fasting blood glucose. Notably, there were no significant difference in outcomes of mental state, global state and adverse events between groups which switched medications and those that remained on previous medication.</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2013-01-22 14:52:24 +0000" MODIFIED_BY="[Empty name]">
<ABS_BACKGROUND>
<P>Weight gain is common for people with schizophrenia and this has serious implications for a patient's health and well being. Switching strategies have been recommended as a management option.</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES>
<P>To determine the effects of antipsychotic medication switching as a strategy for reducing or preventing weight gain and metabolic problems in people with schizophrenia.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY MODIFIED="2013-01-22 14:52:12 +0000" MODIFIED_BY="[Empty name]">
<P>We searched key databases and the Cochrane Schizophrenia Group's trials register (January 2005 and June 2007), reference sections within relevant papers and contacted the first author of each relevant study and other experts to collect further information.</P>
<P>We updated this search November 2012 and added 167 new trials to the awaiting classification section.</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA MODIFIED="2013-01-22 14:52:05 +0000" MODIFIED_BY="[Empty name]">
<P>All clinical randomised controlled trials comparing switching of antipsychotic medication as an intervention for antipsychotic induced weight gain and metabolic problems with continuation of medication and/or other weight loss treatments (pharmacological and non pharmacological) in people with schizophrenia or schizophrenia-like illnesses.</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION MODIFIED="2010-10-28 18:15:12 +0100" MODIFIED_BY="[Empty name]">
<P>Studies were reliably selected, quality assessed and data extracted. For dichotomous data we calculated risk ratio (RR) and their 95% confidence intervals (CI) on an intention-to-treat basis, based on a fixed-effect model. The primary outcome measures were weight loss, metabolic syndrome, relapse and general mental state.</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS MODIFIED="2010-10-28 17:42:35 +0100" MODIFIED_BY="[Empty name]">
<P>We included four studies for the review with a total of 636 participants. All except one study had a duration of 26 weeks or less. There was a mean weight loss of 1.94 kg (2 RCT, n = 287, CI -3.9 to 0.08) when switched to aripiprazole or quetiapine from olanzapine. BMI also decreased when switched to quetiapine (1 RCT, n = 129, MD -0.52 CI -1.26 to 0.22) and aripiprazole (1 RCT, n = 173, RR 0.28 CI 0.13 to 0.57) from olanzapine.</P>
<P>Fasting blood glucose showed a significant decrease when switched to aripiprazole or quetiapine from olanzapine. (2 RCT, MD -2.53 n = 280 CI -2.94 to -2.11). One RCT also showed a favourable lipid profile when switched to aripiprazole but these measures were reported as percentage changes, rather than means with standard deviation.</P>
<P>People are less likely to leave the study early if they remain on olanzapine compared to switching to quetiapine or aripiprazole.</P>
<P>There was no significant difference in outcomes of mental state, global state, and adverse events between groups which switched medications and those that remained on previous medication. Three different switching strategies were compared and no strategy was found to be superior to the others for outcomes of weight gain, mental state and global state.</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS MODIFIED="2013-01-22 14:52:24 +0000" MODIFIED_BY="[Empty name]">
<P>Evidence from this review suggests that switching antipsychotic medication to one with lesser potential for causing weight gain or metabolic problems could be an effective way to manage these side effects, but the data were weak due to the limited number of trials in this area and small sample sizes. Poor reporting of data also hindered using some trials and outcomes. There was no difference in mental state, global state and other treatment related adverse events between switching to another medication and continuing on the previous one. When the three switching strategies were compared none of them had an advantage over the others in their effects on the primary outcomes considered in this review. Better designed trials with adequate power would provide more convincing evidence for using medication switching as an intervention strategy.</P>
<P>Note: the 167 citations in the awaiting classification section of the review may alter the conclusions of the review once assessed.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2013-01-24 12:54:38 +0000" MODIFIED_BY="[Empty name]">
<BACKGROUND MODIFIED="2010-10-28 17:51:54 +0100" MODIFIED_BY="[Empty name]">
<CONDITION MODIFIED="2010-10-28 17:47:30 +0100" MODIFIED_BY="[Empty name]">
<P>Obesity is a common problem in people with schizophrenia. Weight gain and metabolic disturbance are recognised side effects of many second-generation antipsychotic drugs, which is the mainstay of treatment for schizophrenia (<LINK REF="REF-Allison-1999" TYPE="REFERENCE">Allison 1999</LINK>; <LINK REF="REF-Casey-2004" TYPE="REFERENCE">Casey 2004</LINK>; <LINK REF="REF-Homel-2002" TYPE="REFERENCE">Homel 2002</LINK>). The prevalence of obesity in people with schizophrenia has been reported to be 1.5 to 4 times higher than the general population (<LINK REF="REF-ADA_x002f_APA-2004" TYPE="REFERENCE">ADA/APA 2004</LINK>; <LINK REF="REF-Coodin-2001" TYPE="REFERENCE">Coodin 2001</LINK>; <LINK REF="REF-Silverstone-1988" TYPE="REFERENCE">Silverstone 1988</LINK>). People with schizophrenia have a marked increase in standardised mortality ratio for both natural and unnatural causes of death .The rise in mortality may be attributed to the increased risk of coronary heart disease (<LINK REF="REF-Cohn-2004" TYPE="REFERENCE">Cohn 2004</LINK>; <LINK REF="REF-Goff-2005" TYPE="REFERENCE">Goff 2005</LINK>; <LINK REF="REF-Henderson-2005" TYPE="REFERENCE">Henderson 2005</LINK>; <LINK REF="REF-Mackin-2005" TYPE="REFERENCE">Mackin 2005</LINK>; <LINK REF="REF-Saari-2005" TYPE="REFERENCE">Saari 2005</LINK>), and increased prevalence of obesity in this population (<LINK REF="REF-Coodin-2001" TYPE="REFERENCE">Coodin 2001</LINK>; <LINK REF="REF-Daumit-2003" TYPE="REFERENCE">Daumit 2003</LINK>; <LINK REF="REF-Susce-2005" TYPE="REFERENCE">Susce 2005</LINK>). Obesity doubles the risk of all-cause mortality, coronary heart disease, stroke and Type II diabetes. It also increases the risk of some cancers, musculoskeletal problems and loss of function, and carries negative psychological consequences (<LINK REF="REF-DoH-2004" TYPE="REFERENCE">DoH 2004</LINK>).</P>
<P>Many factors such as genetics, adverse effects of medications, poor diet and inactive lifestyle may contribute to the prevalence of obesity in schizophrenia. In a meta-analysis, every antipsychotic medication except ziprasidone and molindone was found to be associated with some degree of weight gain after just 10 weeks of treatment (<LINK REF="REF-Allison-1999" TYPE="REFERENCE">Allison 1999</LINK>). The effects were greatest with olanzapine and clozapine, which swiftly increased body weight by 4-4.5 kilograms. There is no consensus on exactly how the newer antipsychotic drugs cause weight gain.</P>
<P>Quality of life is further reduced for people with schizophrenia with high body mass index (<LINK REF="REF-Kurzthaler-2001" TYPE="REFERENCE">Kurzthaler 2001</LINK>; <LINK REF="REF-Strassnig-2003" TYPE="REFERENCE">Strassnig 2003</LINK>) and those gaining weight (<LINK REF="REF-Allison-2003" TYPE="REFERENCE">Allison 2003</LINK>). Furthermore, <LINK REF="REF-Weiden-2004" TYPE="REFERENCE">Weiden 2004</LINK> reported a significant positive association between obesity, subjective distress from weight gain and medication non-compliance in a sample of people with schizophrenia. People suffering from schizophrenia also face the combined challenges of living with schizophrenia, and for many, obesity and related illnesses. This combination is a major public health problem (<LINK REF="REF-Wirshing-2004" TYPE="REFERENCE">Wirshing 2004</LINK>) and carries considerable human cost.</P>
<P>Second-generation antipsychotic drugs, in spite of their benefits, have been associated with the so-called metabolic syndrome, the triad of weight gain, diabetes and dyslipidaemia. The International Diabetes Federation published a consensus statement on the definition of metabolic syndrome in 2006 (<LINK REF="REF-IDF" TYPE="REFERENCE">IDF</LINK>). The criteria for the syndrome includes central obesity (defined as waist circumference of more than 94cm for Europoid* men and 80 cm for Europoid women with ethnic specific values for other groups), as well as any two from the following four factors:<BR/>- raised triglyceride levels or specific treatment for this lipid abnormality;<BR/>- reduced HDL cholesterol;<BR/>- raised blood pressure or treatment of previously diagnosed hypertension;<BR/>- raised plasma glucose or previously diagnosed Type II diabetes.<BR/>
<BR/> (* Europoid: a technical term used to describe a physical type like one of the phenotypes, or genotypes types found today in Europe (<LINK REF="REF-Wikipedia-2007" TYPE="REFERENCE">Wikipedia 2007</LINK>)).</P>
</CONDITION>
<INTERVENTION MODIFIED="2010-10-28 17:48:19 +0100" MODIFIED_BY="[Empty name]">
<P>Recognition of the metabolic syndromes in people who are on second-generation antipsychotic medication and the resulting increase in morbidity and mortality has led to discussions on effective intervention strategies (<LINK REF="REF-Birt-2003" TYPE="REFERENCE">Birt 2003</LINK>; <LINK REF="REF-Catapana-2004" TYPE="REFERENCE">Catapana 2004</LINK>; <LINK REF="REF-Green-2000" TYPE="REFERENCE">Green 2000</LINK>; <LINK REF="REF-Le-Fevre-2001" TYPE="REFERENCE">Le Fevre 2001</LINK>; <LINK REF="REF-Osborn-2001" TYPE="REFERENCE">Osborn 2001</LINK>) and consensus statements on its management (e.g., <LINK REF="REF-ADA_x002f_APA-2004" TYPE="REFERENCE">ADA/APA 2004</LINK>; <LINK REF="REF-De-Nayer-2005" TYPE="REFERENCE">De Nayer 2005</LINK>). Treatment of obesity in this population involves non-pharmacological and pharmacological interventions. Existing evidence suggests that even effective treatments for adult obesity only produce modest weight loss (approximately 2 kg to 5 kg) compared to no treatment or usual care (<LINK REF="REF-Faulkner-2007" TYPE="REFERENCE">Faulkner 2007</LINK>). Switching to a drug with less potential for weight gain and metabolic problems can also lead to weight loss and metabolic improvement.</P>
</INTERVENTION>
<THEORY MODIFIED="2010-10-28 17:51:12 +0100" MODIFIED_BY="[Empty name]">
<P>Studies have shown that when one atypical antipsychotic is switched to another, changes in weight occur. In <LINK REF="REF-Ried-2003" TYPE="REFERENCE">Ried 2003</LINK>, when people were switched from olanzapine to risperidone and risperidone to olanzapine, the group switched to olanzapine gained weight while those changed to risperidone lost. <LINK REF="REF-Hester--2005" TYPE="REFERENCE">Hester 2005</LINK> found that for people who had gained weight on olanzapine, switching to another antipsychotic drug was an effective option to reduce weight in some patients. The consensus statement on the management of metabolic syndrome associated with atypical antipsychotic use also recommends that if a stable patient on a second-generation antipsychotic gains 5% of his or her initial weight at any time during therapy, one should consider switching the medication (<LINK REF="REF-ADA_x002f_APA-2004" TYPE="REFERENCE">ADA/APA 2004</LINK>).</P>
<P>Four different switch strategies can be used:<BR/>- the cross-taper strategy (gradually titrating up the new medication while tapering off the older medication);<BR/>- starting new medication at the therapeutic dose while tapering off the older one;<BR/>- stopping older antipsychotic drugs abruptly while gradually increasing the new one; or<BR/>- starting the new drug at therapeutic dose and stopping the old one abruptly.<BR/>
<BR/>The cross-taper strategy is considered to be the safest approach.</P>
<P>A recent review looked at four randomised controlled trials on switching strategies and suggested that available evidence does not yet support the clinical superiority of switching antipsychotic drugs on various outcome measures, including weight gain (<LINK REF="REF-Remington-2005" TYPE="REFERENCE">Remington 2005</LINK>).</P>
</THEORY>
<IMPORTANCE MODIFIED="2010-10-28 17:51:54 +0100" MODIFIED_BY="[Empty name]">
<P>Anyone might have difficulties undergoing available pharmacological and non-pharmacological interventions for weight gain due to lack of motivation or other lifestyle factors. For people with schizophrenia these problems may be particularly acute; hence switching to an antipsychotic medication which is less likely to cause weight gain seems to be a practical alternative. Using an antipsychotic which is less likely to cause weight gain initially may also be critical for preventing or reducing weight gain. A recent Cochrane review (<LINK REF="REF-Faulkner-2007" TYPE="REFERENCE">Faulkner 2007</LINK>) looked at pharmacological (anti-obesity agents) and non-pharmacological (diet/exercise) interventions for reducing or preventing weight gain in people with schizophrenia but specifically excluded medication switching as an intervention strategy. This sister review extends the investigation by focusing on randomised trials in which switching antipsychotic medication is used as an intervention for people with schizophrenia who have antipsychotic induced weight or metabolic problems.</P>
</IMPORTANCE>
</BACKGROUND>
<OBJECTIVES>
<P>To determine the effects of antipsychotic medication switching as a strategy for reducing or preventing weight gain in people with schizophrenia who have neuroleptic induced weight or metabolic problems.</P>
</OBJECTIVES>
<METHODS MODIFIED="2013-01-21 16:54:07 +0000" MODIFIED_BY="[Empty name]">
<SELECTION_CRITERIA MODIFIED="2010-10-28 17:57:13 +0100" MODIFIED_BY="[Empty name]">
<CRIT_STUDIES MODIFIED="2010-10-28 17:53:37 +0100" MODIFIED_BY="[Empty name]">
<P>All relevant randomised controlled trials. Where a trial was described as 'double-blind', but it was only implied that the study was randomised, we have included these trials in a sensitivity analysis. If there was no substantive difference within primary outcomes (see <LINK TAG="CRIT_OUTCOMES" TYPE="SECTION">Types of outcome measures</LINK>) when these 'implied randomisation' studies were added, then we included those in the final analysis. If there was a substantive difference, we used only clearly randomised trials and described the results of the sensitivity analysis in the text. We excluded quasi-randomised studies, such as those allocating by using alternate days of the week.</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS MODIFIED="2010-10-28 17:54:29 +0100" MODIFIED_BY="[Empty name]">
<P>People diagnosed with schizophrenia or schizophrenia-like illnesses, using any criteria, with weight or metabolic problems. We included trials where it was implied that the majority (more than 50%) of participants had a severe mental illness likely to be schizophrenia.</P>
<P>For purposes of this review we use two definitions of weight or metabolic problems - a grade 'A' definition and a less stringent grade 'B'.<BR/>A - Everyone starting had weight or metabolic problems as defined by the trialists and there was, at least, a suggestion that this problem had been caused by use of antipsychotic medication.<BR/>B - Everyone participating had measures relevant to weight or metabolic problems recorded, whether or not they fell into the category of obese or metabolic syndrome.</P>
<P>We did not exclude participants on the basis of age, nationality, sex or setting of treatment.</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS MODIFIED="2010-10-28 17:55:25 +0100" MODIFIED_BY="[Empty name]">
<P>A. COMPARISON 01: Absolute effect of switching.<BR/>1. Any antipsychotic medication switching; versus<BR/>2. continuation of medication as before.</P>
<P>B. COMPARISON 02: Comparative effect of switching versus other weight management techniques.<BR/>1. Any antipsychotic medication switching; versus<BR/>2. continuation of antipsychotic plus adjunctive pharmacological interventions (used for weight or metabolic benefit such as orlistat, nizatidine); or<BR/>3. continuation of antipsychotic plus non-pharmacological interventions (e.g. diet, exercise, counselling); or<BR/>4. discontinuation of antipsychotic plus pharmacological interventions (used for weight or metabolic benefit such as orlistat, nizatidine); or<BR/>5. discontinuation of antipsychotic plus non-pharmacological interventions (e.g. diet, exercise, counselling).</P>
<P>C. COMPARISON 03: Comparative effect of different techniques of switching.<BR/>1. Abrupt discontinuation + abrupt replacement; versus<BR/>2. abrupt discontinuation + gradual replacement; or<BR/>3. gradual discontinuation + abrupt replacement; or<BR/>4. gradual discontinuation + gradual replacement.</P>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES MODIFIED="2010-10-28 17:57:13 +0100" MODIFIED_BY="[Empty name]">
<CRIT_OUTCOMES_PRIMARY MODIFIED="2010-06-23 19:43:52 +0100" MODIFIED_BY="[Empty name]">
<P>1. Weight and physiological measures<BR/>1.1 No clinically important change in body weight (as defined by individual studies)<BR/>1.2 Presence of metabolic syndrome</P>
<P>2. Global state<BR/>2.1 Relapse</P>
<P>3. Mental state (with particular reference to the positive and negative symptoms of schizophrenia)<BR/>3.1 No clinically important change in general mental state</P>
</CRIT_OUTCOMES_PRIMARY>
<CRIT_OUTCOMES_SECONDARY MODIFIED="2010-10-28 17:57:13 +0100" MODIFIED_BY="[Empty name]">
<P>1. Weight and physiological measures<BR/>1.1 Total body weight (lbs/kg)<BR/>1.2 Change in body weight<BR/>1.3 No clinically important change in body mass index (BMI) (as defined by individual studies)<BR/>1.4 Total BMI<BR/>1.5 Change in BMI<BR/>1.6 No clinically important change in waist circumference (as defined by individual studies)<BR/>1.7 Total waist circumference<BR/>1.8 Change in waist circumference<BR/>1.9 No clinically important change in waist-to-hip circumference ratio (as defined by individual studies)<BR/>1.10 Total waist-to-hip circumference ratio<BR/>1.11 Change in waist-to-hip circumference ratio<BR/>1.12 No clinically important change in total percent body fat (as defined by individual studies)<BR/>1.13 Total percent body fat<BR/>1.14 Change in percent body fat<BR/>1.15 Serum cholesterol, HDL, LDL, triglyceride profile</P>
<P>2. Global state<BR/>2.1 No clinically important change in global state (as defined by individual studies)<BR/>2.2 Average endpoint global state score<BR/>2.3 Average change in global state scores</P>
<P>3. Mental state (with particular reference to the positive and negative symptoms of schizophrenia)<BR/>3.1 Average endpoint general mental state score<BR/>3.2 Average change in general mental state scores<BR/>3.3 No clinically important change in specific symptoms (positive symptoms of schizophrenia, negative symptoms of schizophrenia, depression, mania)<BR/>3.4 Average endpoint specific symptom score<BR/>3.5 Average change in specific symptom scores</P>
<P>4. Service outcomes<BR/>4.1 Hospitalisation<BR/>4.2 Time to hospitalisation</P>
<P>5. General functioning<BR/>5.1 No clinically important change in general functioning<BR/>5.2 Average endpoint general functioning score<BR/>5.3 Average change in general functioning scores<BR/>5.4 No clinically important change in specific aspects of functioning, such as social or life skills<BR/>5.5 Average endpoint specific aspects of functioning, such as social or life skills<BR/>5.6 Average change in specific aspects of functioning, such as social or life skills</P>
<P>6. Behaviour<BR/>6.1 No clinically important change in general behaviour<BR/>6.2 Average endpoint general behaviour score<BR/>6.3 Average change in general behaviour scores<BR/>6.4 No clinically important change in specific aspects of behaviour<BR/>6.5 Average endpoint specific aspects of behaviour<BR/>6.6 Average change in specific aspects of behaviour</P>
<P>7. Adverse effects - general and specific<BR/>7.1 Clinically important general adverse effects<BR/>7.2 Average endpoint general adverse effect score<BR/>7.3 Average change in general adverse effect scores<BR/>7.4 Clinically important specific adverse effects<BR/>7.5 Average endpoint specific adverse effects<BR/>7.6 Average change in specific adverse effects<BR/>7.7 Death - suicide and natural causes</P>
<P>8. Engagement with services</P>
<P>9. Satisfaction with treatment<BR/>9.1 Leaving the studies early<BR/>9.2 Recipient of care not satisfied with treatment<BR/>9.3 Recipient of care average satisfaction score<BR/>9.4 Recipient of care average change in satisfaction scores<BR/>9.5 Carer not satisfied with treatment<BR/>9.6 Carer average satisfaction score<BR/>9.7 Carer average change in satisfaction scores</P>
<P>10. Quality of life<BR/>10.1 No clinically important change in quality of life<BR/>10.2 Average endpoint quality of life score<BR/>10.3 Average change in quality of life scores<BR/>10.4 No clinically important change in specific aspects of quality of life<BR/>10.5 Average endpoint specific aspects of quality of life<BR/>10.6 Average change in specific aspects of quality of life</P>
<P>11. Economic outcomes<BR/>11.1 Direct costs<BR/>11.2 Indirect costs</P>
<P>We planned to divide outcome periods into short-term (less than three months), medium-term (3-12 months) and long-term follow-up (longer than one year).</P>
<P> </P>
</CRIT_OUTCOMES_SECONDARY>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2013-01-21 16:54:07 +0000" MODIFIED_BY="[Empty name]">
<P>We followed recommendations of the Schizophrenia Review Group search strategy and the <I>Cochrane Reviewers' Handbook</I> in developing our search strategy (<LINK REF="REF-Higgins-2005" TYPE="REFERENCE">Higgins 2005</LINK>).</P>
<ELECTRONIC_SEARCHES MODIFIED="2013-01-21 16:54:07 +0000" MODIFIED_BY="[Empty name]">
<P>The studies included in this review are from three separate searches: (a) all the references that came up in the 2005 search for the review looking at the interventions other than switching antipsychotics for reducing or preventing weight gain (<LINK REF="REF-Faulkner-2007" TYPE="REFERENCE">Faulkner 2007</LINK>); (b) additional references that came up in the update search in 2007 and (c) other relevant articles identified by the authors as the review progressed through searching registers of ongoing clinical trials, inspecting reference list of all identified studies, including existing reviews for relevant citations and asking representatives from major pharmaceutical companies (Eli Lilly, Astra Zeneca, and Bristol-Myers Squibb) if they have conducted or were currently undertaking any weight-related interventions in relation to schizophrenia. This was done along with the update search.</P>
<SUBSECTION>
<HEADING LEVEL="4">1. Update search (2007)</HEADING>
<P>The Cochrane Schizophrenia Group Trials Register was searched (June 2007) using the phrase:</P>
<P>[ (weight* or body mass* or bmi* or diet* or * eat* or waist* or obes* or * fat* or metaboli* in title, abstract, index terms of REFERENCE) or ( (switch* in intervention field) and (weight* or body mass* or diet* or eat* or waist* or obes* or metaboli* in outcome field) of study)].</P>
<P>This register is compiled by systematic searches of major databases, hand searches and conference proceedings (see <A HREF="http://onlinelibrary.wiley.com/o/cochrane/clabout/articles/SCHIZ/frame.html">Group Module</A>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">2. Cochrane Schizophrenia Group Trials Register register (November 2012)</HEADING>
<P>The Trials Search Co-ordinator, Samantha Roberts, searched the Cochrane Schizophrenia Group Trials Register register (November 2012) using the phrase:</P>
<P>[ (weight* or body mass* or bmi* or diet* or * eat* or waist* or obes* or * fat* or metaboli* in title, abstract, index terms of REFERENCE) or ( (switch* in intervention field) and (weight* or body mass* or diet* or eat* or waist* or obes* or metaboli* in health care conditions field of study)].</P>
<P>The Cochrane Schizophrenia Group&#8217;s Trials Register is compiled by systematic searches of major databases, handsearches of relevant journals and conference proceedings (see <A HREF="http://onlinelibrary.wiley.com/o/cochrane/clabout/articles/SCHIZ/frame.html">Group Module</A>). Incoming trials are assigned to relevant existing or new review titles.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">2. Previous search strategy (2005)</HEADING>
<P>See <LINK REF="APP-01" TYPE="APPENDIX">Appendix 1</LINK>
</P>
</SUBSECTION>
</ELECTRONIC_SEARCHES>
<OTHER_SEARCHES MODIFIED="2010-10-28 18:12:24 +0100" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="4">1. Reference searching</HEADING>
<P>We inspected the reference lists of all identified studies, including existing reviews, for relevant citations.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">2. Personal contact</HEADING>
<P>We contacted the first author of each relevant study for information on unpublished trials. We also consulted experts in the area of schizophrenia and weight gain. We contacted authors and experts by email or post to establish missing details in the methods and results sections of the written reports and to determine their knowledge of or involvement in any current work in the area. We also asked contacts at major pharmaceutical companies if they have conducted or were currently undertaking any weight-related interventions in relation to schizophrenia (including representatives from Janssen Pharmaceuticals, Pfizer Inc, Eli Lilly and Company, Astra Zeneca, and Bristol-Myers Squibb).</P>
</SUBSECTION>
</OTHER_SEARCHES>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2010-10-28 18:25:45 +0100" MODIFIED_BY="[Empty name]">
<STUDY_SELECTION MODIFIED="2010-10-28 18:00:53 +0100" MODIFIED_BY="[Empty name]">
<P>Four review authors (AM, GF, TC, GR) independently assessed the abstracts of the studies returned by the searches for relevance. When the authors disagreed or the abstract was unclear, we obtained the full report, repeated the assessment process and reached a decision on inclusion by consensus.</P>
</STUDY_SELECTION>
<DATA_EXTRACTION MODIFIED="2010-10-28 18:12:42 +0100" MODIFIED_BY="[Empty name]">
<P>AM independently extracted data from selected trials. When disputes arose we attempted to resolve these by discussion. When this was not possible and further information was necessary to resolve the dilemma, we did not enter data and added the trial to the list of those awaiting assessment.</P>
<SUBSECTION>
<HEADING LEVEL="4">1. Extraction</HEADING>
<P>AM independently extracted data from included studies. Again, we discussed any disagreement, documented decisions and, if necessary, contacted authors of studies for clarification. When this was not possible and further information was necessary to resolve the dilemma, we did not enter data and added the trial to the list of those awaiting assessment.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">2. Management</HEADING>
<P>We extracted the data onto standard, simple forms. Where possible, we entered data into Review Manager (RevMan) (RevMan 2008) in such a way that the area to the left of the 'line of no effect' indicates a 'favourable' outcome for the experimental treatment. Where this was not possible (e.g. scales that calculate higher scores = improvement) we have labelled the graphs in RevMan analyses accordingly so that the direction of effects was clear.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">3. Scale-derived data</HEADING>
<P>A wide range of instruments are available to measure outcomes in mental health studies. These instruments vary in quality and many are not validated, or are even ad hoc. It is accepted generally that measuring instruments should have the properties of reliability (the extent to which a test effectively measures anything at all) and validity (the extent to which a test measures that which it is supposed to measure). Unpublished scales are known to be subject to bias in trials of treatments for schizophrenia (<LINK REF="REF-Marshall-2000" TYPE="REFERENCE">Marshall 2000</LINK>). Therefore we included continuous data from rating scales only if the measuring instrument had been described in a peer-reviewed journal. In addition, we set the following minimum standards for instruments: the instrument should either be (a) a self-report or (b) completed by an independent rater or relative (not the therapist) and (c) the instrument should be a global assessment of an area of functioning.<BR/>
<BR/>Whenever possible we took the opportunity to make direct comparisons between trials that used the same measurement instrument to quantify specific outcomes. Where continuous data were presented from different scales rating the same effect, we presented both sets of data and inspected the general direction of effect.</P>
</SUBSECTION>
</DATA_EXTRACTION>
<QUALITY_ASSESSMENT MODIFIED="2010-10-28 18:11:43 +0100" MODIFIED_BY="[Empty name]">
<P>We assessed risk of bias using the tool described in the <I>Cochrane Handbook for Systematic Reviews of Interventions</I> (<LINK REF="REF-Higgins-2009" TYPE="REFERENCE">Higgins 2009</LINK>). This tool encourages consideration of how the sequence was generated, how allocation was concealed, the integrity of blinding at outcome, the completeness of outcome data, selective reporting and other biases. We would not have included studies where sequence generation was at high risk of bias or where allocation was clearly not concealed.<BR/>
<BR/>The categories are defined below.<BR/>YES - low risk of bias.<BR/>NO - high risk of bias.<BR/>UNCLEAR - uncertain risk of bias.</P>
<P>If disputes arose as to which category a trial has to be allocated, again, we resolved these by discussion, after working with a third reviewer.</P>
<P>In addition, we completed the 'Risk of bias' table for each included trial. In this we recorded our opinions of where each of the studies was vulnerable to bias.</P>
</QUALITY_ASSESSMENT>
<EFFECT_MEASURES MODIFIED="2010-10-28 18:19:20 +0100" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="4">1. Binary data</HEADING>
<P>We carried out an intention-to-treat analysis. On the condition that more than 60% of people completed the study, we counted everyone allocated to the intervention, whether they completed the follow-up or not. We assumed that those who dropped out had the negative outcome, with the exception of death.<BR/>Where possible, we made efforts to convert outcome measures to binary data. This can be done by identifying cut-off points on rating scales and dividing participants accordingly into "clinically improved" or "not clinically improved". If the authors of a study had used a predefined cut-off point for determining clinical effectiveness, we used this where appropriate. Otherwise we generally assumed that if there had been a 50% reduction in a scale-derived score, this could be considered as a clinically significant response. Similarly, we considered a rating of "at least much improved" according to the Clinical Global Impression Scale (<LINK REF="REF-Guy-1976" TYPE="REFERENCE">Guy 1976</LINK>) as a clinically significant response.</P>
<P>For binary outcomes we calculated a standard estimation of the fixed-effect risk ratio (RR) and its 95% confidence interval (CI). It has been shown that RR is more intuitive (<LINK REF="REF-Boissel-1999" TYPE="REFERENCE">Boissel 1999</LINK>) than odds ratios (ORs) and that ORs tend to be interpreted as RR by clinicians (<LINK REF="REF-Deeks-2000" TYPE="REFERENCE">Deeks 2000</LINK>). This misinterpretation then leads to an overestimate of the impression of the effect. When the overall results were significant we calculated the number needed to treat (NNT) and the number needed to harm (NNH) as the inverse of the risk difference.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">2. Continuous data</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">2.1 Summary statistic</HEADING>
<P>For continuous outcomes we estimated a mean difference (MD) between groups, based on the fixed-effect model.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">2.2 Endpoint versus change data</HEADING>
<P>Where both final endpoint data and change data were available for the same outcome category, we have presented only final endpoint data. We acknowledge that by doing this much of the published change data may be excluded, but argue that endpoint data are more clinically relevant and that if change data were to be presented along with endpoint data, it would be given undeserved equal prominence. Where studies reported only change data, we contacted authors for endpoint figures, but if endpoint data were unavailable, we reported change data.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">2.3 Skewed data</HEADING>
<P>Normally distributed data: continuous data on clinical and social outcomes are often not normally distributed. To avoid the pitfall of applying parametric tests to non-parametric data, we applied the following standards to all data before inclusion: </P>
<P>(a) standard deviations and means were reported in the paper or were obtainable from the authors; </P>
<P>(b) when a scale started from the finite number zero, the standard deviation, when multiplied by two, was less than the mean (as otherwise the mean is unlikely to be an appropriate measure of the centre of the distribution, (<LINK REF="REF-Altman-1996" TYPE="REFERENCE">Altman 1996</LINK>); </P>
<P>(c) if a scale started from a positive value (such as PANSS which can have values from 30 to 210) we modified the calculation described above to take the scale starting point into account. In these cases skew is present if 2SD&gt; (S-Smin), where S is the mean score and Smin is the minimum score. Endpoint scores on scales often have a finite start and end point and these rules can be applied to them. When continuous data are presented on a scale which includes a possibility of negative values (such as change on a scale), it is difficult to tell whether data are non-normally distributed (skewed) or not. </P>
<P>We would have entered skewed data from studies of fewer than 200 participants in additional tables rather than into an analysis. Skewed data poses less of a problem when looking at means if the sample size is large and we would have entered them into a synthesis.</P>
</SUBSECTION>
</SUBSECTION>
</EFFECT_MEASURES>
<UNIT_OF_ANALYSIS MODIFIED="2010-10-28 18:21:52 +0100" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="4">1. Cluster trials</HEADING>
<P>Studies increasingly employ 'cluster randomisation' (such as randomisation by clinician or practice) but analysis and pooling of clustered data poses problems. Firstly, authors often fail to account for intra-class correlation in clustered studies, leading to a 'unit of analysis' error (<LINK REF="REF-Divine-1992" TYPE="REFERENCE">Divine 1992</LINK>) whereby P values are spuriously low, confidence intervals unduly narrow and statistical significance overestimated. This causes type I errors (<LINK REF="REF-Bland-1997" TYPE="REFERENCE">Bland 1997</LINK>; <LINK REF="REF-Gulliford-1999" TYPE="REFERENCE">Gulliford 1999</LINK>).<BR/>
<BR/>Where clustering was not accounted for in primary studies, we presented the data in a table, with a (*) symbol to indicate the presence of a probable unit of analysis error. In subsequent versions of this review we will seek to contact first authors of studies to obtain intra-class correlation co-efficients of their clustered data and to adjust for this using accepted methods (<LINK REF="REF-Gulliford-1999" TYPE="REFERENCE">Gulliford 1999</LINK>). Where clustering has been incorporated into the analysis of primary studies, we will also present these data as if from a non-cluster randomised study, but adjusted for the clustering effect.<BR/>
<BR/>We have sought statistical advice and have been advised that binary data presented in a report should be divided by a 'design effect'. This is calculated using the mean number of participants per cluster (m) and the intra-class correlation co-efficient (ICC) (Design effect = 1+ (m-1)*ICC) (<LINK REF="REF-Donner-2002" TYPE="REFERENCE">Donner 2002</LINK>). If the ICC was not reported we have assumed it to be 0.1 (<LINK REF="REF-Ukoumunne-1999" TYPE="REFERENCE">Ukoumunne 1999</LINK>).<BR/>
<BR/>If cluster studies had been appropriately analysed taking into account ICC and relevant data documented in the report, synthesis with other studies would have been possible using the generic inverse variance technique.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">2. Studies with multiple treatment groups</HEADING>
<P>Where a study involved more than two treatment arms, if relevant, we have presented the additional treatment arms in comparisons. Where the additional treatment arms were not relevant, we have not reproduced these data.</P>
</SUBSECTION>
</UNIT_OF_ANALYSIS>
<MISSING_DATA MODIFIED="2009-11-16 16:49:00 +0000" MODIFIED_BY="[Empty name]">
<P>We attempted to include all people who had been randomised to either switching of medication or continuing on their previous antipsychotic. Where possible, we gave cases lost to follow-up at the end of the study the worst outcome. For example, those lost to follow-up for the outcome of relapse were treated in the analysis as having relapsed. Suicide was treated as relapse. We agreed these rules before knowing the studies included. The effects of inclusion of this assumption were tested with sensitivity analyses for the primary outcome.</P>
</MISSING_DATA>
<HETEROGENEITY_ASSESSMENT MODIFIED="2010-10-28 18:23:14 +0100" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="4">1. Clinical heterogeneity</HEADING>
<P>We considered all included studies without any comparison to judge clinical heterogeneity.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">2. Statistical</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">2.1 Visual inspection</HEADING>
<P>We visually inspected graphs to investigate the possibility of statistical heterogeneity.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">2.2 Employing the I<SUP>2</SUP> statistic</HEADING>
<P>This provided an estimate of the percentage of inconsistency thought to be due to chance. We interpreted I<SUP>2</SUP> estimates greater than or equal to 50% as evidence of high levels of heterogeneity (<LINK REF="REF-Higgins-2003" TYPE="REFERENCE">Higgins 2003</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
</HETEROGENEITY_ASSESSMENT>
<BIAS_ASSESSMENT MODIFIED="2010-10-28 18:23:44 +0100" MODIFIED_BY="[Empty name]">
<P>Reporting biases arise when the dissemination of research findings is influenced by the nature and direction of results. These are described in section 10.1 of the <I>Handbook</I> (<LINK REF="REF-Higgins-2009" TYPE="REFERENCE">Higgins 2009</LINK>). We are aware that funnel plots may be useful in investigating reporting biases but are of limited power to detect small-study effects (<LINK REF="REF-Egger-1997" TYPE="REFERENCE">Egger 1997</LINK>). We did not use funnel plots for outcomes where there were 10 or fewer studies, or where all studies were of similar sizes. In other cases, where funnel plots were possible, we sought statistical advice in their interpretation.</P>
</BIAS_ASSESSMENT>
<DATA_SYNTHESIS MODIFIED="2010-10-28 18:24:57 +0100" MODIFIED_BY="[Empty name]">
<P>Where possible we employed a fixed-effect model for analyses. We understand that there is no closed argument for preference for use of fixed-effect or random-effects models. The random-effects method incorporates an assumption that the different studies are estimating different, yet related, intervention effects. This does seem true to us; however, random-effects does put added weight onto the smaller of the studies - those trials that are most vulnerable to bias. For this reason we favour using the fixed-effect model.</P>
<P>In this review, in the three instances where meta-analysis was possible, the l<SUP>2</SUP> statistic was substantially less than 50%. When true inter-trial variability is low as denoted by low values of l<SUP>2</SUP> statistics, the fixed-effect model may give better precision estimate of a common effect.</P>
</DATA_SYNTHESIS>
<SUBGROUP_ANALYSIS MODIFIED="2010-10-28 18:25:45 +0100" MODIFIED_BY="[Empty name]">
<P>When we found heterogeneous results , we investigated the reasons for this. Where heterogeneous data substantially altered the results and we identified the reasons for the heterogeneity, we have not summated these studies in the meta-analysis, but presented them separately and discussed them in the text.</P>
</SUBGROUP_ANALYSIS>
<SENSITIVITY_ANALYSIS MODIFIED="2010-06-28 12:08:50 +0100" MODIFIED_BY="[Empty name]">
<P>We wished to investigate the sensitivity of the results of the primary outcomes to grouping drugs into broad families such as 'typical' and 'atypical'. This proved impossible as each comparison compared medications within the same broad families of drugs or did not give details of prior treatment.</P>
</SENSITIVITY_ANALYSIS>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2013-01-22 14:53:12 +0000" MODIFIED_BY="[Empty name]">
<STUDY_DESCRIPTION MODIFIED="2013-01-22 14:53:12 +0000" MODIFIED_BY="[Empty name]">
<P>For description of the studies see: <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK>; <LINK TAG="CHARACTERISTICS_OF_EXCLUDED_STUDIES" TYPE="SECTION">Characteristics of excluded studies</LINK>; <LINK TAG="CHARACTERISTICS_OF_ONGOING_STUDIES" TYPE="SECTION">Characteristics of ongoing studies</LINK>.</P>
<SEARCH_RESULTS MODIFIED="2010-10-28 18:28:28 +0100" MODIFIED_BY="[Empty name]">
<P>The original search identified 814 references from 83 studies. We conducted an update search in 2007 and identified an additional 266 studies and 625 new references. We searched the ISI citation index for each selected trial in order to identify further studies, and inspected the reference sections of selected studies for additional trials. We also identified five additional studies possibly relevant to this review (in addition to the above search methods, we also searched registers of ongoing clinical trials, and contacted representatives from major pharmaceutical companies) from which we have included two in the review. In total we selected 32 relevant trials, but we were able to include only four studies which were directly relevant for the review.</P>
</SEARCH_RESULTS>
<INCLUDED_STUDIES_DESCR MODIFIED="2010-10-28 18:46:54 +0100" MODIFIED_BY="[Empty name]">
<P>We identified four studies which we could include. All were described as randomised. In one study, the participants were randomised to three switching strategies (<LINK REF="STD-Casey-2003" TYPE="STUDY">Casey 2003</LINK>). Only three were double blind (<LINK REF="STD-Cookson-1986" TYPE="STUDY">Cookson 1986</LINK>; <LINK REF="STD-Eli-Lilly-2004" TYPE="STUDY">Eli Lilly 2004</LINK>; <LINK REF="STD-Newcomer-2008" TYPE="STUDY">Newcomer 2008</LINK>).</P>
<SUBSECTION>
<HEADING LEVEL="4">1. Length of trials</HEADING>
<P>One study (<LINK REF="STD-Casey-2003" TYPE="STUDY">Casey 2003</LINK>) reported data on short-term follow-up (up to 12 weeks).Two studies had follow-up of 13 to 26 weeks (<LINK REF="STD-Eli-Lilly-2004" TYPE="STUDY">Eli Lilly 2004</LINK>; <LINK REF="STD-Newcomer-2008" TYPE="STUDY">Newcomer 2008</LINK>). Only one study had follow-up of one year's duration (<LINK REF="STD-Cookson-1986" TYPE="STUDY">Cookson 1986</LINK>) .The ongoing study has an intended duration of one year (<LINK REF="STD-Tang-2003" TYPE="STUDY">Tang 2003</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">2. Participants</HEADING>
<P>All but one study used clear operationalised criteria for diagnosis (<LINK REF="STD-Cookson-1986" TYPE="STUDY">Cookson 1986</LINK>). The rest included participants with either schizophrenia or schizoaffective disorder (DSM IV). The majority of participants in all studies except one (<LINK REF="STD-Cookson-1986" TYPE="STUDY">Cookson 1986</LINK>) were male, and had a mean age in their mid to late thirties to early to mid forties.Two studies excluded participants with other axis 1 DSM IV diagnoses, suicide risk and substance dependence (<LINK REF="STD-Casey-2003" TYPE="STUDY">Casey 2003</LINK>; <LINK REF="STD-Newcomer-2008" TYPE="STUDY">Newcomer 2008</LINK>). One study excluded patients who had been on any other antipsychotic except olanzapine, which was the control antipsychotic (<LINK REF="STD-Eli-Lilly-2004" TYPE="STUDY">Eli Lilly 2004</LINK>).</P>
<P>Being overweight or obese and/or having metabolic complications were an inclusion criteria in only three studies (<LINK REF="STD-Cookson-1986" TYPE="STUDY">Cookson 1986</LINK>; <LINK REF="STD-Eli-Lilly-2004" TYPE="STUDY">Eli Lilly 2004</LINK>; <LINK REF="STD-Newcomer-2008" TYPE="STUDY">Newcomer 2008</LINK>). In the other study it was difficult to make out if the participants were obese or overweight at entry, as they had provided only a mean body weight and no BMI (<LINK REF="STD-Casey-2003" TYPE="STUDY">Casey 2003</LINK>).</P>
<P>All the studies required patients to be stable mentally or be on a stable dose of medication. In the <LINK REF="STD-Casey-2003" TYPE="STUDY">Casey 2003</LINK> study, there needed to be a reason for switching, like poor tolerability or inadequate response to previous medication.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">3. Setting</HEADING>
<P>Two studies were described as occurring in out-patient settings (<LINK REF="STD-Casey-2003" TYPE="STUDY">Casey 2003</LINK>; <LINK REF="STD-Eli-Lilly-2004" TYPE="STUDY">Eli Lilly 2004</LINK>). One study was done in a depot injection clinic (<LINK REF="STD-Cookson-1986" TYPE="STUDY">Cookson 1986</LINK>). The setting was not mentioned in <LINK REF="STD-Newcomer-2008" TYPE="STUDY">Newcomer 2008</LINK>, but it could be inferred that this was conducted in an out-patient setting as it had as one of its exclusion criteria an increase in symptoms requiring hospitalisation.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">4. Study size</HEADING>
<P>The study by <LINK REF="STD-Casey-2003" TYPE="STUDY">Casey 2003</LINK> had the maximum participants (311). Two studies had between 100 and 200 participants (<LINK REF="STD-Eli-Lilly-2004" TYPE="STUDY">Eli Lilly 2004</LINK>; <LINK REF="STD-Newcomer-2008" TYPE="STUDY">Newcomer 2008</LINK>). In the study by <LINK REF="STD-Eli-Lilly-2004" TYPE="STUDY">Eli Lilly 2004</LINK> the enrolment target was 340 but the study was terminated with only 33% of the original target enrolled. The fewest number of participants were enrolled in <LINK REF="STD-Cookson-1986" TYPE="STUDY">Cookson 1986</LINK> (19).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">5. Interventions</HEADING>
<P>Although all studies looked at the absolute effect of switching, only three studies (<LINK REF="STD-Cookson-1986" TYPE="STUDY">Cookson 1986</LINK>; <LINK REF="STD-Eli-Lilly-2004" TYPE="STUDY">Eli Lilly 2004</LINK>; <LINK REF="STD-Newcomer-2008" TYPE="STUDY">Newcomer 2008</LINK>) compared the effect of switching of antipsychotic medication with continuation of previous medication. In the study by <LINK REF="STD-Casey-2003" TYPE="STUDY">Casey 2003</LINK>, which looked at switching from previous antipsychotic medications to another, there was no comparative group continuing on the original medication. In this study baseline measures were compared to before and after switching of medication. For the purposes of this review we have called the different ways of switching 'Technique 1, 2 and 3'.</P>
<P>Technique 1 - immediate initiation + immediate discontinuation of current antipsychotic.</P>
<P>Technique 2 - immediate initiation + tapering of current antipsychotic.</P>
<P>Technique 3 - titrating switch medication upwards + tapering of current antipsychotic .</P>
<P>In all studies except one, oral antipsychotics were used. In one study (<LINK REF="STD-Cookson-1986" TYPE="STUDY">Cookson 1986</LINK>) depot antipsychotics were used.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">6. Outcomes</HEADING>
<P>Mean weight changes with measures of dispersion are reported in three studies (<LINK REF="STD-Cookson-1986" TYPE="STUDY">Cookson 1986</LINK>; <LINK REF="STD-Eli-Lilly-2004" TYPE="STUDY">Eli Lilly 2004</LINK>; <LINK REF="STD-Newcomer-2008" TYPE="STUDY">Newcomer 2008</LINK>). The percentage of people who experienced clinically significant weight gain or weight loss was reported in <LINK REF="STD-Casey-2003" TYPE="STUDY">Casey 2003</LINK>; mean weight change was also reported but it was not possible to use this as there were no measures of dispersion.</P>
<P>Changes in BMI are reported in <LINK REF="STD-Eli-Lilly-2004" TYPE="STUDY">Eli Lilly 2004</LINK> (mean and standard deviation) and <LINK REF="STD-Newcomer-2008" TYPE="STUDY">Newcomer 2008</LINK> (number of people experiencing clinically relevant BMI increase).</P>
<P>The percentage of people with high waist circumference is reported in <LINK REF="STD-Newcomer-2008" TYPE="STUDY">Newcomer 2008</LINK> but no other studies reported this outcome. Body fat and waist to hip circumference ratio was not an outcome measure in any of the studies.</P>
<P>Laboratory measures for Metabolic Syndrome were measured in two studies. Serum cholesterol, triglycerides HDL, LDL and blood glucose levels were measured in <LINK REF="STD-Eli-Lilly-2004" TYPE="STUDY">Eli Lilly 2004</LINK> and <LINK REF="STD-Newcomer-2008" TYPE="STUDY">Newcomer 2008</LINK>.</P>
<P>Time to relapse was the primary outcome measure in the study by <LINK REF="STD-Eli-Lilly-2004" TYPE="STUDY">Eli Lilly 2004</LINK>. None of the other studies looked at relapse. Global state was assessed using the CGI I and CGI S scales in 2 studies (<LINK REF="STD-Casey-2003" TYPE="STUDY">Casey 2003</LINK>; <LINK REF="STD-Newcomer-2008" TYPE="STUDY">Newcomer 2008</LINK>).</P>
<P>Hospitalisation as one of the criteria for relapse was looked at in <LINK REF="STD-Eli-Lilly-2004" TYPE="STUDY">Eli Lilly 2004</LINK>.</P>
<P>General functioning and behaviour were not an outcome measure in any of the studies.</P>
<P>Number of deaths was an outcome measure in only two studies; no deaths reported (<LINK REF="STD-Eli-Lilly-2004" TYPE="STUDY">Eli Lilly 2004</LINK>; <LINK REF="STD-Newcomer-2008" TYPE="STUDY">Newcomer 2008</LINK>). Number of people discontinuing treatment was considered in three studies (<LINK REF="STD-Cookson-1986" TYPE="STUDY">Cookson 1986</LINK>; <LINK REF="STD-Eli-Lilly-2004" TYPE="STUDY">Eli Lilly 2004</LINK>; <LINK REF="STD-Newcomer-2008" TYPE="STUDY">Newcomer 2008</LINK>).</P>
<P>None of the studies looked at quality of life measures, economic outcomes or engagement with services.</P>
<P>All the studies looked at dropouts, but only three studies stated the reasons for discontinuation of treatment (<LINK REF="STD-Cookson-1986" TYPE="STUDY">Cookson 1986</LINK>; <LINK REF="STD-Eli-Lilly-2004" TYPE="STUDY">Eli Lilly 2004</LINK>; <LINK REF="STD-Newcomer-2008" TYPE="STUDY">Newcomer 2008</LINK>).</P>
<SUBSECTION>
<HEADING LEVEL="5">6.1 Outcome scales</HEADING>
<P>Details of scales that provided usable data are shown below. Reasons for exclusions of data are given under 'Outcomes' in the 'Included studies' section.</P>
<P>
<I>6.1.1 Global state - Clinical Global Impression Scale - CGI Scale</I> (<LINK REF="REF-Guy-1976" TYPE="REFERENCE">Guy 1976</LINK>).<BR/>This is used to assess both severity of illness and clinical improvement, by comparing the conditions of the person standardised against other people with the same diagnosis. The review has looked at the two components of the scale, CGI -I (clinical improvement) and CGI-S (severity of illness). A seven-point scoring system is usually used, with low scores showing decreased severity and/or overall improvement. This scale was used in two studies (<LINK REF="STD-Casey-2003" TYPE="STUDY">Casey 2003</LINK>; <LINK REF="STD-Newcomer-2008" TYPE="STUDY">Newcomer 2008</LINK>).</P>
<P>
<I>6.1.2 Mental state - Positive and Negative Syndrome Scale - PANSS</I> (<LINK REF="REF-Kay-1986" TYPE="REFERENCE">Kay 1986</LINK>)<BR/>This schizophrenia scale has 30 items, each of which can be defined on a seven-point scoring system varying from 1 - absent to 7 - extreme. This scale can be divided into three sub-scales for measuring the severity of general psychopathology, positive symptoms (PANSS-P), and negative symptoms (PANSS-N). A low score indicates lesser severity.<I> </I>PANSS was used in two studies (<LINK REF="STD-Casey-2003" TYPE="STUDY">Casey 2003</LINK>; <LINK REF="STD-Eli-Lilly-2004" TYPE="STUDY">Eli Lilly 2004</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">6.2 Redundant data</HEADING>
<P>We were unable to use some data on a number of outcomes (vital signs, concomitant medications and laboratory measures) used as there were no numerical data (<LINK REF="STD-Casey-2003" TYPE="STUDY">Casey 2003</LINK>; <LINK REF="STD-Newcomer-2008" TYPE="STUDY">Newcomer 2008</LINK>).Though specific scales were used to measure mental state and side effects, the results provided no usable data (<LINK REF="STD-Casey-2003" TYPE="STUDY">Casey 2003</LINK>; <LINK REF="STD-Cookson-1986" TYPE="STUDY">Cookson 1986</LINK>; <LINK REF="STD-Eli-Lilly-2004" TYPE="STUDY">Eli Lilly 2004</LINK>; <LINK REF="STD-Newcomer-2008" TYPE="STUDY">Newcomer 2008</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">6.3 Missing outcome</HEADING>
<P>Primary outcome measures in the review were weight and metabolic measures, global state and mental state. In the four studies which we have included in the review, there were inconsistencies in reporting outcomes. All the primary outcomes were considered in three studies (<LINK REF="STD-Casey-2003" TYPE="STUDY">Casey 2003</LINK>; <LINK REF="STD-Cookson-1986" TYPE="STUDY">Cookson 1986</LINK>; <LINK REF="STD-Eli-Lilly-2004" TYPE="STUDY">Eli Lilly 2004</LINK>). In <LINK REF="STD-Casey-2003" TYPE="STUDY">Casey 2003</LINK> and <LINK REF="STD-Cookson-1986" TYPE="STUDY">Cookson 1986</LINK>, other measures of weight like BMI, waist circumference and metabolic syndrome were not considered. In the study by <LINK REF="STD-Eli-Lilly-2004" TYPE="STUDY">Eli Lilly 2004</LINK> relapse was used as an outcome to measure global state, but no other scales were used to measure global state. In this study a number of outcomes (waist circumference, health outcomes and resource utilisation) discussed in the methods section were not reported, probably due to the early termination of the study. <LINK REF="STD-Newcomer-2008" TYPE="STUDY">Newcomer 2008</LINK> did not measure mental state.</P>
</SUBSECTION>
</SUBSECTION>
</INCLUDED_STUDIES_DESCR>
<EXCLUDED_STUDIES_DESCR MODIFIED="2013-01-22 14:53:12 +0000" MODIFIED_BY="[Empty name]">
<P>We excluded 28 studies from the review. One was a presentation on guidelines for the prescription of long-acting atypical depot antipsychotics (<LINK REF="STD-Kane-2004" TYPE="STUDY">Kane 2004</LINK>). Another study (<LINK REF="STD-Ducate-2003" TYPE="STUDY">Ducate 2003</LINK>) was excluded as there was no comparative group.</P>
<P>We excluded eight studies because there was no switching after randomisation (<LINK REF="STD-Alvarez-2006" TYPE="STUDY">Alvarez 2006</LINK>; <LINK REF="STD-Chrzanowski-2006" TYPE="STUDY">Chrzanowski 2006</LINK>; <LINK REF="STD-Brar-2005" TYPE="STUDY">Brar 2005</LINK>; <LINK REF="STD-Emsley-2005" TYPE="STUDY">Emsley 2005</LINK>; <LINK REF="STD-CATIE-_x002d_-Phase-I-_x002d_-2006" TYPE="STUDY">CATIE - Phase I - 2006</LINK>; <LINK REF="STD-Nasrallah-2001" TYPE="STUDY">Nasrallah 2001</LINK>; <LINK REF="STD-STAR-trials-2006" TYPE="STUDY">STAR trials 2006</LINK>; <LINK REF="STD-Wang-2006" TYPE="STUDY">Wang 2006</LINK>). We excluded six studies as they involved no switching of medications (<LINK REF="STD-CATIE-_x002d_-Phase-II-_x002d_-2006" TYPE="STUDY">CATIE - Phase II - 2006</LINK>; <LINK REF="STD-Covell-1999" TYPE="STUDY">Covell 1999</LINK>; <LINK REF="STD-Kane-2005" TYPE="STUDY">Kane 2005</LINK>; <LINK REF="STD-Kane-2007" TYPE="STUDY">Kane 2007</LINK>; <LINK REF="STD-Newcomer-2006" TYPE="STUDY">Newcomer 2006</LINK>; <LINK REF="STD-Zhang-2004" TYPE="STUDY">Zhang 2004</LINK>). Four studies were not randomised (<LINK REF="STD-Kim-2007" TYPE="STUDY">Kim 2007</LINK>; O'Halloran 2003; <LINK REF="STD-Robinson-2000" TYPE="STUDY">Robinson 2000</LINK>; <LINK REF="STD-Su-2005" TYPE="STUDY">Su 2005</LINK>). Weight and metabolic parameters were not measured as outcomes in one study (<LINK REF="STD-Irwin-2003" TYPE="STUDY">Irwin 2003</LINK>,). We excluded another four studies because the primary aim of the switch was not as an intervention for weight gain or metabolic problems. This aim was difficult to consider as inferred as the switch was to olanzapine which is known to cause both weight gain and metabolic problems (<LINK REF="STD-Godleski-2003" TYPE="STUDY">Godleski 2003</LINK>; <LINK REF="STD-Kinon-2000" TYPE="STUDY">Kinon 2000</LINK>; <LINK REF="STD-Kinon-2004" TYPE="STUDY">Kinon 2004</LINK>; <LINK REF="STD-Lee-2002" TYPE="STUDY">Lee 2002</LINK>). As this review was specifically looking at switching of medication as an intervention, we had to exclude one crossover trial (<LINK REF="STD-Kelly-2003" TYPE="STUDY">Kelly 2003</LINK>). The first half of this study (eight weeks) was a comparison between high dose olanzapine and clozapine on various outcome measures including weight. The second half of the study involved crossover (switching). As data for weight and metabolic problems were not provided after the crossover (switching), we had to exclude the study. One study (<LINK REF="STD-Horacek-2004" TYPE="STUDY">Horacek 2004</LINK>) provided no measure of dispersions for weight (the primary outcome for the review) and so it had to be excluded. We excluded <LINK REF="STD-Weiden-Daniel-2003" TYPE="STUDY">Weiden Daniel 2003</LINK> because there were no data as per the original randomised groups (randomised to three switching strategies, from three different antipsychotic groups to ziprasidone). The data given were the pooled data from the three switching strategies for the three groups as per the original antipsychotic they were on prior to the switch to ziprasidone.</P>
<P>
<B>2. Awaiting assessment</B>
<BR/>One hundred and sixty seven studies are awaiting assessment.<BR/>
</P>
<P>
<B>3. Ongoing studies<BR/>
</B>One study (<LINK REF="STD-Tang-2003" TYPE="STUDY">Tang 2003</LINK>) is still ongoing. E-mail (04/03/2008) contact from one of the authors stated that the study is ongoing and they have 50 patients recruited. However, they were planning to terminate the study soon due to funding issues. We have received no reply to further e-mails requesting updates.</P>
</EXCLUDED_STUDIES_DESCR>
</STUDY_DESCRIPTION>
<STUDY_QUALITY MODIFIED="2010-10-29 03:27:41 +0100" MODIFIED_BY="[Empty name]">
<P>For graphical representation of risk of bias please see <LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK> and <LINK REF="FIG-02" TYPE="FIGURE">Figure 2</LINK>.</P>
<ALLOCATION MODIFIED="2010-10-29 03:17:53 +0100" MODIFIED_BY="[Empty name]">
<P>All included studies were reported as randomised. Only two studies attempted to describe the method of randomisation. In <LINK REF="STD-Casey-2003" TYPE="STUDY">Casey 2003</LINK>, randomisation was via a centralised telephone call-in system, and <LINK REF="STD-Cookson-1986" TYPE="STUDY">Cookson 1986</LINK> used randomisation sequences (separate for males and females).The rest of the studies did not describe the randomisation or allocation concealment methods used. Concealment of allocation has repeatedly been shown to be of key importance in excluding selection biases (<LINK REF="REF-J_x00fc_ni-2001" TYPE="REFERENCE">Jüni 2001</LINK>).</P>
</ALLOCATION>
<BLINDING MODIFIED="2010-10-29 03:19:20 +0100" MODIFIED_BY="[Empty name]">
<P>Three studies were double blind (<LINK REF="STD-Cookson-1986" TYPE="STUDY">Cookson 1986</LINK>; <LINK REF="STD-Eli-Lilly-2004" TYPE="STUDY">Eli Lilly 2004</LINK>; <LINK REF="STD-Newcomer-2008" TYPE="STUDY">Newcomer 2008</LINK>). <LINK REF="STD-Newcomer-2008" TYPE="STUDY">Newcomer 2008</LINK> had a two-week open-label observation period where participants continued to receive their prior medication. <LINK REF="STD-Casey-2003" TYPE="STUDY">Casey 2003</LINK> was open label. None of the double-blind studies reported any tests for blinding, which is important to test minimisation of observation bias. Lack of blinding for objective outcomes like weight, BMI and metabolic syndrome (major primary objectives in this review) is less likely to cause bias.</P>
</BLINDING>
<EXCLUSIONS MODIFIED="2010-10-29 03:24:38 +0100" MODIFIED_BY="[Empty name]">
<P>Most studies used last observation carried forward (LOCF) or observed case data set. Reasons for discontinuation were stated in most studies.</P>
<P>In <LINK REF="STD-Newcomer-2008" TYPE="STUDY">Newcomer 2008</LINK> in the LOCF and observed case data set there was 32% dropout.</P>
<P>In <LINK REF="STD-Eli-Lilly-2004" TYPE="STUDY">Eli Lilly 2004</LINK> the protocol was terminated early, with only a fraction of the intended enrolment. The drop-out percentage was 33% percent. In <LINK REF="STD-Casey-2003" TYPE="STUDY">Casey 2003</LINK>, the drop-out rate was 28%. In the <LINK REF="STD-Cookson-1986" TYPE="STUDY">Cookson 1986</LINK> study, only two people dropped out (11%).</P>
<P>All studies used LOCF and <LINK REF="STD-Newcomer-2008" TYPE="STUDY">Newcomer 2008</LINK> conducted observed case analysis (observed cases, defined as those completing the trial) as well.</P>
<P>The drop-out rates were different among the three groups in <LINK REF="STD-Casey-2003" TYPE="STUDY">Casey 2003</LINK> with one group having more drop-outs than the other.This was because more people withdrew consent in this group. Also all the randomised participants were not considered in reporting of some data. It is not clear what happened to the rest.</P>
<P>In the <LINK REF="STD-Cookson-1986" TYPE="STUDY">Cookson 1986</LINK> study, the only drop-outs were in the intervention group who were weighed before withdrawal; one person gaining weight (2.9 kg) and the other losing it (0.9 kg).</P>
<P>There were more drop-outs in the intervention group compared to control group in <LINK REF="STD-Eli-Lilly-2004" TYPE="STUDY">Eli Lilly 2004</LINK> and <LINK REF="STD-Newcomer-2008" TYPE="STUDY">Newcomer 2008</LINK>. The reasons for discontinuation were different in the two groups. It is therefore likely that these studies could be affected by attrition bias.</P>
<P>There were no numerical data on vital signs and concomitant medications in the <LINK REF="STD-Casey-2003" TYPE="STUDY">Casey 2003</LINK> study. In <LINK REF="STD-Newcomer-2008" TYPE="STUDY">Newcomer 2008</LINK> there was no data on vital signs, ECG and routine laboratory tests. In the <LINK REF="STD-Cookson-1986" TYPE="STUDY">Cookson 1986</LINK> study, even though methodology stated use of scales to measure mental state and side effects, there were no data reported in the results.</P>
</EXCLUSIONS>
<SELECTIVE_REPORTING MODIFIED="2010-10-29 03:27:15 +0100" MODIFIED_BY="[Empty name]">
<P>We were unable to identify any intentional underreporting of outcomes in the trials with the possible exception of the <LINK REF="STD-Eli-Lilly-2004" TYPE="STUDY">Eli Lilly 2004</LINK> study. Here a number of outcomes stated in the protocol were not reported or analysed. Authors state that this was because the protocol was terminated early as only 33% of the target enrolment was reached.</P>
</SELECTIVE_REPORTING>
<OTHER_BIAS_SOURCES MODIFIED="2010-10-29 03:27:41 +0100" MODIFIED_BY="[Empty name]">
<P>Our judgement on the risk of bias in the different studies is shown in <LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK>
</P>
<P>All but one trial (<LINK REF="STD-Cookson-1986" TYPE="STUDY">Cookson 1986</LINK>) were supported by interested drug industries. In the <LINK REF="STD-Eli-Lilly-2004" TYPE="STUDY">Eli Lilly 2004</LINK> trial, protocol was terminated early prior to breaking the blind.This would not cause bias for the primary outcome (time to relapse) but could affect some outcomes of interest like weight, BMI and metabolic syndrome. We estimated the risk of bias to be unclear or high in the studies, and this is likely to overestimate positive effects.</P>
</OTHER_BIAS_SOURCES>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2010-10-29 04:27:27 +0100" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="3">1. Switching - new antipsychotic regimen versus continuation on previous regimen: 1a. different depot from depot &#8211; medium term (1 year) </HEADING>
<P>(<LINK REF="SOF-01" TYPE="SOF">Summary of findings table 1</LINK>)</P>
<P>There was only one trial included in this group (<LINK REF="STD-Cookson-1986" TYPE="STUDY">Cookson 1986</LINK>, n = 19).</P>
<SUBSECTION>
<HEADING LEVEL="4">1.1 Weight: body weight</HEADING>
<P>There was no clear difference between groups with an average loss of 2.80 kg by the end of the year in those allocated to haloperidol decanoate but the trial was small (n = 19) and confidence intervals wide (-7.04 to 1.44).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">1.2 Global state</HEADING>
<P>We only found one proxy outcome for global state. Based on dose change (the need for extra medication) there was no clear difference between groups (1 RCT, n = 19, RR 0.18 CI 0.01 to 3.35). This finding was based on only two events.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">1.3 Mental state</HEADING>
<P>Two people were reported to have had a deterioration in mental state in the fluphenazine group but no significant difference between the two groups (1 RCT, n = 19, RR 0.18 CI 0.01 to 3.35).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">1.4 Loss to follow-up</HEADING>
<P>Two people left from the group switched to haloperidol decanoate (1 RCT, n = 19, RR 4.55 CI 0.25 to 83.70) and again there was no clear difference between the groups.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">2. Switching antipsychotic regimen versus continuation on previous regimen: 2. New atypical from olanzapine</HEADING>
<P>(<LINK REF="SOF-02" TYPE="SOF">Summary of findings table 2</LINK>)</P>
<SUBSECTION>
<HEADING LEVEL="4">2.1 Weight: 1. Body weight (kg)</HEADING>
<P>There was a statistically non-significant mean weight loss of 1.94 kg in people who were switched from olanzapine to other medications compared to those who remained on it (2 RCTs, n = 287, CI -3.97 to 0.08). The average weight loss when switched to aripiprazole was 3.21 kg but the confidence intervals were very wide (-9.03 to 2.61). The weight loss was 1.77 kg when switched to quetiapine (CI -3.93 to 0.39).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">2.2 Weight: 2a. BMI increase</HEADING>
<P>There was a significant difference in the number of patients who had clinically relevant BMI increase (more than 1 kg/m2) between aripiprazole (8 out of 88) and olanzapine (28 out of 85). This was based on 1 RCT (n = 173, RR 0.28, CI 0.13 to 0.57).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">2.3 Weight: 2b. BMI average change</HEADING>
<P>The average BMI was lower in the group switched to quetiapine compared to those who remained on olanzapine (1 RCT, n = 129 MD -0.52 CI -1.26 to 0.22), though this was not statistically significant.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">2.4 Waist circumference increase</HEADING>
<P>Even though fewer people who switched to aripiprazole had an increase in waist circumference compared to those remaining on olanzapine at the end of 16 weeks; the difference between the groups was not significant (1 RCT, n = 173, RR 0.92 CI 0.76 to 1.11).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">2.5 Physiological measures: 1a. Average changes</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">2.5.1 Change in cholesterol</HEADING>
<P>There was no difference in change in cholesterol levels in the two groups (1 RCT, n = 130, MD 0.02 CI -0.23 to 0.27).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">2.5.2 LDL levels</HEADING>
<P>There was no difference in LDL levels between the two groups. This was based on one RCT (n = 130, MD -0.02 CI -0.24 to 0.20).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">2.5.3 HDL levels</HEADING>
<P>With HDL levels as well there was no difference between the groups. There were no changes to the HDL levels in patients switched to quetiapine but HDL levels increased by 0.03 mmol/l in those remaining on olanzapine (1 RCT, n = 130 CI -0.05 to 0.11).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">2.5.4 Triglyceride levels</HEADING>
<P>No difference were observed between groups in triglyceride levels (1 RCT, n = 130, MD 0.13 CI-0.18 to 0.44).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">2.6 Physiological measures: 1b. Percentage changes</HEADING>
<P>Only percentage changes were reported in one RCT which looked at switching to aripiprazole and continuing on olanzapine.</P>
<SUBSECTION>
<HEADING LEVEL="5">2.6.1 Cholesterol</HEADING>
<P>There was a decrease in cholesterol by 9.5 % (n = 80 SE 1.5) in those switched to aripiprazole and 3.3% (n = 76 SE1.6) in those who remained on the olanzapine. The reported P value for this difference was 0.005.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">2.6.2 Triglycerides</HEADING>
<P>The triglycerides decreased by 14.46 % in those switched to aripiprazole (n = 54 SE 4.5 which was estimated from a graph) and increased by 5.3% in the group continuing on olanzapine (n = 61 SE 5.6- estimate from graph). The P value was 0.002.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">2.6.3 LDL levels</HEADING>
<P>The percentage decrease for low density lipoproteins was 11.2% (n = 80 SE 2.5) in the group switched to aripiprazole and it was 4.7% (n = 76 SE 2.7) in the group which stayed on olanzapine.The P value was 0.072.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">2.6.4 HDL levels</HEADING>
<P>The high density lipoproteins increased by 1.7% (n = 80 SE 1.8) in the aripiprazole group and decreased by 5.9% (n = 76 SE1.7) in the olanzapine group. The P value was 0.002.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">2.7 Physiological measures: 1c. Average changes - sugar</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">2.7.1 Fasting insulin level</HEADING>
<P>There were no difference between the two groups in the fasting insulin level. A very small decrease of 0.3 &#956;U/ml was noted in the aripiprazole group (1 RCT, n = 155 CI -4.04 to 3.44).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">2.7.2 Insulin levels</HEADING>
<P>No clear difference between groups in insulin levels.<BR/>There was an average increase in insulin of 8.63 in the quetiapine group but the confidence intervals were wide (1 RCT, n = 125 CI-8.82 to 26.08).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">2.7.3 c-peptide levels</HEADING>
<P>There was no difference between the two groups in the c-peptide levels. The aripiprazole group had a very small increase of 0.36ng/ml (1 RCT, n = 153 CI -0.19 to 0.91).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">2.7.4 Fasting blood glucose</HEADING>
<P>There was a significant difference between the groups in fasting blood glucose.The glucose levels decreased by an average of 2.53 mg/dL in the groups switched to aripiprazole and quetiapine from olanzapine (2 RCTs, n = 280 CI -2.94 to -2.11). Both the studies had used different units of measurement for glucose. Millimoles per litre were converted to milligrams per decilitre for analysis.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">2.8 Global state: 1a. Relapse</HEADING>
<P>There was no difference in the number of relapses in the group switched to quetiapine and in those continuing on olanzapine (1 RCT, n = 133 RR1.31 CI 0.55 to 3.11).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">2.9 Global state: 1b. Average change</HEADING>
<P>There was no difference between groups in the average changes to the CGI S scores at the end point of treatment in those switched to aripiprazole or those who stayed on olanzapine (1 RCT, n = 164, MD 0.29 CI -0.01 to 0.59).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">2.10 Mental state</HEADING>
<P>There was no difference between the groups in the average PANSS scores. The group switched to quetiapine had decreased by 3.63 in the PANSS score but the confidence intervals were wide (-10.31 to 3.05). The mean change in the PANSS scores were reported but the standard deviation had to be calculated from the reported P values.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">2.11 Loss to follow-up</HEADING>
<P>Data from the two studies in this group indicate that people are less likely to leave the study early if they are on olanzapine (RR 1.65 CI 1.21-2.25). In the study by <LINK REF="STD-Newcomer-2008" TYPE="STUDY">Newcomer 2008</LINK>, 36% dropped out in the aripiprazole group compared to 25% in the olanzapine group. In the <LINK REF="STD-Eli-Lilly-2004" TYPE="STUDY">Eli Lilly 2004</LINK> study, the drop-out was 56% in those switched to quetiapine and only 20% in those continuing on olanzapine. Leaving the study early data may be used as a proxy measure for the acceptability of treatment.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">2.12 Adverse events: 1. Serious adverse events</HEADING>
<P>There was no difference between the groups which switched medication (aripiprazole, quetiapine) and those who remained on olanzapine (2 RCTs, n = 305 RR 0.99 CI 0.48 to 2.07).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">2.13 Adverse events: 2. Treatment emergent adverse events</HEADING>
<P>There was no difference in the treatment-induced side effects between the groups which switched medication (aripiprazole, quetiapine) and those who remained on olanzapine (2 RCTs, n = 302 RR1.07 CI 0.92 to 1.24).The data were heterogenous (I<SUP>2</SUP> statistic 51%).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">3. Switching - techniques: to aripiprazole from previous regimen </HEADING>
<P>(<LINK REF="SOF-03" TYPE="SOF">Summary of findings table 3</LINK>)<BR/>Technique 1 = Immediate initiation + immediate discontinuation of current antipsychotic.</P>
<P>Technique 2 = immediate initiation + tapering of current antipsychotic.</P>
<P>Technique 3 = titrating switch medication upwards + tapering of current antipsychotic.</P>
<SUBSECTION>
<HEADING LEVEL="4">3.1 Weight: Gain (&#8805;7% from baseline)</HEADING>
<P>There was no clear difference between any different technique for antipsychotic switching on the outcome of weight gain (technique 1 versus 2: 1 RCT, n = 207, RR 0.61 CI 0.15 to 2.47; technique 1 versus 3: 1 RCT, n = 205, RR 0.99 CI<I> </I>0.20 to 4.79; technique 2 versus 3: 1 RCT, n = 206, RR1.63 CI 0.40 to 6.66).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">3.2 Global state: 1a. Average change (CGI-I, high = good)</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">3.2.1 Technique 1 versus technique 2</HEADING>
<P>There was no significant difference in the CGI I scores between the groups. The CGI I scores showed a decline of 0.14 in the group switched to aripiprazole immediately compared to the group where the dose of previous medication was gradually tapered (1 RCT, n = 203 CI -0.49 to 0.21).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">3.2.2 Technique 1 versus technique 3</HEADING>
<P>There was no significant difference in the CGI I scores between the groups. The CGI I scores showed a mean difference of 0.01 (1 RCT, n = 203 CI -0.34 to 0.36).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">3.2.3 Technique 2 versus technique 3</HEADING>
<P>We found no significant difference between groups with the CGI I scores. There was a very small increase of 0.15 in these scores in the first group (1 RCT, n = 204 CI -0.20 to 0.50).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">3.3 Global state: 1b. Average change (CGI-S decline = good)</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">3.3.1 Technique 1 versus technique 2</HEADING>
<P>We found no significant difference between groups with the CGI S scores. The immediate initiation and the immediate discontinuation group had a decrease of 0.06 compared to the second group (1 RCT, n = 203 CI-0.27 to 0.15).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">3.3.2 Technique 1 versus technique 3</HEADING>
<P>We found no significant difference between groups with the CGI S scores. There was a mean decrease of 0.04 in the immediate initiation and immediate discontinuation group (1 RCT, n = 203 CI -0.24 to 0.16).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">3.3.3 Technique 2 versus technique 3</HEADING>
<P>We found no significant difference between groups with the CGI S scores (mean difference 0.02, 1 RCT, n = 204 CI -0.20 to 0.24).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">3.4 Mental state: average change (PANSS, high decline = good)</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">3.4.1 Technique 1 versus technique 2</HEADING>
<P>We found no clear difference between the groups but the PANSS score was higher by 0.59 in the group where aripiprazole was initiated immediately and the current antipsychotic was discontinued without tapering (1 RCT, n = 197 CI -4.51 to 5.69).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">3.4.2 Technique 1 versus technique 3</HEADING>
<P>We found no difference between groups but the PANSS score showed an increase of 2.52 in the immediate initiation + immediate discontinuation group (1 RCT, n = 198 CI -2.39 to 7.43).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">3.4.3 Technique 2 versus technique 3</HEADING>
<P>There was no difference between the two groups. The group where the medication was initiated immediately and the current antipsychotic tapered and stopped indicated a small increase in the PANSS score by 1.93 (1 RCT, n = 201 CI -2.63 to 6.49).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">3.5 Loss to follow-up: 1a. Any reason</HEADING>
<P>Fewer people were lost to follow-up in the group comparing technique 2 to technique 3 compared to the other groups (1 RCT, n = 207 RR 0.82 CI 0.70 to 0.97).There was no difference between the other groups for this outcome (technique 1 vs 2 1 RCT, n = 208 RR 1.04 CI 0.87 to 1.26; technique1 vs 3 n = 207 RR 0.86 CI 0.73 to1.01).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">3.6 Loss to follow-up: 1b. Various specific reasons</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">3.6.1 to 3.6.5: Technique 1 versus technique 2</HEADING>
<P>We found no difference between the groups in the numbers lost to follow-up for different reasons including adverse events (1 RCT, n = 208, RR 0.60 CI 0.23 to 1.59), worsening of illness (1 RCT, n = 208, RR1.00 CI 0.43 to 2.30), withdrawal of consent (1 RCT, n = 208, RR 0.58 CI 0.24 to 1.42) non-compliance (1 RCT, n = 208, RR 4.00 CI 0.45 to 35.19) and other causes (1 RCT, n = 208, RR 2.50 CI 0.50 to 12.60).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">3.6.6 to 3.6.10: Technique 1 versus technique 3</HEADING>
<P>We found no difference between the groups in the numbers lost to follow-up for different reasons including adverse events (1 RCT, n = 207, RR 0.99 CI 0.33 to 2.97), worsening of illness (1 RCT, n = 207 RR 1.24 CI 0.51 to 3.01), withdrawal of consent (1 RCT, n = 207 RR 6.93 CI 0.87 to 55.35) non-compliance (1 RCT, n = 207 RR 3.96 CI 0.45 to 34.85) and other causes (1 RCT, n = 207, RR1.24 CI 0.34 to 4.48).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">3.6.11 to 3.6.15: Technique 2 versus technique 3</HEADING>
<P>The number that was lost to follow-up through withdrawing of consent was more in the immediate initiation + tapering of current antipsychotics group compared to the titrating switch medication upwards and tapering current antipsychotic group favouring the second group (1 RCT, n = 207, RR 11.88 CI 1.57 to 89.74). There was no difference between the groups for other reasons like adverse events (1 RCT, n = 207, RR 1.65 CI 0.62 to 4.38), worsening of illness (1 RCT, n = 207, RR 1.24 CI 0.51 to 3.01), non-compliance (1 RCT, n = 207, RR 0.99 CI 0.06 to 15.62) and other causes (1 RCT, n = 207, RR 0.50 CI 0.09 to 2.64).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">3.7 Adverse events: any event</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">3.7.1 Technique 1 versus technique 2</HEADING>
<P>There was no difference between groups (1 RCT, n = 207, RR 1.00 CI 0.91 to 1.10).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">3.7.2 Technique 1 versus technique 3</HEADING>
<P>There was no clear difference between the groups (1 RCT, n = 205, RR1.10 CI 0.98 to1.23).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">3.7.3 Technique 2 versus technique 3</HEADING>
<P>There was no clear difference between the groups (1 RCT, n = 208, RR 1.12 CI 1.00 to 1.26).</P>
</SUBSECTION>
</SUBSECTION>
</SUBSECTION>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION MODIFIED="2010-10-29 06:04:16 +0100" MODIFIED_BY="[Empty name]">
<SUMMARY_OF_RESULTS MODIFIED="2010-10-29 06:02:47 +0100" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="3">1. Switching - new antipsychotic regimen versus continuation on previous regimen: 1a. different depot from depot &#8211; medium term (1 year)</HEADING>
<P>Weight gain whilst taking depot medication is a real problem (<LINK REF="REF-Silverstone-1988" TYPE="REFERENCE">Silverstone 1988</LINK>) and we were surprised to only find one very small trial (<LINK REF="STD-Cookson-1986" TYPE="STUDY">Cookson 1986</LINK>, n = 19). From such a tiny trial no clear effects would be expected but this study shows that such studies are possible and, if larger, could be informative.</P>
<SUBSECTION>
<HEADING LEVEL="4">1.1 Body weight</HEADING>
<P>There was a mean weight loss of 1.3 kg in the switch group (S.D 3.8).The fluphenazine group showed a mean increase in weight by 1.5 kg (S.D 5.4) thereby favouring the intervention group (switch to haloperidol decanoate). Here the authors had not given measures of dispersion for the mean weight change. So the standard deviation had to be calculated using the individual weights from the graph provided.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">1.2 Global state</HEADING>
<P>No scales were used to assess global state in this study. Two out of nine patients in the control group (continuation on fluphenazine decanoate) deteriorated and needed extra medication. Using measurable scales would have made this finding more robust.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">1.3 Mental state</HEADING>
<P>No valid scales were used to assess mental state, but two people among the fluphenazine group were found to have a slight deterioration in their mental state. This may suggest that patients on haloperidol had a better outcome.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">1.4 Loss to follow-up</HEADING>
<P>Two people left the study early in the group switched to haloperidol decanoate, but there were no dropouts in the group continuing on fluphenazine decanoate. The reasons for drop-out were unclear. As drop-outs could be a proxy indicator of tolerability, this may indicate that people tolerate fluphenazine better than haloperidol. However, such a conclusion should be treated with caution given that the study group was very small.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">2 Switching antipsychotic regimen versus continuation on previous regimen: 2. new atypical from olanzapine</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">2.1 Weight: 1. Body weight (kg)</HEADING>
<P>Weight gain is a well-recognised side effect, particularly with the newer antipsychotics (<LINK REF="REF-Allison-1999" TYPE="REFERENCE">Allison 1999</LINK>; <LINK REF="REF-Casey-2004" TYPE="REFERENCE">Casey 2004</LINK>; <LINK REF="REF-Homel-2002" TYPE="REFERENCE">Homel 2002</LINK>). Two studies in this group showed a mean weight loss of 1.95 kg when switched to aripiprazole and quetiapine from olanzapine. The individual studies showed an average weight loss of 3.21 kg when switched to aripiprazole and 1.77 kg when switched to quetiapine. The sample size was small in both studies and they were medium term in duration.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">2.2 Weight: 2a. BMI increase</HEADING>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">2.3 Weight: 2b. BMI average change</HEADING>
<P>More individuals who switched to aripiprazole had a decrease in their BMI when compared to olanzapine.<B> </B>In the other study, average changes in BMI were reported, which showed people who switched to quetiapine had a higher mean decrease in BMI compared to those remaining on olanzapine. Overall, switching from olanzapine to either aripiprazole or quetiapine could decrease BMI. A meta-analysis would have provided more robust results, but this was impossible as changes in BMI were reported differently in the studies.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">2.4 Waist circumference increase</HEADING>
<P>Waist circumference did not show a difference between those switched to aripiprazole and those remaining on olanzapine but the graph revealed a trend favouring aripiprazole as fewer people in this group had an increase in their waist circumference. The study duration was only 16 weeks and longer term studies might show a greater effect. No other study in this review looked at waist circumference.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">2.5 Physiological measures: 1a. Average changes</HEADING>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">2.6 Physiological measures: 1b. Percentage changes</HEADING>
<P>One RCT did not show any significant difference in lipid levels between the groups switched to quetiapine and those remaining on olanzapine. The power of this study was small; the study was terminated early as they were not able to recruit enough participants (only 33% of the enrolment target as per their protocol). Larger and longer term studies may be needed to detect a real treatment effect.</P>
<P>The other study reported a significant percentage decrease in cholesterol and triglycerides and a significant increase in high-density lipoproteins when switched to aripiprazole, indicating that a switch to aripiprazole can lead to a favourable lipid profile. The change in low-density lipoproteins were not significant (P = 0.072) at the end of the study.<B> </B>They used percentage changes to report the findings instead of mean changes with measures of dispersion making it difficult to interpret the results.<B> </B>
</P>
<P>Although there were two studies in this group, meta-analysis was not possible as only one study gave a measure of central tendency (<LINK REF="STD-Newcomer-2008" TYPE="STUDY">Newcomer 2008</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">2.7 Physiological measures: 1c. Average changes - sugar</HEADING>
<P>Insulin levels did not show any difference in the groups switched to aripiprazole or quetiapine compared to continuing on olanzapine. The graph favoured a trend towards staying on olanzapine compared to switching to quetiapine.</P>
<P>Meta-analysis again was not possible as the two studies used different units of measurement. Using international units in studies would make interpreting the results of interventions more uniform and understandable.</P>
<P>Plasma glucose levels were also measured differently in the two studies in this group. Fortunately it was easy to convert millimoles per litre to milligrams per litre as both units are commonly used. Meta-analysis was then possible, which showed a definite advantage in levels of fasting glucose when switched to aripiprazole or quetiapine compared to remaining on olanzapine</P>
<P>One RCT did not show any difference between switching to aripiprazole and remaining on olanzapine in c-peptide levels.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">2.8 Global state: 1a. Relapse</HEADING>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">2.9 Global state: 1b. Average change (CGI-S high decline = good)</HEADING>
<P>Relapse as an indicator for change in global state was measured in only one study (continuing on olanzapine compared to switching to quetiapine). There was no difference between the groups. In the other study, where participants were switched to aripiprazole from olanzapine, there was no difference between the groups in average changes in the CGI-S scores, but the graph favoured olanzapine. Longer term studies again may indicate a differential effect.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">2.10 Mental state (PANSS, high decline = good)</HEADING>
<P>This was measured using a scale in one study (<LINK REF="STD-Eli-Lilly-2004" TYPE="STUDY">Eli Lilly 2004</LINK>). Based on the PANSS scores, there was no difference between the group switched to quetiapine and those remaining on olanzapine, although the graph tended to favour quetiapine. Only average changes in the scores were reported in the study but we were able to calculate the standard deviation needed for analysis from the reported P values. In the other study (<LINK REF="STD-Newcomer-2008" TYPE="STUDY">Newcomer 2008</LINK>), mental state was not an outcome so meta-analysis was not possible for this outcome.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">2.11 Loss to follow-up</HEADING>
<P>This showed a clear advantage for olanzapine as fewer people remaining on it dropped out. This could indicate that olanzapine has a better tolerability profile. Alternatively, the CATIE trials (<LINK REF="REF-CATIE-2006" TYPE="REFERENCE">CATIE 2006</LINK>) have shown that people continuing on their prior antipsychotics do remain in treatment longer than those switched to a new medication irrespective of the medications involved, so this finding may not be specific for olanzapine.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">2.12 Adverse events: 1. Serious adverse events</HEADING>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">2.13 Adverse events: 2. Treatment emergent adverse events</HEADING>
<P>We found no difference between the two groups in the serious adverse events or in any treatment induced adverse events.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">3. Switching - techniques: to aripiprazole from previous regiment</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">3.1 Weight gain ( (&#8805;7% from baseline)</HEADING>
<P>Technique 1 vs technique 2, technique 1 vs technique 3 and technique 2 vs technique 3.</P>
<P>There was no difference between the groups in weight gain.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">3.2 to 3.3 Global state (CGI Iand CGI S)</HEADING>
<P>Technique 1 versus technique 2, technique 1 versus technique 3 and technique 2 versus technique 3.</P>
<P>There was no difference in the global state as measured by the CGI-I and CGI-S scales when all groups were compared to each other showing that the method of switching medication does not affect this outcome.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">3.4 Mental state</HEADING>
<P>Technique 1 versus technique 2, technique 1 versus technique 3 and technique 2 versus technique 3.</P>
<P>Mental state as measured by PANSS did not show a difference between groups but the graph tended to favour the group where the switch medication was titrated upwards and current antipsychotic was tapered and stopped.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">3.5 Loss to follow-up: 1a. Any reason</HEADING>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">3.6 Loss to follow-up: 1b. Various specific reasons</HEADING>
<P>Technique 1 versus technique 2, technique 1 versus technique 3, technique 2 versus technique 3.</P>
<P>The number lost to follow-up for any reason was significantly less in technique 3 compared to technique 2 (1 RCT, n = 207 RR 0.82 CI 0.70 to 0.97). Looking at the breakdown of reasons reported for loss to follow-up, the number of people who withdrew consent was the least in the group switched using technique 3 and most in the group switched using technique 2. It is difficult to draw any inferences as the study does not give reasons for why consent was withdrawn. Hence it is difficult to attach any significance to this finding.</P>
<P>The loss to follow-up due to other reasons (adverse events, worsening of illness, non-compliance and other causes which included protocol violation, meeting withdrawal criteria) were the same in all other comparison groups.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">3.7 Adverse events - any event</HEADING>
<P>Technique 1 versus technique 2, technique 1 versus technique 3, technique 2 versus technique 3.<BR/>Even though there was no clear difference between the groups, the graph favoured the group where aripiprazole was titrated up and prior medication was tapered and stopped. There could be two reasons to explain this. There is a high likelihood of developing adverse side effects on abrupt introduction of an antipsychotic medication compared to gradual introduction and also the potential for a combined effect of two antipsychotics when the first medication is tapered and the switch medication initiated at the full dose.</P>
</SUBSECTION>
</SUBSECTION>
</SUMMARY_OF_RESULTS>
<APPLICABILITY_OF_FINDINGS MODIFIED="2010-10-29 06:04:16 +0100" MODIFIED_BY="[Empty name]">
<P>Weight gain and metabolic problems associated with the use of antipsychotic medications, particularly with atypical antipsychotic medications are a well recognised and disabling side effect. This can, in addition to the impact on health, affect compliance as well. As the potential to cause these problems varies between different medications, switching to one with a lesser potential for causing weight gain and metabolic problems could be a pragmatic approach to deal with the issue of weight gain.</P>
<P>Surprisingly studies looking at this very important clinical issue were scarce. We were able to include only three studies which primarily looked at switching of medications as an intervention to deal with this problem. The other study included in this review looked at other primary outcomes, but the study had some data on body weight before and after the switch.</P>
<P>As the studies reported data using different units of measure, it was difficult to conduct a meta-analysis which would have increased the applicability of the findings. Some of the relevant outcomes were reported with means only without giving standard deviations - this made some data unusable. Other possibly relevant studies also had to be excluded due the poor reporting of data.</P>
<P>The majority of the included studies were less than a year in duration. As this review was primarily looking at weight gain and metabolic issues which are likely to be affected over a longer period of time, studies of longer duration would be more informative.</P>
<P>Except for one study (<LINK REF="STD-Cookson-1986" TYPE="STUDY">Cookson 1986</LINK>), the studies had a reasonable number of participants. The drop-out rate was high (around 30%) in all studies except one (<LINK REF="STD-Cookson-1986" TYPE="STUDY">Cookson 1986</LINK>). Although last observation was carried forwards in all the included studies, the large drop-out rate casts some doubt on applying these findings in routine clinical settings.</P>
<P>Only one study was a multicentre, multinational study (<LINK REF="STD-Newcomer-2008" TYPE="STUDY">Newcomer 2008</LINK>). One study was conducted in the United Kingdom and the other in the United States of America. The setting of the other study is described as multicentre, but in one country which is likely to be in the western hemisphere. This should be taken into account when applying these findings in different care settings.</P>
<P>In all the studies, the majority of the participants were males, making the applicability of these findings to females less clear.</P>
</APPLICABILITY_OF_FINDINGS>
<QUALITY_OF_EVIDENCE MODIFIED="2010-10-29 04:54:07 +0100" MODIFIED_BY="[Empty name]">
<P>The outcomes, if reported using similar units of measurement, would have increased the quality of evidence, particularly as the number of studies that could be included in this review was very limited. One study reported outcomes using percentage changes which made it difficult to include the study for meta-analysis.</P>
<P>Three of the four included studies were sponsored by interested pharmaceutical industries, which can be a potential source of bias.</P>
</QUALITY_OF_EVIDENCE>
<POTENTIAL_BIASES MODIFIED="2010-07-22 19:07:04 +0100" MODIFIED_BY="[Empty name]">
<P>One study was incomplete and the findings were available from the pharmaceutical company&#8217;s trial information. The findings may have been different if the study was completed. There may well be other unpublished studies or reports not included in the review which could lead to a reporting and publishing bias.</P>
<P>We do acknowledge that the electronic search for this review was undertaken some time ago and that new trials may have become available since 2007. We are also aware that <LINK REF="STD-Eli-Lilly-2004" TYPE="STUDY">Eli Lilly 2004</LINK> and <LINK REF="STD-Newcomer-2008" TYPE="STUDY">Newcomer 2008</LINK> both became known to us after the electronic search date and that inclusion of these trials does not reflect the results of the systematic search. This is a potential bias in the review. We plan for a swift update search to bring this review fully in line with current trials.</P>
<P>In addition we have stated in the protocol that we would undertake independent data extraction from selected studies. This did not happen because of time constraints so there is a potential for bias to be operating at this juncture.</P>
</POTENTIAL_BIASES>
<AGREEMENT MODIFIED="2010-07-22 19:07:29 +0100" MODIFIED_BY="[Empty name]">
<P>This review replicated the finding from a previous study (<LINK REF="REF-Remington-2005" TYPE="REFERENCE">Remington 2005</LINK>) that using different switching strategies does not have a significant impact on the outcome of weight gain.</P>
</AGREEMENT>
</DISCUSSION>
<CONCLUSIONS MODIFIED="2013-01-22 14:53:34 +0000" MODIFIED_BY="[Empty name]">
<IMPLICATIONS_PRACTICE MODIFIED="2013-01-22 14:53:34 +0000" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="3">1. For people with schizophrenia</HEADING>
<P>Schizophrenia is a serious mental health problem needing long-term care and treatment with antipsychotic medications. Drawbacks of the traditional antipsychotics were the extra-pyramidal side effects, limiting its prescription and affecting compliance. The newer antipsychotic medications were a relief to both prescribers and patients in this regard. It has now become evident that the long-term use of some of these medications can affect physical health adversely (weight gain and metabolic problems). Although this review could include only a few studies, the results show that switching to a medication which is less likely to cause weight gain and metabolic problems will reduce body weight, BMI and provide other health benefits. Switching medication may be a pragmatic approach to reduce these side effects without affecting compliance and efficacy.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">2. For clinicians</HEADING>
<P>Clinicians face a dilemma between efficacy and side effects when prescribing anti-psychotic medication to patients with schizophrenia, as they are related to a higher risk of obesity and diabetes. A reasonable approach to manage side effects is to consider making appropriate changes to medications. Even though this review was limited by the small number of studies and poor reporting in the studies, the findings indicate that switching medications to one with the least potential for weight gain and metabolic side effects could be effective in addressing these adverse events. Switching should be done cautiously, as the potential for relapse may be higher and also people may be more likely to drop out of treatment after switching, as indicated by the <LINK REF="STD-Eli-Lilly-2004" TYPE="STUDY">Eli Lilly 2004</LINK> study.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">3. For policy makers</HEADING>
<P>Obesity and metabolic problems are serious health hazards which have direct and indirect implications on healthcare resources. The newer antipsychotic prescriptions have increased dramatically and people on these medications risk having these side effects. In the current climate of finite resources, appropriate interventions to tackle these side effects have to be a priority for healthcare providers. There may also be medico-legal implications which can affect individual practitioners and healthcare providers. Switching might be more cost-effective than pharmacological or behavioral interventions in preventing and treating obesity in this population. However, none of the included studies had any data on service or economic outcomes. Studies reporting these outcomes will make it easier for organisations to review the cost effectiveness of their services.</P>
<P>4. Note: the 167 citations in the awaiting classification section of the review may alter the conclusions of the review once assessed.<BR/>
</P>
</SUBSECTION>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH MODIFIED="2010-10-29 04:59:58 +0100" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="3">1. General</HEADING>
<P>Though obesity and metabolic problems associated with atypical antipsychotic use are well recognised and many clinicians do attempt to switch medications to minimise these effects, studies looking at this were surprisingly limited. To support clinical practice, more robust evidence is needed. Multicentre trials in different countries, with a comparison group or groups, and a good number of participants over an adequate length of time would provide more applicable evidence. Poor reporting of data made some of the outcome measures unusable and some possible relevant trials had to be excluded. Having internationally recognised standards of measuring outcomes and reporting would help in summing up and analysing the data, which would enhance the strength of evidence.</P>
<P>Including economic analyses in the trials would help clinicians, service providers and policy makers in making cost effective choices.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">2. Specific</HEADING>
<P>No studies looked at patient satisfaction or their engagement with the services, which is an important outcome in such trials.<BR/>There were no studies which compared other methods like lifestyle modifications in controlling weight and metabolic problems in patients on antipsychotic medications.</P>
<P>One suggested outline for a trial is presented in <LINK REF="TBL-01" TYPE="TABLE">Table 1</LINK>
</P>
</SUBSECTION>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS MODIFIED="2010-10-29 05:00:11 +0100" MODIFIED_BY="[Empty name]">
<P>We thank Judith Wright and Samantha Roberts for their assistance in the literature searches. We would also like to thank Clive Adams from the Cochrane Schizophrenia Group for his help and support throughout this review. We fully acknowledge the use of standard text in the Methods section of this review. The Cochrane Schizophrenia Group uses a template for protocols that are adapted for each review. Guy Faulkner was supported by a publication grant from the Ontario Mental Health Foundation.</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST>
<P>None known.</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS MODIFIED="2010-07-22 17:45:31 +0100" MODIFIED_BY="[Empty name]">
<P>Anitha Mukundan - Instigated the review, participated in literature searches, selected studies, extracted data and wrote report.</P>
<P>Guy Faulkner - participated in literature searches, selected studies, and contributed to the report.</P>
<P>Tony Cohn - participated in literature searches, selected studies.</P>
<P>Gary Remington - participated in literature searches, selected studies.</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF MODIFIED="2010-10-29 05:02:38 +0100" MODIFIED_BY="[Empty name]">
<P>a. We did not calculate NNT as per protocol, as largely this has been superseded by the use of the Summary of Findings table.</P>
<P>Also, this review has been ongoing for some time. During this period Summary of Findings tables became possible. We did not pre-state outcomes that should be the focus of this table, but have chosen these post-hoc: These outcomes were chosen after the data were known.</P>
<P>1. Weight - no clinically important change in body weight (as defined by individual studies)</P>
<P>2. Change in BMI</P>
<P>3. Presence of metabolic syndrome</P>
<P>4. Global state - no clinically important change in global state (as defined by individual studies)</P>
<P>5. Mental state (with particular reference to the positive and negative symptoms of schizophrenia) - no clinically important change in general mental state</P>
<P>6. Averse effects - serious</P>
<P>7. Satisfaction with treatment - recipient of care not satisfied with treatment</P>
<P>b. In the protocol, a random-effects model was planned to be used for measuring treatment effect but the review has used a fixed-effect model and the reasons for this have been detailed under data synthesis. The Methods section also had to be modified slightly to accommodate the requirements of RevMan 5 (published protocol used RevMan 4).</P>
<P>c. The original protocol states that we were to work independently in extraction of data. Time constraints precluded this so these data were only extracted by AM - but the review has been checked by GF, TC and GR.</P>
</PRO_REV_DIFF>
<PUBLIC_NOTES/>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2013-01-22 14:49:26 +0000" MODIFIED_BY="[Empty name]">
<STUDIES MODIFIED="2013-01-22 14:49:26 +0000" MODIFIED_BY="[Empty name]">
<INCLUDED_STUDIES MODIFIED="2010-11-29 14:06:19 +0000" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Casey-2003" MODIFIED="2010-09-27 13:51:33 +0100" MODIFIED_BY="[Empty name]" NAME="Casey 2003" YEAR="2003">
<REFERENCE MODIFIED="2010-09-27 13:51:23 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Casey DE, Carson WH, Saha AR, Liebeskind A, Ali MW, Jody D, Ingenito GG</AU>
<TI>Switching patients to aripiprazole from other antipsychotic agents: A multicenter randomized study</TI>
<SO>Psychopharmacology</SO>
<YR>2003</YR>
<VL>166</VL>
<NO>4</NO>
<PG>391-9</PG>
<IDENTIFIERS MODIFIED="2010-09-27 13:51:18 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE MODIFIED="2010-09-27 13:51:33 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Medori R, Gharbia N, Saha A, Ali M, Stock E, Ingenito G</AU>
<TI>Switching to aripiprazole monotherapy</TI>
<SO>Journal of the European College of Neuropsychopharmacology</SO>
<YR>2002</YR>
<VL>12</VL>
<NO>Suppl 3</NO>
<PG>S292</PG>
<IDENTIFIERS MODIFIED="2010-09-27 13:51:33 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Cookson-1986" MODIFIED="2010-09-27 13:51:59 +0100" MODIFIED_BY="[Empty name]" NAME="Cookson 1986" YEAR="1986">
<REFERENCE MODIFIED="2010-09-27 13:51:59 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cookson JC, Kennedy NM, Gribbon D</AU>
<TI>Weight gain and prolactin levels in patients on long-term antipsychotic medication: a double-blind comparative trial of haloperidol decanoate and fluphenazine decanoate</TI>
<SO>International Clinical Psychopharmacology</SO>
<YR>1986</YR>
<VL>1</VL>
<NO>Suppl 1</NO>
<PG>41-51</PG>
<IDENTIFIERS MODIFIED="2010-09-27 13:51:59 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2010-09-27 13:51:59 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="3549879"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Eli-Lilly-2004" MODIFIED="2010-04-20 15:21:45 +0100" MODIFIED_BY="[Empty name]" NAME="Eli Lilly 2004" YEAR="2004">
<REFERENCE PRIMARY="NO" TYPE="OTHER">
<AU>Eli Lilly and Company</AU>
<TI>Comparison of continuing olanzapine to switching to quetiapine in overweight or obese patients with schizophrenia and schizoaffective disorder</TI>
<SO>Eli Lilly and Company Clinical Trial Registry</SO>
<YR>2004</YR>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="8894"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Newcomer-2008" MODIFIED="2010-11-29 14:06:19 +0000" MODIFIED_BY="[Empty name]" NAME="Newcomer 2008" YEAR="2007">
<REFERENCE MODIFIED="2009-11-16 15:51:01 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Newcomer JW, Campos JA, Marcus RN, Breder C, Berman RM, Kerselaers W, L'Italien GJ, Nys M, Carson WH, McQuade RD</AU>
<TI>A multicenter, randomized, double-blind study of the effects of aripiprazole in overweight subjects with schizophrenia or schizoaffective disorder switched from olanzapine</TI>
<SO>Journal of Clinical Psychiatry</SO>
<YR>2008</YR>
<VL>69</VL>
<NO>7</NO>
<PG>1046-56</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2010-11-29 14:06:19 +0000" MODIFIED_BY="[Empty name]"/>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES MODIFIED="2010-09-27 14:18:53 +0100" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Alvarez-2006" MODIFIED="2010-09-27 13:53:05 +0100" MODIFIED_BY="[Empty name]" NAME="Alvarez 2006" YEAR="2006">
<REFERENCE MODIFIED="2010-09-27 13:52:42 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Alvarez E, Ciudad A, Olivares JM, Bousono M, Gomez JC</AU>
<TI>A randomized, 1-year follow-up study of olanzapine and risperidone in the treatment of negative symptoms in outpatients with schizophrenia</TI>
<SO>Journal of Clinical Psychopharmacology</SO>
<YR>2006</YR>
<VL>26</VL>
<NO>3</NO>
<PG>238-49</PG>
<CY>United States</CY>
<IDENTIFIERS MODIFIED="2010-09-27 13:52:42 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2010-09-27 13:52:42 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="16702888"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2010-09-27 13:53:05 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ciudad A, Olivares JM, Bouson~o M, Gomez JC, Alvarez E</AU>
<TI>Improvement in social functioning in outpatients with schizophrenia with prominent negative symptoms treated with olanzapine or risperidone in a 1 year randomized, open-label trial</TI>
<SO>Progress in Neuro-Psychopharmacology and Biological Psychiatry</SO>
<YR>2006</YR>
<VL>30</VL>
<NO>8</NO>
<PG>1515-22</PG>
<CY>United States</CY>
<IDENTIFIERS MODIFIED="2010-09-27 13:53:05 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2010-09-27 13:53:05 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="16820255"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Brar-2005" MODIFIED="2010-09-27 13:53:25 +0100" MODIFIED_BY="[Empty name]" NAME="Brar 2005" YEAR="2005">
<REFERENCE MODIFIED="2010-09-27 13:53:25 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Brar JS, Ganguli R, Pandina G, Turkoz I, Berry S, Mahmoud R</AU>
<TI>Effects of behavioral therapy on weight loss in overweight and obese patients with schizophrenia or schizoaffective disorder</TI>
<SO>Journal of Clinical Psychiatry</SO>
<YR>2005</YR>
<VL>66</VL>
<NO>2</NO>
<PG>205-12</PG>
<CY>United States</CY>
<IDENTIFIERS MODIFIED="2010-09-27 13:53:25 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2010-09-27 13:53:25 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="15705006"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-CATIE-_x002d_-Phase-I-_x002d_-2006" MODIFIED="2010-09-27 13:53:47 +0100" MODIFIED_BY="[Empty name]" NAME="CATIE - Phase I - 2006" YEAR="2006">
<REFERENCE MODIFIED="2010-09-27 13:53:32 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Keefe R, Perkins DO, Davis S, Davis CE, Lebowitz B, Hsiao J</AU>
<TI>CATIE trial results</TI>
<SO>Journal of the European College of Neuropsychopharmacology</SO>
<YR>2006</YR>
<VL>16</VL>
<NO>Suppl 4</NO>
<PG>S184</PG>
<IDENTIFIERS MODIFIED="2010-09-27 13:53:32 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE MODIFIED="2010-09-27 13:53:47 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Stroup TS</AU>
<TI>Comparison of ziprasidone versus other atypical drugs in prospectively defined, unresponsive patients</TI>
<SO>Proceedings of the 159th Annual Meeting of the American Psychiatric Association; 2006 May 20-25, Toronto, Canada</SO>
<YR>2006</YR>
<IDENTIFIERS MODIFIED="2010-09-27 13:53:47 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-CATIE-_x002d_-Phase-II-_x002d_-2006" MODIFIED="2010-09-27 13:54:19 +0100" MODIFIED_BY="[Empty name]" NAME="CATIE - Phase II - 2006" YEAR="2006">
<REFERENCE MODIFIED="2010-09-27 13:54:19 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Stroup TS, Lieberman JA, McEvoy JP, Swartz MS, Davis SM, Rosenheck RA, Perkins DO, Keefe RS, Davis CE, Severe J, Hsiao JK</AU>
<TI>Effectiveness of olanzapine, quetiapine, risperidone, and ziprasidone in patients with chronic schizophrenia following discontinuation of a previous atypical antipsychotic</TI>
<SO>American Journal of Psychiatry</SO>
<YR>2006</YR>
<VL>163</VL>
<NO>4</NO>
<PG>611-22</PG>
<IDENTIFIERS MODIFIED="2010-09-27 13:54:19 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2010-09-27 13:54:19 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="16585435"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Chrzanowski-2006" MODIFIED="2010-09-27 13:54:40 +0100" MODIFIED_BY="[Empty name]" NAME="Chrzanowski 2006" YEAR="2006">
<REFERENCE MODIFIED="2010-09-27 13:54:40 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Chrzanowski WK, Marcus RN, Torbeyns A, Nyilas M, McQuade RD</AU>
<TI>Effectiveness of long-term aripiprazole therapy in patients with acutely relapsing or chronic, stable schizophrenia: a 52-week, open-label comparison with olanzapine</TI>
<SO>Psychopharmacology</SO>
<YR>2006</YR>
<VL>189</VL>
<NO>2</NO>
<PG>259-66</PG>
<CY>Germany</CY>
<IDENTIFIERS MODIFIED="2010-09-27 13:54:40 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2010-09-27 13:54:40 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="17058105"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Covell-1999" MODIFIED="2010-09-27 13:55:00 +0100" MODIFIED_BY="[Empty name]" NAME="Covell 1999" YEAR="1999">
<REFERENCE MODIFIED="2010-09-27 13:55:00 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Covell NH, Essock SM</AU>
<TI>Weight with clozapine as compared to conventional antipsychotic medications</TI>
<SO>Schizophrenia Research</SO>
<YR>1999</YR>
<VL>1, 2 &amp; 3</VL>
<PG>354</PG>
<IDENTIFIERS MODIFIED="2010-09-27 13:55:00 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ducate-2003" MODIFIED="2010-09-27 13:55:17 +0100" MODIFIED_BY="[Empty name]" NAME="Ducate 2003" YEAR="2003">
<REFERENCE MODIFIED="2010-09-27 13:55:17 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Ducate S, Pondrom M, Thivierge S, Patel H</AU>
<TI>Switching to ziprasidone in correctional inpatients: Efficacy and safety</TI>
<SO>Proceedings of the 156th Annual meeting of the American Psychiatric Association; 2003 May 17-22; San Francisco, California USA</SO>
<YR>2003</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2009-09-22 13:22:38 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="OTHER" VALUE=""/>
</IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Emsley-2005" MODIFIED="2010-09-27 13:55:28 +0100" MODIFIED_BY="[Empty name]" NAME="Emsley 2005" YEAR="2005">
<REFERENCE MODIFIED="2010-09-27 13:55:28 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Emsley R, Turner HJ, Schronen J, Botha K, Smit R, Oosthuizen PP</AU>
<TI>Effects of quetiapine and haloperidol on body mass index and glycaemic control: a long-term, randomized, controlled trial</TI>
<SO>International Journal of Neuropsychopharmacology</SO>
<YR>2005</YR>
<VL>8</VL>
<NO>2</NO>
<PG>175-82</PG>
<CY>England</CY>
<IDENTIFIERS MODIFIED="2010-09-27 13:55:28 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Godleski-2003" MODIFIED="2010-09-27 13:55:37 +0100" MODIFIED_BY="[Empty name]" NAME="Godleski 2003" YEAR="2003">
<REFERENCE MODIFIED="2010-09-27 13:55:37 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Godleski LS, Goldsmith LJ, Vieweg WV, Zettwoch NC, Stikovac DM, Lewis SJ</AU>
<TI>Switching from depot antipsychotic drugs to olanzapine in patients with chronic schizophrenia</TI>
<SO>Journal of Clinical Psychiatry</SO>
<YR>2003</YR>
<VL>64</VL>
<NO>2</NO>
<PG>119-22</PG>
<EN>2</EN>
<CY>United States of America</CY>
<IDENTIFIERS MODIFIED="2010-09-27 13:55:37 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Horacek-2004" MODIFIED="2010-09-27 13:57:13 +0100" MODIFIED_BY="[Empty name]" NAME="Horacek 2004" YEAR="2004">
<REFERENCE MODIFIED="2010-09-27 13:55:48 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Horacek J, Janu L, Seifertova D</AU>
<TI>The effect of quetiapine on different domains of cognition and negative symptoms in schizophrenia</TI>
<SO>Schizophrenia Research</SO>
<YR>2004</YR>
<VL>67</VL>
<NO>1</NO>
<PG>168</PG>
<IDENTIFIERS MODIFIED="2010-09-27 13:55:48 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE MODIFIED="2010-09-27 13:57:13 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Horacek J, Seifertova D, Janu L, Petranova T</AU>
<TI>The effect of quetiapine on different domains of cognition and negative symptoms in schizophrenia</TI>
<SO>Proceedings of the 12th Biennial Winter Workshop on Schizophrenia; 2004 Feb 7-13; Davos, Switzerland</SO>
<YR>2004</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Irwin-2003" MODIFIED="2010-09-27 13:57:23 +0100" MODIFIED_BY="[Empty name]" NAME="Irwin 2003" YEAR="2003">
<REFERENCE MODIFIED="2010-09-27 13:57:23 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Irwin J, Moses SN, Edgar JC, Torres F, Thoma RJ, Hanlon FM, Anderson L, Weisend MP, Miller GA, Tuason VB, Canive JM</AU>
<TI>Olanzapine and risperidone in schizophrenia: a randomized double-blind crossover study</TI>
<SO>Schizophrenia Research</SO>
<YR>2003</YR>
<VL>60</VL>
<NO>1</NO>
<PG>286</PG>
<IDENTIFIERS MODIFIED="2010-09-27 13:57:23 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kane-2004" MODIFIED="2010-09-27 13:57:31 +0100" MODIFIED_BY="[Empty name]" NAME="Kane 2004" YEAR="2004">
<REFERENCE MODIFIED="2010-09-27 13:57:31 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kane JM, Conley RR, Keith SJ, Nasrallah HA, Turner M</AU>
<TI>Guidelines for the use of long-acting injectable atypical antipsychotics</TI>
<SO>Journal of Clinical Psychiatry</SO>
<YR>2004</YR>
<VL>65</VL>
<NO>1</NO>
<PG>120-31</PG>
<IDENTIFIERS MODIFIED="2010-09-27 13:57:31 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kane-2005" MODIFIED="2010-09-27 13:57:48 +0100" MODIFIED_BY="[Empty name]" NAME="Kane 2005" YEAR="2005">
<REFERENCE MODIFIED="2010-09-27 13:57:48 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Kane JM</AU>
<TI>Ziprasidone&#8217;s long-term efficacy in treatment- refractory schizophrenia</TI>
<SO>Proceedings of the 158th Annual Meeting of the American Psychiatric Association; 2005 May 21-26; Atlanta, Georgia, USA</SO>
<YR>2005</YR>
<IDENTIFIERS MODIFIED="2010-09-27 13:57:48 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kane-2007" MODIFIED="2010-09-27 13:58:00 +0100" MODIFIED_BY="[Empty name]" NAME="Kane 2007" YEAR="2007">
<REFERENCE MODIFIED="2010-09-27 13:58:00 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kane JM, Meltzer HY, Carson WH Jr, McQuade RD, Marcus RN, Sanchez R, Aripiprazole Study Group</AU>
<TI>Aripiprazole for treatment-resistant schizophrenia: results of a multicenter, randomized, double-blind, comparison study versus perphenazine</TI>
<SO>Journal of Clinical Psychiatry</SO>
<YR>2007</YR>
<VL>68</VL>
<NO>2</NO>
<PG>213-23</PG>
<IDENTIFIERS MODIFIED="2010-09-27 13:57:57 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kelly-2003" MODIFIED="2010-09-27 13:58:15 +0100" MODIFIED_BY="[Empty name]" NAME="Kelly 2003" YEAR="2003">
<REFERENCE MODIFIED="2010-09-27 13:58:15 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kelly DL, Conley RR, Richardson CM, Tamminga CA, Carpenter Jr WT</AU>
<TI>Adverse effects and laboratory parameters of high-dose olanzapine vs. clozapine in treatment-resistant schizophrenia</TI>
<SO>Annals of Clinical Psychiatry</SO>
<YR>2003</YR>
<VL>15</VL>
<NO>3-4</NO>
<PG>181-6</PG>
<IDENTIFIERS MODIFIED="2010-09-27 13:58:15 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kim-2007" MODIFIED="2010-09-27 13:58:30 +0100" MODIFIED_BY="[Empty name]" NAME="Kim 2007" YEAR="2007">
<REFERENCE MODIFIED="2010-09-27 13:58:30 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kim SH, Ivanova O, Abbasi FA, Lamendola CA, Reaven GM</AU>
<TI>Metabolic impact of switching antipsychotic therapy to aripiprazole after weight gain</TI>
<SO>Journal of Clinical Psychopharmacology</SO>
<YR>2007</YR>
<VL>27</VL>
<NO>4</NO>
<PG>365-68</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2009-11-15 14:15:32 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-11-15 14:15:32 +0000" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE="Study identified by one of the reviewers"/>
</IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kinon-2000" MODIFIED="2010-09-27 13:59:49 +0100" MODIFIED_BY="[Empty name]" NAME="Kinon 2000" YEAR="2000">
<REFERENCE MODIFIED="2010-09-27 13:58:52 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Kinon B, Basson B, Malcolm S, Breier A</AU>
<TI>Strategies for switching from conventional antipsychotic drugs or risperidone to olanzapine</TI>
<SO>Proceedings of the 39th Annual Meeting of the New Clinical Drug Evaluation Unit; 1999 Jun 1-4; Boca Raton, Florida, USA</SO>
<YR>1999</YR>
<IDENTIFIERS MODIFIED="2010-09-27 13:58:52 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE MODIFIED="2010-09-27 13:59:09 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Kinon B, Breier A, Malcolm S, Basson B</AU>
<TI>Strategies for switching from conventional antipsychotic drugs or risperidone to olanzapine</TI>
<SO>11th World Congress of Psychiatry; 1999 Aug 6-11; Hamburg, Germany</SO>
<YR>1999</YR>
<IDENTIFIERS MODIFIED="2010-09-27 13:59:02 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE MODIFIED="2010-09-27 13:59:31 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Kinon BJ, Basson B, Wang J, Malcolm SK, Stauffer VL</AU>
<TI>Rapid reduction in hyperprolactinemia upon switching treatment to olanzapine from conventional antipsychotic drugs or risperidone</TI>
<SO>Proceedings of the 40th Annual Meeting of the New Clinical Drug Evaluation Unit; 2000 May 30 - Jun 2; Boca Raton, Florida, USA</SO>
<YR>2000</YR>
<IDENTIFIERS MODIFIED="2010-09-27 13:59:31 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE MODIFIED="2010-09-27 13:59:42 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kinon BJ, Basson BR, Gilmore JA, Malcolm S, Stauffer VL</AU>
<TI>Strategies for switching from conventional antipsychotic drugs or risperidone to olanzapine</TI>
<SO>Journal of Clinical Psychiatry</SO>
<YR>2000</YR>
<VL>61</VL>
<NO>11</NO>
<PG>833-40</PG>
<IDENTIFIERS MODIFIED="2010-09-27 13:59:42 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE MODIFIED="2010-09-27 13:59:49 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Kinon BJ, Basson BR, Wang J, Malcolm SK, Stauffer VL</AU>
<TI>Rapid reduction in hyperprolactinemia</TI>
<SO>Proceedings of the 153rd Annual Meeting of the American Psychiatric Association; 2000 May 13-18; Chicago, Illinois, USA</SO>
<YR>2000</YR>
<IDENTIFIERS MODIFIED="2010-09-27 13:59:49 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kinon-2004" MODIFIED="2010-09-27 14:00:11 +0100" MODIFIED_BY="[Empty name]" NAME="Kinon 2004" YEAR="2004">
<REFERENCE MODIFIED="2010-09-27 14:00:01 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kinon BJ, Ahl J, Liu-Seifert H, Maguire GA</AU>
<TI>Improvement in hyperprolactinemia and reproductive co-morbidities in patients with schizophrenia switched from conventional antipsychotics or risperidone to olanzapine</TI>
<SO>Psychoneuroendocrinology</SO>
<YR>2006</YR>
<VL>31</VL>
<NO>5</NO>
<PG>577-88</PG>
<IDENTIFIERS MODIFIED="2010-09-27 14:00:01 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE MODIFIED="2010-09-27 14:00:11 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kinon BJ, Liu-Seifert H, Ahl J, Ahmed S, Baker RW</AU>
<TI>Longitudinal effect of olanzapine on fasting serum lipids: a randomized, prospective, 4-month study</TI>
<SO>Annals of the New York Academy of Sciences</SO>
<YR>2004</YR>
<VL>1032</VL>
<PG>295-6</PG>
<IDENTIFIERS MODIFIED="2010-09-27 14:00:11 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lee-2002" MODIFIED="2010-09-27 14:00:30 +0100" MODIFIED_BY="[Empty name]" NAME="Lee 2002" YEAR="2002">
<REFERENCE MODIFIED="2010-09-27 14:00:30 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lee CT, Conde BJ, Mazlan M, Visanuyothin T, Wang A, Wong MM, Walker DJ, Roychowdhury SM, Wang H, Tran PV</AU>
<TI>Switching to olanzapine from previous antipsychotics: a regional collaborative multicenter trial assessing 2 switching techniques in Asia Pacific</TI>
<SO>Journal of Clinical Psychiatry</SO>
<YR>2002</YR>
<VL>63</VL>
<NO>7</NO>
<PG>569-76</PG>
<IDENTIFIERS MODIFIED="2010-09-27 14:00:30 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Nasrallah-2001" MODIFIED="2010-09-27 14:00:50 +0100" MODIFIED_BY="[Empty name]" NAME="Nasrallah 2001" YEAR="2001">
<REFERENCE MODIFIED="2009-11-18 08:48:23 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Emsley RA, Bailey P, Jones AM, Raniwalla J</AU>
<TI>Efficacy of quetiapine fumarate in partial responders</TI>
<SO>Proceedings of the 152nd Annual Meeting of the American Psychiatric Association; 1999 May 15-20; Washington DC, USA</SO>
<YR>1999</YR>
<IDENTIFIERS MODIFIED="2009-11-18 08:48:23 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE MODIFIED="2010-09-27 14:00:43 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Nasrallah HA, Rennie P, Altman C</AU>
<TI>Patterns of response in patients with schizophrenia partially responsive to fluphenazine and switched to quetiapine or haloperidol</TI>
<SO>European Neuropsychopharmacology</SO>
<YR>2001</YR>
<VL>11</VL>
<NO>3</NO>
<PG>262</PG>
<IDENTIFIERS MODIFIED="2010-09-27 14:00:43 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE MODIFIED="2010-09-27 14:00:50 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Weiden PJ, Ashworth P</AU>
<TI>Switching from fluphenazine to quetiapine ameliorates extrapyramidal symptoms and neuroendocrine side effects in patients with schizophrenia</TI>
<SO>European Neuropsychopharmacology</SO>
<YR>2001</YR>
<VL>11</VL>
<NO>3</NO>
<PG>262</PG>
<IDENTIFIERS MODIFIED="2010-09-27 14:00:50 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Newcomer-2006" MODIFIED="2010-09-27 14:03:28 +0100" MODIFIED_BY="[Empty name]" NAME="Newcomer 2006" YEAR="2006">
<REFERENCE MODIFIED="2010-09-27 14:03:28 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Newcomer JW, L'Italien G, Vester-Blokland, McQuade RD, Carson WH, Marcus RN</AU>
<TI>Improvement of non-hdl cholesterol levels among patients randomized to aripiprazole versus olanzapine</TI>
<SO>Proceedings of the 159th Annual Meeting of the American Psychiatric Association; 2006 May 20-25, Toronto, Canada</SO>
<YR>2006</YR>
<IDENTIFIERS MODIFIED="2010-09-27 14:03:28 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-O_x0027_Halloran--2003" MODIFIED="2010-09-27 14:05:09 +0100" MODIFIED_BY="[Empty name]" NAME="O'Halloran  2003" YEAR="2003">
<REFERENCE MODIFIED="2010-09-27 14:05:09 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="CONFERENCE_PROC">
<AU>O'Halloran RA, Hodge A, Kim K-S, Habil MHH, Barahona A, Vargas MT, Woodbury MA</AU>
<TI>Comparison of olanzapine and quetiapine treatments for schizophrenia</TI>
<SO>Proceedings of the 156th Annual Meeting of the American Psychiatric Association; 2003 May 17-22; San Francisco, California, USA</SO>
<YR>2003</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Robinson-2000" MODIFIED="2010-09-27 14:05:21 +0100" MODIFIED_BY="[Empty name]" NAME="Robinson 2000" YEAR="2000">
<REFERENCE MODIFIED="2010-09-27 14:05:21 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Robinson G, Wheeler A, Byrd J, Visser S</AU>
<TI>Longer-term effects of switching from typical to atypical antipsychotics in patients with stable schizophrenia</TI>
<SO>Journal of the European College of Neuropsychopharmacology</SO>
<YR>2000</YR>
<VL>10</VL>
<NO>Suppl 3</NO>
<PG>S291</PG>
<IDENTIFIERS MODIFIED="2010-09-27 14:05:21 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-STAR-trials-2006" MODIFIED="2010-09-27 14:06:46 +0100" MODIFIED_BY="[Empty name]" NAME="STAR trials 2006" YEAR="2006">
<REFERENCE MODIFIED="2010-09-27 14:05:39 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Corey-Lisle P, Kolotkin RL, Crosby RD, L'Italien G</AU>
<TI>Changes in weight and weight-related quality of life in aripiprazole versus standard-of-care treatment</TI>
<SO>Proceedings of the 14th Congress of the Association of European Psychiatrists; 2006 March 4-8; Nice, France</SO>
<YR>2006</YR>
<IDENTIFIERS MODIFIED="2010-09-27 14:05:39 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE MODIFIED="2010-09-27 14:06:02 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Hanssens L, L'Italien G, Marcus RN, McQuade RD, Carson WH, Beuzen J-N</AU>
<TI>Reasons for switching among community-treated schizophrenic patients in a naturalistic setting: schizophrenia trial of aripiprazole: STAR study</TI>
<SO>Proceedings of the 159th Annual Meeting of the American Psychiatric Association; 2006 May 20-25, Toronto, Canada</SO>
<YR>2006</YR>
<IDENTIFIERS MODIFIED="2010-09-27 14:06:02 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE MODIFIED="2010-09-27 14:06:18 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>L'Italien G, Hanssens L, Marcus RN, McQuade RD, Carson WH, Beuzen J-N</AU>
<TI>Metabolic effects of aripiprazole versus standard of care (the STAR trial)</TI>
<SO>Proceedings of the 159th Annual Meeting of the American Psychiatric Association; 2006 May 20-25, Toronto, Canada</SO>
<YR>2006</YR>
<IDENTIFIERS MODIFIED="2010-09-27 14:06:18 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE MODIFIED="2010-09-27 14:06:36 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>McQuade R, Radhakrishnan M, Stock E, Lam S, Iwamoto T, Pans M, Carson W</AU>
<TI>Investigator assessment of clinical parameters after initiating aripiprazole therapy</TI>
<SO>Proceedings of the 158th Annual Meeting of the American Psychiatric Association; 2005 May 21-26, Atlanta, GA, USA</SO>
<YR>2005</YR>
<IDENTIFIERS MODIFIED="2010-09-27 14:06:36 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE MODIFIED="2010-09-27 14:06:46 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Riera L, Hu R, Stock E, Nyilas M, Torbeyns a, Borian F, Gentile K, Carson W, Iwamoto T</AU>
<TI>Broad effectiveness trial with aripiprazole</TI>
<SO>Schizophrenia Research</SO>
<YR>2004</YR>
<VL>67</VL>
<NO>1</NO>
<PG>157</PG>
<IDENTIFIERS MODIFIED="2010-09-27 14:06:46 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE MODIFIED="2009-12-01 16:08:28 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Riera L, Tandon R, Stock EG, Kujawa MJ, Torbeyns AF, Borian FE, McQuade RD, IwamotoT</AU>
<TI>Broad Effectiveness Trial with Aripiprazole</TI>
<SO>Proceedings of the Twelfth Biennial Winter Workshop on Schizophrenia; 2004 Feb 7-13; Davos Switzerland</SO>
<YR>2004</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Su-2005" MODIFIED="2010-09-27 14:07:02 +0100" MODIFIED_BY="[Empty name]" NAME="Su 2005" YEAR="2005">
<REFERENCE MODIFIED="2010-09-27 14:07:02 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Su K-P,Wu P-L, Pariante CM</AU>
<TI>A crossover study on lipid and weight changes associated with olanzapine and risperidone</TI>
<SO>Psychopharmacology</SO>
<YR>2005</YR>
<VL>183</VL>
<PG>383-86</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2008-09-11 13:13:32 +0100" MODIFIED_BY="[Empty name]"/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wang-2006" MODIFIED="2010-09-27 14:07:15 +0100" MODIFIED_BY="[Empty name]" NAME="Wang 2006" YEAR="2006">
<REFERENCE MODIFIED="2010-09-27 14:07:15 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wang X, Savage R, Borisov A, Rosenberg J, Woolwine B, Tucker M, May R, Feldman J, Nemeroff CB, Miller AH</AU>
<TI>Efficacy of risperidone versus olanzapine in patients with schizophrenia previously on chronic conventional antipsychotic therapy: a switch study</TI>
<SO>Journal of Psychiatric Research</SO>
<YR>2006</YR>
<VL>40</VL>
<NO>7</NO>
<PG>669-76</PG>
<IDENTIFIERS MODIFIED="2010-09-27 14:07:15 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Weiden-Daniel-2003" MODIFIED="2010-09-27 14:18:34 +0100" MODIFIED_BY="[Empty name]" NAME="Weiden Daniel 2003" YEAR="2003">
<REFERENCE MODIFIED="2010-09-27 14:07:47 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cutler NR, Simpson G, Weiden PJ, Romanoa SJ</AU>
<TI>Effects of oral ziprasidone on weight and serum lipids in patients with schizophrenia</TI>
<SO>Schizophrenia Research</SO>
<YR>2002</YR>
<VL>53</VL>
<NO>3 Suppl 1</NO>
<PG>160</PG>
<IDENTIFIERS MODIFIED="2010-09-27 14:07:47 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE MODIFIED="2010-09-27 14:08:12 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Daniel D, Lieberman J, Birnbaum R</AU>
<TI>Improvement in markers of health status 6 weeks after switching from olanzapine to ziprasidone</TI>
<SO>Journal of the European College of Neuropsychopharmacology</SO>
<YR>1999</YR>
<VL>9</VL>
<PG>S265</PG>
<IDENTIFIERS MODIFIED="2010-09-27 14:08:12 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE MODIFIED="2010-09-27 14:08:23 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Daniel D, Stern R, Kramer T</AU>
<TI>Switching from olanzapine to ziprasidone: an interim analysis of a 6-week study</TI>
<SO>Journal of the European College of Neuropsychopharmacology</SO>
<YR>1999</YR>
<VL>9</VL>
<PG>S265</PG>
<IDENTIFIERS MODIFIED="2010-09-27 14:08:23 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE MODIFIED="2010-09-27 14:07:36 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Daniel DG, Lieberman JA, Birnbaum RJ</AU>
<TI>Improvement in markers of health status six weeks after switching from olanzapine to ziprasidone</TI>
<SO>Proceedings of the 152nd Annual Meeting of the American Psychiatric Association; 1999 May 15-20; Washington DC, USA</SO>
<YR>1999</YR>
<IDENTIFIERS MODIFIED="2009-11-18 08:50:39 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE MODIFIED="2009-11-18 08:51:04 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Daniel DG, Weiden P, O'Sullivan RL</AU>
<TI>Improvement in indices of health status in outpatients with schizophrenia following a switch to ziprasidone from conventional antipsychotics, olanzapine or risperidone</TI>
<SO>Proceedings of the 153rd Annual Meeting of the American Psychiatric Association; 2000 May 13-18; Chicago, Illinois, USA</SO>
<YR>2000</YR>
<IDENTIFIERS MODIFIED="2009-11-18 08:50:48 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE MODIFIED="2010-09-27 14:16:57 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Daniel DG, Weiden P, O'Sullivan RL</AU>
<TI>Improvement in indices of health status in outpatients with schizophrenia following a switch to ziprasidone from conventional antipsychotics, olanzapine or risperidone</TI>
<SO>Proceedings of the 155th Annual Meeting of the American Psychiatric Association; 2002 May 18-23; Philadelphia, Pennsylvania, USA</SO>
<YR>2002</YR>
<IDENTIFIERS MODIFIED="2010-09-27 14:16:49 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE MODIFIED="2010-09-27 14:17:14 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Romano SJ, Cutler NR, Weiden PJ, Simpson GM</AU>
<TI>Ziprasidone's effects on weight and lipids in patients with schizophrenia</TI>
<SO>Proceedings of the 155th Annual Meeting of the American Psychiatric Association; 2002 May 18-23; Philadelphia, Pennsylvania, USA</SO>
<YR>2002</YR>
<IDENTIFIERS MODIFIED="2010-09-27 14:17:14 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE MODIFIED="2010-09-27 14:17:23 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Weiden P, Simpson G, Kramer T, Harvey P</AU>
<TI>Switching from conventional antipsychotics to ziprasidone: an interim analysis of a 6-week study</TI>
<SO>Journal of the European College of Neuropsychopharmacology</SO>
<YR>1999</YR>
<VL>9</VL>
<PG>S264</PG>
<IDENTIFIERS MODIFIED="2010-09-27 14:17:23 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE MODIFIED="2010-09-27 14:17:32 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Weiden PJ, Daniel DD, Simpson G, Romano SJ</AU>
<TI>Improvement in indices of health status In outpatients with schizophrenia switched to ziprasidone</TI>
<SO>Journal of Clinical Psychopharmacology</SO>
<YR>2003</YR>
<VL>23</VL>
<NO>6</NO>
<PG>595-600</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2010-09-27 14:17:59 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Weiden PJ, Kramer TAM, Harvey PD, Powchik P, Simpson GM; Switch Study Group</AU>
<TI>Switching from conventional antipsychotics to ziprasidone: an interim analysis of a six-week study</TI>
<SO>Proceedings of the 152nd Annual Meeting of the American Psychiatric Association; 1999 May 15-20; Washington DC, USA</SO>
<YR>1999</YR>
<IDENTIFIERS MODIFIED="2010-09-27 14:17:59 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE MODIFIED="2009-11-18 08:57:13 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Weiden PJ, Newcomer JW, Loebel AD, Yang R, Lebovitz HE</AU>
<TI>Long-term changes in weight and plasma lipids during maintenance treatment with ziprasidone</TI>
<SO>Neuropsychopharmacology</SO>
<YR>2008</YR>
<VL>33</VL>
<NO>5</NO>
<PG>985-94</PG>
<IDENTIFIERS MODIFIED="2009-11-18 08:51:13 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE MODIFIED="2010-09-27 14:18:18 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Weiden PJ, Simpson GM, Potkin SG, O'Sullivan RL</AU>
<TI>Effectiveness of switching to ziprasidone for stable but symptomatic outpatients with schizophrenia</TI>
<SO>Journal of Clinical Psychiatry</SO>
<YR>2003</YR>
<VL>64</VL>
<PG>580-8</PG>
<IDENTIFIERS MODIFIED="2010-09-27 14:18:18 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE MODIFIED="2010-09-27 14:18:34 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Weiden PJ, Weiden PJ, Daniel DG, Simpson G, Romano SJ</AU>
<TI>Health status in stable patients switched to ziprasidone</TI>
<SO>Proceedings of the 12th World Congress of Psychiatry; 2002 Aug 24-29; Yokohama, Japan</SO>
<YR>2002</YR>
<IDENTIFIERS MODIFIED="2010-09-27 14:18:34 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="Additional article after the original search"/>
</IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Zhang-2004" MODIFIED="2010-09-27 14:18:53 +0100" MODIFIED_BY="[Empty name]" NAME="Zhang 2004" YEAR="2004">
<REFERENCE MODIFIED="2009-11-18 08:58:20 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kim SH, Ivanova O, Abbasi FA, Lamendola CA, Reaven GM, Glick ID</AU>
<TI>Metabolic impact of switching antipsychotic therapy to aripiprazole after weight gain</TI>
<SO>Journal of Clinical Psychopharmacology</SO>
<YR>2007</YR>
<VL>27</VL>
<NO>4</NO>
<PG>365-68 </PG>
<IDENTIFIERS MODIFIED="2009-11-18 08:57:25 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE MODIFIED="2010-09-27 14:18:53 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Zhang Y, Zhang G, Tang Q</AU>
<TI>A control study of weight gain caused by chlorpromazine, clozapine and sulpiride in schizophrenics</TI>
<SO>Journal of Clinical Psychosomatic Diseases</SO>
<YR>2004</YR>
<VL>10</VL>
<NO>3</NO>
<PG>182-84</PG>
<IDENTIFIERS MODIFIED="2010-09-27 14:18:53 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES MODIFIED="2013-01-22 14:49:26 +0000" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Ader-2008" MODIFIED="2013-01-17 14:25:01 +0000" MODIFIED_BY="[Empty name]" NAME="Ader 2008" YEAR="2008">
<REFERENCE MODIFIED="2013-01-17 14:25:01 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ader M, Garvey WT, Phillips LS, Nemeroff CB, Gharabawi G, Mahmoud R, et al</AU>
<TI>Ethnic heterogeneity in glucoregulatory function during treatment with atypical antipsychotics in patients with schizophrenia</TI>
<SO>Journal of Psychiatric Research</SO>
<YR>2008</YR>
<VL>42</VL>
<NO>13</NO>
<PG>1076-85</PG>
<CY>United Kingdom</CY>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Alvarez_x002d_Jimenez-2010" MODIFIED="2013-01-21 15:46:09 +0000" MODIFIED_BY="[Empty name]" NAME="Alvarez-Jimenez 2010" YEAR="2010">
<REFERENCE MODIFIED="2013-01-21 15:46:09 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Alvarez-Jimenez M, Martinez-Garcia O, Perez-Iglesias R, Ramirez ML, Vazquez-Barquero JL, Crespo-Facorro B</AU>
<TI>Prevention of antipsychotic-induced weight gain with early behavioural intervention in first-episode psychosis: 2-year results of a randomized controlled trial</TI>
<SO>Schizophrenia Research</SO>
<YR>2010</YR>
<VL>116</VL>
<NO>1</NO>
<PG>16-9</PG>
<CY>Netherlands</CY>
<IDENTIFIERS MODIFIED="2013-01-17 14:24:59 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="MEDLINE" VALUE="19896336"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Arman-2008" MODIFIED="2013-01-21 15:46:52 +0000" MODIFIED_BY="[Empty name]" NAME="Arman 2008" YEAR="2008">
<REFERENCE MODIFIED="2013-01-21 15:46:52 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Arman S, Sadramely MR, Nadi M, Koleini N</AU>
<TI>A randomized, double-blind, placebo-controlled trial of metformin treatment for weight gain associated with initiation of risperidone in children and adolescents</TI>
<SO>Saudi Medical Journal</SO>
<YR>2008</YR>
<VL>29</VL>
<NO>8</NO>
<PG>1130-4</PG>
<CY>Saudi Arabia</CY>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Attux-2011" MODIFIED="2013-01-21 15:59:11 +0000" MODIFIED_BY="[Empty name]" NAME="Attux 2011" YEAR="2011">
<REFERENCE MODIFIED="2013-01-21 15:59:11 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Attux C, Martini LC, Reis AF, Bressan RA</AU>
<TI>A non-pharmacological intervention for weight gain management for patients with schizophrenia: Multicentric, randomized controlled clinical trial-are modest effects important for challenging outcomes</TI>
<SO>Schizophrenia Bulletin</SO>
<YR>2011</YR>
<VL>1</VL>
<PG>294</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ballon-2011" MODIFIED="2013-01-21 16:10:04 +0000" MODIFIED_BY="[Empty name]" NAME="Ballon 2011" YEAR="2011">
<REFERENCE MODIFIED="2013-01-21 16:10:04 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ballon JS, Hamer RM, Catellier DJ, Stewart D, Lavange L, Golden L, et al</AU>
<TI>Metformin and impaired glucose tolerance in overweight persons with schizophrenia</TI>
<SO>Schizophrenia Bulletin</SO>
<YR>2011</YR>
<VL>1</VL>
<PG>24</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Baptista-2008" MODIFIED="2013-01-21 15:46:52 +0000" MODIFIED_BY="[Empty name]" NAME="Baptista 2008" YEAR="2008">
<REFERENCE MODIFIED="2013-01-21 15:46:52 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Baptista T, Uzcategui E, Rangel N, El Fakih Y, Galeazzi T, Beaulieu S, et al</AU>
<TI>Metformin plus sibutramine for olanzapine-associated weight gain and metabolic dysfunction in schizophrenia: a 12-week double-blind, placebo-controlled pilot study</TI>
<SO>Psychiatry Research</SO>
<YR>2008</YR>
<VL>159</VL>
<NO>1-2</NO>
<PG>250-3</PG>
<CY>Ireland</CY>
<IDENTIFIERS MODIFIED="2013-01-17 14:24:59 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="MEDLINE" VALUE="18374423"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Baptista-2009" MODIFIED="2013-01-21 15:46:52 +0000" MODIFIED_BY="[Empty name]" NAME="Baptista 2009" YEAR="2009">
<REFERENCE MODIFIED="2013-01-21 15:46:52 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Baptista T, Rangel N, El Fakih Y, Uzcategui E, Galeazzi T, Beaulieu S, et al</AU>
<TI>Rosiglitazone in the assistance of metabolic control during olanzapine administration in schizophrenia: a pilot double-blind, placebo-controlled, 12-week trial</TI>
<SO>Pharmacopsychiatry</SO>
<YR>2009</YR>
<VL>42</VL>
<NO>1</NO>
<PG>14-9</PG>
<CY>Germany</CY>
<IDENTIFIERS MODIFIED="2013-01-17 14:24:59 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="MEDLINE" VALUE="19153941"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Barak-2010" MODIFIED="2013-01-21 15:59:57 +0000" MODIFIED_BY="[Empty name]" NAME="Barak 2010" YEAR="2010">
<REFERENCE MODIFIED="2013-01-21 15:59:57 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Barak N</AU>
<TI>Betahistine safely mitigates olanzapine adverse: Role of histamine receptors in weight gain and somnolence</TI>
<SO>Proceedings of the 163rd Annual Meeting of the American Psychiatric Association; 2010 May 22-26; New Orleans, LA</SO>
<YR>2010</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Biedermann-2010" MODIFIED="2013-01-21 15:46:52 +0000" MODIFIED_BY="[Empty name]" NAME="Biedermann 2010" YEAR="2010">
<REFERENCE MODIFIED="2013-01-21 15:46:52 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Biedermann F, Lechleitner M, Hofer A, Huber R, Futhmu NE-, Ebenbichler C, et al</AU>
<TI>Sibutramine in the treatment of antipsychotic-induces weight gain: a randomized, placebo-controlled double-blind study</TI>
<SO>Schizophrenia Research</SO>
<YR>2010</YR>
<VL>117</VL>
<NO>2-3</NO>
<PG>260-1</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bobo-2011" MODIFIED="2013-01-17 14:25:01 +0000" MODIFIED_BY="[Empty name]" NAME="Bobo 2011" YEAR="2011">
<REFERENCE MODIFIED="2013-01-17 14:25:01 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bobo WV, Bonaccorso S, Jayathilake K, Meltzer HY</AU>
<TI>Prediction of long-term metabolic effects of olanzapine and risperidone treatment from baseline body mass index in schizophrenia and bipolar disorder</TI>
<SO>Psychiatry Research</SO>
<YR>2011</YR>
<VL>189</VL>
<NO>2</NO>
<PG>200-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Borba-2011" MODIFIED="2013-01-21 16:00:16 +0000" MODIFIED_BY="[Empty name]" NAME="Borba 2011" YEAR="2011">
<REFERENCE MODIFIED="2013-01-21 16:00:16 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Borba CPC, Fan X, Copeland PM, Paiva A, Freudenreich O, Henderson DC</AU>
<TI>placebo-controlled pilot study of ramelteon for adiposity and lipids in patients with schizophrenia</TI>
<SO>Journal of Clinical Psychopharmacology</SO>
<YR>2011</YR>
<VL>31</VL>
<NO>5</NO>
<PG>653-8</PG>
<IDENTIFIERS MODIFIED="2013-01-21 16:00:16 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Brown-2011" MODIFIED="2013-01-21 15:46:09 +0000" MODIFIED_BY="[Empty name]" NAME="Brown 2011" YEAR="2011">
<REFERENCE MODIFIED="2013-01-21 15:46:09 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Brown C, Goetz J, Hamera E</AU>
<TI>Weight loss intervention for people with serious mental illness: A randomized controlled trial of the renew program</TI>
<SO>Psychiatric Services</SO>
<YR>2011</YR>
<VL>62</VL>
<NO>7</NO>
<PG>800-2</PG>
<IDENTIFIERS MODIFIED="2013-01-17 14:24:59 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="MEDLINE" VALUE="21724796"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Buchanan-2011" MODIFIED="2013-01-21 16:00:31 +0000" MODIFIED_BY="[Empty name]" NAME="Buchanan 2011" YEAR="2011">
<REFERENCE MODIFIED="2013-01-21 16:00:31 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Buchanan RW, Boggs DL, Conley RR, Gorelick DA, McMahon RP, Gold JM, et al</AU>
<TI>A pilot study evaluating the cognitive effects of rimonabant in people with schizophrenia</TI>
<SO>Proceedings of the 50th Annual Meeting of the American College of Neuropsychopharmacology; 2011 Dec 4-8; Waikoloa, Hawaii</SO>
<YR>2011</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bustillo-2003" MODIFIED="2013-01-17 14:25:01 +0000" MODIFIED_BY="[Empty name]" NAME="Bustillo 2003" YEAR="2003">
<REFERENCE MODIFIED="2013-01-17 14:25:01 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bustillo JR, Lauriello J, Parker K, Hammond R, Rowland L, Bogenschutz M, et al</AU>
<TI>Treatment of weight gain with fluoxetine in olanzapine-treated schizophrenic outpatients</TI>
<SO>Neuropsychopharmacology</SO>
<YR>2003</YR>
<VL>28</VL>
<NO>3</NO>
<PG>527-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Capra-2009" MODIFIED="2013-01-17 14:25:01 +0000" MODIFIED_BY="[Empty name]" NAME="Capra 2009" YEAR="2009">
<REFERENCE MODIFIED="2013-01-17 14:25:01 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Capra C</AU>
<TI>Effects of a nutritional supplement on weight gain after initiation of atypical antipsychotic medication in early psychosis patients</TI>
<SO>Australian New Zealand Clinical Trials Registry</SO>
<YR>2009</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Carina-2009" MODIFIED="2013-01-17 14:25:01 +0000" MODIFIED_BY="[Empty name]" NAME="Carina 2009" YEAR="2009">
<REFERENCE MODIFIED="2013-01-17 14:25:01 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Carina C</AU>
<TI>Effects of a nutritional supplement on weight gain after initiation of atypical antipsychotic medication in early psychosis patients</TI>
<SO>Australian New Zealand Clinical Trials Registry</SO>
<YR>2009</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Citrome-2009" MODIFIED="2013-01-17 14:25:01 +0000" MODIFIED_BY="[Empty name]" NAME="Citrome 2009" YEAR="2009">
<REFERENCE MODIFIED="2013-01-17 14:25:01 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Citrome L, Stauffer VL, Chen L, Kinon BJ, Kurtz DL, Jacobson JG, et al</AU>
<TI>Olanzapine plasma concentrations after treatment with 10, 20, and 40 mg/d in patients with schizophrenia: an analysis of correlations with efficacy, weight gain, and prolactin concentration</TI>
<SO>Journal of Clinical Psychopharmacology</SO>
<YR>2009</YR>
<VL>29</VL>
<NO>3</NO>
<PG>278-83</PG>
<CY>United States</CY>
<IDENTIFIERS MODIFIED="2013-01-17 14:24:59 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="MEDLINE" VALUE="19440083"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Czobor-2002" MODIFIED="2013-01-17 14:25:01 +0000" MODIFIED_BY="[Empty name]" NAME="Czobor 2002" YEAR="2002">
<REFERENCE MODIFIED="2013-01-17 14:25:01 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Czobor P, Volavka J, Sheitman B, Lindenmayer J-P, Citrome L, McEnvoy J, et al</AU>
<TI>Antipsychotic-induced weight gain and therapeutic response: a differential association</TI>
<SO>Journal of Clinical Psychopharmacology</SO>
<YR>2002</YR>
<VL>22</VL>
<NO>3</NO>
<PG>244-51</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Day_x002d_Poulsen-2009" MODIFIED="2013-01-21 15:46:09 +0000" MODIFIED_BY="[Empty name]" NAME="Day-Poulsen 2009" YEAR="2009">
<REFERENCE MODIFIED="2013-01-21 15:46:09 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Day-Poulsen H, Thomas P, Loze JY, Fortan L, Kerselaers W, Owen R</AU>
<TI>A 16-week, multicentre, randomized, open-label study assessing effects of aripiprazole versus other atypicals for schizophrenia patients with metabolic syndrome</TI>
<SO>Proceedings of the 17th European Psychiatric Association, EPA Congress; 2009 Jan 24-28; Lisbon Portugal</SO>
<YR>2009</YR>
<VL>24</VL>
<PG>S1181</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Deberdt-2004" MODIFIED="2013-01-17 14:25:01 +0000" MODIFIED_BY="[Empty name]" NAME="Deberdt 2004" YEAR="2004">
<REFERENCE MODIFIED="2013-01-17 14:25:01 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Deberdt W, Trzaskoma Q, Carlson C, Bymaster F, Winokur A, Floris M</AU>
<TI>Amantadine for weight gain in olanzapine-treated patients</TI>
<SO>Proceedings of the Thematic Conference of the World Psychiatric Association on "Treatments in Psychiatry: An Update"; 2004 Nov 10-13; Florence, Italy</SO>
<YR>2004</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Deberdt-2008" MODIFIED="2013-01-21 15:46:35 +0000" MODIFIED_BY="[Empty name]" NAME="Deberdt 2008" YEAR="2008">
<REFERENCE MODIFIED="2013-01-21 15:46:35 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Deberdt W, Lipkovich I, Heinloth AN, Liu L, Kollack-Walker S, Edwards SE, et al</AU>
<TI>double-blind, randomized trial comparing efficacy and safety of continuing olanzapine versus switching to quetiapine in overweight or obese patients with schizophrenia or schizoaffective disorder</TI>
<SO>Therapeutics and Clinical Risk Management</SO>
<YR>2008</YR>
<VL>4</VL>
<NO>4</NO>
<PG>713-20</PG>
<CY>New Zealand</CY>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-De-Lima-2007" MODIFIED="2013-01-21 15:46:09 +0000" MODIFIED_BY="[Empty name]" NAME="De Lima 2007" YEAR="2007">
<REFERENCE MODIFIED="2013-01-21 15:46:09 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>De Lima MS, Oliveira AV, Dossenbach M, Mari JJ</AU>
<TI>Weight gain associated with olanzapine and first generation antipsychotics: results from a pragmatic randomized controlled trial</TI>
<SO>European Neuropsychopharmacology</SO>
<YR>2007</YR>
<VL>17</VL>
<NO>Suppl 4</NO>
<PG>S467</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Detke-2008" MODIFIED="2013-01-21 16:00:59 +0000" MODIFIED_BY="[Empty name]" NAME="Detke 2008" YEAR="2008">
<REFERENCE MODIFIED="2013-01-21 16:00:59 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Detke H, McDonnell D, Andersen S, Watson S</AU>
<TI>Olanzapine long-acting injection in patients with schizophrenia at risk of relapse: 12-week switching data</TI>
<SO>European Neuropsychopharmacology</SO>
<YR>2008</YR>
<VL>18</VL>
<PG>S435</PG>
<IDENTIFIERS MODIFIED="2013-01-21 16:00:59 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Eli-2007" MODIFIED="2013-01-17 14:25:01 +0000" MODIFIED_BY="[Empty name]" NAME="Eli 2007" YEAR="2007">
<REFERENCE MODIFIED="2013-01-17 14:25:01 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Eli LandC</AU>
<TI>The comparison of efficacy and safety of continuing olanzapine to switching to quetiapine in overweight or obese patients with schizophrenia or schizoaffective disorder</TI>
<SO>Eli Lilly and Company Clinical Trial Registry</SO>
<YR>2007</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Faries-2008" MODIFIED="2013-01-21 15:46:09 +0000" MODIFIED_BY="[Empty name]" NAME="Faries 2008" YEAR="2008">
<REFERENCE MODIFIED="2013-01-21 15:46:09 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Faries DE, Ascher-Svanum H, Nyhuis AW, Kinon BJ</AU>
<TI>Switching from risperidone to olanzapine in a one-year, randomized, open-label effectiveness study of schizophrenia</TI>
<SO>Current Medical Research and Opinion</SO>
<YR>2008</YR>
<VL>24</VL>
<NO>5</NO>
<PG>1399-405</PG>
<CY>England</CY>
<IDENTIFIERS MODIFIED="2013-01-17 14:24:59 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="MEDLINE" VALUE="18397549"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Firestone-2011" MODIFIED="2013-01-17 14:25:01 +0000" MODIFIED_BY="[Empty name]" NAME="Firestone 2011" YEAR="2011">
<REFERENCE MODIFIED="2013-01-17 14:25:01 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Firestone L, Ames D, Aragaki DLR, Erickson Z, Kim H, Lee C, et al</AU>
<TI>Efficacy and safety of a lifestyle balance program for antipsychotic medication associated obesity</TI>
<SO>PM and R</SO>
<YR>2011</YR>
<VL>3</VL>
<NO>10</NO>
<PG>S258-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Fleischhacker-2008" MODIFIED="2013-01-21 16:01:18 +0000" MODIFIED_BY="[Empty name]" NAME="Fleischhacker 2008" YEAR="2008">
<REFERENCE MODIFIED="2013-01-21 16:01:18 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Fleischhacker W, Heikkinen ME, Olie JP, Dewaele P, McQuade R, Hennicken D, et al</AU>
<TI>Long-term effect on weight of aripiprazole-clozapine in schizophrenia patients with suboptimal response on clozapine</TI>
<SO>European Neuropsychopharmacology</SO>
<YR>2008</YR>
<VL>18</VL>
<PG>S447</PG>
<IDENTIFIERS MODIFIED="2013-01-21 16:01:18 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Fleischhacker-2008a" MODIFIED="2013-01-21 15:46:35 +0000" MODIFIED_BY="[Empty name]" NAME="Fleischhacker 2008a" YEAR="2008">
<REFERENCE MODIFIED="2013-01-21 15:46:35 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Fleischhacker WW, Heikkinen ME, Olie JP, Landsberg W, Dewaele P, McQuade R, et al</AU>
<TI>Weight change on aripiprazole-clozapine combination in schizophrenic patients with weight gain and suboptimal response on clozapine: 16-week double-blind study</TI>
<SO>European Psychiatry</SO>
<YR>2008</YR>
<VL>23</VL>
<PG>S114-S5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Fleischhacker-2010" MODIFIED="2013-01-21 16:01:31 +0000" MODIFIED_BY="[Empty name]" NAME="Fleischhacker 2010" YEAR="2010">
<REFERENCE MODIFIED="2013-01-21 16:01:31 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Fleischhacker WW, Heikkinen ME, Olie J-P, Landsberg W, Dewaele P, McQuade RD, et al</AU>
<TI>Effects of adjunctive treatment with aripiprazole on body weight and clinical efficacy in schizophrenia patients treated with clozapine: A randomized, double-blind, placebo-controlled trial</TI>
<SO>International Journal of Neuropsychopharmacology</SO>
<YR>2010</YR>
<VL>13</VL>
<NO>8</NO>
<PG>1115-25</PG>
<IDENTIFIERS MODIFIED="2013-01-21 16:01:31 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ganguli-2008" MODIFIED="2013-01-21 15:46:09 +0000" MODIFIED_BY="[Empty name]" NAME="Ganguli 2008" YEAR="2008">
<REFERENCE MODIFIED="2013-01-21 15:46:09 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ganguli R, Brar JS, Mahmoud R, Berry SA, Pandina GJ</AU>
<TI>Assessment of strategies for switching patients from olanzapine to risperidone: a randomized, open-label, rater-blinded study</TI>
<SO>BMC Medicine</SO>
<YR>2008</YR>
<VL>6</VL>
<PG>17</PG>
<CY>England</CY>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ganguli-2011" MODIFIED="2013-01-22 14:41:10 +0000" MODIFIED_BY="[Empty name]" NAME="Ganguli 2011" YEAR="2011">
<REFERENCE MODIFIED="2013-01-22 14:41:10 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ganguli R, Brar JS</AU>
<TI>Behavioural intervention for weight loss in schizophrenia: An rct with active controls</TI>
<SO>Indian Journal of Psychiatry</SO>
<YR>2011</YR>
<VL>5</VL>
<NO>Suppl 1</NO>
<PG>S44</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2013-01-21 16:10:42 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ganguli R, Brar JS</AU>
<TI>Weight reduction in schizophrenia, by lifestyle change: A randomized clinical trial</TI>
<SO>Canadian Journal of Diabetes</SO>
<YR>2011</YR>
<VL>2</VL>
<PG>153</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ginsberg-2004" MODIFIED="2013-01-17 14:25:01 +0000" MODIFIED_BY="[Empty name]" NAME="Ginsberg 2004" YEAR="2004">
<REFERENCE MODIFIED="2013-01-17 14:25:01 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ginsberg DL</AU>
<TI>Add-on sibutramine for olanzapine-induced weight gain</TI>
<SO>Primary Psychiatry</SO>
<YR>2004</YR>
<VL>11</VL>
<NO>7</NO>
<PG>24</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Henderson-2004" MODIFIED="2013-01-21 15:46:52 +0000" MODIFIED_BY="[Empty name]" NAME="Henderson 2004" YEAR="2004">
<REFERENCE MODIFIED="2013-01-21 15:46:52 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Henderson DC, Daley TB, Louie P</AU>
<TI>A placebo-controlled trial of sibutramine added to patients with olanzapine-induced weight gain</TI>
<SO>World Journal of Biological Psychiatry</SO>
<YR>2004</YR>
<VL>5</VL>
<NO>suppl 1</NO>
<PG>152</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Henderson-2009" MODIFIED="2013-01-17 14:25:01 +0000" MODIFIED_BY="[Empty name]" NAME="Henderson 2009" YEAR="2009">
<REFERENCE MODIFIED="2013-01-17 14:25:01 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Henderson DC, Fan X, Copeland PM, Sharma B, Borba CP, Boxill R, et al</AU>
<TI>Aripiprazole added to overweight and obese olanzapine-treated schizophrenia patients</TI>
<SO>Journal of Clinical Psychopharmacology</SO>
<YR>2009</YR>
<VL>29</VL>
<NO>2</NO>
<PG>165-9</PG>
<CY>United States</CY>
<IDENTIFIERS MODIFIED="2013-01-17 14:24:59 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="MEDLINE" VALUE="19512978"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Henderson-2011" MODIFIED="2013-01-17 14:25:01 +0000" MODIFIED_BY="[Empty name]" NAME="Henderson 2011" YEAR="2011">
<REFERENCE MODIFIED="2013-01-17 14:25:01 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Henderson DC, Freudenreich O, Borba CPC, Wang X, Copeland PM, Macklin E, et al</AU>
<TI>Effects of modafinil on weight, glucose and lipid metabolism in clozapine-treated patients with schizophrenia</TI>
<SO>Schizophrenia Research</SO>
<YR>2011</YR>
<VL>130</VL>
<NO>1-3</NO>
<PG>53-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hoffmann-2009" MODIFIED="2013-01-17 14:25:01 +0000" MODIFIED_BY="[Empty name]" NAME="Hoffmann 2009" YEAR="2009">
<REFERENCE MODIFIED="2013-01-17 14:25:01 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Hoffmann V, Case M, Jacobson J</AU>
<TI>Algorithms including amantadine, metformin and zonisamide for mitigation of weight gain during olanzapine treatment in outpatients with schizophrenia</TI>
<SO>Proceedings of the 162nd Annual Meeting of the American Psychiatric Association; 2009 May 16-21; San Francisco, CA</SO>
<YR>2009</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Iglesias_x002d_Garcia-2010" MODIFIED="2013-01-21 16:02:06 +0000" MODIFIED_BY="[Empty name]" NAME="Iglesias-Garcia 2010" YEAR="2010">
<REFERENCE MODIFIED="2013-01-21 16:02:06 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Iglesias-Garcia C, Toimil-Iglesias A, Alonso-Villa MJ</AU>
<TI>Pilot study of the efficacy of an educational programme to reduce weight, on overweight and obese patients with chronic stable schizophrenia</TI>
<SO>Journal of Psychiatric and Mental Health Nursing</SO>
<YR>2010</YR>
<VL>17</VL>
<NO>9</NO>
<PG>849-51</PG>
<IDENTIFIERS MODIFIED="2013-01-21 16:02:06 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-IRCT201009112181N5" MODIFIED="2013-01-21 15:48:43 +0000" MODIFIED_BY="[Empty name]" NAME="IRCT201009112181N5" YEAR="2010">
<REFERENCE MODIFIED="2013-01-21 15:48:43 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>IRCT201009112181N5</AU>
<TI>The role of ranitidine in the prevention of olanzapine induced weight gain</TI>
<SO>http://www.irct.ir/</SO>
<YR>2010</YR>
<IDENTIFIERS MODIFIED="2013-01-21 15:48:36 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-IRCT201107187049N1" MODIFIED="2013-01-21 15:48:29 +0000" MODIFIED_BY="[Empty name]" NAME="IRCT201107187049N1" YEAR="2011">
<REFERENCE MODIFIED="2013-01-17 14:25:01 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>IRCT201107187049N1</AU>
<TI>An assessment of effects of melatonin on metabolic effects of olanzapine in patients with schizophrenia</TI>
<SO>http://www.irct.ir/searchresult.php?id=7049&amp;number=1</SO>
<YR>2011</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Joffe-2008" MODIFIED="2013-01-21 15:46:52 +0000" MODIFIED_BY="[Empty name]" NAME="Joffe 2008" YEAR="2008">
<REFERENCE MODIFIED="2013-01-21 15:46:52 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Joffe G, Takala P, Tchoukhine E, Hakko H, Raidma M, Putkonen H, et al</AU>
<TI>Orlistat in clozapine- or olanzapine-treated patients with overweight or obesity: a 16-week randomized, double-blind, placebo-controlled trial</TI>
<SO>Journal of Clinical Psychiatry</SO>
<YR>2008</YR>
<VL>69</VL>
<NO>5</NO>
<PG>706-11</PG>
<CY>United States</CY>
<IDENTIFIERS MODIFIED="2013-01-17 14:24:59 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="MEDLINE" VALUE="18426261"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Karagianis-2010" MODIFIED="2013-01-17 14:25:01 +0000" MODIFIED_BY="[Empty name]" NAME="Karagianis 2010" YEAR="2010">
<REFERENCE MODIFIED="2013-01-17 14:25:01 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Karagianis J, Landry J, Hoffmann VP, Grossman L, De Haan L, Maguire G, et al</AU>
<TI>An exploratory analysis of factors associated with weight change in a 16-week trial of oral vs. Orally disintegrating olanzapine: The platypus study</TI>
<SO>International Journal of Clinical Practice</SO>
<YR>2010</YR>
<VL>64</VL>
<NO>11</NO>
<PG>1520-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kelly-2008" MODIFIED="2013-01-21 15:46:35 +0000" MODIFIED_BY="[Empty name]" NAME="Kelly 2008" YEAR="2008">
<REFERENCE MODIFIED="2013-01-21 15:46:35 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kelly DL, Conley RR, Love RC, Morrison JA, McMahon RP</AU>
<TI>Metabolic risk with second-generation antipsychotic treatment: a double-blind randomized 8-week trial of risperidone and olanzapine</TI>
<SO>Annals of Clinical Psychiatry</SO>
<YR>2008</YR>
<VL>20</VL>
<NO>2</NO>
<PG>71-8</PG>
<CY>United States</CY>
<IDENTIFIERS MODIFIED="2013-01-17 14:24:59 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="MEDLINE" VALUE="18568578"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kelly-2011" MODIFIED="2013-01-21 16:02:37 +0000" MODIFIED_BY="[Empty name]" NAME="Kelly 2011" YEAR="2011">
<REFERENCE MODIFIED="2013-01-21 16:02:37 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kelly DL, Gorelick DA, Conley RR, Boggs DL, Linthicum J, Liu F, et al</AU>
<TI>Effects of the cannabinoid-1 receptor antagonist rimonabant on psychiatric symptoms in overweight people with schizophrenia. A randomized, double-blind, pilot study</TI>
<SO>Journal of Clinical Psychopharmacology</SO>
<YR>2011</YR>
<VL>31</VL>
<NO>1</NO>
<PG>86-91</PG>
<IDENTIFIERS MODIFIED="2013-01-21 16:02:37 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kelly-2011a" MODIFIED="2013-01-21 16:12:39 +0000" MODIFIED_BY="[Empty name]" NAME="Kelly 2011a" YEAR="2011">
<REFERENCE MODIFIED="2013-01-21 16:12:39 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kelly DL, Gorelick D, Conley R, Boggs DL, Linthicum J, Liu F, et al</AU>
<TI>Effects of the cannabinoid-1 receptor antagonist rimonabant on psychiatric symptoms in overweight people with schizophrenia: A randomized, doubleblind pilot study</TI>
<SO>Schizophrenia Bulletin</SO>
<YR>2011</YR>
<VL>1</VL>
<PG>310</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kent-2011" MODIFIED="2013-01-17 14:25:01 +0000" MODIFIED_BY="[Empty name]" NAME="Kent 2011" YEAR="2011">
<REFERENCE MODIFIED="2013-01-17 14:25:01 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kent JM, Daly EJ, Janssens L, Newcomer JW, Van Osselaer N, Husken G, et al</AU>
<TI>Metabolic and body mass parameters observed with jnj-37822681, a novel fast-dissociating d receptor antagonist, versus olanzapine</TI>
<SO>Biological Psychiatry</SO>
<YR>2011</YR>
<VL>69</VL>
<NO>9 Suppl</NO>
<PG>228</PG>
<IDENTIFIERS MODIFIED="2013-01-17 14:24:59 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="MEDLINE" VALUE="BIOSIS:PREV201100354601"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kim-2006" MODIFIED="2013-01-21 15:46:09 +0000" MODIFIED_BY="[Empty name]" NAME="Kim 2006" YEAR="2006">
<REFERENCE MODIFIED="2013-01-21 15:46:09 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Kim J, Yim S, Nam J</AU>
<TI>A 12-week, randomized, open-label, parallel-group trial of topiramate in limiting weight gain during olanzapine treatment in patients with schizophrenia</TI>
<SO>Proceedings of the 13th Biennial Winter Workshop on Schizophrenia Research; 2006 Feb 4-10; Davos, Switzerland</SO>
<YR>2006</YR>
<PG>86</PG>
<PB>Elsevier Science Bv</PB>
<CY>Davos, SWITZERLAND</CY>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kim-2007a" MODIFIED="2013-01-17 14:25:01 +0000" MODIFIED_BY="[Empty name]" NAME="Kim 2007a" YEAR="2007">
<REFERENCE MODIFIED="2013-01-17 14:25:01 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kim SW, Yoon JS, Lee SH, Yang DS, Lee JH, Kim WJ, et al</AU>
<TI>Effectiveness of switching from risperidone to amisulpride in stabilized schizophrenic patients with depression</TI>
<SO>European Neuropsychopharmacology</SO>
<YR>2007</YR>
<VL>17</VL>
<NO>Suppl 4</NO>
<PG>S440</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kim-2007b" MODIFIED="2013-01-17 14:25:01 +0000" MODIFIED_BY="[Empty name]" NAME="Kim 2007b" YEAR="2007">
<REFERENCE MODIFIED="2013-01-17 14:25:01 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Kim SI, Sung YM, Paik KW, Yun KW, Kim YC, Lim W</AU>
<TI>The efficacy of topiramate for weight loss and psychiatric symptom severity in overweight or obese patients maintained on atypical antipsychotics</TI>
<SO>Proceedings of the 160th Annual Meeting of the American Psychiatric Association; 2007 May 19-24; San Diego, CA</SO>
<YR>2007</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kim-2012" MODIFIED="2013-01-21 15:46:09 +0000" MODIFIED_BY="[Empty name]" NAME="Kim 2012" YEAR="2012">
<REFERENCE MODIFIED="2013-01-21 15:46:09 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kim SW, Chung YC, Lee YH, Lee JH, Kim SY, Bae KY, et al</AU>
<TI>Paliperidone er versus risperidone for neurocognitive function in patients with schizophrenia: A randomized, open-label, controlled trial</TI>
<SO>International Clinical Psychopharmacology</SO>
<YR>2012</YR>
<VL>27</VL>
<NO>5</NO>
<PG>267-74</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Klein-2006" MODIFIED="2013-01-21 15:46:52 +0000" MODIFIED_BY="[Empty name]" NAME="Klein 2006" YEAR="2006">
<REFERENCE MODIFIED="2013-01-21 15:46:52 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Klein DJ, Cottingham EM, Sorter M, Barton BA, Morrison JA</AU>
<TI>A randomized, double-blind, placebo-controlled trial of metformin treatment of weight gain associated with initiation of atypical antipsychotic therapy in children and adolescents</TI>
<SO>American Journal of Psychiatry</SO>
<YR>2006</YR>
<VL>163</VL>
<NO>12</NO>
<PG>2072-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Klein-2008" MODIFIED="2013-01-17 14:25:01 +0000" MODIFIED_BY="[Empty name]" NAME="Klein 2008" YEAR="2008">
<REFERENCE MODIFIED="2013-01-17 14:25:01 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Klein DJ</AU>
<TI>Metformin treatment of weight gain associated with antipsychotic drug therapy</TI>
<SO>International Journal of Neuropsychopharmacology</SO>
<YR>2008</YR>
<VL>11</VL>
<NO>Suppl 1</NO>
<PG>32</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kluge-2007" MODIFIED="2013-01-22 14:40:12 +0000" MODIFIED_BY="[Empty name]" NAME="Kluge 2007" YEAR="2007">
<REFERENCE MODIFIED="2013-01-21 15:46:35 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kluge M, Schuld A, Himmerich H, Dalal M, Schacht A, Wehmeier PM, et al</AU>
<TI>Clozapine and olanzapine are associated with food craving and binge eating: results from a randomized double-blind study</TI>
<SO>Journal of Clinical Psychopharmacology</SO>
<YR>2007</YR>
<VL>27</VL>
<NO>6</NO>
<PG>662-6</PG>
<CY>United States</CY>
<IDENTIFIERS MODIFIED="2013-01-17 14:24:59 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="MEDLINE" VALUE="18004133"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2013-01-22 14:40:12 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kluge M, Schuld A, Schacht A, Himmerich H, Dalal MA, Wehmeier PM, et al</AU>
<TI>Effects of clozapine and olanzapine on cytokine systems are closely linked to weight gain and drug-induced fever</TI>
<SO>Psychoneuroendocrinology</SO>
<YR>2009</YR>
<VL>34</VL>
<NO>1</NO>
<PG>118-28</PG>
<CY>United Kingdom</CY>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ko-2005" MODIFIED="2013-01-17 14:25:01 +0000" MODIFIED_BY="[Empty name]" NAME="Ko 2005" YEAR="2005">
<REFERENCE MODIFIED="2013-01-17 14:25:01 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ko YH, Joe SH, Jung IK, Kim SH</AU>
<TI>Topiramate as an adjuvant treatment with atypical antipsychotics in schizophrenic patients experiencing weight gain</TI>
<SO>Clinical Neuropharmacology</SO>
<YR>2005</YR>
<VL>28</VL>
<NO>4</NO>
<PG>169-75</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Krakowski-2009" MODIFIED="2013-01-21 15:46:35 +0000" MODIFIED_BY="[Empty name]" NAME="Krakowski 2009" YEAR="2009">
<REFERENCE MODIFIED="2013-01-21 15:46:35 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Krakowski M, Czobor P, Citrome L</AU>
<TI>Weight gain, metabolic parameters, and the impact of race in aggressive inpatients randomized to double-blind clozapine, olanzapine or haloperidol</TI>
<SO>Schizophrenia Research</SO>
<YR>2009</YR>
<VL>110</VL>
<NO>1-3</NO>
<PG>95-102</PG>
<CY>Netherlands</CY>
<IDENTIFIERS MODIFIED="2013-01-17 14:24:59 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="MEDLINE" VALUE="19269139"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kuang-2007" MODIFIED="2013-01-17 14:25:01 +0000" MODIFIED_BY="[Empty name]" NAME="Kuang 2007" YEAR="2007">
<REFERENCE MODIFIED="2013-01-17 14:25:01 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kuang Y-H, Zhao L</AU>
<TI>A comparative study on the efficacy and weight gain between quetiapine and clozapine in the treatment of schizophrenia</TI>
<TO>&#21945;&#30827;&#24179;&#19982;&#27695;&#27694;&#24179;&#23545;&#31934;&#31070;&#20998;&#35010;&#30151;&#24739;&#32773;&#30103;&#25928;&#21450;&#20307;&#37325;&#30340;&#24433;&#21709;</TO>
<SO>Shandong Archives of Psychiatry [&#23665;&#19996;&#31934;&#31070;&#21307;&#23398;]</SO>
<YR>2007</YR>
<VL>20</VL>
<NO>4</NO>
<PG>217-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kwon-2006" MODIFIED="2013-01-21 15:46:09 +0000" MODIFIED_BY="[Empty name]" NAME="Kwon 2006" YEAR="2006">
<REFERENCE MODIFIED="2013-01-21 15:46:09 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kwon JS, Choi J-S, Bahk W-M, Kim CY, Kim CH, Shin YC, et al</AU>
<TI>Weight management program for treatment-emergent weight gain in olanzapine-treated patients with schizophrenia or schizoaffective disorder: a 12-week randomized controlled clinical trial</TI>
<SO>Journal of Clinical Psychiatry</SO>
<YR>2006</YR>
<VL>67</VL>
<NO>4</NO>
<PG>547-53</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lambert-2009" MODIFIED="2013-01-17 14:25:01 +0000" MODIFIED_BY="[Empty name]" NAME="Lambert 2009" YEAR="2009">
<REFERENCE MODIFIED="2013-01-17 14:25:01 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lambert TJ</AU>
<TI>Switching to aripiprazole from olanzapine leads to weight loss in overweight people with schizophrenia or schizoaffective disorder</TI>
<SO>Evidence-Based Mental Health</SO>
<YR>2009</YR>
<VL>12</VL>
<NO>2</NO>
<PG>50</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lan-2008" MODIFIED="2013-01-17 14:25:01 +0000" MODIFIED_BY="[Empty name]" NAME="Lan 2008" YEAR="2008">
<REFERENCE MODIFIED="2013-01-17 14:25:01 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lan T, Chiu H, Hu T, Huang H, Wu B, Tuan Y</AU>
<TI>Prolactin level as an indicator to clinical psychopathological severity in aripiprazole treated schizophrenia</TI>
<SO>European Neuropsychopharmacology</SO>
<YR>2008</YR>
<VL>18</VL>
<PG>S440</PG>
<IDENTIFIERS MODIFIED="2013-01-17 14:24:59 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="MEDLINE" VALUE="ISI:000259593801205"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lencz-2010" MODIFIED="2013-01-17 14:25:01 +0000" MODIFIED_BY="[Empty name]" NAME="Lencz 2010" YEAR="2010">
<REFERENCE MODIFIED="2013-01-17 14:25:01 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lencz T, Robinson DG, Napolitano B, Sevy S, Kane JM, Goldman D, et al</AU>
<TI>Drd2 promoter region variation predicts antipsychotic-induced weight gain in first episode schizophrenia</TI>
<SO>Pharmacogenetics and Genomics</SO>
<YR>2010</YR>
<VL>20</VL>
<NO>9</NO>
<PG>569-72</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Li-2008" MODIFIED="2013-01-17 14:25:01 +0000" MODIFIED_BY="[Empty name]" NAME="Li 2008" YEAR="2008">
<REFERENCE MODIFIED="2013-01-17 14:25:01 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Li J, Kong L-S, Kong L-X</AU>
<TI>Aripiprazole in the treatment of schizophrenia with diabetes caused by antipsychotic drugs of the safety study</TI>
<TO>&#38463;&#31435;&#21708;&#21777;&#22312;&#27835;&#30103;&#25239;&#31934;&#31070;&#30149;&#33647;&#29289;&#25152;&#33268;&#31958;&#23615;&#30149;13&#20363;&#30340;&#23433;&#20840;&#24615;&#30740;&#31350;</TO>
<SO>Medical Journal of Chinese People's Health [&#20013;&#22269;&#27665;&#24247;&#21307;&#23398;]</SO>
<YR>2008</YR>
<VL>20</VL>
<NO>23</NO>
<PG>2784-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lieberman-2010" MODIFIED="2013-01-21 16:12:49 +0000" MODIFIED_BY="[Empty name]" NAME="Lieberman 2010" YEAR="2010">
<REFERENCE MODIFIED="2013-01-21 16:12:49 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Lieberman J, Jarskog LF, Hamer R, Catellier D, Stewart D, LaVange L, et al</AU>
<TI>Metformin for obesity and metabolic abnormalities in schizophrenia</TI>
<SO>Proceedings of the 49th Annual meeting of the Americam College of Neuropsychopharmacology; 2010 Dec 5-9; Miami, Florida</SO>
<YR>2010</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Linne-2008" MODIFIED="2013-01-21 15:46:09 +0000" MODIFIED_BY="[Empty name]" NAME="Linne 2008" YEAR="2008">
<REFERENCE MODIFIED="2013-01-21 15:46:09 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Linne Y, Rossner S, Neovius M</AU>
<TI>Body composition and metabolic changes during antipsychotic treatment. A randomized trial comparing sertindole and olanzapine study design presentation</TI>
<SO>Proceedings of the 14th Biennial Winter Workshop on Schizophrenia and Bipolar Disorders; 2008 Feb 3-7; Montreux, Switzerland</SO>
<YR>2008</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mauri-2008" MODIFIED="2013-01-17 14:25:01 +0000" MODIFIED_BY="[Empty name]" NAME="Mauri 2008" YEAR="2008">
<REFERENCE MODIFIED="2013-01-17 14:25:01 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mauri M, Simoncini M, Castrogiovanni S, Iovieno N, Cecconi D, Dell'Agnello G, et al</AU>
<TI>A psychoeducational program for weight loss in patients who have experienced weight gain during antipsychotic treatment with olanzapine</TI>
<SO>Pharmacopsychiatry</SO>
<YR>2008</YR>
<VL>41</VL>
<PG>17-23</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-McElroy-2012" MODIFIED="2013-01-21 15:46:52 +0000" MODIFIED_BY="[Empty name]" NAME="McElroy 2012" YEAR="2012">
<REFERENCE MODIFIED="2013-01-21 15:46:52 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>McElroy SL, Winstanley E, Mori N, Martens B, McCoy J, Moeller D, et al</AU>
<TI>A randomized, placebo-controlled study of zonisamide to prevent olanzapine-associated weight gain</TI>
<SO>Journal of Clinical Psychopharmacology</SO>
<YR>2012</YR>
<VL>32</VL>
<NO>2</NO>
<PG>165-72</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Meyer-2009" MODIFIED="2013-01-17 14:25:01 +0000" MODIFIED_BY="[Empty name]" NAME="Meyer 2009" YEAR="2009">
<REFERENCE MODIFIED="2013-01-17 14:25:01 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Meyer JM, Rosenblatt LC, Kim E, Baker RA, Whitehead R</AU>
<TI>The moderating impact of ethnicity on metabolic outcomes during treatment with olanzapine and aripiprazole in patients with schizophrenia</TI>
<SO>Journal of Clinical Psychiatry</SO>
<YR>2009</YR>
<VL>70</VL>
<NO>3</NO>
<PG>318-25</PG>
<CY>United States</CY>
<IDENTIFIERS MODIFIED="2013-01-17 14:24:59 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="MEDLINE" VALUE="19192469"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Meyer-2009a" MODIFIED="2013-01-17 14:25:01 +0000" MODIFIED_BY="[Empty name]" NAME="Meyer 2009a" YEAR="2009">
<REFERENCE MODIFIED="2013-01-17 14:25:01 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Meyer JM, Henry RR, Braff DL</AU>
<TI>Antipsychotic stay vs. switch for metabolic benefit: psychiatric cost</TI>
<SO>Schizophrenia Bulletin</SO>
<YR>2009</YR>
<VL>35</VL>
<NO>Suppl 1</NO>
<PG>26</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Millar-2008" MODIFIED="2013-01-21 15:46:35 +0000" MODIFIED_BY="[Empty name]" NAME="Millar 2008" YEAR="2008">
<REFERENCE MODIFIED="2013-01-21 15:46:35 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Millar H, Felter C, Landsberg W</AU>
<TI>The effects of aripiprazole in combination with clozapine: patient functioning results from a double-blind, 16-week study in patients with schizophrenia (CN138-170)</TI>
<SO>Journal of Psychopharmacology</SO>
<YR>2008</YR>
<VL>22</VL>
<NO>5</NO>
<PG>A17</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Millar-2008a" MODIFIED="2013-01-17 14:25:01 +0000" MODIFIED_BY="[Empty name]" NAME="Millar 2008a" YEAR="2008">
<REFERENCE MODIFIED="2013-01-17 14:25:01 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Millar H, Felter C, Dudley E, Sullivan G</AU>
<TI>Weight outcomes in an open-label comparision of switching strategies from risperidone to aripiprazole in patients with schizophrenia (CN138-169)</TI>
<SO>Journal of Psychopharmacology</SO>
<YR>2008</YR>
<VL>22</VL>
<NO>5</NO>
<PG>A17</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Moore-2006" MODIFIED="2013-01-17 14:25:01 +0000" MODIFIED_BY="[Empty name]" NAME="Moore 2006" YEAR="2006">
<REFERENCE MODIFIED="2013-01-17 14:25:01 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Moore N</AU>
<TI>Switching to aripiprazole from other second-generation antipsychotics</TI>
<SO>Australian New Zealand Clinical Trials Registry</SO>
<YR>2006</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-NCT00095524" MODIFIED="2013-01-22 14:44:43 +0000" MODIFIED_BY="[Empty name]" NAME="NCT00095524" YEAR="2008">
<REFERENCE MODIFIED="2013-01-22 14:44:29 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>L'ltalien GJ, Newcomer JW, Berman R, Marcus RN, Kerselaers W, McQuade RD</AU>
<TI>Rates of metabolic syndrome and non-high-density lippprotein-cholesterol among overweight patients switched from olanzapine to aripiprazole (Study CN138-122)</TI>
<SO>Proceedings of the 160th Annual Meeting of the American Psychiatric Association; 2007 May 19-24; San Diego, CA</SO>
<YR>2007</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2013-01-21 15:46:35 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Newcomer JW, Campos A, Marcus RN, Breder C, Berman R, Kerselaers W, et al</AU>
<TI>A multicenter, randomized, double-blind study of the effects of aripiprazole in overweight subjects with schizophrenia or schizoaffective disorder switched from olanzapine</TI>
<SO>Journal of Clinical Psychiatry</SO>
<YR>2008</YR>
<VL>69</VL>
<NO>7</NO>
<PG>1046-56</PG>
<IDENTIFIERS MODIFIED="2013-01-17 14:24:59 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="MEDLINE" VALUE="18605811"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-NCT00303602" MODIFIED="2013-01-22 14:43:05 +0000" MODIFIED_BY="[Empty name]" NAME="NCT00303602" YEAR="2009">
<REFERENCE MODIFIED="2013-01-22 14:42:54 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Karagianis J, Grossman L, Landry J, Reed VA, de Haan L, Maguire GA, et al</AU>
<TI>A randomized controlled trial of the effect of sublingual orally disintegrating olanzapine versus oral olanzapine on body mass index: the PLATYPUS Study</TI>
<SO>Schizophrenia Research</SO>
<YR>2009</YR>
<VL>113</VL>
<NO>1</NO>
<PG>41-8</PG>
<CY>Netherlands</CY>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="19535229"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2013-01-21 16:12:30 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Karagianis J, Landry J, Grossman L, Hoffmann V, Maguire GA, Milev R, et al</AU>
<TI>Factors associated with weight change in a 16-week randomized double-blind, double-dummy trial of sublingual orally disintegrating olanzapine vs. oral olanzapine in patients who gained weight during olanzapine treatment: the PLATYPUS Study</TI>
<SO>Biological Psychiatry</SO>
<YR>2009</YR>
<VL>1</VL>
<PG>302</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-NCT00423878" MODIFIED="2013-01-22 14:46:26 +0000" MODIFIED_BY="[Empty name]" NAME="NCT00423878" YEAR="2007">
<REFERENCE MODIFIED="2013-01-22 14:46:14 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Stroup T</AU>
<TI>A randomized trial examining the effectiveness of switching from olanzapine, quetiapine, orrisperidone to aripiprazole to reduce metabolic risk</TI>
<SO>Proceedings of the 164th annual general meeting of the American Psychiatric Association; 2011 May 14-18; Honolulu, Hawaii</SO>
<YR>2011</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2013-01-17 14:25:01 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Stroup TS, McEvoy JP, Swartz MS, Hamer RM, Perkins DO, Lieberman JA</AU>
<TI>Comparison of Antipsychotics for Metabolic Problems (CAMP): a NIMH schizophrenia trials network study</TI>
<SO>Clinical Schizophrenia and Related Psychoses</SO>
<YR>2007</YR>
<VL>1</VL>
<NO>1</NO>
<PG>69-72</PG>
<CY>United States</CY>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-NCT00645099" MODIFIED="2013-01-21 15:48:56 +0000" MODIFIED_BY="[Empty name]" NAME="NCT00645099" YEAR="2008">
<REFERENCE MODIFIED="2013-01-17 14:25:01 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>NCT00645099</AU>
<TI>A 6 month study to compare the metabolic effects of paliperidone er and olanzapine in patients with schizophrenia</TI>
<SO>http://www.clinicaltrials.gov</SO>
<YR>2008</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-NCT00690235" MODIFIED="2013-01-21 15:49:00 +0000" MODIFIED_BY="[Empty name]" NAME="NCT00690235" YEAR="2008">
<REFERENCE MODIFIED="2013-01-17 14:25:01 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>NCT00690235</AU>
<TI>Demonstrate the effects of pramlintide on weight reduction in schizophrenia</TI>
<SO>http://www.clinicaltrials.gov</SO>
<YR>2008</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-NCT00709202" MODIFIED="2013-01-21 15:49:05 +0000" MODIFIED_BY="[Empty name]" NAME="NCT00709202" YEAR="2008">
<REFERENCE MODIFIED="2013-01-17 14:25:01 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>NCT00709202</AU>
<TI>To examine the effect of betahistine on antipsychotic induced weight gain in adolescents</TI>
<SO>http://www.clinicaltrials.gov</SO>
<YR>2008</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-NCT00734435" MODIFIED="2013-01-21 15:49:10 +0000" MODIFIED_BY="[Empty name]" NAME="NCT00734435" YEAR="2008">
<REFERENCE MODIFIED="2013-01-17 14:25:01 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>NCT00734435</AU>
<TI>Olanzapine given in combination with zonisamide sr to prevent weight gain in schizophrenic subjects</TI>
<SO>http://www.clinicaltrials.gov</SO>
<YR>2008</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-NCT00759460" MODIFIED="2013-01-21 15:49:15 +0000" MODIFIED_BY="[Empty name]" NAME="NCT00759460" YEAR="2008">
<REFERENCE MODIFIED="2013-01-17 14:25:01 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>NCT00759460</AU>
<TI>Study on metabolic parameters of sertindole in patients with schizophrenia</TI>
<SO>http://www.clinicaltrials.gov</SO>
<YR>2008</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-NCT00759993" MODIFIED="2013-01-21 15:49:19 +0000" MODIFIED_BY="[Empty name]" NAME="NCT00759993" YEAR="2008">
<REFERENCE MODIFIED="2013-01-17 14:25:01 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>NCT00759993</AU>
<TI>Chromium piccolinate in the prevention of weight gain induced by serotonergic medications initiated on psychiatric inpatient units</TI>
<SO>http://www.clinicaltrials.gov</SO>
<YR>2008</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-NCT00793780" MODIFIED="2013-01-21 15:49:32 +0000" MODIFIED_BY="[Empty name]" NAME="NCT00793780" YEAR="2008">
<REFERENCE MODIFIED="2013-01-21 15:49:32 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>NCT00793780</AU>
<TI>Pilot trial of naltrexone for obesity in women with schizophrenia</TI>
<SO>http://www.clinicaltrials.gov</SO>
<YR>2008</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-NCT00806234" MODIFIED="2013-01-21 15:49:39 +0000" MODIFIED_BY="[Empty name]" NAME="NCT00806234" YEAR="2008">
<REFERENCE MODIFIED="2013-01-17 14:25:01 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>NCT00806234</AU>
<TI>Reducing weight gain and improving metabolic function in children being treated with antipsychotics</TI>
<SO>http://www.clinicaltrials.gov</SO>
<YR>2008</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-NCT00816907" MODIFIED="2013-01-21 15:49:43 +0000" MODIFIED_BY="[Empty name]" NAME="NCT00816907" YEAR="2009">
<REFERENCE MODIFIED="2013-01-17 14:25:01 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>NCT00816907</AU>
<TI>The use of metformin in the treatment of antipsychotic-induced weight gain in schizophrenia (The METS Study)</TI>
<SO>http://www.clinicaltrials.gov</SO>
<YR>2009</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-NCT00845507" MODIFIED="2013-01-21 15:50:07 +0000" MODIFIED_BY="[Empty name]" NAME="NCT00845507" YEAR="2008">
<REFERENCE MODIFIED="2013-01-21 15:50:07 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>NCT00845507</AU>
<TI>Exenatide for the treatment of weight gain associated with olanzapine in obese adults</TI>
<SO>http://ClinicalTrials.gov/show/NCT00845507</SO>
<YR>2008</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-NCT00857818" MODIFIED="2013-01-21 15:50:13 +0000" MODIFIED_BY="[Empty name]" NAME="NCT00857818" YEAR="2009">
<REFERENCE MODIFIED="2013-01-17 14:25:01 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>NCT00857818</AU>
<TI>Metabolic abnormalities - OPT</TI>
<SO>http://www.clinicaltrials.gov</SO>
<YR>2009</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-NCT00902694" MODIFIED="2013-01-21 15:50:28 +0000" MODIFIED_BY="[Empty name]" NAME="NCT00902694" YEAR="2009">
<REFERENCE MODIFIED="2013-01-21 15:50:28 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>NCT00902694</AU>
<TI>Examining an exercise and nutrition program for reducing weight in people with severe mental illnesses (the achieve study)</TI>
<SO>http://ClinicalTrials.gov/show/NCT00902694</SO>
<YR>2009</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-NCT00934908" MODIFIED="2013-01-21 15:50:35 +0000" MODIFIED_BY="[Empty name]" NAME="NCT00934908" YEAR="2009">
<REFERENCE MODIFIED="2013-01-17 14:25:01 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>NCT00934908</AU>
<TI>Prevention of weight gain and dyslipidemia by green tea in patients initiating therapy with olanzapine</TI>
<SO>http://www.clinicaltrials.gov</SO>
<YR>2009</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-NCT00990925" MODIFIED="2013-01-21 15:50:41 +0000" MODIFIED_BY="[Empty name]" NAME="NCT00990925" YEAR="2009">
<REFERENCE MODIFIED="2013-01-17 14:25:01 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>NCT00990925</AU>
<TI>Lifestyle modification for weight loss in schizophrenia</TI>
<SO>http://www.clinicaltrials.gov</SO>
<YR>2009</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-NCT01052714" MODIFIED="2013-01-21 15:50:44 +0000" MODIFIED_BY="[Empty name]" NAME="NCT01052714" YEAR="2010">
<REFERENCE MODIFIED="2013-01-17 14:25:01 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>NCT01052714</AU>
<TI>Healthy lifestyles for mentally ill people who have experienced weight gain from their antipsychotic medications - 2</TI>
<SO>http://www.clinicaltrials.gov</SO>
<YR>2010</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-NCT01075295" MODIFIED="2013-01-21 15:51:01 +0000" MODIFIED_BY="[Empty name]" NAME="NCT01075295" YEAR="2010">
<REFERENCE MODIFIED="2013-01-21 15:51:01 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>NCT01075295</AU>
<TI>Prevention of weight gain in early schizophrenia and schizoaffective disorder</TI>
<SO>http://www.clinicaltrials.gov</SO>
<YR>2010</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-NCT01167348" MODIFIED="2013-01-21 15:51:25 +0000" MODIFIED_BY="[Empty name]" NAME="NCT01167348" YEAR="2010">
<REFERENCE MODIFIED="2013-01-21 15:51:25 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>NCT01167348</AU>
<TI>The effectiveness of auricular acupressure on bodybweight parameters on patients with schizophrenia</TI>
<SO>http://ClinicalTrials.gov/show/NCT01167348</SO>
<YR>2010</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-NCT01272752" MODIFIED="2013-01-21 15:51:39 +0000" MODIFIED_BY="[Empty name]" NAME="NCT01272752" YEAR="2011">
<REFERENCE MODIFIED="2013-01-21 15:51:39 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>NCT01272752</AU>
<TI>Anti-psychotic medication (new use) weight loss study</TI>
<SO>http://ClinicalTrials.gov/show/NCT01272752</SO>
<YR>2011</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-NCT01272765" MODIFIED="2013-01-21 15:51:56 +0000" MODIFIED_BY="[Empty name]" NAME="NCT01272765" YEAR="2011">
<REFERENCE MODIFIED="2013-01-21 15:51:56 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>NCT01272765</AU>
<TI>Anti-psychotic medication (stable dose) weight loss study</TI>
<TO>her: placebo|Dietary Supplement: IHBG-10</TO>
<SO>http://ClinicalTrials.gov/show/NCT01272765</SO>
<YR>2011</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-NCT01295372" MODIFIED="2013-01-21 15:52:36 +0000" MODIFIED_BY="[Empty name]" NAME="NCT01295372" YEAR="2011">
<REFERENCE MODIFIED="2013-01-21 15:52:36 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>NCT01295372</AU>
<TI>Safety and efficacy of zicronapine in patients with schizophrenia</TI>
<SO>http://ClinicalTrials.gov/show/NCT01295372</SO>
<YR>2011</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-NCT01300637" MODIFIED="2013-01-21 15:52:43 +0000" MODIFIED_BY="[Empty name]" NAME="NCT01300637" YEAR="2011">
<REFERENCE MODIFIED="2013-01-21 15:52:43 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>NCT01300637</AU>
<TI>Effects of adjunctive metformin on metabolic profiles in clozapine-treated schizophrenic patients</TI>
<SO>http://ClinicalTrials.gov/show/NCT01300637</SO>
<YR>2011</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-NCT01324973" MODIFIED="2013-01-21 15:52:57 +0000" MODIFIED_BY="[Empty name]" NAME="NCT01324973" YEAR="2011">
<REFERENCE MODIFIED="2013-01-21 15:52:57 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>NCT01324973</AU>
<TI>Web-based weight management for individuals with mental illness</TI>
<SO>http://ClinicalTrials.gov/show/NCT01324973</SO>
<YR>2011</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-NCT01491490" MODIFIED="2013-01-21 15:53:08 +0000" MODIFIED_BY="[Empty name]" NAME="NCT01491490" YEAR="2011">
<REFERENCE MODIFIED="2013-01-21 15:53:08 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>NCT01491490</AU>
<TI>Treatment on iatrogenic weight gain and dyslipidaemia associated with olanzapine</TI>
<SO>http://ClinicalTrials.gov/show/NCT01491490</SO>
<YR>2011</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-NCT01567124" MODIFIED="2013-01-21 15:53:29 +0000" MODIFIED_BY="[Empty name]" NAME="NCT01567124" YEAR="2012">
<REFERENCE MODIFIED="2013-01-21 15:53:29 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>NCT01567124</AU>
<TI>Alleviating the metabolic side effects of antipsychotic medications</TI>
<SO>http://ClinicalTrials.gov/show/NCT01567124</SO>
<YR>2012</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-NCT01593774" MODIFIED="2013-01-21 15:53:39 +0000" MODIFIED_BY="[Empty name]" NAME="NCT01593774" YEAR="2012">
<REFERENCE MODIFIED="2013-01-21 15:53:39 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>NCT01593774</AU>
<TI>Melatonin for prevention of metabolic side effects of olanzapine</TI>
<SO>http://ClinicalTrials.gov/show/NCT01593774</SO>
<YR>2012</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Newcomer-2009" MODIFIED="2013-01-21 15:46:09 +0000" MODIFIED_BY="[Empty name]" NAME="Newcomer 2009" YEAR="2009">
<REFERENCE MODIFIED="2013-01-21 15:46:09 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Newcomer JW, Haupt DW, Fahnestock PA, Flavin KS, Nicol GE, Schweiger JA, et al</AU>
<TI>Changes in adiposity, insulin sensitivity and lipid metabolism during randomized antipsychotic treatment in schizophrenia</TI>
<SO>Proceedings of the 162nd Annual Meeting of the American Psychiatric Association; 2009 May 16-21; San Francisco, CA</SO>
<YR>2009</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Newcomer-2010" MODIFIED="2013-01-21 16:03:46 +0000" MODIFIED_BY="[Empty name]" NAME="Newcomer 2010" YEAR="2010">
<REFERENCE MODIFIED="2013-01-21 16:03:46 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Newcomer JW, Nicol GE, Haupt DW, Flavin KS, Schweiger JA, Yingling MD</AU>
<TI>Changes in adiposity, insulin sensitivity and related metabolic measures during randomized medication switches to aripiprazole from other atypical antipsychotics</TI>
<SO>Diabetes</SO>
<YR>2010</YR>
<VL>59</VL>
<NO>Suppl 1</NO>
<PG>488</PG>
<IDENTIFIERS MODIFIED="2013-01-21 16:03:46 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Nicol-2009" MODIFIED="2013-01-17 14:25:01 +0000" MODIFIED_BY="[Empty name]" NAME="Nicol 2009" YEAR="2009">
<REFERENCE MODIFIED="2013-01-17 14:25:01 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Nicol G, Haupt DW, Yingling MD, Fahnestock PA, Flavin KS, Schweiger JA, et al</AU>
<TI>Changes in adiposity and metabolic measures during medication switches to aripiprazole from other atypical antipsychotics</TI>
<SO>Proceedings of the 162nd Annual Meeting of the American Psychiatric Association; 2009 May 16-21; San Francisco, CA</SO>
<YR>2009</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Oliveira-2005" MODIFIED="2013-01-21 16:04:21 +0000" MODIFIED_BY="[Empty name]" NAME="Oliveira 2005" YEAR="2005">
<REFERENCE MODIFIED="2013-01-21 16:04:21 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Oliveira AVG</AU>
<TI>Ganho de peso em pacientes em uso de olanzapina e antipsicóticos típicos: um ensaio clínico randomizado</TI>
<SO>PhD thesis</SO>
<YR>2005</YR>
<CY>São Paulo</CY>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Pae-2007" MODIFIED="2013-01-21 15:46:09 +0000" MODIFIED_BY="[Empty name]" NAME="Pae 2007" YEAR="2007">
<REFERENCE MODIFIED="2013-01-21 15:46:09 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Pae C-U, Lim H-K, Patkar AA, Masand P, Lee C, Paik I-H</AU>
<TI>Switching strategies to aripiprazole from other antipsychotics in stabilized schizophrenia: a randomized, 12 week, open label, parallel group study</TI>
<SO>Proceedings of the 160th Annual Meeting of the American Psychiatric Association; 2007 May 19-24; San Diego, CA</SO>
<YR>2007</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Perez_x002d_Iglesias-2008" MODIFIED="2013-01-21 15:46:09 +0000" MODIFIED_BY="[Empty name]" NAME="Perez-Iglesias 2008" YEAR="2008">
<REFERENCE MODIFIED="2013-01-21 15:46:09 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Perez-Iglesias R, Crespo-Facorro B, Martinez-Garcia O, Ramirez-Bonilla ML, Alvarez-Jimenez M, Pelayo-Teran JM, et al</AU>
<TI>Weight gain induced by haloperidol, risperidone and olanzapine after 1 year: findings of a randomized clinical trial in a drug-naive population</TI>
<SO>Schizophrenia Research</SO>
<YR>2008</YR>
<VL>99</VL>
<NO>1-3</NO>
<PG>13-22</PG>
<CY>Netherlands</CY>
<IDENTIFIERS MODIFIED="2013-01-17 14:24:59 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="MEDLINE" VALUE="18053689"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Perez_x002d_Iglesias-2008a" MODIFIED="2013-01-17 14:25:01 +0000" MODIFIED_BY="[Empty name]" NAME="Perez-Iglesias 2008a" YEAR="2008">
<REFERENCE MODIFIED="2013-01-17 14:25:01 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Perez-Iglesias R, Vazquez-Barquero JL, Amado JA, Berja A, Garcia-Unzueta MT, Pelayo-Teran JM, et al</AU>
<TI>Effect of antipsychotics on peptides involved in energy balance in drug-naive psychotic patients after 1 year of treatment</TI>
<SO>Journal of Clinical Psychopharmacology</SO>
<YR>2008</YR>
<VL>28</VL>
<NO>3</NO>
<PG>289-95</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Perez_x002d_Iglesias-2010" MODIFIED="2013-01-17 14:25:01 +0000" MODIFIED_BY="[Empty name]" NAME="Perez-Iglesias 2010" YEAR="2010">
<REFERENCE MODIFIED="2013-01-17 14:25:01 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Perez-Iglesias R, Martinez-Garcia O, Mata I, Pelayo-Teran JM, Pardo-Garcia G, Vazquez-Barquero JL, et al</AU>
<TI>Predictors of antipsychotic-induced weight gain after the first 3 years of treatment</TI>
<SO>Early Intervention in Psychiatry</SO>
<YR>2010</YR>
<VL>4</VL>
<NO>Suppl 1</NO>
<PG>141</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Peuskens-2003" MODIFIED="2013-01-21 15:46:35 +0000" MODIFIED_BY="[Empty name]" NAME="Peuskens 2003" YEAR="2003">
<REFERENCE MODIFIED="2013-01-21 15:46:35 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Peuskens J</AU>
<TI>Less weight gain with amisulpride: results from double-blind studies vs. risperidone and olanzapine</TI>
<SO>Proceedings of the 16th European College of Neuropsychopharmacology Congress; 2003 Sep 20-24; Prague, Czech Republic</SO>
<YR>2003</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Poulin-2007" MODIFIED="2013-01-17 14:25:01 +0000" MODIFIED_BY="[Empty name]" NAME="Poulin 2007" YEAR="2007">
<REFERENCE MODIFIED="2013-01-17 14:25:01 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Poulin M-J, Chaput J-P, Simard V, Vincent P, Bernier J, Gauthier Y, et al</AU>
<TI>Management of antipsychotic-induced weight gain: prospective naturalistic study of the effectiveness of a supervised exercise programme</TI>
<SO>Australian and New Zealand Journal of Psychiatry</SO>
<YR>2007</YR>
<VL>41</VL>
<NO>12</NO>
<PG>980-9</PG>
<CY>England</CY>
<IDENTIFIERS MODIFIED="2013-01-17 14:24:59 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="MEDLINE" VALUE="17999270"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Poyurovsky-2007" MODIFIED="2013-01-21 16:13:10 +0000" MODIFIED_BY="[Empty name]" NAME="Poyurovsky 2007" YEAR="2007">
<REFERENCE MODIFIED="2013-01-21 16:13:10 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Poyurovsky M, Fuchs C, Pashinian A, Levi A, Faragian S, Maayan R, et al</AU>
<TI>Attenuating effect of reboxetine on appetite and weight gain in olanzapine-treated schizophrenia patients: a double-blind placebo-controlled study</TI>
<SO>Proceedings of the 62nd Annual Scientific Meeting of the Society of Biological Psychiatry</SO>
<YR>2007</YR>
<PG>129</PG>
<EN>Soc Biol P</EN>
<PB>Elsevier Science Inc</PB>
<CY>San Diego, CA</CY>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Raposo-2011" MODIFIED="2013-01-21 16:04:44 +0000" MODIFIED_BY="[Empty name]" NAME="Raposo 2011" YEAR="2011">
<REFERENCE MODIFIED="2013-01-21 16:04:44 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Raposo NRB, Ferreira AS, Gattaz WF</AU>
<TI>Body mass index increase, serum leptin, adiponectin, neuropeptide y and lipid levels during treatment with olanzapine and haloperidol</TI>
<SO>Pharmacopsychiatry</SO>
<YR>2011</YR>
<VL>44</VL>
<NO>5</NO>
<PG>169-72</PG>
<IDENTIFIERS MODIFIED="2013-01-21 16:04:44 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ratliff-2011" MODIFIED="2013-01-21 16:14:07 +0000" MODIFIED_BY="[Empty name]" NAME="Ratliff 2011" YEAR="2011">
<REFERENCE MODIFIED="2013-01-21 16:14:07 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ratliff JC, Palmese LB, Tonizzo KM, Reutenauer EL, Tek C</AU>
<TI>Pilot trial of contingency management for the treatment of antipsychotic-induced weight gain</TI>
<SO>Obesity</SO>
<YR>2011</YR>
<VL>1</VL>
<PG>S99-S100</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Saddichha-2010" MODIFIED="2013-01-21 16:14:48 +0000" MODIFIED_BY="[Empty name]" NAME="Saddichha 2010" YEAR="2010">
<REFERENCE MODIFIED="2013-01-21 16:14:48 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Saddichha S, Manjunatha N, Akhtar S</AU>
<TI>Obesity, diabetes and hypertension associated with antipsychotic use in drug nave schizophrenia</TI>
<SO>Australian and New Zealand Journal of Psychiatry</SO>
<YR>2010</YR>
<VL>1</VL>
<PG>12-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Safa-2008" MODIFIED="2013-01-17 14:25:01 +0000" MODIFIED_BY="[Empty name]" NAME="Safa 2008" YEAR="2008">
<REFERENCE MODIFIED="2013-01-17 14:25:01 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Safa M, Sadr S, Delfan B, Saki M, Javad Tarrahi M</AU>
<TI>Metabolic effects of olanzapine and risperidone in patients with psychotic disorders</TI>
<SO>International Journal of Psychiatry in Clinical Practice</SO>
<YR>2008</YR>
<VL>12</VL>
<NO>4</NO>
<PG>299-302</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Schneiderhan-2011" MODIFIED="2013-01-21 15:46:09 +0000" MODIFIED_BY="[Empty name]" NAME="Schneiderhan 2011" YEAR="2011">
<REFERENCE MODIFIED="2013-01-21 15:46:09 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Schneiderhan ME, Tomaszewski D, Fike J, Madden S, Schweiss S, Davey CS</AU>
<TI>Preliminary data of metabolic risk at 6 months in subjects on antipsychotic agents: A 12-month randomized multi-centered trial</TI>
<SO>Journal of Pharmacy Practice</SO>
<YR>2011</YR>
<VL>2</VL>
<PG>276</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Smith-2010" MODIFIED="2013-01-21 16:14:55 +0000" MODIFIED_BY="[Empty name]" NAME="Smith 2010" YEAR="2010">
<REFERENCE MODIFIED="2013-01-21 16:14:55 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Smith RC, Kanellopoulou I, Rachakonda S, Lindenmayer J-P, Davis JM</AU>
<TI>Olanzapine vs. Risperidone effects on appetite and ghrelin in chronic schizophrenic patients</TI>
<SO>Proceedings of the 49th Annual meeting of the Americam College of Neuropsychopharmacology; 2010 Dec 5-9; Miami, Florida</SO>
<YR>2010</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Smith-2010a" MODIFIED="2013-01-17 14:25:01 +0000" MODIFIED_BY="[Empty name]" NAME="Smith 2010a" YEAR="2010">
<REFERENCE MODIFIED="2013-01-17 14:25:01 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Smith RC, Kanellopoulou I, Rachakonda S, Lindenmayer JP, Davis JM</AU>
<TI>Olanzapine vs. Risperidone effects on appetite and ghrelin in chronic schizophrenic patients</TI>
<SO>Neuropsychopharmacology</SO>
<YR>2010</YR>
<VL>35</VL>
<PG>S315-S6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Spivak-2009" MODIFIED="2013-01-17 14:25:01 +0000" MODIFIED_BY="[Empty name]" NAME="Spivak 2009" YEAR="2009">
<REFERENCE MODIFIED="2013-01-17 14:25:01 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Spivak B</AU>
<TI>Sibutramine for schizophrenia</TI>
<SO>Stanley Foundation Research Programs</SO>
<YR>2009</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Stroup-2011a" MODIFIED="2013-01-21 15:46:09 +0000" MODIFIED_BY="[Empty name]" NAME="Stroup 2011a" YEAR="2011">
<REFERENCE MODIFIED="2013-01-21 15:46:09 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Stroup TS, McEvoy JP, Ring KD, Hamer RH, LaVange LM, Swartz MS, et al</AU>
<TI>A randomized trial examining the effectiveness of switching from olanzapine, quetiapine, or risperidone to aripiprazole to reduce metabolic risk: Comparison of antipsychotics for metabolic problems (camp)</TI>
<SO>American Journal of Psychiatry</SO>
<YR>2011</YR>
<VL>168</VL>
<NO>9</NO>
<PG>947-56</PG>
<IDENTIFIERS MODIFIED="2013-01-17 14:24:59 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="MEDLINE" VALUE="BIOSIS:PREV201100598466"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Stroup-2011b" MODIFIED="2013-01-21 16:15:20 +0000" MODIFIED_BY="[Empty name]" NAME="Stroup 2011b" YEAR="2011">
<REFERENCE MODIFIED="2013-01-21 16:15:20 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Stroup TS, Hamer RM, Ray N, Esscok SM, Lieberman JA</AU>
<TI>The effect of switching from olanzapine, quetiapine, or risperidone to aripiprazole on risk of cardiovascular disease: Results from the comparison of antipsychotics for metabolic problems (camp) study</TI>
<SO>Proceedings of the 50th Annual Meeting of the American College of Neuropsychopharmacology; 2011 Dec 4-8;a, Waikoloa, Hawaii</SO>
<YR>2011</YR>
<PG>S101</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sun-2007" MODIFIED="2013-01-17 14:25:01 +0000" MODIFIED_BY="[Empty name]" NAME="Sun 2007" YEAR="2007">
<REFERENCE MODIFIED="2013-01-17 14:25:01 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Sun J</AU>
<TI>Ranitidine prevention and treatment of olanzapine-induced weight gain and glucose metabolism disorders</TI>
<TO>&#38647;&#23612;&#26367;&#19969;&#38450;&#27835;&#22885;&#27694;&#24179;&#25152;&#33268;&#20307;&#37325;&#22686;&#21152;&#21450;&#31958;&#20195;&#35874;&#38556;&#30861;&#30340;&#30740;&#31350;</TO>
<SO>Chinese Journal of Nervous and Mental Disorders [&#20013;&#22269;&#31070;&#32463;&#31934;&#31070;&#30142;&#30149;&#26434;&#24535;]</SO>
<YR>2007</YR>
<VL>33</VL>
<NO>9</NO>
<PG>560-2</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Takeuchi-2008" MODIFIED="2013-01-21 15:46:09 +0000" MODIFIED_BY="[Empty name]" NAME="Takeuchi 2008" YEAR="2008">
<REFERENCE MODIFIED="2013-01-21 15:46:09 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Takeuchi H, Suzuki T, Uchida H, Nakajima S, Nomura K, Kikuchi T, et al</AU>
<TI>A randomized, open-label comparison of 2 switching strategies to aripiprazole treatment in patients with schizophrenia: add-on, wait, and tapering of previous antipsychotics versus add-on and simultaneous tapering</TI>
<SO>Journal of Clinical Psychopharmacology</SO>
<YR>2008</YR>
<VL>28</VL>
<NO>5</NO>
<PG>540-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tao-2008" MODIFIED="2013-01-21 16:15:50 +0000" MODIFIED_BY="[Empty name]" NAME="Tao 2008" YEAR="2008">
<REFERENCE MODIFIED="2013-01-21 16:15:50 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Tao S-W, Chen Q, Yang C, Pan R-D, Pan T-W, Li L, et al</AU>
<TI>A comparison of the effects on lipid metabolic among four different atypical antipsychotic agents</TI>
<TO>4&#31181;&#38750;&#20856;&#22411;&#25239;&#31934;&#31070;&#30149;&#33647;&#29289;&#23545;&#31934;&#31070;&#20998;&#35010;&#30151;&#24739;&#32773;&#33026;&#20195;&#35874;&#30340;&#24433;&#21709;</TO>
<SO>Journal of the Youjiang Medical College for Nationalities</SO>
<YR>2008</YR>
<VL>6</VL>
<PG>927-30</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tek-2011" MODIFIED="2013-01-21 16:15:58 +0000" MODIFIED_BY="[Empty name]" NAME="Tek 2011" YEAR="2011">
<REFERENCE MODIFIED="2013-01-21 16:15:58 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Tek C, Ratliff JC, Reutenauer EL, Palmese LB, Tonizzo KM, O'Malley SS</AU>
<TI>Low-dose naltrexone for antipsychotic-induced weight gain in women with schizophrenia</TI>
<SO>Obesity</SO>
<YR>2011</YR>
<VL>1</VL>
<PG>S181</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tian-2008" MODIFIED="2013-01-17 14:25:01 +0000" MODIFIED_BY="[Empty name]" NAME="Tian 2008" YEAR="2008">
<REFERENCE MODIFIED="2013-01-17 14:25:01 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Tian H, Zhu Q</AU>
<TI>A comparative study of new antipsychopathic drugs lead to gain weight</TI>
<TO>&#19977;&#31181;&#38750;&#20856;&#22411;&#25239;&#31934;&#31070;&#30149;&#33647;&#29289;&#25152;&#33268;&#20307;&#37325;&#22686;&#21152;&#30340;&#23545;&#29031;&#30740;&#31350;</TO>
<SO>Medical Journal of Chinese People's Health [&#20013;&#22269;&#27665;&#24247;&#21307;&#23398;]</SO>
<YR>2008</YR>
<VL>20</VL>
<NO>18</NO>
<PG>2119, 2122</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tiwari-2010" MODIFIED="2013-01-17 14:25:01 +0000" MODIFIED_BY="[Empty name]" NAME="Tiwari 2010" YEAR="2010">
<REFERENCE MODIFIED="2013-01-17 14:25:01 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Tiwari AK, Zai CC, Meltzer HY, Lieberman JA, Muller DJ, Kennedy JL</AU>
<TI>Association study of polymorphisms in insulin induced gene 2 (insig2) with antipsychotic-induced weight gain in european and african-american schizophrenia patients</TI>
<SO>Human Psychopharmacology</SO>
<YR>2010</YR>
<VL>25</VL>
<NO>3</NO>
<PG>253-9</PG>
<IDENTIFIERS MODIFIED="2013-01-17 14:24:59 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="MEDLINE" VALUE="20373477"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Uzcategui-2007" MODIFIED="2013-01-21 15:46:52 +0000" MODIFIED_BY="[Empty name]" NAME="Uzcategui 2007" YEAR="2007">
<REFERENCE MODIFIED="2013-01-21 15:46:52 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Uzcategui E, EIFakih Y, Rangel N, Galeazzi T, Baptista T</AU>
<TI>Metformin plus sibutramine in the treatment of weight gain and metabolic dysfunction during olanzapine administration: a double-blind, placebo controlled pilot study</TI>
<SO>Proceedings of the 160th Annual Meeting of the American Psychiatric Association; 2007 May 19-24; San Diego, CA</SO>
<YR>2007</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Vaz_x002d_Leal-2008" MODIFIED="2013-01-17 14:25:01 +0000" MODIFIED_BY="[Empty name]" NAME="Vaz-Leal 2008" YEAR="2008">
<REFERENCE MODIFIED="2013-01-17 14:25:01 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Vaz-Leal FJ</AU>
<TI>Metformin plus a lifestyle intervention was more effective than either alone for antipsychotic-induced weight gain: commentary</TI>
<SO>Evidence-Based Medicine</SO>
<YR>2008</YR>
<VL>13</VL>
<NO>5</NO>
<PG>146</PG>
<CY>United Kingdom</CY>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wang-2008" MODIFIED="2013-01-17 14:25:01 +0000" MODIFIED_BY="[Empty name]" NAME="Wang 2008" YEAR="2008">
<REFERENCE MODIFIED="2013-01-17 14:25:01 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wang BH, Du GP</AU>
<TI>Behavioural intervention for antipsychotic caused weight gain</TI>
<TO>&#34892;&#20026;&#24178;&#39044;&#23545;&#25239;&#31934;&#31070;&#30149;&#33647;&#29289;&#25152;&#33268;&#20307;&#36136;&#37327;&#22686;&#21152;&#30340;&#24433;&#21709;</TO>
<SO>Medical Journal of Chinese People's Health [&#20013;&#22269;&#27665;&#24247;&#21307;&#23398;]</SO>
<YR>2008</YR>
<VL>20</VL>
<NO>18</NO>
<PG>2117-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wang-2012" MODIFIED="2013-01-21 15:46:52 +0000" MODIFIED_BY="[Empty name]" NAME="Wang 2012" YEAR="2012">
<REFERENCE MODIFIED="2013-01-21 15:46:52 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wang M, Tong J-h, Zhu G, Liang G-m, Yan H-f, Wang X-z</AU>
<TI>Metformin for treatment of antipsychotic-induced weight gain: A randomized, placebo-controlled study</TI>
<SO>Schizophrenia Research</SO>
<YR>2012</YR>
<VL>138</VL>
<NO>1</NO>
<PG>54-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Warren-2011" MODIFIED="2013-01-21 16:16:07 +0000" MODIFIED_BY="[Empty name]" NAME="Warren 2011" YEAR="2011">
<REFERENCE MODIFIED="2013-01-21 16:16:07 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Warren KR, Buchanan RW, Feldman S, Conley R, Linthicum J, Patricia Ball M, et al</AU>
<TI>Effects of the cannabinoid-1 receptor antagonist rimonabant on satiety signaling in overweight people with schizophrenia: A randomized, double-blind pilot study</TI>
<SO>Schizophrenia Bulletin</SO>
<YR>2011</YR>
<VL>1</VL>
<PG>29</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Weiden" MODIFIED="2013-01-21 15:46:52 +0000" MODIFIED_BY="[Empty name]" NAME="Weiden" YEAR="">
<REFERENCE MODIFIED="2013-01-21 15:46:52 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="UNPUBLISHED">
<AU>Weiden P, Radulovic L, Wang C, Allison D</AU>
<TI>Sibutramine for the treatment of obesity in schizophrenia: randomized, placebo controlled pilot study</TI>
<SO>Unpublished</SO>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Weiden-2008" MODIFIED="2013-01-22 14:39:25 +0000" MODIFIED_BY="[Empty name]" NAME="Weiden 2008" YEAR="2008">
<REFERENCE MODIFIED="2013-01-22 14:39:25 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Harvey PD, Meltzer H, Simpson GM, Potkin SG, Loebel A, Siu C, et al</AU>
<TI>Improvement in cognitive function following a switch to ziprasidone from conventional antipsychotics, olanzapine, or risperidone in outpatients with schizophrenia</TI>
<SO>Schizophrenia Research</SO>
<YR>2004</YR>
<VL>66</VL>
<NO>2-3</NO>
<PG>101-13</PG>
<CY>Netherlands</CY>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="15061242"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2013-01-17 14:25:01 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Weiden PJ, Newcomer JW, Loebel AD, Yang R, Lebovitz HE</AU>
<TI>Long-term changes in weight and plasma lipids during maintenance treatment with ziprasidone</TI>
<SO>Neuropsychopharmacology</SO>
<YR>2008</YR>
<VL>33</VL>
<NO>5</NO>
<PG>985-94</PG>
<IDENTIFIERS MODIFIED="2013-01-17 14:24:59 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="MEDLINE" VALUE="17637612"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wirshing-2009" MODIFIED="2013-01-21 16:17:37 +0000" MODIFIED_BY="[Empty name]" NAME="Wirshing 2009" YEAR="2009">
<REFERENCE MODIFIED="2013-01-21 16:17:37 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Wirshing DA, Erickson ZD, Mena SJ, Guzik LH, Vesterman E, Tran K</AU>
<TI>Management of obesity associated with antipsychotic medication</TI>
<SO>Proceedings of the World Psychiatric Association International congress; 2009 April 1-4th; Florence Italy</SO>
<YR>2009</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wu-2008a" MODIFIED="2013-01-22 14:37:20 +0000" MODIFIED_BY="[Empty name]" NAME="Wu 2008a" YEAR="2008">
<REFERENCE MODIFIED="2013-01-22 14:37:20 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wu R-R, Zhao J-P, Guo X-F, He Y-Q, Fang M-S, Guo W-B, et al</AU>
<TI>Metformin addition attenuates olanzapine-induced weight gain in drug-naive first-episode schizophrenia patients: a double-blind, placebo-controlled study</TI>
<SO>American Journal of Psychiatry</SO>
<YR>2008</YR>
<VL>165</VL>
<NO>3</NO>
<PG>352-8</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="18245179"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2013-01-21 16:05:15 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wu R-R, Zhao J-P, Guo X-F, He Y-Q, Fang M-S, Guo W-B, et al</AU>
<TI>Metformin addition attenuates olanzapine-induced weight gain in drug-naive first-episode schizophrenia patients: a double-blind, placebo-controlled study: correction</TI>
<SO>American Journal of Psychiatry</SO>
<YR>2008</YR>
<VL>165</VL>
<NO>4</NO>
<PG>540</PG>
<IDENTIFIERS MODIFIED="2013-01-21 16:05:15 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wu-2012" MODIFIED="2013-01-21 15:46:52 +0000" MODIFIED_BY="[Empty name]" NAME="Wu 2012" YEAR="2012">
<REFERENCE MODIFIED="2013-01-21 15:46:52 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wu RR, Jin H, Gao K, Twamley EW, Ou JJ, Shao P, et al</AU>
<TI>Metformin for treatment of antipsychotic-induced amenorrhea and weight gain in women with first-episode schizophrenia: A double-blind, randomized, placebo-controlled study</TI>
<SO>American Journal of Psychiatry</SO>
<YR>2012</YR>
<VL>169</VL>
<NO>8</NO>
<PG>813-21</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Yoon-2008" MODIFIED="2013-01-17 14:25:01 +0000" MODIFIED_BY="[Empty name]" NAME="Yoon 2008" YEAR="2008">
<REFERENCE MODIFIED="2013-01-17 14:25:01 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Yoon B-H, Bahk W-M, Bae A, Kim M-K, Jon D-I, Min KJ</AU>
<TI>Effects of 3-months trial of zonisamide and weight management program in obese schizophrenic inpatients</TI>
<SO>International Journal of Neuropsychopharmacology</SO>
<YR>2008</YR>
<VL>11</VL>
<NO>Suppl 1</NO>
<PG>150</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Yoon-2009" MODIFIED="2013-01-21 16:17:47 +0000" MODIFIED_BY="[Empty name]" NAME="Yoon 2009" YEAR="2009">
<REFERENCE MODIFIED="2013-01-21 16:17:47 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Yoon B-H, Bahk W-M, Bae A, Min KJ, Shin Y-C, Jon D-I, et al</AU>
<TI>The effect of weight loss on obesity-related quality of life and body image in obese schizophrenic patients</TI>
<SO>Biological Psychiatry</SO>
<YR>2009</YR>
<VL>1</VL>
<PG>288</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Zhang-2009" MODIFIED="2013-01-17 14:25:01 +0000" MODIFIED_BY="[Empty name]" NAME="Zhang 2009" YEAR="2009">
<REFERENCE MODIFIED="2013-01-17 14:25:01 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Zhang P</AU>
<TI>antipsychotic drugs on body mass of patients with schizophrenia and intervention] Google Translate</TI>
<TO>&#25239;&#31934;&#31070;&#30149;&#33647;&#29289;&#23545;&#31934;&#31070;&#20998;&#35010;&#30151;&#24739;&#32773;&#20307;&#36136;&#37327;&#30340;&#24433;&#21709;&#21450;&#24178;&#39044; [</TO>
<SO>Chinese Journal of Pharmaco Epidemiology [&#33647;&#29289;&#27969;&#34892;&#30149;&#23398;&#26434;&#24535;]</SO>
<YR>2009</YR>
<VL>18</VL>
<NO>6</NO>
<PG>396-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-_x4f46__x96ea__x59e3_-2010" MODIFIED="2013-01-21 16:18:12 +0000" MODIFIED_BY="[Empty name]" NAME="&#20294;&#38634;&#23011; 2010" YEAR="2010">
<REFERENCE MODIFIED="2013-01-21 16:18:12 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>&#20294;&#38634;&#23011;</AU>
<TI>Quetiapine and clozapine on blood lipids, body weight control study [Google Translate]</TI>
<TO>&#22862;&#30827;&#24179;&#19982;&#27695;&#27694;&#24179;&#23545;&#34880;&#33026;&#12289;&#20307;&#37325;&#24433;&#21709;&#23545;&#29031;&#30740;&#31350;</TO>
<SO>Journal of Chinese Rural Physician [&#20013;&#22269;&#31038;&#21306;&#21307;&#24072;&#65306;&#32508;&#21512;&#29256;]</SO>
<YR>2010</YR>
<VL>1</VL>
<PG>30</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-_x5218__x5efa__x91d1_-2011" MODIFIED="2013-01-17 14:25:01 +0000" MODIFIED_BY="[Empty name]" NAME="&#21016;&#24314;&#37329; 2011" YEAR="2011">
<REFERENCE MODIFIED="2013-01-17 14:25:01 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>&#21016;&#24314;&#37329;</AU>
<TI>Topiramate combined olanzapine Prevention second-generation antipsychotic-induced body weight and metabolic dysfunction</TI>
<TO>&#25176;&#21537;&#37231;&#32852;&#21512;&#22885;&#27694;&#24179;&#38450;&#27835;&#31532;&#20108;&#20195;&#25239;&#31934;&#31070;&#30149;&#33647;&#25152;&#33268;&#20307;&#36136;&#37327;&#22686;&#21152;&#21450;&#20195;&#35874;&#21151;&#33021;&#38556;&#30861;&#30340;&#30740;&#31350;</TO>
<SO>&#29616;&#20195;&#23454;&#29992;&#21307;&#23398;</SO>
<YR>2011</YR>
<VL>23</VL>
<NO>06</NO>
<PG>665-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-_x5218__x671d__x519b_-2009" MODIFIED="2013-01-21 15:54:17 +0000" MODIFIED_BY="[Empty name]" NAME="&#21016;&#26397;&#20891; 2009" YEAR="2009">
<REFERENCE MODIFIED="2013-01-17 14:25:01 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>&#21016;&#26397;&#20891;, &#30000;&#32032;&#33521;, &#24352;&#20256;&#33437;, &#21346;&#19990;&#33251;, &#38889;&#40527;</AU>
<TI>Influences on serum prolactin, blood glucose and body we ight for patients with first-episode schizophrenia treated with aripiprazole</TI>
<TO>&#38463;&#31435;&#21708;&#21777;&#23545;&#39318;&#21457;&#31934;&#31070;&#20998;&#35010;&#30151;&#24739;&#32773;&#20195;&#35874;&#30340;&#24433;&#21709;</TO>
<SO>Linchuang Jingshen Yixue Zazhi [&#20020;&#24202;&#31934;&#31070;&#21307;&#23398;&#26434;&#24535;]</SO>
<YR>2009</YR>
<VL>19</VL>
<NO>4</NO>
<PG>244</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-_x5218__x6839_-2010" MODIFIED="2013-01-21 15:54:24 +0000" MODIFIED_BY="[Empty name]" NAME="&#21016;&#26681; 2010" YEAR="2010">
<REFERENCE MODIFIED="2013-01-17 14:25:01 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>&#21016;&#26681;&#20964;, &#38472;&#23020;, &#24464;&#33805;, &#29579;&#20908;&#20113;</AU>
<TI>Systematic health education of diabetic patients with schizophrenia</TI>
<TO>&#31995;&#32479;&#21270;&#20581;&#24247;&#25945;&#32946;&#23545;&#31934;&#31070;&#20998;&#35010;&#30151;&#20276;&#31958;&#23615;&#30149;&#24739;&#32773;&#30340;&#24433;&#21709;</TO>
<SO>&#40784;&#40065;&#25252;&#29702;&#26434;&#24535;</SO>
<YR>2010</YR>
<VL>16</VL>
<NO>25</NO>
<PG>9-10</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-_x5218__x732e__x6807_--2010" MODIFIED="2013-01-21 16:18:44 +0000" MODIFIED_BY="[Empty name]" NAME="&#21016;&#29486;&#26631;  2010" YEAR="2010">
<REFERENCE MODIFIED="2013-01-21 16:18:44 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>&#21016;&#29486;&#26631;, &#21556;&#26149;&#39321;, &#32918;&#27704;&#29645;</AU>
<TI>Quetiapine and sulpiride on serum prolactin in schizophrenic patients and the impact of body weight [Google Translate]</TI>
<TO>&#21945;&#30827;&#24179;&#19982;&#33298;&#24517;&#21033;&#23545;&#31934;&#31070;&#20998;&#35010;&#30151;&#24739;&#32773;&#20307;&#37325;&#21450;&#34880;&#28165;&#20652;&#20083;&#32032;&#30340;&#24433;&#21709;</TO>
<SO>Hebei Medicine [&#27827;&#21271;&#21307;&#23398;]</SO>
<YR>2010</YR>
<VL>16</VL>
<NO>6</NO>
<PG>683-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-_x54c8__x79c0__x82f1_--2011" MODIFIED="2013-01-21 15:54:36 +0000" MODIFIED_BY="[Empty name]" NAME="&#21704;&#31168;&#33521;  2011" YEAR="2011">
<REFERENCE MODIFIED="2013-01-17 14:25:01 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>&#21704;&#31168;&#33521;, &#26690;&#26790;&#33620;, &#29579;&#28113;&#33714;</AU>
<TI>Atypical antipsychotics caused weight gain in clinical research</TI>
<TO>&#38750;&#20856;&#22411;&#25239;&#31934;&#31070;&#30149;&#33647;&#29289;&#25152;&#33268;&#20307;&#37325;&#22686;&#21152;&#30340;&#20020;&#24202;&#30740;&#31350;</TO>
<SO>&#23425;&#22799;&#21307;&#23398;&#26434;&#24535;</SO>
<YR>2011</YR>
<VL>33</VL>
<NO>08</NO>
<PG>775-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-_x5d14__x5f00__x8273__x002c_-2010" MODIFIED="2013-01-21 16:06:03 +0000" MODIFIED_BY="[Empty name]" NAME="&#23828;&#24320;&#33395;, 2010" YEAR="2010">
<REFERENCE MODIFIED="2013-01-21 16:06:03 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>&#23828;&#24320;&#33395;, &#21016;&#20848;&#33452;, &#26472;&#20029;&#25935;</AU>
<TI>Ziprasidone and risperidone on prolactin in patients with schizophrenia and body mass, blood glucose, blood lipid [Google Translate]</TI>
<TO>&#40784;&#25289;&#35199;&#37230;&#19982;&#21033;&#22521;&#37230;&#23545;&#31934;&#31070;&#20998;&#35010;&#30151;&#24739;&#32773;&#27852;&#20083;&#32032;&#21450;&#20307;&#36136;&#37327;&#12289;&#34880;&#31958;&#12289;&#34880;&#33026;&#30340;&#24433;&#21709;</TO>
<SO>Shandong Archives of Psychiatry [&#23665;&#19996;&#31934;&#31070;&#21307;&#23398;]</SO>
<YR>2010</YR>
<VL>23</VL>
<NO>1</NO>
<PG>7-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-_x5f20__x4e1c__x536b_--2009" MODIFIED="2013-01-21 16:19:12 +0000" MODIFIED_BY="[Empty name]" NAME="&#24352;&#19996;&#21355;  2009" YEAR="2009">
<REFERENCE MODIFIED="2013-01-21 16:19:12 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>&#24352;&#19996;&#21355;, &#29976;&#26223;&#26792;, &#39640;&#23384;&#21451;, &#27573;&#24800;&#23792;</AU>
<TI>Aripiprazole and risperidone on glucose and lipid [Google Translate]</TI>
<TO>&#38463;&#31435;&#21708;&#21777;&#19982;&#21033;&#22521;&#37230;&#23545;&#34880;&#31958;&#12289;&#34880;&#33026;&#30340;&#24433;&#21709;</TO>
<SO>Linchuang Jingshen Yixue Zazhi [&#20020;&#24202;&#31934;&#31070;&#21307;&#23398;&#26434;&#24535;]</SO>
<YR>2009</YR>
<VL>19</VL>
<NO>5</NO>
<PG>343-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-_x5f20__x534e__x5764_--2010" MODIFIED="2013-01-21 15:54:50 +0000" MODIFIED_BY="[Empty name]" NAME="&#24352;&#21326;&#22372;  2010" YEAR="2010">
<REFERENCE MODIFIED="2013-01-17 14:25:01 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>&#24352;&#21326;&#22372;, &#34081;&#27427;, &#35874;&#37329;&#39321;, &#23385;&#29618;, &#26354;&#24535;&#21531;</AU>
<TI>Antipsychotics due to the intervention of the metabolic syndrome</TI>
<TO>&#25239;&#31934;&#31070;&#30149;&#33647;&#25152;&#33268;&#20195;&#35874;&#32508;&#21512;&#24449;&#30340;&#24178;&#39044;</TO>
<SO>&#20020;&#24202;&#31934;&#31070;&#21307;&#23398;&#26434;&#24535;</SO>
<YR>2010</YR>
<VL>20</VL>
<NO>06</NO>
<PG>380-2</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-_x5f20__x5cf0_--2010" MODIFIED="2013-01-21 15:54:56 +0000" MODIFIED_BY="[Empty name]" NAME="&#24352;&#23792;  2010" YEAR="2010">
<REFERENCE MODIFIED="2013-01-17 14:25:01 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>&#24352;&#23792;, &#38065;&#31168;&#20029;, &#36154;&#21551;&#20803;</AU>
<TI>Change-control study of ziprasidone and risperidone-induced weight and metabolic indicators</TI>
<TO>&#40784;&#25289;&#35199;&#37230;&#19982;&#21033;&#22521;&#37230;&#25152;&#33268;&#20307;&#37325;&#21450;&#20195;&#35874;&#25351;&#26631;&#21464;&#21270;&#23545;&#29031;&#30740;&#31350;</TO>
<SO>&#20013;&#22269;&#27665;&#24247;&#21307;&#23398;</SO>
<YR>2010</YR>
<VL>22</VL>
<NO>22</NO>
<PG>2840-75</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-_x5f6d__x6c38__x7ea2_--2008" MODIFIED="2013-01-21 15:55:07 +0000" MODIFIED_BY="[Empty name]" NAME="&#24429;&#27704;&#32418;  2008" YEAR="2008">
<REFERENCE MODIFIED="2013-01-17 14:25:01 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>&#24429;&#27704;&#32418;, &#21556;&#36745;&#39068;, &#21525;&#26126;&#32500;</AU>
<TI>Agengts treatment antipsychotics due to obesity</TI>
<TO>&#38450;&#39118;&#36890;&#22307;&#20024;&#27835;&#30103;&#25239;&#31934;&#31070;&#30149;&#33647;&#25152;&#33268;&#32933;&#32982;</TO>
<SO>Journal of Traditional Chinese Medicine [Chung i tsa chih ying wen pan][&#20013;&#37291;&#38620;&#24535;]</SO>
<YR>2008</YR>
<VL>23</VL>
<NO>11</NO>
<PG>1718-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-_x638c__x6c38__x8389_--2010" MODIFIED="2013-01-21 15:55:02 +0000" MODIFIED_BY="[Empty name]" NAME="&#25484;&#27704;&#33673;  2010" YEAR="2010">
<REFERENCE MODIFIED="2013-01-17 14:25:01 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>&#25484;&#27704;&#33673;, &#39532;&#20029;&#27874;, &#29579;&#26104;, &#26446;&#23466;&#20255;</AU>
<TI>Aripiprazole male schizophrenia patients with prolactin and blood sugar, weight</TI>
<TO>&#38463;&#31435;&#21708;&#21777;&#23545;&#30007;&#24615;&#31934;&#31070;&#20998;&#35010;&#30151;&#24739;&#32773;&#27852;&#20083;&#32032;&#21450;&#34880;&#31958;&#12289;&#20307;&#37325;&#30340;&#24433;&#21709;</TO>
<SO>&#31934;&#31070;&#21307;&#23398;&#26434;&#24535;</SO>
<YR>2010</YR>
<VL>23</VL>
<NO>04</NO>
<PG>277-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-_x674e__x6653__x4e00_--2011" MODIFIED="2013-01-21 15:55:14 +0000" MODIFIED_BY="[Empty name]" NAME="&#26446;&#26195;&#19968;  2011" YEAR="2011">
<REFERENCE MODIFIED="2013-01-17 14:25:01 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>&#26446;&#26195;&#19968;, &#37026;&#33862;&#24179;, &#31456;&#36814;&#26149;, &#21556;&#30355;</AU>
<TI>Controlled study of aripiprazole and olanzapine in the treatment of metabolic effects in patients with schizophrenia</TI>
<TO>&#38463;&#31435;&#21708;&#21777;&#19982;&#22885;&#27694;&#24179;&#27835;&#30103;&#23545;&#31934;&#31070;&#20998;&#35010;&#30151;&#24739;&#32773;&#20195;&#35874;&#24433;&#21709;&#30340;&#23545;&#29031;&#30740;&#31350;</TO>
<SO>&#20840;&#31185;&#21307;&#23398;&#20020;&#24202;&#19982;&#25945;&#32946;</SO>
<YR>2011</YR>
<VL>9</VL>
<NO>04</NO>
<PG>384-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-_x674e__x6881_--2009" MODIFIED="2013-01-21 16:20:04 +0000" MODIFIED_BY="[Empty name]" NAME="&#26446;&#26753;  2009" YEAR="2009">
<REFERENCE MODIFIED="2013-01-21 16:20:04 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>&#26446;&#26753;, &#40644;&#28023;&#29141;, &#38518;&#19990;&#27494;, &#38472;&#24378;, &#26472;&#35802;, &#28504;&#22825;&#20255;</AU>
<TI>Three kinds of antipsychotic drugs on glucose metabolism in patients with schizophrenia [Google Translate]</TI>
<TO>3&#31181;&#25239;&#31934;&#31070;&#30149;&#33647;&#29289;&#23545;&#31934;&#31070;&#20998;&#35010;&#30151;&#24739;&#32773;&#31958;&#20195;&#35874;&#30340;&#24433;&#21709;</TO>
<SO>&#24403;&#20195;&#21307;&#23398;</SO>
<YR>2009</YR>
<VL>15</VL>
<NO>24</NO>
<PG>1-2</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-_x674e__x8f76__x741b_--2009" MODIFIED="2013-01-21 16:20:12 +0000" MODIFIED_BY="[Empty name]" NAME="&#26446;&#36726;&#29723;  2009" YEAR="2009">
<REFERENCE MODIFIED="2013-01-21 16:20:12 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>&#26446;&#36726;&#29723;, &#38047;&#23453;&#20142;, &#39532;&#31584;, &#40858;&#20256;&#40527;, &#24464;&#26472;, &#21608;&#26195;&#20142;, et al</AU>
<TI>Effects of 6-month aripiprazle, risperidone or clozapine treatment</TI>
<TO>&#38463;&#31435;&#21708;&#21777;&#12289;&#21033;&#22521;&#37230;&#21644;&#27695;&#27694;&#24179;&#23545;&#31934;&#31070;&#20998;&#35010;&#30151;&#24739;&#32773;&#31958;&#33026;&#20195;&#35874;&#21450;&#20307;&#36136;&#37327;&#24433;&#21709;&#30340;6&#20010;&#26376;&#20020;&#24202;&#35266;&#23519;</TO>
<SO>Chinese Mental Health Journal [&#20013;&#22269;&#24515;&#29702;&#21355;&#29983;&#26434;&#24535;]</SO>
<YR>2009</YR>
<VL>23</VL>
<NO>8</NO>
<PG>569-74</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-_x6768__x4e91__x79c0_-2011" MODIFIED="2013-01-17 14:25:01 +0000" MODIFIED_BY="[Empty name]" NAME="&#26472;&#20113;&#31168; 2011" YEAR="2011">
<REFERENCE MODIFIED="2013-01-17 14:25:01 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>&#26472;&#20113;&#31168;</AU>
<TI>The effect of nursing intervention in schizophrenia in patients with diabetes mellitus</TI>
<TO>&#25252;&#29702;&#24178;&#39044;&#22312;&#31934;&#31070;&#20998;&#35010;&#30151;&#21512;&#24182;&#31958;&#23615;&#30149;&#24739;&#32773;&#20013;&#24212;&#29992;&#30340;&#25928;&#26524;&#35266;&#23519;</TO>
<SO>&#29616;&#20195;&#20013;&#35199;&#21307;&#32467;&#21512;&#26434;&#24535;</SO>
<YR>2011</YR>
<VL>20</VL>
<NO>23</NO>
<PG>2963-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-_x6768__x6625__x5f3a_--2009" MODIFIED="2013-01-21 16:20:33 +0000" MODIFIED_BY="[Empty name]" NAME="&#26472;&#26149;&#24378;  2009" YEAR="2009">
<REFERENCE MODIFIED="2013-01-21 16:20:33 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>&#26472;&#26149;&#24378;, &#26446;&#23453;&#29664;</AU>
<TI>Aripiprazole and olanzapine on body weight, blood glucose control study effects [Google Translate]</TI>
<TO>&#38463;&#31435;&#21708;&#21777;&#19982;&#22885;&#27694;&#24179;&#23545;&#20307;&#36136;&#37327;&#12289;&#34880;&#31958;&#24433;&#21709;&#30340;&#23545;&#29031;&#30740;&#31350;</TO>
<SO>Linchuang Jingshen Yixue Zazhi [&#20020;&#24202;&#31934;&#31070;&#21307;&#23398;&#26434;&#24535;]</SO>
<YR>2009</YR>
<VL>19</VL>
<NO>5</NO>
<PG>339-40</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-_x6768__x8bda_--2010" MODIFIED="2013-01-21 15:55:50 +0000" MODIFIED_BY="[Empty name]" NAME="&#26472;&#35802;  2010" YEAR="2010">
<REFERENCE MODIFIED="2013-01-17 14:25:01 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>&#26472;&#35802;, &#38518;&#19990;&#27494;, &#38472;&#24378;, &#28504;&#28070;&#24503;, &#28504;&#22825;&#20255;, &#26446;&#26753;, et al</AU>
<TI>Association study of four kinds of antipsychotics and glucose metabolism in patients with schizophrenia and glycosylated hemoglobin</TI>
<TO>4&#31181;&#25239;&#31934;&#31070;&#30149;&#33647;&#29289;&#19982;&#31934;&#31070;&#20998;&#35010;&#30151;&#24739;&#32773;&#31958;&#20195;&#35874;&#21450;&#31958;&#21270;&#34880;&#32418;&#34507;&#30333;&#30340;&#20851;&#32852;&#24615;&#30740;&#31350;</TO>
<SO>&#20013;&#22269;&#29616;&#20195;&#21307;&#23398;&#26434;&#24535;</SO>
<YR>2010</YR>
<VL>20</VL>
<NO>18</NO>
<PG>2816-20</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-_x6768__x96c0__x5c4f_--2009" MODIFIED="2013-01-21 15:55:57 +0000" MODIFIED_BY="[Empty name]" NAME="&#26472;&#38592;&#23631;  2009" YEAR="2009">
<REFERENCE MODIFIED="2013-01-17 14:25:01 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>&#26472;&#38592;&#23631;, &#26417;&#22521;&#20426;</AU>
<TI>Affect control study of quetiapine and risperidone on serum prolactin</TI>
<TO>&#22862;&#30827;&#24179;&#19982;&#21033;&#22521;&#37230;&#23545;&#34880;&#28165;&#20652;&#20083;&#32032;&#24433;&#21709;&#23545;&#29031;&#30740;&#31350;</TO>
<SO>Linchuang Jingshen Yixue Zazhi [&#20020;&#24202;&#31934;&#31070;&#21307;&#23398;&#26434;&#24535;]</SO>
<YR>2009</YR>
<VL>19</VL>
<NO>1</NO>
<PG>57-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-_x6768__x96c0__x5c4f_--2009a" MODIFIED="2013-01-21 16:21:09 +0000" MODIFIED_BY="[Empty name]" NAME="&#26472;&#38592;&#23631;  2009a" YEAR="2009">
<REFERENCE MODIFIED="2013-01-21 16:21:09 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>&#26472;&#38592;&#23631;, &#26417;&#22521;&#20426;</AU>
<TI>Quetiapine and risperidone on serum prolactin control study [Google Translate]</TI>
<TO>&#22862;&#30827;&#24179;&#19982;&#21033;&#22521;&#37230;&#23545;&#34880;&#28165;&#20652;&#20083;&#32032;&#24433;&#21709;&#23545;&#29031;&#30740;&#31350;</TO>
<SO>Linchuang Jingshen Yixue Zazhi [&#20020;&#24202;&#31934;&#31070;&#21307;&#23398;&#26434;&#24535;]</SO>
<YR>2009</YR>
<VL>19</VL>
<NO>1</NO>
<PG>57-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-_x6c6a__x536b__x534e_--2009" MODIFIED="2013-01-21 15:56:15 +0000" MODIFIED_BY="[Empty name]" NAME="&#27754;&#21355;&#21326;  2009" YEAR="2009">
<REFERENCE MODIFIED="2013-01-17 14:25:01 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>&#27754;&#21355;&#21326;, &#36213;&#27721;&#28165;, &#29579;&#28949;&#26519;, &#23828;&#24246;, &#27754;&#24191;&#21073;, &#20210;&#29233;&#33459;, et al</AU>
<TI>Impact of antipsychotics on metabolic comparison</TI>
<TO>&#25239;&#31934;&#31070;&#30149;&#33647;&#23545;&#20195;&#35874;&#30340;&#24433;&#21709;&#27604;&#36739;</TO>
<SO>Linchuang Jingshen Yixue Zazhi [&#20020;&#24202;&#31934;&#31070;&#21307;&#23398;&#26434;&#24535;]</SO>
<YR>2009</YR>
<VL>19</VL>
<NO>1</NO>
<PG>55-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-_x6c6a__x536b__x534e_--2009a" MODIFIED="2013-01-21 16:21:30 +0000" MODIFIED_BY="[Empty name]" NAME="&#27754;&#21355;&#21326;  2009a" YEAR="2009">
<REFERENCE MODIFIED="2013-01-21 16:21:30 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>&#27754;&#21355;&#21326;, &#36213;&#27721;&#28165;, &#29579;&#28949;&#26519;, &#23828;&#24246;, &#27754;&#24191;&#21073;, &#20210;&#29233;&#33459;, et al</AU>
<TI>Antipsychotics on metabolism [Google Translate]</TI>
<TO>&#25239;&#31934;&#31070;&#30149;&#33647;&#23545;&#20195;&#35874;&#30340;&#24433;&#21709;&#27604;&#36739;</TO>
<SO>Linchuang Jingshen Yixue Zazhi [&#20020;&#24202;&#31934;&#31070;&#21307;&#23398;&#26434;&#24535;]</SO>
<YR>2009</YR>
<VL>19</VL>
<NO>1</NO>
<PG>55-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-_x738b__x79c0__x82b3_-2011" MODIFIED="2013-01-21 15:56:21 +0000" MODIFIED_BY="[Empty name]" NAME="&#29579;&#31168;&#33459; 2011" YEAR="2011">
<REFERENCE MODIFIED="2013-01-17 14:25:01 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>&#29579;&#31168;&#33459;, &#37101;&#32418;&#20029;, &#24352;&#27946;&#20255;, &#21556;&#38634;&#39134;, &#24352;&#24314;</AU>
<TI>Aripiprazole and ziprasidone, the prevalence of metabolic syndrome in patients with schizophrenia</TI>
<TO>&#38463;&#31435;&#21708;&#21777;&#21644;&#40784;&#25289;&#35199;&#37230;&#23545;&#31934;&#31070;&#20998;&#35010;&#30151;&#24739;&#32773;&#20195;&#35874;&#32508;&#21512;&#24449;&#24739;&#30149;&#29575;&#30340;&#24433;&#21709;</TO>
<SO>&#21307;&#23398;&#20449;&#24687;(&#20013;&#26092;&#21002;)</SO>
<YR>2011</YR>
<VL>6</VL>
<PG>2570-1</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-_x767d__x9526__x6ce2_--2010" MODIFIED="2013-01-21 16:21:53 +0000" MODIFIED_BY="[Empty name]" NAME="&#30333;&#38182;&#27874;  2010" YEAR="2010">
<REFERENCE MODIFIED="2013-01-21 16:21:53 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>&#30333;&#38182;&#27874;, &#40644;&#28023;&#29141;, &#38518;&#19990;&#27494;, &#28504;&#22825;&#20255;, &#26446;&#26753;</AU>
<TI>Three kinds of atypical antipsychotic drugs on lipid metabolism in patients with schizophrenia [Google Translate]</TI>
<TO>3&#31181;&#38750;&#20856;&#22411;&#25239;&#31934;&#31070;&#30149;&#33647;&#29289;&#23545;&#31934;&#31070;&#20998;&#35010;&#30151;&#24739;&#32773;&#33026;&#20195;&#35874;&#30340;&#24433;&#21709;</TO>
<SO>&#20013;&#22269;&#21307;&#33647;&#25351;&#21335;</SO>
<YR>2010</YR>
<VL>8</VL>
<NO>17</NO>
<PG>8-10</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-_x7f57__x4ea8__x5168_-2010" MODIFIED="2013-01-21 16:22:13 +0000" MODIFIED_BY="[Empty name]" NAME="&#32599;&#20136;&#20840; 2010" YEAR="2010">
<REFERENCE MODIFIED="2013-01-21 16:22:13 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>&#32599;&#20136;&#20840;</AU>
<TI>Oral Ou Lanning and risperidone cause significant weight gain in contrast observation [Google Translate]</TI>
<TO>&#21475;&#26381;&#27431;&#20848;&#23425;&#19982;&#21033;&#22521;&#37230;&#24341;&#36215;&#20307;&#37325;&#22686;&#21152;&#30340;&#23545;&#27604;&#35266;&#23519;</TO>
<SO>Journal of the Heze Medical College [&#33743;&#27901;&#21307;&#23398;&#19987;&#31185;&#23398;&#26657;&#23398;&#25253;]</SO>
<YR>2010</YR>
<VL>22</VL>
<NO>1</NO>
<PG>21-2</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-_x803f__x5bd2__x677e_--2009" MODIFIED="2013-01-21 16:22:22 +0000" MODIFIED_BY="[Empty name]" NAME="&#32831;&#23506;&#26494;  2009" YEAR="2009">
<REFERENCE MODIFIED="2013-01-21 16:22:22 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>&#32831;&#23506;&#26494;, &#21016;&#33635;&#33465;, &#36793;&#36763;&#19985;, &#33487;&#31168;&#33593;, &#23828;&#26149;&#38738;, &#33931;&#40857;, et al</AU>
<TI>Comparative study of the effects of ariplprazole and risperidone on the therapeutic effect and patients&#8217;weight in patients with schizophrenia</TI>
<TO>&#38463;&#31435;&#21708;&#21777;&#19982;&#21033;&#22521;&#37230;&#23545;&#31934;&#31070;&#20998;&#35010;&#30151;&#30103;&#25928;&#19982;&#20307;&#37325;&#30340;&#23545;&#29031;&#30740;&#31350;</TO>
<SO>Hebei Medical Journal</SO>
<YR>2009</YR>
<VL>31</VL>
<NO>4</NO>
<PG>407-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-_x949f__x6f47__x7426_-2010" MODIFIED="2013-01-21 16:22:41 +0000" MODIFIED_BY="[Empty name]" NAME="&#38047;&#28487;&#29734; 2010" YEAR="2010">
<REFERENCE MODIFIED="2013-01-21 16:22:41 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>&#38047;&#28487;&#29734;, &#37073;&#24314;&#29618;, &#40644;&#38596;</AU>
<TI>Three kinds of antipsychotic therapy on glucose and lipid metabolism in female first-episode schizophrenia and the impact of prolactin [Google Translate]</TI>
<TO>&#19977;&#31181;&#25239;&#31934;&#31070;&#30149;&#33647;&#27835;&#30103;&#22899;&#24615;&#39318;&#21457;&#31934;&#31070;&#20998;&#35010;&#30151;&#23545;&#31958;&#33026;&#20195;&#35874;&#21450;&#20652;&#20083;&#32032;&#30340;&#24433;&#21709;</TO>
<SO>&#20013;&#22269;&#23454;&#29992;&#21307;&#33647;</SO>
<YR>2010</YR>
<VL>5</VL>
<NO>24</NO>
<PG>15-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-_x9648__x4fca__x96c4_-2010" MODIFIED="2013-01-21 15:57:03 +0000" MODIFIED_BY="[Empty name]" NAME="&#38472;&#20426;&#38596; 2010" YEAR="2010">
<REFERENCE MODIFIED="2013-01-17 14:25:01 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>&#38472;&#20426;&#38596;, &#21556;&#26641;&#36291;, &#26519;&#27029;, &#38472;&#24576;&#24681;</AU>
<TI>Metformin combined behavioral intervention therapy of clozapine in the treatment of schizophrenia in patients with body weight, blood glucose, blood lipids</TI>
<TO>&#20108;&#30002;&#21452;&#32973;&#21512;&#24182;&#34892;&#20026;&#24178;&#39044;&#30103;&#27861;&#23545;&#27695;&#27694;&#24179;&#27835;&#30103;&#31934;&#31070;&#20998;&#35010;&#30151;&#24739;&#32773;&#20307;&#37325;&#12289;&#34880;&#31958;&#12289;&#34880;&#33026;&#30340;&#24433;&#21709;</TO>
<SO>&#22235;&#24029;&#31934;&#31070;&#21355;&#29983;</SO>
<YR>2010</YR>
<VL>23</VL>
<NO>04</NO>
<PG>198-202</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-_x9676__x4e16__x6b66_-2009" MODIFIED="2013-01-21 16:23:03 +0000" MODIFIED_BY="[Empty name]" NAME="&#38518;&#19990;&#27494; 2009" YEAR="2009">
<REFERENCE MODIFIED="2013-01-21 16:23:03 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>&#38518;&#19990;&#27494;, &#26472;&#35802;, &#38472;&#24378;, &#28504;&#28070;&#24503;, &#28504;&#22825;&#20255;, &#26446;&#26753;, et al</AU>
<TI>Four kinds of atypical antipsychotics on glucose and lipid metabolism in patients with schizophrenia [Google Translate]</TI>
<TO>4&#31181;&#38750;&#20856;&#22411;&#25239;&#31934;&#31070;&#30149;&#33647;&#29289;&#23545;&#31934;&#31070;&#20998;&#35010;&#30151;&#24739;&#32773;&#34880;&#31958;&#21450;&#34880;&#33026;&#20195;&#35874;&#30340;&#24433;&#21709;</TO>
<SO>Guangxi Medical Journal</SO>
<YR>2009</YR>
<VL>31</VL>
<NO>9</NO>
<PG>1238-41</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-_x9676__x4e16__x6b66_-2010" MODIFIED="2013-01-21 15:57:16 +0000" MODIFIED_BY="[Empty name]" NAME="&#38518;&#19990;&#27494; 2010" YEAR="2010">
<REFERENCE MODIFIED="2013-01-17 14:25:01 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>&#38518;&#19990;&#27494;, &#26472;&#35802;, &#28504;&#28070;&#24503;, &#28504;&#22825;&#20255;, &#26446;&#26753;</AU>
<TI>Four atypical antipsychotics, the prevalence of metabolic syndrome in patients with schizophrenia</TI>
<TO>&#22235;&#31181;&#38750;&#20856;&#22411;&#25239;&#31934;&#31070;&#30149;&#33647;&#29289;&#23545;&#31934;&#31070;&#20998;&#35010;&#30151;&#24739;&#32773;&#20195;&#35874;&#32508;&#21512;&#24449;&#24739;&#30149;&#29575;&#30340;&#24433;&#21709;</TO>
<SO>&#31934;&#31070;&#21307;&#23398;&#26434;&#24535;</SO>
<YR>2010</YR>
<VL>23</VL>
<NO>05</NO>
<PG>365-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</AWAITING_STUDIES>
<ONGOING_STUDIES MODIFIED="2010-09-27 14:19:10 +0100" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Tang-2003" MODIFIED="2010-09-27 14:19:10 +0100" MODIFIED_BY="[Empty name]" NAME="Tang 2003" YEAR="2003">
<REFERENCE MODIFIED="2010-09-27 14:19:10 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Tang T, Meltzer HY</AU>
<TI>Olanzapine causes greater increases in serum lipids than risperidone</TI>
<SO>Schizophrenia Research</SO>
<YR>2003</YR>
<VL>60</VL>
<NO>1</NO>
<PG>367</PG>
<IDENTIFIERS MODIFIED="2010-09-27 14:19:10 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</ONGOING_STUDIES>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2010-10-29 06:03:43 +0100" MODIFIED_BY="[Empty name]">
<ADDITIONAL_REFERENCES MODIFIED="2010-10-29 06:03:43 +0100" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-ADA_x002f_APA-2004" MODIFIED="2010-09-27 14:19:56 +0100" MODIFIED_BY="[Empty name]" NAME="ADA/APA 2004" TYPE="JOURNAL_ARTICLE">
<AU>American Diabetes Association, American Psychiatric Association, American Association of Clinical Endocrinologists, North American Association for the Study of Obesity</AU>
<TI>Consensus development conference on antipsychotic drugs and obesity and diabetes</TI>
<SO>Diabetes Care</SO>
<YR>2004</YR>
<VL>27</VL>
<PG>596-601</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Allison-1999" MODIFIED="2010-10-29 05:49:20 +0100" MODIFIED_BY="[Empty name]" NAME="Allison 1999" TYPE="JOURNAL_ARTICLE">
<AU>Allison DB, Mentore JL, Heo M, Chandler LP, Cappelleri JC, Infante MC, Weiden PJ</AU>
<TI>Antipsychotic-induced weight gain: a comprehensive research synthesis</TI>
<SO>American Journal of Psychiatry</SO>
<YR>1999</YR>
<VL>156</VL>
<NO>11</NO>
<PG>1686-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Allison-2003" MODIFIED="2010-10-29 05:49:35 +0100" MODIFIED_BY="[Empty name]" NAME="Allison 2003" TYPE="JOURNAL_ARTICLE">
<AU>Allison DB, Mackell JA, McDonnell DD</AU>
<TI>The impact of weight gain on quality of life among persons with schizophrenia</TI>
<SO>Psychiatric Services</SO>
<YR>2003</YR>
<VL>54</VL>
<PG>565-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Altman-1996" MODIFIED="2010-09-27 14:21:43 +0100" MODIFIED_BY="[Empty name]" NAME="Altman 1996" TYPE="JOURNAL_ARTICLE">
<AU>Altman DG, Bland JM</AU>
<TI>Detecing skewness from summary information</TI>
<SO>BMJ</SO>
<YR>1996</YR>
<VL>313</VL>
<PG>1200</PG>
<IDENTIFIERS MODIFIED="2010-09-27 14:21:43 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-Birt-2003" NAME="Birt 2003" TYPE="JOURNAL_ARTICLE">
<AU>Birt J</AU>
<TI>Management of weight gain associated with antipsychotics</TI>
<SO>Annals of Clinical Psychiatry</SO>
<YR>2003</YR>
<VL>15</VL>
<PG>49-58</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Bland-1997" MODIFIED="2009-11-16 15:51:01 +0000" MODIFIED_BY="[Empty name]" NAME="Bland 1997" TYPE="JOURNAL_ARTICLE">
<AU>Bland JM, Kerry SM</AU>
<TI>Statistics notes. Trials randomised in clusters</TI>
<SO>BMJ</SO>
<YR>1997</YR>
<VL>315</VL>
<PG>600</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Boissel-1999" MODIFIED="2009-11-16 15:51:01 +0000" MODIFIED_BY="[Empty name]" NAME="Boissel 1999" TYPE="JOURNAL_ARTICLE">
<AU>Boissel JP, Cucherat M, Li W, Chatellier G, Gueyffier F, Buyse M, Boutitie F, Nony P, Haugh M, Mignot G</AU>
<TI>The problem of therapeutic efficacy indices. 3. Comparison of the indices and their use</TI>
<SO>Therapie</SO>
<YR>1999</YR>
<VL>54</VL>
<NO>4</NO>
<PG>405-11</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Casey-2004" MODIFIED="2010-09-27 14:22:12 +0100" MODIFIED_BY="[Empty name]" NAME="Casey 2004" TYPE="JOURNAL_ARTICLE">
<AU>Casey DE, Haupt DW, Newcomer JW, Henderson DC, Sernyak MJ, Davidson M, Lindenmayer JP, Manoukian SV, Banerji, MA, Lebovitz HE, Hennekens CH</AU>
<TI>Antipsychotic-induced weight gain and metabolic abnormalities: Implications for increased mortality in patients with schizophrenia</TI>
<SO>Journal of Clinical Psychiatry</SO>
<YR>2004</YR>
<VL>65</VL>
<NO>Suppl 7</NO>
<PG>4-18</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Catapana-2004" MODIFIED="2010-10-29 05:50:04 +0100" MODIFIED_BY="[Empty name]" NAME="Catapana 2004" TYPE="JOURNAL_ARTICLE">
<AU>Catapana L, Castle D</AU>
<TI>Obesity in schizophrenia: What can be done about it?</TI>
<SO>Australasian Psychiatry</SO>
<YR>2004</YR>
<VL>12</VL>
<PG>23-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-CATIE-2006" MODIFIED="2010-10-29 05:50:15 +0100" MODIFIED_BY="[Empty name]" NAME="CATIE 2006" TYPE="JOURNAL_ARTICLE">
<AU>Essock SM, Covell NH, Davis SM, Stroup TS, Rosenheck RA, Lieberman JA</AU>
<TI>Effectiveness of switching antipsychotic medications</TI>
<SO>American Journal of Psychiatry   </SO>
<YR>2006</YR>
<VL>163</VL>
<PG>2090-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Cohn-2004" MODIFIED="2010-09-27 14:22:44 +0100" MODIFIED_BY="[Empty name]" NAME="Cohn 2004" TYPE="JOURNAL_ARTICLE">
<AU>Cohn T, Prud'homme D, Streiner D, Kameh H, Remington G</AU>
<TI>Characterizing coronary heart disease risk in chronic schizophrenia: High prevalence of the metabolic syndrome</TI>
<SO>Canadian Journal of Psychiatry</SO>
<YR>2004</YR>
<VL>49</VL>
<PG>753-60</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Coodin-2001" NAME="Coodin 2001" TYPE="JOURNAL_ARTICLE">
<AU>Coodin S</AU>
<TI>Body mass index in persons with schizophrenia</TI>
<SO>Canadian Journal of Psychiatry</SO>
<YR>2001</YR>
<VL>46</VL>
<PG>549-55</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Daumit-2003" MODIFIED="2010-09-27 14:22:59 +0100" MODIFIED_BY="[Empty name]" NAME="Daumit 2003" TYPE="JOURNAL_ARTICLE">
<AU>Daumit GL, Clark JM, Steinwachs DM, Graham CM, Lehman A, Ford DE</AU>
<TI>Prevalence and correlates of obesity in a community sample of individuals with severe and persistent mental illness</TI>
<SO>Journal of Nervous and Mental Disease</SO>
<YR>2003</YR>
<VL>191</VL>
<PG>799-805</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-De-Nayer-2005" MODIFIED="2009-11-16 15:51:01 +0000" MODIFIED_BY="[Empty name]" NAME="De Nayer 2005" TYPE="JOURNAL_ARTICLE">
<AU>De Nayer A, De Hert M, Scheen A, Van Gaal L, Peuskens J on behalf of the Consensus Group</AU>
<TI>Belgian consensus on metabolic problems associated with atypical antipsychotics</TI>
<SO>International Journal of Psychiatry in Clinical Practice</SO>
<YR>2005</YR>
<VL>9</VL>
<PG>130-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Deeks-2000" MODIFIED="2010-09-27 14:23:29 +0100" MODIFIED_BY="[Empty name]" NAME="Deeks 2000" TYPE="CONFERENCE_PROC">
<AU>Deeks J</AU>
<TI>Issues in the selection for meta-analyses of binary data</TI>
<SO>Proceedings of the 8th International Cochrane Colloquium; 2000 Oct 25-28th; Cape Town, South Africa</SO>
<YR>2000</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Divine-1992" MODIFIED="2009-11-16 15:51:01 +0000" MODIFIED_BY="[Empty name]" NAME="Divine 1992" TYPE="JOURNAL_ARTICLE">
<AU>Divine GW, Brown JT, Frazer LM</AU>
<TI>The unit of analysis error in studies about physicians' patient care behavior</TI>
<SO>Journal of General Internal Medicine</SO>
<YR>1992</YR>
<VL>7</VL>
<PG>623-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-DoH-2004" MODIFIED="2010-09-27 14:24:25 +0100" MODIFIED_BY="[Empty name]" NAME="DoH 2004" TYPE="BOOK">
<AU>Department of Health</AU>
<SO>At Least Five a Week. A Report From the Chief Medical Officer</SO>
<YR>2004</YR>
<PB>HMSO, London</PB>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Donner-2002" MODIFIED="2010-10-28 11:46:54 +0100" MODIFIED_BY="[Empty name]" NAME="Donner 2002" TYPE="JOURNAL_ARTICLE">
<AU>Donner A, Klar N</AU>
<TI>Issues in the meta-analysis of cluster randomized trials</TI>
<SO>Statistics in Medicine</SO>
<YR>2002</YR>
<VL>21</VL>
<PG>2971-80</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Egger-1997" MODIFIED="2010-06-28 12:37:21 +0100" MODIFIED_BY="[Empty name]" NAME="Egger 1997" TYPE="JOURNAL_ARTICLE">
<AU>Egger M, Davey-Smith G, Schneider M, Minder C</AU>
<TI>Bias in meta-analysis detected by a simple, graphical test</TI>
<SO>BMJ</SO>
<YR>1997</YR>
<VL>315</VL>
<PG>629-34</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Faulkner-2007" MODIFIED="2010-09-27 14:24:41 +0100" MODIFIED_BY="[Empty name]" NAME="Faulkner 2007" TYPE="COCHRANE_REVIEW">
<AU>Faulkner G, Cohn T, Remington G</AU>
<TI>Interventions to reduce weight gain in schizophrenia.</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2007</YR>
<NO>1</NO>
<IDENTIFIERS MODIFIED="2010-06-28 12:55:58 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2010-06-28 12:55:58 +0100" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD005148.pub2"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Goff-2005" MODIFIED="2009-11-16 15:51:01 +0000" MODIFIED_BY="[Empty name]" NAME="Goff 2005" TYPE="JOURNAL_ARTICLE">
<AU>Goff DC, Sullivan LM, McEvoy JP, Meyer JM, Nasrallah NA, Daumit GL, Lamberti S, D'Agostino RB, Stroup TS, Davis S, Lieberman JA</AU>
<TI>A comparison of ten-year cardiac risk estimates in schizophrenia patients from the CATIE study and matched controls</TI>
<SO>Schizophrenia Research</SO>
<YR>2005</YR>
<VL>80</VL>
<PG>45-53</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Green-2000" MODIFIED="2010-09-27 14:25:07 +0100" MODIFIED_BY="[Empty name]" NAME="Green 2000" TYPE="JOURNAL_ARTICLE">
<AU>Green A, Patel J, Goisman R</AU>
<TI>Weight gain from novel antipsychotic drugs: Need for action</TI>
<SO>General Hospital Psychiatry</SO>
<YR>2000</YR>
<VL>22</VL>
<PG>224-35</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Gulliford-1999" MODIFIED="2010-10-29 06:03:13 +0100" MODIFIED_BY="[Empty name]" NAME="Gulliford 1999" TYPE="JOURNAL_ARTICLE">
<AU>Gulliford MC, Ukoumunne OC, Chinn S</AU>
<TI>Components of variance and intraclass correlations for the design of community-based surveys and intervention studies: data from the health survey for England 1994</TI>
<SO>American Journal of Epidemiology</SO>
<YR>1999</YR>
<VL>149</VL>
<PG>876-83</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Guy-1976" MODIFIED="2010-09-27 14:25:33 +0100" MODIFIED_BY="[Empty name]" NAME="Guy 1976" TYPE="BOOK">
<AU>Guy U</AU>
<SO>ECDEU Assessment Manual for Psychopharmacology</SO>
<YR>1976</YR>
<EN>Revised</EN>
<PB>National Institute of Mental Health</PB>
<CY>Rockville</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Henderson-2005" MODIFIED="2009-11-16 15:51:01 +0000" MODIFIED_BY="[Empty name]" NAME="Henderson 2005" TYPE="JOURNAL_ARTICLE">
<AU>Henderson DC, Nguyen DD, Copeland PM, Hayden DL, Borba CP, Louie PM, Freudenreich O, Eden Evins A, Cather C, Goff DC</AU>
<TI>Clozapine, diabetes mellitus, hyperlipidemia, and cardiovascular risks and mortality: Results of a 10-year naturalistic study</TI>
<SO>Journal of Clinical Psychiatry</SO>
<YR>2005</YR>
<VL>66</VL>
<PG>1116-21</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hester--2005" MODIFIED="2010-10-29 05:51:07 +0100" MODIFIED_BY="[Empty name]" NAME="Hester  2005" TYPE="JOURNAL_ARTICLE">
<AU>Hester EK, Thrower MR</AU>
<TI>Current options in the management of olanzapine - associated weight gain</TI>
<SO>Annals of Pharmacotherapy</SO>
<YR>2005</YR>
<VL>39</VL>
<NO>2</NO>
<PG>302-10</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2003" MODIFIED="2009-11-16 15:51:01 +0000" MODIFIED_BY="[Empty name]" NAME="Higgins 2003" TYPE="JOURNAL_ARTICLE">
<AU>Higgins JP, Thompson SG, Deeks JJ, Altman DG</AU>
<TI>Measuring inconsistency in meta-analyses</TI>
<SO>BMJ</SO>
<YR>2003</YR>
<VL>327</VL>
<PG>557-60</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2005" MODIFIED="2010-09-27 14:26:50 +0100" MODIFIED_BY="[Empty name]" NAME="Higgins 2005" TYPE="OTHER">
<AU>Higgins JPT, Green S (editors)</AU>
<TI>Cochrane Handbook for Systematic Reviews of Interventions 4.2.5 [updated May 2005]</TI>
<SO>The Cochrane Library</SO>
<YR>2005</YR>
<NO>3</NO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2009" MODIFIED="2010-09-27 14:27:33 +0100" MODIFIED_BY="[Empty name]" NAME="Higgins 2009" TYPE="OTHER">
<AU>Higgins JPT, Green S (editors)</AU>
<TI>Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.2 [updated September 2009] The Cochrane Collaboration, 2009</TI>
<SO>Available from www.cochrane-handbook.org</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Homel-2002" MODIFIED="2010-09-27 14:28:06 +0100" MODIFIED_BY="[Empty name]" NAME="Homel 2002" TYPE="JOURNAL_ARTICLE">
<AU>Homel P, Casey D, Allison DB</AU>
<TI>Changes in body mass index for individuals with and without schizophrenia</TI>
<SO>Schizophrenia Research</SO>
<YR>2002</YR>
<VL>55</VL>
<PG>277-84</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-IDF" MODIFIED="2010-06-28 12:53:38 +0100" MODIFIED_BY="[Empty name]" NAME="IDF" TYPE="OTHER">
<AU>International Diabetic Federation</AU>
<TI>IDF consensus worldwide definition of the metabolic syndrome</TI>
<SO>http://www.idf.org/webdata/docs/MetS_def_update2006.pdf</SO>
<YR>2006</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-J_x00fc_ni-2001" MODIFIED="2010-06-28 12:42:32 +0100" MODIFIED_BY="[Empty name]" NAME="Jüni 2001" TYPE="JOURNAL_ARTICLE">
<AU>Jüni P, Altman DG, Egger M</AU>
<TI>Assessing the quality of controlled clinical trials</TI>
<SO>BMJ</SO>
<YR>2001</YR>
<VL>323</VL>
<PG>42-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kay-1986" MODIFIED="2010-09-27 14:29:22 +0100" MODIFIED_BY="[Empty name]" NAME="Kay 1986" TYPE="BOOK">
<AU>Kay SR, Opler LA, Fiszbein A</AU>
<SO>Positive and Negative Syndrome Scale (PANSS) Manual</SO>
<YR>1986</YR>
<PB>Multi-Health Systems</PB>
<CY>North Tonawanda (NY)</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kurzthaler-2001" MODIFIED="2010-06-28 12:56:45 +0100" MODIFIED_BY="[Empty name]" NAME="Kurzthaler 2001" TYPE="JOURNAL_ARTICLE">
<AU>Kurzthaler I, Fleischhacker WW</AU>
<TI>The clinical implications of weight gain in schizophrenia</TI>
<SO>Journal of Clinical Psychiatry</SO>
<YR>2001</YR>
<VL>62</VL>
<NO>Suppl 7</NO>
<PG>32-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Le-Fevre-2001" MODIFIED="2009-11-16 14:34:49 +0000" MODIFIED_BY="[Empty name]" NAME="Le Fevre 2001" TYPE="JOURNAL_ARTICLE">
<AU>Le Fevre PD</AU>
<TI>Improving the physical health of patients with schizophrenia: Therapeutic nihilism or realism?</TI>
<SO>Scottish Medical Journal</SO>
<YR>2001</YR>
<VL>46</VL>
<PG>11-31</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Mackin-2005" MODIFIED="2010-09-27 14:29:40 +0100" MODIFIED_BY="[Empty name]" NAME="Mackin 2005" TYPE="JOURNAL_ARTICLE">
<AU>Mackin P, Watkinson HM, Young AH</AU>
<TI>Prevalence of obesity, glucose homeostasis disorders and metabolic syndrome in psychiatric patients taking typical or atypical antipsychotic drugs: A cross-sectional study</TI>
<SO>Diabetologia</SO>
<YR>2005</YR>
<VL>48</VL>
<PG>215-21</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Marshall-2000" MODIFIED="2009-11-16 15:51:01 +0000" MODIFIED_BY="[Empty name]" NAME="Marshall 2000" TYPE="JOURNAL_ARTICLE">
<AU>Marshall M, Lockwood A, Adams C, Bradley C, Joy C, Fenton M</AU>
<TI>Unpublished rating scales - a major source of bias in randomised controlled trials of treatments for schizophrenia?</TI>
<SO>British Journal of Psychiatry</SO>
<YR>2000</YR>
<VL>176</VL>
<PG>249-52</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Osborn-2001" MODIFIED="2010-09-27 14:30:06 +0100" MODIFIED_BY="[Empty name]" NAME="Osborn 2001" TYPE="JOURNAL_ARTICLE">
<AU>Osborn DPJ</AU>
<TI>The poor physical health of people with mental illness</TI>
<SO>Western Journal of Medicine</SO>
<YR>2001</YR>
<VL>175</VL>
<PG>329-32</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Remington-2005" MODIFIED="2010-09-27 14:30:48 +0100" MODIFIED_BY="[Empty name]" NAME="Remington 2005" TYPE="JOURNAL_ARTICLE">
<AU>Remington G, Chue P, Stip E, Kopala L, Girard T, Christensen B</AU>
<TI>The crossover approach to switching antipsychotics: What is the evidence?</TI>
<SO>Schizophrenia Research</SO>
<YR>2005</YR>
<VL>76</VL>
<PG>267-72</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Ried-2003" MODIFIED="2010-10-29 06:03:43 +0100" MODIFIED_BY="[Empty name]" NAME="Ried 2003" TYPE="JOURNAL_ARTICLE">
<AU>Ried LD, Renner BT, Bengston MA, Wilcox BM, Acholonu WW</AU>
<TI>Weight change after an atypical antipsychotic switch</TI>
<SO>The Annals of Pharmacotherapy</SO>
<YR>October 2003</YR>
<VL>37</VL>
<PG>1381-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Saari-2005" MODIFIED="2010-09-27 14:31:08 +0100" MODIFIED_BY="[Empty name]" NAME="Saari 2005" TYPE="JOURNAL_ARTICLE">
<AU>Saari KM, Lindeman SM, Viilo KM, Isohanni MK, Jarvelin MR, Lauren LH, Savolainen MJ, Koponen HJ</AU>
<TI>A 4-fold risk of metabolic syndrome in patients with schizophrenia: The Northern Finland 1966 birth cohort study</TI>
<SO>Journal of Clinical Psychiatry</SO>
<YR>2005</YR>
<VL>66</VL>
<PG>559-63</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Silverstone-1988" MODIFIED="2010-10-29 05:52:59 +0100" MODIFIED_BY="[Empty name]" NAME="Silverstone 1988" TYPE="JOURNAL_ARTICLE">
<AU>Silverstone T, Smith G, Goodall E</AU>
<TI>Prevalence of obesity in patients receiving depot antipsychotics</TI>
<SO>British Journal of Psychiatry</SO>
<YR>1988</YR>
<VL>153</VL>
<PG>214-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Strassnig-2003" MODIFIED="2010-09-27 14:31:24 +0100" MODIFIED_BY="[Empty name]" NAME="Strassnig 2003" TYPE="JOURNAL_ARTICLE">
<AU>Strassnig M, Brar JS, Ganguli R</AU>
<TI>Body mass index and quality of life in community-dwelling patients with schizophrenia</TI>
<SO>Schizophrenia Research</SO>
<YR>2003</YR>
<VL>62</VL>
<PG>73-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Susce-2005" MODIFIED="2010-10-29 05:53:21 +0100" MODIFIED_BY="[Empty name]" NAME="Susce 2005" TYPE="JOURNAL_ARTICLE">
<AU>Susce MT, Villanueva N, Diaz FJ, De Leon J</AU>
<TI>Obesity and associated complications in patients with severe mental illnesses: a cross-sectional survey</TI>
<SO>Journal of Clinical Psychiatry</SO>
<YR>2005</YR>
<VL>66</VL>
<PG>167-73</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Ukoumunne-1999" MODIFIED="2010-09-27 14:31:43 +0100" MODIFIED_BY="[Empty name]" NAME="Ukoumunne 1999" TYPE="JOURNAL_ARTICLE">
<AU>Ukoumunne OC, Gulliford MC, Chinn S, Sterne JAC, Burney PGJ</AU>
<TI>Methods for evaluating area-wide and organisation-based interventions in health and health care: a systematic review</TI>
<SO>Health Technology Assessment</SO>
<YR>1999</YR>
<VL>3</VL>
<NO>5</NO>
<PG>iii-92</PG>
<IDENTIFIERS MODIFIED="2010-09-27 14:31:43 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-Weiden-2004" MODIFIED="2010-09-27 14:31:50 +0100" MODIFIED_BY="[Empty name]" NAME="Weiden 2004" TYPE="JOURNAL_ARTICLE">
<AU>Weiden PJ, Mackell JA, McDonnell DD</AU>
<TI>Obesity as a risk factor for antipsychotic noncompliance</TI>
<SO>Schizophrenia Research</SO>
<YR>2004</YR>
<VL>66</VL>
<PG>51-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Wikipedia-2007" MODIFIED="2010-09-27 14:32:25 +0100" MODIFIED_BY="[Empty name]" NAME="Wikipedia 2007" TYPE="OTHER">
<AU>Wikipedia</AU>
<TI>Europoid</TI>
<SO>http: //en.wikipedia.org/wiki/Europoid</SO>
<YR>(accessed 10 January 2007)</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Wirshing-2004" MODIFIED="2010-09-27 14:32:36 +0100" MODIFIED_BY="[Empty name]" NAME="Wirshing 2004" TYPE="JOURNAL_ARTICLE">
<AU>Wirshing DA</AU>
<TI>Schizophrenia and obesity: impact of antipsychotic medications</TI>
<SO>Journal of Clinical Psychiatry</SO>
<YR>2004</YR>
<VL>65</VL>
<NO>Suppl 18</NO>
<PG>13-26</PG>
<IDENTIFIERS/>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES MODIFIED="2008-09-18 12:17:37 +0100" MODIFIED_BY="[Empty name]"/>
<PENDING_REFERENCES MODIFIED="2009-06-15 14:35:26 +0100" MODIFIED_BY="[Empty name]"/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES MODIFIED="2013-01-22 14:49:26 +0000" MODIFIED_BY="[Empty name]">
<CHARACTERISTICS_OF_INCLUDED_STUDIES MODIFIED="2010-10-29 05:22:11 +0100" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR MODIFIED="2010-10-29 05:17:08 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Casey-2003">
<CHAR_METHODS MODIFIED="2010-10-29 05:03:29 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised. <BR/>Blindness: open. <BR/>Duration: 8 weeks. <BR/>Setting: outpatients, multicentre, United States.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-10-29 05:17:08 +0100" MODIFIED_BY="[Empty name]">
<P>Diagnosis: schizophrenia or schizoaffective disorder. <BR/>N = 311. <BR/>Age: 18 to 65 years; mean ~39±10. <BR/>Weight: ~ mean 90 kg (SD 20). <BR/>Sex: 218 men, 93 women. <BR/>History: chronic and stable illness, on single oral typical (haloperidol or thioridazine) or atypical (olanzapine or risperidone) antipsychotic, adequate clinical reason for switch, no hospitalisation for 2 months prior to study, no risk of suicide, not pregnant, no neurological diagnosis, no acute or unstable diagnosis, no alcohol or psychoactive substance dependence.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-10-29 05:04:12 +0100" MODIFIED_BY="[Empty name]">
<P>1. Switch to aripiprazole 30mg: immediate initiation with immediate discontinuation of current antipsychotic. N = 104.</P>
<P>2. Switch to aripiprazole 30mg: immediate initiation and tapering of current antipsychotics over two weeks. N = 104.</P>
<P>3. Switch to aripiprazole 30mg: titrating aripiprazole upwards and tapering of current antipsychotic over two weeks. N = 103.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-10-29 05:04:27 +0100" MODIFIED_BY="[Empty name]">
<P>Body weight. Global state: CGI-S,  CGI-I Mental state: PANSS. Loss to follow-up. Adverse events.</P>
<P>Unable to use - vital signs and laboratory measures (no numerical data).</P>
<P>Adverse events: AIMS, Barnes Akathesia scale, SAS.</P>
<P>prolactin, QTc interval.* Concomitant medication: (no numerical data reported).**</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-10-29 05:04:45 +0100" MODIFIED_BY="[Empty name]">
<P>* safety data set total N = 309.</P>
<P>** may cause weight gain.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-10-29 05:18:06 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Cookson-1986">
<CHAR_METHODS MODIFIED="2010-10-29 05:06:57 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised, stratified by sex, no further details. <BR/>Blindness: double. <BR/>Duration: 1 year. <BR/>Setting: depot injection clinic, London, United Kingdom.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-10-29 05:18:06 +0100" MODIFIED_BY="[Empty name]">
<P>Diagnosis: unclear, likely schizophrenia. <BR/>N = 19. <BR/>Age: average ~43 years, range 26-60. BMI &gt; 25. <BR/>Sex: 9 male, 10 female. <BR/>History: regular attenders, stable.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-10-29 05:07:40 +0100" MODIFIED_BY="[Empty name]">
<P>1. Haloperidol decanoate: dose (four times the dose and the same frequency as previously prescribed fluphenazine decanoate) N = 10. <BR/>2. Fluphenazine decanoate: same dose and frequency as had previously been on. N = 9.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-10-29 05:07:55 +0100" MODIFIED_BY="[Empty name]">
<P>Weight: final average change. <BR/>Global state: dose change, extra medication. <BR/>Mental state: overall impression. Loss to follow-up.</P>
<P>Unable to use - Mental state: Krawiecka-Goldberg scale, Schizophrenia Change Scale and Comprehensive Psychopathological Rating Scale (no numerical data). Adverse effects: Simpson and Angus Scale and Abnormal Involuntary Movement Scale (no usable data).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-11-16 14:34:49 +0000" MODIFIED_BY="[Empty name]">
<P>Weight data: mean change reported but SD calculated by reading off graph.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-10-29 05:11:17 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Eli-Lilly-2004">
<CHAR_METHODS MODIFIED="2010-10-29 05:08:47 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised. <BR/>Blindness: double. <BR/>Duration: 24 weeks. <BR/>Setting: 26 outpatient study centres in one country.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-10-29 05:09:31 +0100" MODIFIED_BY="[Empty name]">
<P>Diagnosis: schizophrenia or schizoaffective disorder. <BR/>N = 133. <BR/>Age = 45.4 (olanzapine) 42.5 (quetiapine). BMI =/&gt;25. <BR/>Sex: 81 men, 52 women. <BR/>History: obese or overweight patients with metabolic complications, on stable dose of olanzapine and compliant for the last 15 days. <BR/>Excluded: people who received any antipsychotic except olanzapine in the past 30 days.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-10-29 05:09:58 +0100" MODIFIED_BY="[Empty name]">
<P>1.Continue on the same olanzapine dose (mean modal dose of 16.9 mg per day). N = 68.</P>
<P>2.Switch to quetiapine (mean dose = 439.7mg). N = 65.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-10-29 05:11:01 +0100" MODIFIED_BY="[Empty name]">
<P>Weight, BMI. Laboratory: cholesterol, triglycerides, LDL, HDL, fasting glucose, insulin relapse. Mental state: PANSS. Loss to follow-up. Adverse events, serious adverse events, treatment emergent adverse events. Unable to use: no numerical data. Waist circumference. Barnes Akathesia scale, Simpson Angus rating scale. Health outcome: quality of life SF36, GAF, DAI 10 eating behaviour. Resource utilisation questionnaire.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-10-29 05:11:17 +0100" MODIFIED_BY="[Empty name]">
<P>Protocol was terminated early prior to breaking the blind as only 33% of the enrolment target as per protocol enrolled.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-10-29 05:16:17 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Newcomer-2008">
<CHAR_METHODS MODIFIED="2010-10-29 05:14:29 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised. <BR/>Blindness: double. <BR/>Duration: 16 weeks. <BR/>Setting: multicentre.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-10-29 05:15:22 +0100" MODIFIED_BY="[Empty name]">
<P>Diagnosis: schizophrenia or schizoaffective disorder. N = 173. <BR/>Age: ~39 years (SD 10). <BR/>BMI: &gt; 27kg/m<SUP>2</SUP>. <BR/>Sex: 111 male and 62 females. <BR/>History: 10-20 mg olanzapine 1-24 month prior to screening, CGI score &#8806; 4, weight gain prior to olanzapine verified.</P>
<P>Excluded: other axis 1 disorder, Type I or II diabetes mellitus, any clinically significant neurological abnormality, stroke, TIA, increased risk of suicide, substance dependence except caffeine and nicotine, increase in symptoms requiring hospitalisation or change in antipsychotic therapy, weight loss 3 months before screening, vital sign ECG or laboratory test abnormalities etc.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-10-29 05:15:56 +0100" MODIFIED_BY="[Empty name]">
<P>1. Switch to aripiprazole monotherapy: mean dose 16 mg per day. N = 88.</P>
<P>2. Continue olanzapine monotherapy: mean dose 15.9mg per day. N = 85.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-10-29 05:16:17 +0100" MODIFIED_BY="[Empty name]">
<P>Weight: body weight, BMI, waist circumference. Physiological: triglyceride, fasting plasma glucose, fasting insulin, fasting c-peptide, fasting lipids Global state: CGI- I, CGI-S. Loss to follow-up. Adverse events: serious adverse events, treatment emergent adverse events.</P>
<P>Unable to use - Physiological measures: vital signs, ECG, routine laboratory tests (no usable data). Adverse effects: AIMS, Simpson-Angus scale (no usable data).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<FOOTNOTES>
<P>AIMS<BR/>BMI<BR/>CGI-I<BR/>CGI-S<BR/>DAI<BR/>ECG<BR/>GAF<BR/>HDL<BR/>LDL<BR/>PANSS<BR/>QTc<BR/>SAS<BR/>SD<BR/>SF10<BR/>TIA</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES MODIFIED="2010-10-29 05:28:50 +0100" MODIFIED_BY="[Empty name]" SORT_BY="STUDY">
<EXCLUDED_CHAR MODIFIED="2010-10-29 05:22:29 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Alvarez-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-10-29 05:22:29 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised.<BR/>Participants: outpatients with schizophrenia with negative symptoms.<BR/>Interventions: olanzapine versus risperidone, previously on conventional antipsychotics, no switching after randomisation.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-10-29 05:22:37 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Brar-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-10-29 05:22:37 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised.<BR/>Participants: people with schizophrenia, formally on olanzapine already switched to risperidone remaining overweight.<BR/>Interventions: behavioural therapy versus usual care, no switching after randomisation.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-10-29 05:22:52 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-CATIE-_x002d_-Phase-I-_x002d_-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-10-29 05:22:52 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised.<BR/>Participants: people with schizophrenia.<BR/>Interventions: olanzapine, quetiapine, risperidone and ziprasidone versus perphenazine - no switching after randomisation.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-06-29 19:55:29 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-CATIE-_x002d_-Phase-II-_x002d_-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-06-29 19:55:29 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised.<BR/>Partcipants: subjects with schizophrenia who had discontinued randomly assigned atypical antipsychotic during the phase 1 CATIE trials.<BR/>Interventions: randomly assigned to a different antipsychotic. No switching after randomisation (Phase 2 CATIE trials).</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-10-29 05:23:12 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Chrzanowski-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-10-29 05:23:12 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised.<BR/>Participants: patients with acutely relapsing or chronic stable schizophrenia.<BR/>Interventions: aripiprazole versus olanzapine, no switching after randomisation.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-10-29 05:23:21 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Covell-1999">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-10-29 05:23:21 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised.<BR/>Participants: unsure - extract from conference proceedings, unable to find full text version.<BR/>Interventions: clozapine versus conventional antipsychotics, no switching.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-11-16 15:51:01 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Ducate-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-11-16 15:51:01 +0000" MODIFIED_BY="[Empty name]">
<P>Allocation: not randomised, case series of randomly selected people.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-10-29 05:23:30 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Emsley-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-10-29 05:23:30 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised.<BR/>Participants: patients with schizophrenia.<BR/>Interventions: quetiapine versus haloperidol, no switching after randomisation.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-10-29 05:23:47 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Godleski-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-10-29 05:23:47 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised.<BR/>Participants: stable people with schizophrenia.<BR/>Interventions: continue on current depot or switch to oral olanzapine; aim of switch was not specifically as an intervention for weight gain or metabolic problems and as the switch was to a medication known to cause weight gain and metabolic problems this was difficult to be inferred.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-10-29 05:23:58 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Horacek-2004">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-10-29 05:23:58 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised.<BR/>Participants: people with schizophrenia receiving typical antipsychotics, not clearly over weight. Interventions: continue on typical antipsychotic versus switching to flexibly dosed quetiapine. Outcome: weight change, mental state, cognitive functions, adverse events, vital signs - no usable data (means, no measures of dispersion).</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-10-29 05:24:13 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Irwin-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-10-29 05:24:13 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised, crossover.<BR/>Participants: people with schizophrenia.<BR/>Interventions: olanzapine versus risperidone. Outcome: no weight or physiological measure data for metabolic syndrome.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-11-16 15:51:01 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Kane-2004">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-11-16 15:51:01 +0000" MODIFIED_BY="[Empty name]">
<P>Allocation: not randomised, presentation on guidelines on use of long-acting injectable atypical antipsychotics.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-10-29 05:24:20 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Kane-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-10-29 05:24:20 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: unclear.<BR/>Participants: people with treatment refractory schizophrenia on ziprasidone.<BR/>Interventions: chlorpromazine versus ziprasidone, no switching.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-06-28 12:27:01 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Kane-2007">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-06-28 12:27:01 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised. <BR/>Participants: people with schizophrenia with history of antipsychotic resistance. <BR/>Interventions: aripiprazole versus perphenazine, no switching.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-06-28 12:26:45 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Kelly-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-06-28 12:26:45 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised, crossover. <BR/>Participants: patients with treatment resistant schizophrenia. <BR/>Interventions: clozapine versus high dose olanzapine (50mg). Outcome: weight, metabolic parameters, side effects, blood pressure (no usable data - data only pre-switch).</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-11-16 14:37:27 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Kim-2007">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-11-16 14:37:27 +0000" MODIFIED_BY="[Empty name]">
<P>Allocation: not randomised.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-10-29 05:25:35 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Kinon-2000">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-10-29 05:25:35 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised.<BR/>Participants: people with schizophrenia or schizoaffective disorder.<BR/>Interventions: switching from conventional antipsychotics to olanzapine through four switching strategies - aim of switch was not specifically as an intervention for weight gain or metabolic problems and as the switch was to a medication known to cause weight gain and metabolic problems this was difficult to infer.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-10-29 05:25:46 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Kinon-2004">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-10-29 05:25:46 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised.<BR/>Participants: people with schizophrenia.<BR/>Interventions: remain on baseline antipsychotic therapy vs switch to olanzapine - aim of switch was not specifically as an intervention for weight gain or metabolic problems and as the switch was to a medication known to cause weight gain and metabolic problems this was difficult to infer.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-10-29 05:25:56 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Lee-2002">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-10-29 05:25:56 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised.<BR/>Participants: people with schizophrenia.<BR/>Interventions: switch from typical antipsychotics to olanzapine using 2 switching techniques - aim of switch was not specifically as an intervention for weight gain or metabolic problems and as the switch was to a medication known to cause weight gain and metabolic problems this was difficult to infer.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-06-29 19:56:26 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Nasrallah-2001">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-06-29 19:56:26 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised.<BR/>Participants: patients with schizophrenia on oral fluphenazine and showing partial response.<BR/>Interventions: randomised to quetiapine or haloperidol, no switching after randomisation.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-10-29 05:26:08 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Newcomer-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-10-29 05:26:08 +0100" MODIFIED_BY="[Empty name]">
<P>Allocaton: randomised.<BR/>Participants: patients with schizophrenia with abnormal values for non HDL cholesterol.<BR/>Interventions: aripiprazole versus olanzapine, no switching.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-06-28 12:25:00 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-O_x0027_Halloran--2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-06-28 12:25:00 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: not randomised, observational study.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-06-28 12:25:08 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Robinson-2000">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-06-28 12:25:08 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: not randomised, continuation of a trial 5 people continued on double blind olanzapine or risperidone.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-06-28 12:24:49 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-STAR-trials-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-06-28 12:24:49 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised. <BR/>Participants: people with schizophrenia in the community. <BR/>Interventions: STAR study-randomised to aripiprazole or standard of care (olanzapine/risperidone/quetiapine), no switching after randomisation.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-11-16 14:34:29 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Su-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-11-16 14:34:29 +0000" MODIFIED_BY="[Empty name]">
<P>Allocation: not randomised.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-10-29 05:26:32 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Wang-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-10-29 05:26:32 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised.<BR/>Participants: people with schizophrenia.<BR/>Interventions: risperidone versus olanzapine, no switching.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-06-28 12:24:36 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Weiden-Daniel-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-06-28 12:24:36 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised. <BR/>Participants: people with schizophrenia or schizoaffective disorder. <BR/>Interventions: switched from conventional antipsychotics, olanzapine or risperidone to ziprasidone through 3 switching strategies. <BR/>Outcome: weight change, BMI, non-fasting triglycerides, total cholesterol, prolactin levels, CGI-I and CGI-S, PANSS, BPRS, Simpson-Angus scale, BAS, AIMS, Vital signs, ECG, routine laboratory tests, exacerbation of pre existing illnesses, treatment emergent illnesses, adverse drug reactions - no usable data (reported pooled data which was not from the original randomised group).</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-10-29 05:27:21 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Zhang-2004">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-10-29 05:27:21 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: unclear.<BR/>Participants: inpatient men with schizophrenia.<BR/>Interventions: chlorpromazine versus clozapine and sulpiride, no switching.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES>
<P>AIMS - Abnormal Involuntary Movement Scale<BR/>
</P>
<P>BAS<BR/>BMI - Body Mass Index</P>
<P>BPRS - Brief Psychiatric Rating Scale</P>
<P>CATIE - Clinical Antipsychotic Trials in Intervention Effectiveness</P>
<P>CGI - Clinical Global Improvement</P>
<P>DAI-10  - Drug Attitude Inventory</P>
<P>ECG - Electrocardiogram</P>
<P>GAF - Global Assessment of Functioning</P>
<P>HDL - High Density Lipoprotein</P>
<P>LDL - Low Density Lipoprotein</P>
<P>PANSS - Positive and Negative Syndrome Scale</P>
<P>RCT - Randomised Control Trial</P>
<P>SAS - Simpson Angus Scale</P>
<P>SD - Standard Deviation</P>
<P>SF36 - Short Form (36)</P>
<P>STAR - Schizophrenia Trial of Aripiprazole</P>
<P>TIA -Transient Ischaemic Attack</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES MODIFIED="2013-01-22 14:49:26 +0000" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<AWAITING_CHAR MODIFIED="2013-01-21 16:27:24 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Ader-2008">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2013-01-21 16:27:24 +0000" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2013-01-21 16:27:30 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Alvarez_x002d_Jimenez-2010">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2013-01-21 16:27:30 +0000" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2013-01-21 16:27:34 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Arman-2008">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2013-01-21 16:27:34 +0000" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2013-01-21 16:27:40 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Attux-2011">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2013-01-21 16:27:40 +0000" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2013-01-21 16:27:43 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Ballon-2011">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2013-01-21 16:27:43 +0000" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2013-01-21 16:27:49 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Baptista-2008">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2013-01-21 16:27:49 +0000" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2013-01-21 16:27:54 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Baptista-2009">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2013-01-21 16:27:54 +0000" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2013-01-21 16:28:00 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Barak-2010">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2013-01-21 16:28:00 +0000" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2013-01-21 16:28:03 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Biedermann-2010">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2013-01-21 16:28:03 +0000" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2013-01-21 16:28:09 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Bobo-2011">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2013-01-21 16:28:09 +0000" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2013-01-21 16:28:14 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Borba-2011">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2013-01-21 16:28:14 +0000" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2013-01-21 16:28:17 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Brown-2011">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2013-01-21 16:28:17 +0000" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2013-01-21 16:28:23 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Buchanan-2011">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2013-01-21 16:28:23 +0000" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2013-01-21 16:28:26 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Bustillo-2003">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2013-01-21 16:28:26 +0000" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2013-01-21 16:28:33 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Capra-2009">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2013-01-21 16:28:33 +0000" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2013-01-21 16:28:37 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Carina-2009">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2013-01-21 16:28:37 +0000" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2013-01-21 16:28:40 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Citrome-2009">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2013-01-21 16:28:40 +0000" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2013-01-21 16:28:46 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Czobor-2002">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2013-01-21 16:28:46 +0000" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2013-01-21 16:28:54 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Day_x002d_Poulsen-2009">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2013-01-21 16:28:54 +0000" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2013-01-21 16:28:56 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-De-Lima-2007">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2013-01-21 16:28:56 +0000" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2013-01-21 16:29:07 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Deberdt-2004">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2013-01-21 16:29:07 +0000" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2013-01-21 16:29:10 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Deberdt-2008">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2013-01-21 16:29:10 +0000" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2013-01-21 16:29:13 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Detke-2008">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2013-01-21 16:29:13 +0000" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2013-01-21 16:29:24 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Eli-2007">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2013-01-21 16:29:24 +0000" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2013-01-21 16:29:27 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Faries-2008">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2013-01-21 16:29:27 +0000" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2013-01-21 16:29:31 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Firestone-2011">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2013-01-21 16:29:31 +0000" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2013-01-21 16:29:38 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Fleischhacker-2008">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2013-01-21 16:29:38 +0000" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2013-01-21 16:29:41 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Fleischhacker-2008a">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2013-01-21 16:29:41 +0000" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2013-01-21 16:29:44 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Fleischhacker-2010">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2013-01-21 16:29:44 +0000" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2013-01-21 16:29:51 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Ganguli-2008">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2013-01-21 16:29:51 +0000" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2013-01-21 16:29:55 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Ganguli-2011">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2013-01-21 16:29:55 +0000" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2013-01-21 16:30:08 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Ginsberg-2004">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2013-01-21 16:30:08 +0000" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2013-01-21 16:30:14 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Henderson-2004">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2013-01-21 16:30:14 +0000" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2013-01-21 16:30:22 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Henderson-2009">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2013-01-21 16:30:22 +0000" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2013-01-21 16:30:25 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Henderson-2011">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2013-01-21 16:30:25 +0000" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2013-01-21 16:30:31 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Hoffmann-2009">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2013-01-21 16:30:31 +0000" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2013-01-21 16:30:37 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Iglesias_x002d_Garcia-2010">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2013-01-21 16:30:37 +0000" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2013-01-21 16:30:43 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-IRCT201009112181N5">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2013-01-21 16:30:43 +0000" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2013-01-21 16:30:46 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-IRCT201107187049N1">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2013-01-21 16:30:46 +0000" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2013-01-21 16:30:52 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Joffe-2008">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2013-01-21 16:30:52 +0000" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2013-01-21 16:31:04 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Karagianis-2010">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2013-01-21 16:31:04 +0000" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2013-01-21 16:31:09 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Kelly-2008">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2013-01-21 16:31:09 +0000" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2013-01-21 16:31:13 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Kelly-2011">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2013-01-21 16:31:13 +0000" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2013-01-21 16:31:22 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Kelly-2011a">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2013-01-21 16:31:22 +0000" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2013-01-21 16:31:25 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Kent-2011">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2013-01-21 16:31:25 +0000" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2013-01-21 16:31:28 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Kim-2006">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2013-01-21 16:31:28 +0000" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2013-01-21 16:31:34 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Kim-2007a">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2013-01-21 16:31:34 +0000" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2013-01-21 16:31:37 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Kim-2007b">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2013-01-21 16:31:37 +0000" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2013-01-21 16:31:41 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Kim-2012">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2013-01-21 16:31:41 +0000" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2013-01-21 16:31:50 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Klein-2006">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2013-01-21 16:31:50 +0000" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2013-01-21 16:31:53 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Klein-2008">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2013-01-21 16:31:53 +0000" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2013-01-21 16:32:06 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Kluge-2007">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2013-01-21 16:32:06 +0000" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2013-01-21 16:32:13 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Ko-2005">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2013-01-21 16:32:13 +0000" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2013-01-21 16:32:19 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Krakowski-2009">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2013-01-21 16:32:19 +0000" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2013-01-21 16:32:25 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Kuang-2007">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2013-01-21 16:32:25 +0000" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2013-01-21 16:32:28 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Kwon-2006">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2013-01-21 16:32:28 +0000" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2013-01-21 16:32:44 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Lambert-2009">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2013-01-21 16:32:44 +0000" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2013-01-21 16:32:53 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Lan-2008">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2013-01-21 16:32:53 +0000" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2013-01-21 16:32:57 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Lencz-2010">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2013-01-21 16:32:57 +0000" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2013-01-21 16:33:00 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Li-2008">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2013-01-21 16:33:00 +0000" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2013-01-21 16:33:07 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Lieberman-2010">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2013-01-21 16:33:07 +0000" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2013-01-21 16:33:10 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Linne-2008">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2013-01-21 16:33:10 +0000" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2013-01-21 16:33:14 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Mauri-2008">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2013-01-21 16:33:14 +0000" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2013-01-21 16:33:24 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-McElroy-2012">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2013-01-21 16:33:24 +0000" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2013-01-21 16:33:27 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Meyer-2009">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2013-01-21 16:33:27 +0000" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2013-01-21 16:33:30 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Meyer-2009a">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2013-01-21 16:33:30 +0000" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2013-01-21 16:33:35 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Millar-2008">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2013-01-21 16:33:35 +0000" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2013-01-21 16:33:38 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Millar-2008a">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2013-01-21 16:33:38 +0000" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2013-01-21 16:33:41 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Moore-2006">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2013-01-21 16:33:41 +0000" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2013-01-21 16:36:00 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-NCT00095524">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2013-01-21 16:36:00 +0000" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2013-01-21 16:30:55 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-NCT00303602">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2013-01-21 16:30:55 +0000" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2013-01-21 16:42:00 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-NCT00423878">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2013-01-21 16:42:00 +0000" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2013-01-21 16:34:43 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-NCT00645099">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2013-01-21 16:34:43 +0000" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2013-01-21 16:34:47 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-NCT00690235">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2013-01-21 16:34:47 +0000" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2013-01-21 16:34:49 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-NCT00709202">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2013-01-21 16:34:49 +0000" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2013-01-21 16:34:51 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-NCT00734435">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2013-01-21 16:34:51 +0000" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2013-01-21 16:34:55 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-NCT00759460">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2013-01-21 16:34:55 +0000" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2013-01-21 16:34:57 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-NCT00759993">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2013-01-21 16:34:57 +0000" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2013-01-21 16:34:59 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-NCT00793780">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2013-01-21 16:34:59 +0000" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2013-01-21 16:35:05 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-NCT00806234">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2013-01-21 16:35:05 +0000" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2013-01-21 16:35:06 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-NCT00816907">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2013-01-21 16:35:06 +0000" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2013-01-21 16:35:08 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-NCT00845507">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2013-01-21 16:35:08 +0000" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2013-01-21 16:35:14 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-NCT00857818">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2013-01-21 16:35:14 +0000" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2013-01-21 16:35:16 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-NCT00902694">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2013-01-21 16:35:16 +0000" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2013-01-21 16:35:18 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-NCT00934908">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2013-01-21 16:35:18 +0000" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2013-01-21 16:35:24 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-NCT00990925">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2013-01-21 16:35:24 +0000" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2013-01-21 16:35:26 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-NCT01052714">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2013-01-21 16:35:26 +0000" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2013-01-21 16:35:27 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-NCT01075295">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2013-01-21 16:35:27 +0000" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2013-01-21 16:35:32 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-NCT01167348">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2013-01-21 16:35:32 +0000" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2013-01-21 16:35:34 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-NCT01272752">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2013-01-21 16:35:34 +0000" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2013-01-21 16:35:36 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-NCT01272765">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2013-01-21 16:35:36 +0000" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2013-01-21 16:35:42 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-NCT01295372">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2013-01-21 16:35:42 +0000" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2013-01-21 16:35:44 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-NCT01300637">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2013-01-21 16:35:44 +0000" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2013-01-21 16:35:46 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-NCT01324973">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2013-01-21 16:35:46 +0000" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2013-01-21 16:35:51 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-NCT01491490">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2013-01-21 16:35:51 +0000" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2013-01-21 16:35:53 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-NCT01567124">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2013-01-21 16:35:53 +0000" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2013-01-21 16:35:55 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-NCT01593774">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2013-01-21 16:35:55 +0000" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2013-01-21 16:36:02 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Newcomer-2009">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2013-01-21 16:36:02 +0000" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2013-01-21 16:36:04 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Newcomer-2010">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2013-01-21 16:36:04 +0000" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2013-01-21 16:36:10 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Nicol-2009">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2013-01-21 16:36:10 +0000" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2013-01-21 16:36:11 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Oliveira-2005">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2013-01-21 16:36:11 +0000" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2013-01-21 16:36:13 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Pae-2007">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2013-01-21 16:36:13 +0000" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2013-01-21 16:36:21 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Perez_x002d_Iglesias-2008">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2013-01-21 16:36:21 +0000" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2013-01-21 16:36:22 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Perez_x002d_Iglesias-2008a">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2013-01-21 16:36:22 +0000" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2013-01-21 16:36:24 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Perez_x002d_Iglesias-2010">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2013-01-21 16:36:24 +0000" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2013-01-21 16:36:34 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Peuskens-2003">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2013-01-21 16:36:34 +0000" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2013-01-21 16:36:36 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Poulin-2007">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2013-01-21 16:36:36 +0000" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2013-01-21 16:36:38 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Poyurovsky-2007">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2013-01-21 16:36:38 +0000" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2013-01-21 16:40:37 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Raposo-2011">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2013-01-21 16:40:37 +0000" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2013-01-21 16:40:38 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Ratliff-2011">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2013-01-21 16:40:38 +0000" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2013-01-21 16:41:39 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Saddichha-2010">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2013-01-21 16:41:39 +0000" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2013-01-21 16:41:41 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Safa-2008">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2013-01-21 16:41:41 +0000" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2013-01-21 16:41:43 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Schneiderhan-2011">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2013-01-21 16:41:43 +0000" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2013-01-21 16:41:51 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Smith-2010">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2013-01-21 16:41:51 +0000" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2013-01-21 16:41:53 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Smith-2010a">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2013-01-21 16:41:53 +0000" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2013-01-21 16:41:58 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Spivak-2009">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2013-01-21 16:41:58 +0000" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2013-01-21 16:40:44 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Stroup-2011a">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2013-01-21 16:40:44 +0000" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2013-01-21 16:40:45 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Stroup-2011b">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2013-01-21 16:40:45 +0000" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2013-01-21 16:40:47 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Sun-2007">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2013-01-21 16:40:47 +0000" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2013-01-21 16:40:53 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Takeuchi-2008">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2013-01-21 16:40:53 +0000" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2013-01-21 16:40:55 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Tao-2008">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2013-01-21 16:40:55 +0000" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2013-01-21 16:41:01 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Tek-2011">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2013-01-21 16:41:01 +0000" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2013-01-21 16:41:03 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Tian-2008">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2013-01-21 16:41:03 +0000" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2013-01-21 16:41:08 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Tiwari-2010">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2013-01-21 16:41:08 +0000" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2013-01-21 16:41:11 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Uzcategui-2007">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2013-01-21 16:41:11 +0000" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2013-01-21 16:41:15 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Vaz_x002d_Leal-2008">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2013-01-21 16:41:15 +0000" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2013-01-21 16:41:17 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Wang-2008">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2013-01-21 16:41:17 +0000" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2013-01-21 16:41:19 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Wang-2012">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2013-01-21 16:41:19 +0000" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2013-01-21 16:41:24 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Warren-2011">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2013-01-21 16:41:24 +0000" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2013-01-21 16:41:26 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Weiden">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2013-01-21 16:41:26 +0000" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2013-01-21 16:41:31 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Weiden-2008">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2013-01-21 16:41:31 +0000" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2013-01-21 16:41:33 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Wirshing-2009">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2013-01-21 16:41:33 +0000" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2013-01-21 16:43:21 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Wu-2008a">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2013-01-21 16:43:21 +0000" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2013-01-21 16:43:23 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Wu-2012">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2013-01-21 16:43:23 +0000" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2013-01-21 16:43:29 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Yoon-2008">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2013-01-21 16:43:29 +0000" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2013-01-21 16:43:31 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Yoon-2009">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2013-01-21 16:43:31 +0000" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2013-01-21 16:44:37 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Zhang-2009">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2013-01-21 16:44:37 +0000" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2013-01-21 16:44:39 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-_x4f46__x96ea__x59e3_-2010">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2013-01-21 16:44:39 +0000" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2013-01-21 16:44:41 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-_x5218__x5efa__x91d1_-2011">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2013-01-21 16:44:41 +0000" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2013-01-21 16:44:48 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-_x5218__x671d__x519b_-2009">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2013-01-21 16:44:48 +0000" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2013-01-21 16:44:50 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-_x5218__x6839_-2010">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2013-01-21 16:44:50 +0000" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2013-01-21 16:44:52 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-_x5218__x732e__x6807_--2010">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2013-01-21 16:44:52 +0000" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2013-01-21 16:44:57 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-_x54c8__x79c0__x82f1_--2011">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2013-01-21 16:44:57 +0000" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2013-01-21 16:44:59 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-_x5d14__x5f00__x8273__x002c_-2010">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2013-01-21 16:44:59 +0000" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2013-01-21 16:43:36 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-_x5f20__x4e1c__x536b_--2009">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2013-01-21 16:43:36 +0000" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2013-01-21 16:43:38 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-_x5f20__x534e__x5764_--2010">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2013-01-21 16:43:38 +0000" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2013-01-21 16:43:40 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-_x5f20__x5cf0_--2010">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2013-01-21 16:43:40 +0000" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2013-01-21 16:43:44 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-_x5f6d__x6c38__x7ea2_--2008">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2013-01-21 16:43:44 +0000" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2013-01-21 16:43:48 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-_x638c__x6c38__x8389_--2010">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2013-01-21 16:43:48 +0000" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2013-01-21 16:45:04 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-_x674e__x6653__x4e00_--2011">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2013-01-21 16:45:04 +0000" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2013-01-21 16:45:06 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-_x674e__x6881_--2009">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2013-01-21 16:45:06 +0000" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2013-01-21 16:45:08 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-_x674e__x8f76__x741b_--2009">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2013-01-21 16:45:08 +0000" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2013-01-21 16:45:13 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-_x6768__x4e91__x79c0_-2011">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2013-01-21 16:45:13 +0000" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2013-01-21 16:45:15 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-_x6768__x6625__x5f3a_--2009">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2013-01-21 16:45:15 +0000" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2013-01-21 16:45:20 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-_x6768__x8bda_--2010">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2013-01-21 16:45:20 +0000" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2013-01-21 16:45:38 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-_x6768__x96c0__x5c4f_--2009">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2013-01-21 16:45:38 +0000" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2013-01-21 16:45:40 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-_x6768__x96c0__x5c4f_--2009a">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2013-01-21 16:45:40 +0000" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2013-01-21 16:44:00 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-_x6c6a__x536b__x534e_--2009">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2013-01-21 16:44:00 +0000" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2013-01-21 16:44:02 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-_x6c6a__x536b__x534e_--2009a">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2013-01-21 16:44:02 +0000" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2013-01-21 16:44:04 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-_x738b__x79c0__x82b3_-2011">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2013-01-21 16:44:04 +0000" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2013-01-21 16:44:09 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-_x767d__x9526__x6ce2_--2010">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2013-01-21 16:44:09 +0000" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2013-01-21 16:44:11 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-_x7f57__x4ea8__x5168_-2010">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2013-01-21 16:44:11 +0000" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2013-01-21 16:44:16 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-_x803f__x5bd2__x677e_--2009">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2013-01-21 16:44:16 +0000" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2013-01-21 16:44:23 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-_x949f__x6f47__x7426_-2010">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2013-01-21 16:44:23 +0000" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2013-01-21 16:44:25 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-_x9648__x4fca__x96c4_-2010">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2013-01-21 16:44:25 +0000" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2013-01-21 16:44:27 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-_x9676__x4e16__x6b66_-2009">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2013-01-21 16:44:27 +0000" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2013-01-21 16:44:31 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-_x9676__x4e16__x6b66_-2010">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2013-01-21 16:44:31 +0000" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES MODIFIED="2010-10-29 05:29:47 +0100" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<ONGOING_CHAR MODIFIED="2010-10-29 05:29:47 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Tang-2003">
<CHAR_STUDY_NAME MODIFIED="2010-04-27 13:02:38 +0100" MODIFIED_BY="[Empty name]">
<P>Olanzapine causes greater increases in serum lipids than risperidone.</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2010-06-28 12:19:53 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised. Duration: 1 year. Site: multicenter.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-10-29 05:29:36 +0100" MODIFIED_BY="[Empty name]">
<P>Diagnosis: schizophrenia or related disorders. N = currently 50.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-10-29 05:29:47 +0100" MODIFIED_BY="[Empty name]">
<P>Switching from other psychotropic drugs to: 1. olanzapine 2. risperidone.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-06-28 12:19:53 +0100" MODIFIED_BY="[Empty name]">
<P>Weight: body weight, BMI. Physiological: triglycerides, cholesterol, glucose, HBA1c, high density and low density lipoproteins.</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE MODIFIED="2009-11-16 15:01:27 +0000" MODIFIED_BY="[Empty name]">
<P>Unclear.</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION MODIFIED="2009-02-23 10:41:43 +0000" MODIFIED_BY="[Empty name]">
<P>herbert.meltzer@Vanderbilt.Edu</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES MODIFIED="2010-04-27 13:03:05 +0100" MODIFIED_BY="[Empty name]">
<P>E-mail contact 2008 - planning to terminate study soon due to funding issues. Not ready to publish.</P>
</CHAR_NOTES>
</ONGOING_CHAR>
<FOOTNOTES>
<P>HbA1c-Haemoglobin A1c BMI-Body Mass Index</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS MODIFIED="2010-10-29 05:16:55 +0100" MODIFIED_BY="[Empty name]">
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" MODIFIED="2010-10-29 05:11:28 +0100" MODIFIED_BY="[Empty name]" NO="1">
<NAME>Random sequence generation (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-10-29 05:05:09 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Casey-2003">
<DESCRIPTION>
<P>Quote:"were randomised to one of the three aripiprazole treatment groups".</P>
<P>Comment: method not stated but authors report this was done via a "centralised telephone system". We feel this indicates the likely use of a random sequence generation process.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-10-12 04:23:04 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Cookson-1986">
<DESCRIPTION>
<P>Quote:"separate randomisation sequences were used for male and female patients". </P>
<P>Comment: we feel there is adequate sequence generation</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-10-29 05:11:28 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Eli-Lilly-2004">
<DESCRIPTION>
<P>Quote: "were randomly assigned".</P>
<P>Comment: as the method is not stated it is not clear whether there was adequate sequence generation.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-10-12 04:24:13 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Newcomer-2008">
<DESCRIPTION>
<P>Quote: "evenly randomly assigned". </P>
<P>Comment: we do not feel this is an adequate random sequence generation process.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" MODIFIED="2010-10-29 05:05:16 +0100" MODIFIED_BY="[Empty name]" NO="2">
<NAME>Allocation concealment (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-10-29 05:05:16 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Casey-2003">
<DESCRIPTION>
<P>Quote: randomised "via a centralised telephone call-in system".</P>
<P>Comment: this would adequately conceal allocation.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-10-12 04:23:18 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Cookson-1986">
<DESCRIPTION>
<P>No mention about concealment of allocation.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-06-27 17:36:39 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Eli-Lilly-2004">
<DESCRIPTION>
<P>No data in the report about allocation concealment.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-04-20 15:18:28 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Newcomer-2008">
<DESCRIPTION>
<P>Not mentioned.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" MODIFIED="2010-10-29 05:16:33 +0100" MODIFIED_BY="[Empty name]" NO="3">
<NAME>Blinding (performance bias and detection bias)</NAME>
<DESCRIPTION>
<P>Performance bias or detection bias due to knowledge of the allocated interventions after assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-03.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-10-12 04:22:36 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Casey-2003">
<DESCRIPTION>
<P>Quote: "Open label". </P>
<P>Comment: lack of blinding is less prone to cause bias for outcomes like weight. Lack of blinding may introduce bias for subjective outcomes like adverse events.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-10-12 04:23:21 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Cookson-1986">
<DESCRIPTION>
<P>Quote:" double blind" </P>
<P>Comment: the methods used if any to ensure participants and trialists were blind to the interventions used are not described. We feel as the primary outcome is objective (weight) inadequate blinding is unlikely to cause bias.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-10-29 05:11:39 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Eli-Lilly-2004">
<DESCRIPTION>
<P>Quote: "double blind".</P>
<P>Comment: the methods used if any to ensure participants and trialists were blind to the interventions used are not reported, but both the intervention medication and the control were in capsule forms. We feel inadequate blinding is not likely to introduce bias for objective outcomes like weight BMI and metabolic syndrome.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-10-29 05:16:33 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Newcomer-2008">
<DESCRIPTION>
<P>Quote:"double blind study".</P>
<P>Comment: methods taken to ensure blindness not reported. For outcomes like weight, BMI, waist circumference and metabolic syndrome, inadequate blinding is unlikely to cause bias.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-07" LEVEL="GROUP" NO="7">
<NAME>Blinding of participants and personnel (performance bias)</NAME>
<DESCRIPTION>
<P>Performance bias due to knowledge of the allocated interventions by participants and personnel during the study</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-08" LEVEL="GROUP" NO="8">
<NAME>Blinding of outcome assessment (detection bias)</NAME>
<DESCRIPTION>
<P>Detection bias due to knowledge of the allocated interventions by outcome assessors</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" MODIFIED="2010-10-29 05:16:43 +0100" MODIFIED_BY="[Empty name]" NO="4">
<NAME>Incomplete outcome data (attrition bias)</NAME>
<DESCRIPTION>
<P>Attrition bias due to amount, nature or handling of incomplete outcome data</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-04.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-10-29 05:06:08 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Casey-2003">
<DESCRIPTION>
<P>There was a difference in drop-outs between 3 groups.The reason for the difference was due to administrative reasons (between group differences in those who withdrew consent). The discontinuation was similar across groups for other reasons. For 4%, reason for discontinuation stated as "other which included lost to follow up, protocol violation and meeting withdrawal criteria. No further details.</P>
<P>There were no numerical data reported on vital signs and concomitant medication.</P>
<P>The total number randomised was 311 but safety data set had 309 people only. Unsure what happened to the rest.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-10-29 05:08:30 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Cookson-1986">
<DESCRIPTION>
<P>Both the 2 drop-outs were in the intervention group. One had lost weight which was the primary outcome measure but the other person had gained weight. Missing data not inputted into the final analysis.</P>
<P>Scales were used for assessment of mental state and side effects, but no data available from these.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-10-29 05:13:20 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Eli-Lilly-2004">
<DESCRIPTION>
<P>20/68 missing from the control group compared to 37/65 in the intervention group. Reasons for discontinuation differ across both groups particularly in lack of efficacy (3/65 in intervention group and 1/68 in control group), clinical decision/lost to follow-up 3/65 intervention group vs 0/68 in control group and patient decision (3/65 vs 1/68).</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-10-29 05:16:43 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Newcomer-2008">
<DESCRIPTION>
<P>32/88 missing from the intervention group compared to 22/85 in the control group. Reasons for discontinuation were roughly the same in both groups except in lack of efficacy 7/56 versus 0/63.</P>
<P>No numerical data on vital signs, ECG and routine laboratory tests.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" MODIFIED="2010-10-29 05:13:37 +0100" MODIFIED_BY="[Empty name]" NO="5">
<NAME>Selective reporting (reporting bias)</NAME>
<DESCRIPTION>
<P>Reporting bias due to selective outcome reporting</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-06-27 11:56:16 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Casey-2003">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-06-27 11:59:05 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Cookson-1986">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-10-29 05:13:37 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Eli-Lilly-2004">
<DESCRIPTION>
<P>No reports from the various scales mentioned in the methods section. Authors state as the protocol was terminated early "some planned secondary analysis unfeasible or irrelevant".</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-06-27 12:00:37 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Newcomer-2008">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" MODIFIED="2010-10-29 05:16:55 +0100" MODIFIED_BY="[Empty name]" NO="6">
<NAME>Other bias</NAME>
<DESCRIPTION>
<P>Bias due to problems not covered elsewhere in the table</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-07-03 11:30:51 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Casey-2003">
<DESCRIPTION>
<P>Sponsored by interested industry.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-07-03 12:19:37 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Cookson-1986">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-07-03 12:23:01 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Eli-Lilly-2004">
<DESCRIPTION>
<P>Protocol was terminated early prior to breaking the blind. Sponsored by interested industry.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-10-29 05:16:55 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Newcomer-2008">
<DESCRIPTION>
<P>Some authors are employed by an interested drug industry.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES MODIFIED="2010-10-16 20:59:55 +0100" MODIFIED_BY="[Empty name]">
<SOF_TABLE ID="SOF-01" MODIFIED="2010-10-16 20:57:52 +0100" MODIFIED_BY="[Empty name]" NO="1" READONLY="YES">
<TITLE MODIFIED="2010-06-28 10:51:55 +0100" MODIFIED_BY="Grade Profiler">SWITCHING - NEW ANTIPSYCHOTIC REGIMEN compared to CONTINUATION ON PREVIOUS REGIMEN: 1a. DIFFERENT DEPOT from DEPOT-medium term (3-12 months) for people with schizophrenia who have neuroleptic-induced weight or metabolic problems</TITLE>
<TABLE COLS="7" ROWS="9">
<TR>
<TD COLSPAN="7">
<P>
<B>SWITCHING - NEW ANTIPSYCHOTIC REGIMEN compared to CONTINUATION ON PREVIOUS REGIMEN: 1a. DIFFERENT DEPOT from DEPOT-medium term (3-12 months) for people with schizophrenia who have neuroleptic-induced weight or metabolic problems</B>
</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>
<B>Patient or population:</B> patients with people with schizophrenia who have neuroleptic-induced weight or metabolic problems<BR/>
<B>Settings:</B> in community<BR/>
<B>Intervention:</B> SWITCHING - NEW ANTIPSYCHOTIC REGIMEN<BR/>
<B>Comparison: </B>CONTINUATION ON PREVIOUS REGIMEN: 1a. DIFFERENT DEPOT from DEPOT-medium term (3-12 months)</P>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Outcomes</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="2" VALIGN="TOP">
<P>Illustrative comparative risks* (95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Relative effect<BR/>(95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>No of Participants<BR/>(studies)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Quality of the evidence<BR/>(GRADE)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Comments</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Assumed risk</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Corresponding risk</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>CONTINUATION ON PREVIOUS REGIMEN: 1a. DIFFERENT DEPOT from DEPOT-medium term (3-12 months)</B>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>SWITCHING - NEW ANTIPSYCHOTIC REGIMEN</B>
</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Weight: Body weight (kg) - switching to haloperidol decanoate from fluphenazine decanoate</B>
<BR/>Follow-up: 12 months</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>The mean Weight: Body weight (kg) - switching to haloperidol decanoate from fluphenazine decanoate in the intervention groups was<BR/>
<B>2.8 lower</B>
<BR/>(7.04 lower to 1.44 higher)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>19<BR/>(1 study)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>low</B>
<SUP>1,2</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>Relevant trial but small study. SD estimated rather than reported directly.</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Weight: BMI not improved</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>Not estimable</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>0<BR/>(0<SUP>3</SUP>)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>Outcome of interest - but no study reported this outcome.</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Physiological measure: Metabolic syndrome</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>Not estimable</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>0<BR/>(0<SUP>3</SUP>)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>Outcome of interest - but no study reported this outcome.</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Global state: Changing dose because of deterioration - switching to haloperidol decanoate from fluphenazine decanoate</B>
<BR/>Follow-up: 12 months</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>222 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>40 per 1000</B>
<BR/>(2 to 744)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>RR 0.18 </B>
<BR/>(0.01 to 3.35)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>19<BR/>(1 study)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>low</B>
<SUP>1,2</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>Stated specific scales were to be used - but no direct data reported form these measures. Criteria for 'deterioration' not explicit</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Mental state: Deteriorated - switching to haloperidol decanoate from fluphenazine decanoate</B>
<BR/>Follow-up: 12 months</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>222 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>40 per 1000</B>
<BR/>(2 to 744)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>RR 0.18 </B>
<BR/>(0.01 to 3.35)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>19<BR/>(1 study)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>low</B>
<SUP>1,2</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>Stated specific scales were to be used - but no direct data reported form these measures. Criteria for 'deterioration' not explicit</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Adverse effects: serious</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>Not estimable</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>0<BR/>(0<SUP>3</SUP>)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>Outcome of interest - but no study reported this outcome.</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Satisfaction with care: Loss to follow up - switching to haloperidol decanoate from fluphenazine decanoate</B>
<BR/>Follow-up: 12 months</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>0 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>0 per 1000</B>
<BR/>(0 to 0)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>RR 4.55 </B>
<BR/>(0.25 to 83.7)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>19<BR/>(1 study)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8861;&#8861;&#8861;<BR/>
<B>very low</B>
<SUP>1,2,4,5</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>Small trial. Unclear if loss to follow up really reflects 'satisfaction'.</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>*The basis for the <B>assumed risk</B> (e.g. the median control group risk across studies) is provided in footnotes. The <B>corresponding risk</B> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <B>relative effect</B> of the intervention (and its 95% CI).<BR/>
<B>CI:</B> Confidence interval; <B>RR:</B> Risk ratio;</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>GRADE Working Group grades of evidence<BR/>
<B>High quality:</B> Further research is very unlikely to change our confidence in the estimate of effect.<BR/>
<B>Moderate quality:</B> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<BR/>
<B>Low quality:</B> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<BR/>
<B>Very low quality:</B> We are very uncertain about the estimate.<BR/>
</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>
<SUP>1</SUP> Randomisation not well described<BR/>
<SUP>2</SUP> Small study, likely that others are not identified<BR/>
<SUP>3</SUP> No study reported this finding<BR/>
<SUP>4</SUP> Loss to follow up not simply measure of satisfaction<BR/>
<SUP>5</SUP> Wide confidence intervals</P>
</FOOTNOTES>
</SOF_TABLE>
<SOF_TABLE ID="SOF-02" MODIFIED="2010-10-16 20:57:52 +0100" MODIFIED_BY="[Empty name]" NO="2" READONLY="YES">
<TITLE MODIFIED="2010-06-28 11:22:20 +0100" MODIFIED_BY="Grade Profiler">SWITCHING - NEW ANTIPSYCHOTIC REGIMEN compared to CONTINUATION ON PREVIOUS REGIMEN: 1b. NEW ATYPICAL from OLANZAPINE - medium term (3-12 months) for people with schizophrenia who have neuroleptic-induced weight or metabolic problems</TITLE>
<TABLE COLS="7" ROWS="9">
<TR>
<TD COLSPAN="7">
<P>
<B>SWITCHING - NEW ANTIPSYCHOTIC REGIMEN compared to CONTINUATION ON PREVIOUS REGIMEN: 1b. NEW ATYPICAL from OLANZAPINE - medium term (3-12 months) for people with schizophrenia who have neuroleptic-induced weight or metabolic problems</B>
</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>
<B>Patient or population:</B> patients with people with schizophrenia who have neuroleptic-induced weight or metabolic problems<BR/>
<B>Settings:</B> community<BR/>
<B>Intervention:</B> SWITCHING - NEW ANTIPSYCHOTIC REGIMEN<BR/>
<B>Comparison: </B>CONTINUATION ON PREVIOUS REGIMEN: 1b. NEW ATYPICAL from OLANZAPINE - medium term (3-12 months)</P>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Outcomes</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="2" VALIGN="TOP">
<P>Illustrative comparative risks* (95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Relative effect<BR/>(95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>No of Participants<BR/>(studies)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Quality of the evidence<BR/>(GRADE)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Comments</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Assumed risk</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Corresponding risk</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>CONTINUATION ON PREVIOUS REGIMEN: 1b. NEW ATYPICAL from OLANZAPINE - medium term (3-12 months)</B>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>SWITCHING - NEW ANTIPSYCHOTIC REGIMEN</B>
</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Weight: 1. Body weight (kg)</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>The mean Weight: 1. Body weight (kg) in the intervention groups was<BR/>
<B>1.94 lower</B>
<BR/>(3.97 lower to 0.08 higher)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>287<BR/>(2 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>low</B>
<SUP>1,2,3</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Weight: 1. Body weight (kg) - switching to aripiprazole</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>The mean Weight: 1. Body weight (kg) - switching to aripiprazole in the intervention groups was<BR/>
<B>3.21 lower</B>
<BR/>(9.03 lower to 2.61 higher)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>158<BR/>(1 study)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>low</B>
<SUP>1,3</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>Weight: 2a. BMI - Increase</B>
</P>
</TD>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Study population</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>RR 0.28 </B>
<BR/>(0.13 to 0.57)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>173<BR/>(1 study)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>&#8853;&#8861;&#8861;&#8861;<BR/>
<B>very low</B>
<SUP>1,4</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>329 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>92 per 1000</B>
<BR/>(43 to 188)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Medium risk population</B>
</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>329 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>92 per 1000</B>
<BR/>(43 to 188)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Physiological measures: 1c. Average fasting glucose change - switching to aripiprazole and quetiapine</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>The mean Physiological measures: 1c. Average fasting glucose change - switching to aripiprazole and quetiapine in the intervention groups was<BR/>
<B>2.53 lower</B>
<BR/>(2.94 to 2.11 lower)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>280<BR/>(2 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>low</B>
<SUP>1,3</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>Global state: Relapse</B>
</P>
</TD>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Study population</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>RR 1.31 </B>
<BR/>(0.55 to 3.11)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>133<BR/>(1 study)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>low</B>
<SUP>1,3</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>118 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>155 per 1000</B>
<BR/>(65 to 367)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Medium risk population</B>
</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>118 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>155 per 1000</B>
<BR/>(65 to 367)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>Adverse events: 1a. Serious adverse event - switching to aripiprazole</B>
</P>
</TD>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Study population</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>RR 0.64 </B>
<BR/>(0.24 to 1.71)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>172<BR/>(1 study)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>low</B>
<SUP>1,3</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>107 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>68 per 1000</B>
<BR/>(26 to 183)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Medium risk population</B>
</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>107 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>68 per 1000</B>
<BR/>(26 to 183)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>Satisfaction with care: Loss to follow up - switching to aripiprazole</B>
</P>
</TD>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Study population</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>RR 1.4 </B>
<BR/>(0.89 to 2.21)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>173<BR/>(1 study)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>&#8853;&#8861;&#8861;&#8861;<BR/>
<B>very low</B>
<SUP>1,3,5</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>259 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>363 per 1000</B>
<BR/>(231 to 572)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Medium risk population</B>
</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>259 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>363 per 1000</B>
<BR/>(231 to 572)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>*The basis for the <B>assumed risk</B> (e.g. the median control group risk across studies) is provided in footnotes. The <B>corresponding risk</B> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <B>relative effect</B> of the intervention (and its 95% CI).<BR/>
<B>CI:</B> Confidence interval; <B>RR:</B> Risk ratio;</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>GRADE Working Group grades of evidence<BR/>
<B>High quality:</B> Further research is very unlikely to change our confidence in the estimate of effect.<BR/>
<B>Moderate quality:</B> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<BR/>
<B>Low quality:</B> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<BR/>
<B>Very low quality:</B> We are very uncertain about the estimate.<BR/>
</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>
<SUP>1</SUP> Randomisation process not described.<BR/>
<SUP>2</SUP> In one study there were no results from the various scales mentioned in the methods section . This study was terminated early as only 33% of the enrolment target was achieved.<BR/>
<SUP>3</SUP> Sponsored by interested industry.<BR/>
<SUP>4</SUP> The study was not published but found in the drug industry's trial register so likely that there are other similar trials which may have been missed.<BR/>
<SUP>5</SUP> Satisfaction with care alone may not account for all loss to follow up.</P>
</FOOTNOTES>
</SOF_TABLE>
<SOF_TABLE ID="SOF-03" MODIFIED="2010-10-16 20:59:55 +0100" MODIFIED_BY="[Empty name]" NO="3" READONLY="YES">
<TITLE MODIFIED="2010-10-16 20:59:53 +0100" MODIFIED_BY="Grade Profiler">SWITCHING - TECHNIQUES: TO ARIPIPRAZOLE from PREVIOUS REGIMEN - THREE DIFFERENT TECHNIQUES -short term (up to 12 months) for people with schizophrenia who have neuroleptic-induced weight or metabolic problems</TITLE>
<TABLE COLS="7" ROWS="9">
<TR>
<TD COLSPAN="7">
<P>
<B>SWITCHING - TECHNIQUES: TO ARIPIPRAZOLE from PREVIOUS REGIMEN - THREE DIFFERENT TECHNIQUES -short term (up to 12 months) for people with schizophrenia who have neuroleptic-induced weight or metabolic problems</B>
</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>
<B>Patient or population:</B> patients with people with schizophrenia who have neuroleptic-induced weight or metabolic problems<BR/>
<B>Settings:</B> <BR/>
<B>Intervention:</B> SWITCHING - TECHNIQUES: TO ARIPIPRAZOLE from PREVIOUS REGIMEN - THREE DIFFERENT TECHNIQUES -short term (up to 12 months)<BR/>
</P>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Outcomes</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="2" VALIGN="TOP">
<P>Illustrative comparative risks* (95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Relative effect<BR/>(95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>No of Participants<BR/>(studies)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Quality of the evidence<BR/>(GRADE)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Comments</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Assumed risk</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Corresponding risk</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Control</B>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>SWITCHING - TECHNIQUES: TO ARIPIPRAZOLE from PREVIOUS REGIMEN - THREE DIFFERENT TECHNIQUES -short term (up to 12 months)</B>
</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>Weight: Gain-more than or equal to 7% from baseline</B>
</P>
</TD>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Study population</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>RR 0.61 </B>
<BR/>(0.15 to 2.47)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>207<BR/>(1 study)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>
<B>moderate</B>
<SUP>1</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>Switching of treatment in this study may not have been for weight control therefore this client group may differ from those in the other trials in this review</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>48 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>29 per 1000</B>
<BR/>(7 to 119)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Medium risk population</B>
</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>48 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>29 per 1000</B>
<BR/>(7 to 119)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Weight: BMI not improved</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>Not estimable</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>0<BR/>(0)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>Outcome of interest-but the study did not report this outcome</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Physiological measure: Metabolic syndrome</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>Not estimable</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>0<BR/>(0)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>Outcome of interest-but the study did not report this outcome</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Global state: Average change (CGI-I, high=good)</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>The mean Global state: Average change (CGI-I, high=good) in the intervention groups was<BR/>
<B>0.14 lower</B>
<BR/>(0.49 lower to 0.21 higher)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>203<BR/>(1 study)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>
<B>moderate</B>
<SUP>1</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Mental state: Average change (PANSS, high decline=good)</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>The mean Mental state: Average change (PANSS, high decline=good) in the intervention groups was<BR/>
<B>2.52 higher</B>
<BR/>(2.39 lower to 7.43 higher)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>198<BR/>(1 study)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>low</B>
<SUP>1,2</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>Adverse events: Any event</B>
</P>
</TD>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Study population</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>RR 1 </B>
<BR/>(0.91 to 1.1)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>207<BR/>(1 study)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>
<B>moderate</B>
<SUP>1</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>894 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>894 per 1000</B>
<BR/>(814 to 983)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Medium risk population</B>
</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>894 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>894 per 1000</B>
<BR/>(814 to 983)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>Satisfaction with care: Loss to follow up - non-compliance</B>
</P>
</TD>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Study population</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>RR 4 </B>
<BR/>(0.45 to 35.19)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>208<BR/>(1 study)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>&#8853;&#8861;&#8861;&#8861;<BR/>
<B>very low</B>
<SUP>1,2,3</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>10 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>40 per 1000</B>
<BR/>(4 to 352)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Medium risk population</B>
</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>10 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>40 per 1000</B>
<BR/>(4 to 352)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>*The basis for the <B>assumed risk</B> (e.g. the median control group risk across studies) is provided in footnotes. The <B>corresponding risk</B> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <B>relative effect</B> of the intervention (and its 95% CI).<BR/>
<B>CI:</B> Confidence interval; <B>RR:</B> Risk ratio; </P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>GRADE Working Group grades of evidence<BR/>
<B>High quality:</B> Further research is very unlikely to change our confidence in the estimate of effect. <BR/>
<B>Moderate quality:</B> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<BR/>
<B>Low quality:</B> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<BR/>
<B>Very low quality:</B> We are very uncertain about the estimate.<BR/>
</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>
<SUP>1</SUP> Sponsored by interested industry.<BR/>
<SUP>2</SUP> Wide confidence intervals.<BR/>
<SUP>3</SUP> Satisfaction with care alone may not account for all loss to follow ups.</P>
</FOOTNOTES>
</SOF_TABLE>
</SOF_TABLES>
<ADDITIONAL_TABLES MODIFIED="2010-10-29 05:41:03 +0100" MODIFIED_BY="[Empty name]">
<ADDITIONAL_TABLE ID="TBL-01" MODIFIED="2010-10-29 05:41:03 +0100" MODIFIED_BY="[Empty name]" NO="1">
<TITLE MODIFIED="2009-06-15 16:34:21 +0100" MODIFIED_BY="[Empty name]">Suggested design of study</TITLE>
<TABLE COLS="2" ROWS="5">
<TR>
<TH>
<P>Methods</P>
</TH>
<TD>
<P>Allocation: randomised, clearly concealed and described. Blinding: double and tested. Duration: one year. CONSORT 2010 guidelines to be incorporated in the protocol and final report. Trial will be prospectively registered in the WHO ICTRP register. Protocol will be published in a peer-reviewed journal.</P>
</TD>
</TR>
<TR>
<TH>
<P>Partipants</P>
</TH>
<TD>
<P>Diagnosis: people with schizophrenia or similar disorders (ICD 10/DSM IV). N = 400-500.* Age: 18-65. Sex: both. Weight: obese and/or metabolic problems(internationally accepted criteria for both). On olanzapine or risperidone. Exclusion: diabetes or hypercholesterolaemia requiring pharmacological management.</P>
</TD>
</TR>
<TR>
<TH>
<P>Interventions</P>
</TH>
<TD>
<P>1.Switching to aripiprazole/quetiapine+ routine advice on life style. N = 100. 2.Continuing on olanzapine/risperidone+ routine advice on life style. N = 100. 3. Switching to aripiprazole/quetiapine+ structured lifestyle modifications. N = 100. 4. Continuing on olanzapine/risperidone + structured lifestyle modifications. N = 100.</P>
</TD>
</TR>
<TR>
<TH>
<P>Outcomes</P>
</TH>
<TD>
<P>Body Weight** BMI**. Waist circumference. Metabolic measures: lipid profile, HbA1c,blood glucose**. Global state-relapse, scales**. Mental state: scales**. Adverse events: scales. Physical health: vital signs Patient satisfaction**. Compliance/engagement with the services**. Loss to follow-up. Economic outcomes.</P>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>
<B>Notes</B>
</P>
</TD>
<TD>
<P>* Powered to be able to identify a difference of ~20% between groups for primary outcome with adequate degree of certainty. ** These were selected as our primary outcomes.</P>
<P/>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>CONSORT- Consolidated Standards of Reporting Trials<BR/>HbA1c- Haemoglobin A1c<BR/>ICTRP- International Clinical Trials Registry Platform <BR/>WHO - World Health Organisation</P>
</FOOTNOTES>
</ADDITIONAL_TABLE>
</ADDITIONAL_TABLES>
<ANALYSES_AND_DATA CALCULATED_DATA="YES" MODIFIED="2010-10-29 06:02:05 +0100" MODIFIED_BY="[Empty name]">
<COMPARISON ID="CMP-001" MODIFIED="2010-10-29 06:00:03 +0100" MODIFIED_BY="[Empty name]" NO="1">
<NAME>Switching - new antipsychotic regimen vs continuation on previous regimen: 1a. different depot from depot - medium term (3-12 months)</NAME>
<CONT_OUTCOME CHI2="4.2104019279516E-32" CI_END="1.4418619869264115" CI_START="-7.041861986926412" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="-2.8000000000000003" ESTIMABLE="YES" I2="100.0" I2_Q="0.0" ID="CMP-001.01" MODIFIED="2009-11-16 16:23:44 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Q="1.0" P_Z="0.19575258583417401" Q="0.0" RANDOM="NO" SCALE="30.01" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="10" TOTAL_2="9" UNITS="" WEIGHT="100.0" Z="1.2937476923167412">
<NAME>Weight: Body weight (kg) - switching to haloperidol decanoate from fluphenazine decanoate</NAME>
<GROUP_LABEL_1>Haloperidol decanoate</GROUP_LABEL_1>
<GROUP_LABEL_2>Fluphenazine decanoate</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours HLP decaonate</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours FLU decanoate</GRAPH_LABEL_2>
<CONT_DATA CI_END="1.441861986926412" CI_START="-7.041861986926412" EFFECT_SIZE="-2.8" ESTIMABLE="YES" MEAN_1="-1.3" MEAN_2="1.5" MODIFIED="2009-11-16 16:19:28 +0000" MODIFIED_BY="[Empty name]" ORDER="123" SD_1="3.8" SD_2="5.4" SE="2.1642550681470056" STUDY_ID="STD-Cookson-1986" TOTAL_1="10" TOTAL_2="9" WEIGHT="100.0"/>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="3.347950944932982" CI_START="0.00987405484232122" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.18181818181818182" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" I2="0.0" I2_Q="0.0" ID="CMP-001.02" LOG_CI_END="0.5247790859696713" LOG_CI_START="-2.0055044649581593" LOG_EFFECT_SIZE="-0.7403626894942439" METHOD="MH" MODIFIED="2009-11-16 16:21:15 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Q="1.0" P_Z="0.25139255463109134" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="10" TOTAL_2="9" WEIGHT="100.0" Z="1.1469735922472648">
<NAME>Global state: Changing dose because of deterioration - switching to haloperidol decanoate from fluphenazine decanoate</NAME>
<GROUP_LABEL_1>Haloperidol decanoate</GROUP_LABEL_1>
<GROUP_LABEL_2>Fluphenazine decanoate</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="3.3479509449329807" CI_START="0.00987405484232123" EFFECT_SIZE="0.18181818181818182" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.5247790859696712" LOG_CI_START="-2.005504464958159" LOG_EFFECT_SIZE="-0.7403626894942439" MODIFIED="2009-11-16 16:20:00 +0000" MODIFIED_BY="[Empty name]" ORDER="124" O_E="0.0" SE="1.4863010829205867" STUDY_ID="STD-Cookson-1986" TOTAL_1="10" TOTAL_2="9" VAR="2.209090909090909" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="3.347950944932982" CI_START="0.00987405484232122" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.18181818181818182" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" I2="0.0" I2_Q="0.0" ID="CMP-001.03" LOG_CI_END="0.5247790859696713" LOG_CI_START="-2.0055044649581593" LOG_EFFECT_SIZE="-0.7403626894942439" METHOD="MH" MODIFIED="2009-11-16 16:30:37 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Q="1.0" P_Z="0.25139255463109134" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="10" TOTAL_2="9" WEIGHT="100.0" Z="1.1469735922472648">
<NAME>Mental state: Deteriorated - switching to haloperidol decanoate from fluphenazine decanoate</NAME>
<GROUP_LABEL_1>Haloperidol decanoate</GROUP_LABEL_1>
<GROUP_LABEL_2>Fluphenazine decanoate</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="3.3479509449329807" CI_START="0.00987405484232123" EFFECT_SIZE="0.18181818181818182" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.5247790859696712" LOG_CI_START="-2.005504464958159" LOG_EFFECT_SIZE="-0.7403626894942439" MODIFIED="2009-11-16 16:20:31 +0000" MODIFIED_BY="[Empty name]" ORDER="125" O_E="0.0" SE="1.4863010829205867" STUDY_ID="STD-Cookson-1986" TOTAL_1="10" TOTAL_2="9" VAR="2.209090909090909" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="83.69877362332457" CI_START="0.24685137105803054" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="4.545454545454546" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-001.04" LOG_CI_END="1.922719094641709" LOG_CI_START="-0.6075644562861214" LOG_EFFECT_SIZE="0.6575773191777938" METHOD="MH" MODIFIED="2009-11-16 16:21:15 +0000" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="1.0" P_Q="1.0" P_Z="0.30833494055530364" Q="0.0" RANDOM="NO" SCALE="764.2679635385352" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="10" TOTAL_2="9" WEIGHT="100.0" Z="1.0187220812989715">
<NAME>Loss to follow up - switching to haloperidol decanoate from fluphenazine decanoate</NAME>
<GROUP_LABEL_1>Haloperidol decanoate</GROUP_LABEL_1>
<GROUP_LABEL_2>Fluphenazine decanoate</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="83.6987736233245" CI_START="0.24685137105803065" EFFECT_SIZE="4.545454545454546" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="1.9227190946417085" LOG_CI_START="-0.6075644562861212" LOG_EFFECT_SIZE="0.6575773191777938" MODIFIED="2009-11-16 16:20:33 +0000" MODIFIED_BY="[Empty name]" ORDER="126" O_E="0.0" SE="1.4863010829205867" STUDY_ID="STD-Cookson-1986" TOTAL_1="10" TOTAL_2="9" VAR="2.209090909090909" WEIGHT="100.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-002" MODIFIED="2010-10-29 06:00:55 +0100" MODIFIED_BY="[Empty name]" NO="2">
<NAME>Switching - new antipsychotic regimen vs continuation on previous regimen: 1b. new atypical from olanzapine - medium term (3-12 months)</NAME>
<CONT_OUTCOME CHI2="0.20676612828217025" CI_END="0.08204106726150995" CI_START="-3.971549992517484" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="MD" EFFECT_SIZE="-1.9447544626279871" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-002.01" MODIFIED="2010-06-19 11:51:07 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.6493139860225744" P_Q="0.6493139860225743" P_Z="0.06002252119302006" Q="0.20676612828217034" RANDOM="NO" SCALE="6.29" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="142" TOTAL_2="145" UNITS="" WEIGHT="100.0" Z="1.8806281390073012">
<NAME>Weight: 1. Body weight (kg)</NAME>
<GROUP_LABEL_1>[Not identical]</GROUP_LABEL_1>
<GROUP_LABEL_2>Olanzapine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="2.608044602862612" CI_START="-9.028044602862611" DF="0" EFFECT_SIZE="-3.21" ESTIMABLE="YES" I2="0.0" ID="CMP-002.01.01" MODIFIED="2009-08-16 20:06:01 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.27953062873418166" STUDIES="1" TAU2="0.0" TOTAL_1="81" TOTAL_2="77" WEIGHT="12.135726571387991" Z="1.081374382602364">
<NAME>switching to aripiprazole</NAME>
<CONT_DATA CI_END="2.608044602862612" CI_START="-9.028044602862611" EFFECT_SIZE="-3.21" ESTIMABLE="YES" MEAN_1="-1.8" MEAN_2="1.41" MODIFIED="2009-08-16 20:06:01 +0100" MODIFIED_BY="[Empty name]" ORDER="19" SD_1="18.9" SD_2="18.41" SE="2.9684446493683585" STUDY_ID="STD-Newcomer-2008" TOTAL_1="81" TOTAL_2="77" WEIGHT="12.135726571387991"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="4.0510637682933463E-32" CI_END="0.3922394000024332" CI_START="-3.932239400002433" DF="0" EFFECT_SIZE="-1.7699999999999998" ESTIMABLE="YES" I2="100.0" ID="CMP-002.01.02" MODIFIED="2009-08-16 20:09:25 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Z="0.1086219012574792" STUDIES="1" TAU2="0.0" TOTAL_1="61" TOTAL_2="68" WEIGHT="87.86427342861201" Z="1.6044182030130392">
<NAME>switching to quetiapine</NAME>
<CONT_DATA CI_END="0.39223940000243296" CI_START="-3.932239400002433" EFFECT_SIZE="-1.77" ESTIMABLE="YES" MEAN_1="-0.66" MEAN_2="1.11" MODIFIED="2009-08-16 20:09:25 +0100" MODIFIED_BY="[Empty name]" ORDER="20" SD_1="6.17" SD_2="6.35" SE="1.1032036389739308" STUDY_ID="STD-Eli-Lilly-2004" TOTAL_1="61" TOTAL_2="68" WEIGHT="87.86427342861201"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.5709536006470807" CI_START="0.13339378703627724" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.275974025974026" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="28" I2="0.0" I2_Q="0.0" ID="CMP-002.02" LOG_CI_END="-0.2433991838762424" LOG_CI_START="-0.8748643976960606" LOG_EFFECT_SIZE="-0.5591317907861515" METHOD="MH" MODIFIED="2010-10-29 05:54:22 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Q="1.0" P_Z="5.187057103812744E-4" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="88" TOTAL_2="85" WEIGHT="100.0" Z="3.4709059139556606">
<NAME>Weight: 2a. BMI - increase</NAME>
<GROUP_LABEL_1>[Not identical]</GROUP_LABEL_1>
<GROUP_LABEL_2>Olanzapine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.5709536006470807" CI_START="0.13339378703627724" EFFECT_SIZE="0.275974025974026" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="28" LOG_CI_END="-0.2433991838762424" LOG_CI_START="-0.8748643976960606" LOG_EFFECT_SIZE="-0.5591317907861515" MODIFIED="2009-09-01 20:28:01 +0100" MODIFIED_BY="[Empty name]" ORDER="69" O_E="0.0" SE="0.370925792400982" STUDY_ID="STD-Newcomer-2008" TOTAL_1="88" TOTAL_2="85" VAR="0.1375859434682964" WEIGHT="100.0"/>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.21586974281754623" CI_START="-1.2558697428175463" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.52" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-002.03" MODIFIED="2010-02-01 20:38:53 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Q="1.0" P_Z="0.16605177004669236" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="61" TOTAL_2="68" UNITS="" WEIGHT="100.0" Z="1.3850022805102984">
<NAME>Weight: 2b. BMI - average change</NAME>
<GROUP_LABEL_1>Quetiapine</GROUP_LABEL_1>
<GROUP_LABEL_2>Olanzapine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.21586974281754623" CI_START="-1.2558697428175463" DF="0" EFFECT_SIZE="-0.52" ESTIMABLE="YES" I2="0.0" ID="CMP-002.03.01" MODIFIED="2009-09-01 20:21:25 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.16605177004669236" STUDIES="1" TAU2="0.0" TOTAL_1="61" TOTAL_2="68" WEIGHT="100.0" Z="1.3850022805102984">
<NAME>switching to quetiapine</NAME>
<CONT_DATA CI_END="0.21586974281754623" CI_START="-1.2558697428175463" EFFECT_SIZE="-0.52" ESTIMABLE="YES" MEAN_1="-0.2" MEAN_2="0.32" MODIFIED="2009-09-01 20:20:58 +0100" MODIFIED_BY="[Empty name]" ORDER="68" SD_1="2.11" SD_2="2.15" SE="0.37545064532919625" STUDY_ID="STD-Eli-Lilly-2004" TOTAL_1="61" TOTAL_2="68" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.112560846051757" CI_START="0.760624196995547" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9199134199134199" ESTIMABLE="YES" EVENTS_1="60" EVENTS_2="63" I2="0.0" I2_Q="0.0" ID="CMP-002.04" LOG_CI_END="0.04632377190637582" LOG_CI_START="-0.11882986291800374" LOG_EFFECT_SIZE="-0.03625304550581397" METHOD="MH" MODIFIED="2010-04-20 14:12:04 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="1.0" P_Q="1.0" P_Z="0.3895314275630829" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="88" TOTAL_2="85" WEIGHT="100.0" Z="0.8604674501635391">
<NAME>Waist circumference - increase</NAME>
<GROUP_LABEL_1>Aripiprazole</GROUP_LABEL_1>
<GROUP_LABEL_2>Olanzapine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.1125608460517569" CI_START="0.760624196995547" EFFECT_SIZE="0.9199134199134199" ESTIMABLE="YES" EVENTS_1="60" EVENTS_2="63" LOG_CI_END="0.04632377190637574" LOG_CI_START="-0.11882986291800374" LOG_EFFECT_SIZE="-0.03625304550581397" MODIFIED="2010-01-12 11:20:15 +0000" MODIFIED_BY="[Empty name]" ORDER="63" O_E="0.0" SE="0.09701206261951774" STUDY_ID="STD-Newcomer-2008" TOTAL_1="88" TOTAL_2="85" VAR="0.00941134029369323" WEIGHT="100.0"/>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.6112028668332897" CI_END="0.10236101574450161" CI_START="-0.043527734017059325" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="MD" EFFECT_SIZE="0.029416640863721144" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-002.05" MODIFIED="2010-10-29 05:54:41 +0100" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.8938630196971079" P_Q="0.8938630196971079" P_Z="0.4292916261402411" Q="0.6112028668332897" RANDOM="NO" SCALE="9.29" SORT_BY="WEIGHT" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="248" TOTAL_2="272" UNITS="" WEIGHT="400.0" Z="0.790404424375071">
<NAME>Physiological measures: 1a. Average changes - switching to quetiapine</NAME>
<GROUP_LABEL_1>Quetiapine</GROUP_LABEL_1>
<GROUP_LABEL_2>Olanzapine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="7.437821198095218E-34" CI_END="0.2693362799266416" CI_START="-0.22933627992664163" DF="0" EFFECT_SIZE="0.019999999999999987" ESTIMABLE="YES" I2="100.0" ID="CMP-002.05.01" MODIFIED="2010-10-29 05:54:41 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.8750757976009654" STUDIES="1" TAU2="0.0" TOTAL_1="62" TOTAL_2="68" WEIGHT="100.0" Z="0.1572145044529182">
<NAME>lipids - cholesterol levels</NAME>
<CONT_DATA CI_END="0.2693362799266416" CI_START="-0.22933627992664163" EFFECT_SIZE="0.01999999999999999" ESTIMABLE="YES" MEAN_1="-0.14" MEAN_2="-0.16" MODIFIED="2009-11-16 12:42:53 +0000" MODIFIED_BY="[Empty name]" ORDER="88" SD_1="0.71" SD_2="0.74" SE="0.12721472531810502" STUDY_ID="STD-Eli-Lilly-2004" TOTAL_1="62" TOTAL_2="68" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.20180952554568266" CI_START="-0.24180952554568264" DF="0" EFFECT_SIZE="-0.01999999999999999" ESTIMABLE="YES" I2="0.0" ID="CMP-002.05.02" MODIFIED="2010-10-12 18:49:37 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.8597244337174131" STUDIES="1" TAU2="0.0" TOTAL_1="62" TOTAL_2="68" WEIGHT="100.00000000000001" Z="0.17672496072639496">
<NAME>lipids - low density lipoproteins</NAME>
<CONT_DATA CI_END="0.20180952554568266" CI_START="-0.24180952554568264" EFFECT_SIZE="-0.01999999999999999" ESTIMABLE="YES" MEAN_1="-0.09" MEAN_2="-0.07" MODIFIED="2009-11-16 12:43:50 +0000" MODIFIED_BY="[Empty name]" ORDER="89" SD_1="0.63" SD_2="0.66" SE="0.11317020480748007" STUDY_ID="STD-Eli-Lilly-2004" TOTAL_1="62" TOTAL_2="68" WEIGHT="100.00000000000001"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="6.513033449858012E-33" CI_END="0.11425907520855583" CI_START="-0.05425907520855583" DF="0" EFFECT_SIZE="0.029999999999999995" ESTIMABLE="YES" I2="100.0" ID="CMP-002.05.03" MODIFIED="2010-10-12 18:49:37 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.0" P_Z="0.4852804834991691" STUDIES="1" TAU2="0.0" TOTAL_1="62" TOTAL_2="68" WEIGHT="100.0" Z="0.6978348550665207">
<NAME>lipids - high density lipoproteins</NAME>
<CONT_DATA CI_END="0.11425907520855583" CI_START="-0.05425907520855583" EFFECT_SIZE="0.03" ESTIMABLE="YES" MEAN_1="0.0" MEAN_2="-0.03" MODIFIED="2009-11-16 12:44:16 +0000" MODIFIED_BY="[Empty name]" ORDER="90" SD_1="0.24" SD_2="0.25" SE="0.04299011403943167" STUDY_ID="STD-Eli-Lilly-2004" TOTAL_1="62" TOTAL_2="68" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.4360683529366177" CI_START="-0.1760683529366177" DF="0" EFFECT_SIZE="0.13" ESTIMABLE="YES" I2="0.0" ID="CMP-002.05.04" MODIFIED="2009-11-16 12:47:41 +0000" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="1.0" P_Z="0.4051389268665384" STUDIES="1" TAU2="0.0" TOTAL_1="62" TOTAL_2="68" WEIGHT="100.0" Z="0.8324784824877711">
<NAME>lipids - triglyceride</NAME>
<CONT_DATA CI_END="0.4360683529366177" CI_START="-0.1760683529366177" EFFECT_SIZE="0.13" ESTIMABLE="YES" MEAN_1="-0.03" MEAN_2="-0.16" MODIFIED="2009-08-16 20:41:27 +0100" MODIFIED_BY="[Empty name]" ORDER="25" SD_1="0.87" SD_2="0.91" SE="0.15616019240702678" STUDY_ID="STD-Eli-Lilly-2004" TOTAL_1="62" TOTAL_2="68" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<OTHER_OUTCOME COLS="5" ID="CMP-002.06" MODIFIED="2010-10-12 18:49:37 +0100" MODIFIED_BY="[Empty name]" NO="6" ROWS_PER_STUDY="2" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES">
<NAME>Physiological measures: 1b. Percentage changes - switching to aripiprazole</NAME>
<TR>
<TH>
<P>Group</P>
</TH>
<TH>
<P>N</P>
</TH>
<TH>
<P>% change</P>
</TH>
<TH>
<P>SE</P>
</TH>
<TH>
<P>stated p</P>
</TH>
</TR>
<OTHER_SUBGROUP ID="CMP-002.06.01" MODIFIED="2009-11-16 13:12:19 +0000" MODIFIED_BY="[Empty name]" NO="1" STUDIES="1">
<NAME>lipids - cholesterol</NAME>
<OTHER_DATA MODIFIED="2009-11-16 13:12:19 +0000" MODIFIED_BY="[Empty name]" ORDER="14" STUDY_ID="STD-Newcomer-2008">
<TR>
<TD>
<P>Switch to aripiprazole</P>
</TD>
<TD>
<P>80</P>
</TD>
<TD>
<P>-9.5</P>
</TD>
<TD>
<P>1.5</P>
</TD>
<TD>
<P>~0.005</P>
</TD>
</TR>
<TR>
<TD>
<P>Stay on olanzapine</P>
</TD>
<TD>
<P>76</P>
</TD>
<TD>
<P>-3.3</P>
</TD>
<TD>
<P>1.6</P>
</TD>
<TD/>
</TR>
</OTHER_DATA>
</OTHER_SUBGROUP>
<OTHER_SUBGROUP ID="CMP-002.06.02" MODIFIED="2010-01-19 12:19:01 +0000" MODIFIED_BY="[Empty name]" NO="2" STUDIES="1">
<NAME>lipids - triglycerides</NAME>
<OTHER_DATA MODIFIED="2010-01-19 12:19:01 +0000" MODIFIED_BY="[Empty name]" ORDER="15" STUDY_ID="STD-Newcomer-2008">
<TR>
<TD>
<P>Switch to aripiprazole</P>
</TD>
<TD>
<P>54</P>
</TD>
<TD>
<P>-14.46</P>
</TD>
<TD>
<P>4.5 (estimate from graph)</P>
</TD>
<TD>
<P>~0.002</P>
</TD>
</TR>
<TR>
<TD>
<P>Stay on olanzapine</P>
</TD>
<TD>
<P>61</P>
</TD>
<TD>
<P>+ 5.3</P>
</TD>
<TD>
<P>5.6 (estimate from graph)</P>
</TD>
<TD/>
</TR>
</OTHER_DATA>
</OTHER_SUBGROUP>
<OTHER_SUBGROUP ID="CMP-002.06.03" MODIFIED="2010-10-12 18:49:37 +0100" MODIFIED_BY="[Empty name]" NO="3" STUDIES="1">
<NAME>lipids - low density lipoproteins</NAME>
<OTHER_DATA MODIFIED="2009-11-16 13:30:06 +0000" MODIFIED_BY="[Empty name]" ORDER="16" STUDY_ID="STD-Newcomer-2008">
<TR>
<TD>
<P>Switch to aripiprazole</P>
</TD>
<TD>
<P>80</P>
</TD>
<TD>
<P>-11.2</P>
</TD>
<TD>
<P>2.5</P>
</TD>
<TD>
<P>~0.072</P>
</TD>
</TR>
<TR>
<TD>
<P>Stay on olanzapine</P>
</TD>
<TD>
<P>76</P>
</TD>
<TD>
<P>-4.7</P>
</TD>
<TD>
<P>2.7</P>
</TD>
<TD/>
</TR>
</OTHER_DATA>
</OTHER_SUBGROUP>
<OTHER_SUBGROUP ID="CMP-002.06.04" MODIFIED="2010-10-12 18:49:37 +0100" MODIFIED_BY="[Empty name]" NO="4" STUDIES="1">
<NAME>lipids - high density lipoproteins</NAME>
<OTHER_DATA MODIFIED="2009-11-16 13:31:43 +0000" MODIFIED_BY="[Empty name]" ORDER="17" STUDY_ID="STD-Newcomer-2008">
<TR>
<TD>
<P>Switch to aripiprazole</P>
</TD>
<TD>
<P>80</P>
</TD>
<TD>
<P>+1.7</P>
</TD>
<TD>
<P>1.8</P>
</TD>
<TD>
<P>~0.002</P>
</TD>
</TR>
<TR>
<TD>
<P>Stay on olanzapine</P>
</TD>
<TD>
<P>76</P>
</TD>
<TD>
<P>-5.9</P>
</TD>
<TD>
<P>1.7</P>
</TD>
<TD/>
</TR>
</OTHER_DATA>
</OTHER_SUBGROUP>
</OTHER_OUTCOME>
<CONT_OUTCOME CHI2="68.58317295490566" CI_END="-1.1494249403530885" CI_START="-1.8103750737513535" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="MD" EFFECT_SIZE="-1.479900007052221" ESTIMABLE="YES" I2="94.16766558375762" I2_Q="95.61816574312465" ID="CMP-002.07" MODIFIED="2010-06-28 12:32:11 +0100" MODIFIED_BY="[Empty name]" NO="7" P_CHI2="4.5075054799781356E-14" P_Q="8.770761894538737E-15" P_Z="1.6802375730358142E-18" Q="68.46447912293402" RANDOM="YES" SCALE="25.45" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="3.8741390219529115" TOTALS="SUB" TOTAL_1="353" TOTAL_2="360" UNITS="" WEIGHT="400.0" Z="8.7769124113185">
<NAME>Physiological measures: 1c. Average changes - sugar</NAME>
<GROUP_LABEL_1>Experimental</GROUP_LABEL_1>
<GROUP_LABEL_2>Olanzapine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="3.442646979206994" CI_START="-4.042646979206994" DF="0" EFFECT_SIZE="-0.3" ESTIMABLE="YES" I2="0.0" ID="CMP-002.07.01" MODIFIED="2010-06-28 12:31:03 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.8751619620177788" STUDIES="1" TAU2="0.0" TOTAL_1="78" TOTAL_2="77" WEIGHT="100.0" Z="0.15710517145450936">
<NAME>fasting insulin level</NAME>
<CONT_DATA CI_END="3.442646979206994" CI_START="-4.042646979206994" EFFECT_SIZE="-0.3" ESTIMABLE="YES" MEAN_1="0.3" MEAN_2="0.6" MODIFIED="2009-11-16 12:51:52 +0000" MODIFIED_BY="[Empty name]" ORDER="93" SD_1="12.36" SD_2="11.4" SE="1.9095488533098135" STUDY_ID="STD-Newcomer-2008" TOTAL_1="78" TOTAL_2="77" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="26.08203540024662" CI_START="-8.822035400246623" DF="0" EFFECT_SIZE="8.629999999999999" ESTIMABLE="YES" I2="0.0" ID="CMP-002.07.02" MODIFIED="2010-06-28 12:31:09 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.3324460957727735" STUDIES="1" TAU2="0.0" TOTAL_1="60" TOTAL_2="65" WEIGHT="100.0" Z="0.9691986521149069">
<NAME>insulin level</NAME>
<CONT_DATA CI_END="26.08203540024662" CI_START="-8.822035400246623" EFFECT_SIZE="8.629999999999999" ESTIMABLE="YES" MEAN_1="10.42" MEAN_2="1.79" MODIFIED="2010-01-31 12:36:10 +0000" MODIFIED_BY="[Empty name]" ORDER="68" SD_1="49.52" SD_2="49.97" SE="8.904263311931265" STUDY_ID="STD-Eli-Lilly-2004" TOTAL_1="60" TOTAL_2="65" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.9145881255959885" CI_START="-0.19458812559598831" DF="0" EFFECT_SIZE="0.36000000000000004" ESTIMABLE="YES" I2="0.0" ID="CMP-002.07.03" MODIFIED="2010-01-31 12:38:32 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Z="0.2032764607919777" STUDIES="1" TAU2="0.0" TOTAL_1="77" TOTAL_2="76" WEIGHT="100.00000000000001" Z="1.2722721635559007">
<NAME>c-peptides</NAME>
<CONT_DATA CI_END="0.9145881255959885" CI_START="-0.19458812559598831" EFFECT_SIZE="0.36000000000000004" ESTIMABLE="YES" MEAN_1="0.4" MEAN_2="0.04" MODIFIED="2009-12-17 11:50:16 +0000" MODIFIED_BY="[Empty name]" ORDER="64" SD_1="1.76" SD_2="1.74" SE="0.28295832472969334" STUDY_ID="STD-Newcomer-2008" TOTAL_1="77" TOTAL_2="76" WEIGHT="100.00000000000001"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.1186938319716411" CI_END="-2.1119193078609544" CI_START="-2.940208615239991" DF="1" EFFECT_SIZE="-2.5260639615504727" ESTIMABLE="YES" I2="0.0" ID="CMP-002.07.04" MODIFIED="2010-06-28 12:32:11 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.7304555293103178" P_Z="6.13203413091274E-33" STUDIES="2" TAU2="0.0" TOTAL_1="138" TOTAL_2="142" WEIGHT="100.0" Z="11.954746591984811">
<NAME>sugar - fasting glucose - switching to aripiprazole and quetiapine</NAME>
<CONT_DATA CI_END="-2.104421021703688" CI_START="-2.935578978296312" EFFECT_SIZE="-2.52" ESTIMABLE="YES" MEAN_1="-1.98" MEAN_2="0.54" MODIFIED="2010-01-31 12:35:43 +0000" MODIFIED_BY="[Empty name]" ORDER="67" SD_1="1.14" SD_2="1.22" SE="0.2120339871417771" STUDY_ID="STD-Eli-Lilly-2004" TOTAL_1="58" TOTAL_2="66" WEIGHT="99.31091346017354"/>
<CONT_DATA CI_END="1.5890192070406388" CI_START="-8.389019207040638" EFFECT_SIZE="-3.4" ESTIMABLE="YES" MEAN_1="1.6" MEAN_2="5.0" MODIFIED="2010-01-31 12:35:43 +0000" MODIFIED_BY="[Empty name]" ORDER="66" SD_1="16.09" SD_2="15.7" SE="2.5454647362877" STUDY_ID="STD-Newcomer-2008" TOTAL_1="80" TOTAL_2="76" WEIGHT="0.6890865398264655"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="3.1066960234795538" CI_START="0.5504430297246582" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.3076923076923077" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="8" I2="0.0" I2_Q="0.0" ID="CMP-002.08" LOG_CI_END="0.4922987615318311" LOG_CI_START="-0.2592876233889567" LOG_EFFECT_SIZE="0.11650556907143717" METHOD="MH" MODIFIED="2010-04-27 12:40:20 +0100" MODIFIED_BY="[Empty name]" NO="8" P_CHI2="1.0" P_Q="1.0" P_Z="0.5434267205818043" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="65" TOTAL_2="68" WEIGHT="100.0" Z="0.6076393185393498">
<NAME>Global state: 1a. Relapse</NAME>
<GROUP_LABEL_1>Quetiapine</GROUP_LABEL_1>
<GROUP_LABEL_2>Olanzapine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours quetiapine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours olanzapine</GRAPH_LABEL_2>
<DICH_DATA CI_END="3.1066960234795538" CI_START="0.5504430297246582" EFFECT_SIZE="1.3076923076923077" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="8" LOG_CI_END="0.4922987615318311" LOG_CI_START="-0.2592876233889567" LOG_EFFECT_SIZE="0.11650556907143717" MODIFIED="2009-12-17 12:03:05 +0000" MODIFIED_BY="[Empty name]" ORDER="65" O_E="0.0" SE="0.4414855629150782" STUDY_ID="STD-Eli-Lilly-2004" TOTAL_1="65" TOTAL_2="68" VAR="0.19490950226244344" WEIGHT="100.0"/>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.5930649530541992" CI_START="-0.013064953054199246" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.29" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-002.09" MODIFIED="2010-02-09 13:21:09 +0000" MODIFIED_BY="[Empty name]" NO="9" P_CHI2="1.0" P_Q="1.0" P_Z="0.06072794415194831" Q="0.0" RANDOM="NO" SCALE="4.82" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="84" TOTAL_2="80" UNITS="" WEIGHT="99.99999999999999" Z="1.8754710823160294">
<NAME>Global state: 1b. Average change (CGI-S, high decline = good) - switching to aripiprazole</NAME>
<GROUP_LABEL_1>Aripiprazole</GROUP_LABEL_1>
<GROUP_LABEL_2>Olanzapine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.5930649530541992" CI_START="-0.013064953054199246" EFFECT_SIZE="0.29" ESTIMABLE="YES" MEAN_1="0.11" MEAN_2="-0.18" MODIFIED="2010-02-09 12:09:59 +0000" MODIFIED_BY="[Empty name]" ORDER="94" SD_1="1.0" SD_2="0.98" SE="0.15462781737049094" STUDY_ID="STD-Newcomer-2008" TOTAL_1="84" TOTAL_2="80" WEIGHT="99.99999999999999"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="1.696097528354221E-32" CI_END="3.0533299367364273" CI_START="-10.313329936736428" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="-3.6300000000000003" ESTIMABLE="YES" I2="100.0" I2_Q="0.0" ID="CMP-002.10" MODIFIED="2009-12-16 10:54:41 +0000" MODIFIED_BY="[Empty name]" NO="10" P_CHI2="0.0" P_Q="1.0" P_Z="0.2870843486667237" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="65" TOTAL_2="68" UNITS="" WEIGHT="100.0" Z="1.0645395829963469">
<NAME>Mental state: Average change (PANSS, high decline = good) - switching to quetiapine</NAME>
<GROUP_LABEL_1>[Not identical]</GROUP_LABEL_1>
<GROUP_LABEL_2>Olanzapine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="3.0533299367364277" CI_START="-10.313329936736427" EFFECT_SIZE="-3.63" ESTIMABLE="YES" MEAN_1="5.79" MEAN_2="9.42" MODIFIED="2009-11-16 12:59:57 +0000" MODIFIED_BY="[Empty name]" ORDER="96" SD_1="19.91" SD_2="19.39" SE="3.4099248707903214" STUDY_ID="STD-Eli-Lilly-2004" TOTAL_1="65" TOTAL_2="68" WEIGHT="100.0"/>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="1.0236287478879291" CI_END="2.2800032192867437" CI_START="1.2175090112885443" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="1.6661105801382154" ESTIMABLE="YES" EVENTS_1="69" EVENTS_2="42" I2="2.3083317986802077" I2_Q="2.025708864764886" ID="CMP-002.11" LOG_CI_END="0.35793546020987543" LOG_CI_START="0.0854721842919341" LOG_EFFECT_SIZE="0.22170382225090474" METHOD="MH" MODIFIED="2010-10-29 05:55:44 +0100" MODIFIED_BY="[Empty name]" NO="11" P_CHI2="0.31166010266871236" P_Q="0.31235902500815005" P_Z="0.0014244424338841519" Q="1.0206759226455517" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.001187495007861366" TOTALS="YES" TOTAL_1="153" TOTAL_2="153" WEIGHT="99.99999999999999" Z="3.189651929293491">
<NAME>Loss to follow-up</NAME>
<GROUP_LABEL_1>[Not identical]</GROUP_LABEL_1>
<GROUP_LABEL_2>Olanzapine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.211501330104966" CI_START="0.8925650910240985" DF="0" EFFECT_SIZE="1.4049586776859504" ESTIMABLE="YES" EVENTS_1="32" EVENTS_2="22" I2="0.0" ID="CMP-002.11.01" LOG_CI_END="0.34468720491162463" LOG_CI_START="-0.04936010278797696" LOG_EFFECT_SIZE="0.14766355106182386" MODIFIED="2009-08-10 20:42:50 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.14185000596515177" STUDIES="1" TAU2="0.0" TOTAL_1="88" TOTAL_2="85" WEIGHT="46.773340026941305" Z="1.4689365274440556">
<NAME>switching to aripiprazole</NAME>
<DICH_DATA CI_END="2.211501330104966" CI_START="0.8925650910240985" EFFECT_SIZE="1.4049586776859504" ESTIMABLE="YES" EVENTS_1="32" EVENTS_2="22" LOG_CI_END="0.34468720491162463" LOG_CI_START="-0.04936010278797696" LOG_EFFECT_SIZE="0.14766355106182386" MODIFIED="2009-08-10 20:42:50 +0100" MODIFIED_BY="[Empty name]" ORDER="15" O_E="0.0" SE="0.2314653391083774" STUDY_ID="STD-Newcomer-2008" TOTAL_1="88" TOTAL_2="85" VAR="0.05357620320855615" WEIGHT="46.773340026941305"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="2.6260892807094408E-31" CI_END="2.959230108372246" CI_START="1.265773012673159" DF="0" EFFECT_SIZE="1.9353846153846155" ESTIMABLE="YES" EVENTS_1="37" EVENTS_2="20" I2="100.0" ID="CMP-002.11.02" LOG_CI_END="0.4711787370128681" LOG_CI_START="0.10235583191992112" LOG_EFFECT_SIZE="0.28676728446639455" MODIFIED="2009-08-10 20:44:57 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Z="0.002305053094346223" STUDIES="1" TAU2="0.0" TOTAL_1="65" TOTAL_2="68" WEIGHT="53.22665997305868" Z="3.0478234498849415">
<NAME>switching to quetiapine</NAME>
<DICH_DATA CI_END="2.959230108372246" CI_START="1.265773012673159" EFFECT_SIZE="1.9353846153846155" ESTIMABLE="YES" EVENTS_1="37" EVENTS_2="20" LOG_CI_END="0.4711787370128681" LOG_CI_START="0.10235583191992112" LOG_EFFECT_SIZE="0.28676728446639455" MODIFIED="2009-08-10 20:44:57 +0100" MODIFIED_BY="[Empty name]" ORDER="883" O_E="0.0" SE="0.2166484001544218" STUDY_ID="STD-Eli-Lilly-2004" TOTAL_1="65" TOTAL_2="68" VAR="0.046936529289470466" WEIGHT="53.22665997305868"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.8095047381260714" CI_END="2.0653632126184847" CI_START="0.47677070290992424" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.992322866129978" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="13" I2="44.73625965546777" I2_Q="44.72122026405616" ID="CMP-002.12" LOG_CI_END="0.3149964372829999" LOG_CI_START="-0.3216904394160435" LOG_EFFECT_SIZE="-0.0033470010665218046" METHOD="MH" MODIFIED="2009-12-16 10:54:39 +0000" MODIFIED_BY="[Empty name]" NO="12" P_CHI2="0.17856780348069656" P_Q="0.17862689336760873" P_Z="0.9835594112703289" Q="1.8090124361948812" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="153" TOTAL_2="152" WEIGHT="100.0" Z="0.02060668057306526">
<NAME>Adverse events: 1. Serious adverse event</NAME>
<GROUP_LABEL_1>[Not identical]</GROUP_LABEL_1>
<GROUP_LABEL_2>Olanzapine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.7105168742818035" CI_START="0.23674637986601613" DF="0" EFFECT_SIZE="0.6363636363636364" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="9" I2="0.0" ID="CMP-002.12.01" LOG_CI_END="0.23312736286561558" LOG_CI_START="-0.625716653153552" LOG_EFFECT_SIZE="-0.19629464514396822" MODIFIED="2009-08-17 19:59:23 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.37029218123248875" STUDIES="1" TAU2="0.0" TOTAL_1="88" TOTAL_2="84" WEIGHT="70.19779282401237" Z="0.8959262163192661">
<NAME>switching to aripiprazole</NAME>
<DICH_DATA CI_END="1.7105168742818035" CI_START="0.23674637986601613" EFFECT_SIZE="0.6363636363636364" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="9" LOG_CI_END="0.23312736286561558" LOG_CI_START="-0.625716653153552" LOG_EFFECT_SIZE="-0.19629464514396822" MODIFIED="2009-08-17 19:59:23 +0100" MODIFIED_BY="[Empty name]" ORDER="37" O_E="0.0" SE="0.5044892263561032" STUDY_ID="STD-Newcomer-2008" TOTAL_1="88" TOTAL_2="84" VAR="0.2545093795093795" WEIGHT="70.19779282401237"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="5.960919430081917" CI_START="0.5622817110086824" DF="0" EFFECT_SIZE="1.8307692307692307" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="4" I2="0.0" ID="CMP-002.12.02" LOG_CI_END="0.7753132517896679" LOG_CI_START="-0.25004604229031757" LOG_EFFECT_SIZE="0.2626336047496752" MODIFIED="2009-08-17 20:00:12 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.3153579054863914" STUDIES="1" TAU2="0.0" TOTAL_1="65" TOTAL_2="68" WEIGHT="29.80220717598763" Z="1.0040429913909505">
<NAME>switching to quetiapine</NAME>
<DICH_DATA CI_END="5.960919430081917" CI_START="0.5622817110086824" EFFECT_SIZE="1.8307692307692307" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="4" LOG_CI_END="0.7753132517896679" LOG_CI_START="-0.25004604229031757" LOG_EFFECT_SIZE="0.2626336047496752" MODIFIED="2009-08-17 20:00:12 +0100" MODIFIED_BY="[Empty name]" ORDER="38" O_E="0.0" SE="0.6023011249529476" STUDY_ID="STD-Eli-Lilly-2004" TOTAL_1="65" TOTAL_2="68" VAR="0.3627666451195863" WEIGHT="29.80220717598763"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="2.032377173854611" CI_END="1.2435185067129453" CI_START="0.9194323561452777" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0692666414591547" ESTIMABLE="YES" EVENTS_1="106" EVENTS_2="100" I2="50.79653457712292" I2_Q="42.94266070779081" ID="CMP-002.13" LOG_CI_END="0.09465225305871058" LOG_CI_START="-0.0364802168701445" LOG_EFFECT_SIZE="0.02908601809428302" METHOD="MH" MODIFIED="2009-12-16 10:54:37 +0000" MODIFIED_BY="[Empty name]" NO="13" P_CHI2="0.1539800122263667" P_Q="0.18554744985957206" P_Z="0.3845928409333941" Q="1.7526229095238297" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="151" TOTAL_2="151" WEIGHT="100.0" Z="0.8694650218882338">
<NAME>Adverse events: 2. Treatment emergent adverse events</NAME>
<GROUP_LABEL_1>[Not identical]</GROUP_LABEL_1>
<GROUP_LABEL_2>Olanzapine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.5315686262094141" CI_START="0.9213142594757241" DF="0" EFFECT_SIZE="1.187878787878788" ESTIMABLE="YES" EVENTS_1="56" EVENTS_2="45" I2="0.0" ID="CMP-002.13.01" LOG_CI_END="0.1851364613556683" LOG_CI_START="-0.03559220707052873" LOG_EFFECT_SIZE="0.07477212714256981" MODIFIED="2009-08-17 20:03:03 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.18421750096747994" STUDIES="1" TAU2="0.0" TOTAL_1="88" TOTAL_2="84" WEIGHT="46.3458110516934" Z="1.3278807623114655">
<NAME>switching to aripiprazole</NAME>
<DICH_DATA CI_END="1.5315686262094141" CI_START="0.9213142594757241" EFFECT_SIZE="1.187878787878788" ESTIMABLE="YES" EVENTS_1="56" EVENTS_2="45" LOG_CI_END="0.1851364613556683" LOG_CI_START="-0.03559220707052873" LOG_EFFECT_SIZE="0.07477212714256981" MODIFIED="2009-08-17 20:03:03 +0100" MODIFIED_BY="[Empty name]" ORDER="39" O_E="0.0" SE="0.12965711245807848" STUDY_ID="STD-Newcomer-2008" TOTAL_1="88" TOTAL_2="84" VAR="0.016810966810966808" WEIGHT="46.3458110516934"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.669407446433114E-30" CI_END="1.1441492052649693" CI_START="0.8169593976420995" DF="0" EFFECT_SIZE="0.9668109668109667" ESTIMABLE="YES" EVENTS_1="50" EVENTS_2="55" I2="100.0" ID="CMP-002.13.02" LOG_CI_END="0.05848266326638883" LOG_CI_START="-0.08779952708834955" LOG_EFFECT_SIZE="-0.014658431910980372" MODIFIED="2009-08-17 20:01:31 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Z="0.69446542384167" STUDIES="1" TAU2="0.0" TOTAL_1="63" TOTAL_2="67" WEIGHT="53.6541889483066" Z="0.39280241218268785">
<NAME>switching to quetiapine</NAME>
<DICH_DATA CI_END="1.1441492052649693" CI_START="0.8169593976420997" EFFECT_SIZE="0.9668109668109668" ESTIMABLE="YES" EVENTS_1="50" EVENTS_2="55" LOG_CI_END="0.05848266326638883" LOG_CI_START="-0.08779952708834944" LOG_EFFECT_SIZE="-0.014658431910980322" MODIFIED="2009-08-17 20:01:31 +0100" MODIFIED_BY="[Empty name]" ORDER="40" O_E="0.0" SE="0.08592688272289381" STUDY_ID="STD-Eli-Lilly-2004" TOTAL_1="63" TOTAL_2="67" VAR="0.007383429174473948" WEIGHT="53.6541889483066"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-003" MODIFIED="2010-10-29 06:02:05 +0100" MODIFIED_BY="[Empty name]" NO="3">
<NAME>Switching - techniques: to aripriprazole from previous regimen - three dfferent techniques - short term (up to 12 months)</NAME>
<DICH_OUTCOME CHI2="0.9584618953411057" CI_END="2.261630293713499" CI_START="0.4366955910820488" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9938027862318982" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="11" I2="0.0" I2_Q="0.0" ID="CMP-003.01" LOG_CI_END="0.3544216127367232" LOG_CI_START="-0.35982119273266305" LOG_EFFECT_SIZE="-0.0026997899979699577" METHOD="MH" MODIFIED="2010-04-27 12:09:42 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.619259496766025" P_Q="0.619259497154377" P_Z="0.9881781248951116" Q="0.9584618940868579" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="310" TOTAL_2="308" WEIGHT="300.0" Z="0.014817065348989049">
<NAME>Weight: gain (&#8805; 7% from baseline)</NAME>
<GROUP_LABEL_1>Experimental</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.469514087401757" CI_START="0.1486220413105725" DF="0" EFFECT_SIZE="0.6058252427184466" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="5" I2="0.0" ID="CMP-003.01.01" LOG_CI_END="0.3926115079478189" LOG_CI_START="-0.8279167779933154" LOG_EFFECT_SIZE="-0.2176526350227482" MODIFIED="2010-04-27 12:08:41 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.48453494456879687" STUDIES="1" TAU2="0.0" TOTAL_1="103" TOTAL_2="104" WEIGHT="100.0" Z="0.6990273485647052">
<NAME>technique 1 vs technique 2</NAME>
<DICH_DATA CI_END="2.469514087401757" CI_START="0.1486220413105725" EFFECT_SIZE="0.6058252427184466" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="5" LOG_CI_END="0.3926115079478189" LOG_CI_START="-0.8279167779933154" LOG_EFFECT_SIZE="-0.2176526350227482" MODIFIED="2010-04-27 12:08:41 +0100" MODIFIED_BY="[Empty name]" ORDER="66" O_E="0.0" SE="0.7169443568742773" STUDY_ID="STD-Casey-2003" TOTAL_1="103" TOTAL_2="104" VAR="0.5140092108538711" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="4.7920301692541525" CI_START="0.20464745613556803" DF="0" EFFECT_SIZE="0.9902912621359223" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="3" I2="0.0" ID="CMP-003.01.02" LOG_CI_END="0.6805195435839588" LOG_CI_START="-0.6889936494704683" LOG_EFFECT_SIZE="-0.004237052943254643" MODIFIED="2010-04-27 12:09:17 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.990323792505604" STUDIES="1" TAU2="0.0" TOTAL_1="103" TOTAL_2="102" WEIGHT="100.00000000000001" Z="0.012127624927580375">
<NAME>technique 1 vs technique 3</NAME>
<DICH_DATA CI_END="4.7920301692541525" CI_START="0.20464745613556803" EFFECT_SIZE="0.9902912621359223" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="3" LOG_CI_END="0.6805195435839588" LOG_CI_START="-0.6889936494704683" LOG_EFFECT_SIZE="-0.004237052943254643" MODIFIED="2010-04-27 12:09:17 +0100" MODIFIED_BY="[Empty name]" ORDER="67" O_E="0.0" SE="0.8044588287998097" STUDY_ID="STD-Casey-2003" TOTAL_1="103" TOTAL_2="102" VAR="0.6471540072339615" WEIGHT="100.00000000000001"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="6.662285173870528" CI_START="0.40105870371636954" DF="0" EFFECT_SIZE="1.6346153846153846" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="3" I2="0.0" ID="CMP-003.01.03" LOG_CI_END="0.8236232183863313" LOG_CI_START="-0.3967920542273442" LOG_EFFECT_SIZE="0.21341558207949357" MODIFIED="2010-04-27 12:09:42 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Z="0.49303929929892065" STUDIES="1" TAU2="0.0" TOTAL_1="104" TOTAL_2="102" WEIGHT="100.0" Z="0.6854828253986766">
<NAME>technique 2 vs technique 3</NAME>
<DICH_DATA CI_END="6.662285173870528" CI_START="0.40105870371636954" EFFECT_SIZE="1.6346153846153846" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="3" LOG_CI_END="0.8236232183863313" LOG_CI_START="-0.3967920542273442" LOG_EFFECT_SIZE="0.21341558207949357" MODIFIED="2010-04-27 12:09:42 +0100" MODIFIED_BY="[Empty name]" ORDER="68" O_E="0.0" SE="0.7168779722863029" STUDY_ID="STD-Casey-2003" TOTAL_1="104" TOTAL_2="102" VAR="0.5139140271493213" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="1.3105103496997854" CI_END="0.21142857132836446" CI_START="-0.19383486997214516" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="MD" EFFECT_SIZE="0.008796850678109638" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-003.02" MODIFIED="2010-10-29 05:56:26 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.5193095650347003" P_Q="0.5193095650347003" P_Z="0.9321914983565736" Q="1.3105103496997854" RANDOM="NO" SCALE="0.31" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="304" TOTAL_2="306" UNITS="" WEIGHT="300.0" Z="0.08508791442496179">
<NAME>Global state: 1a. Average change (CGI-I, high = good)</NAME>
<GROUP_LABEL_1>Experimental</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.21493978243920348" CI_START="-0.4949397824392037" DF="0" EFFECT_SIZE="-0.14000000000000012" ESTIMABLE="YES" I2="0.0" ID="CMP-003.02.01" MODIFIED="2010-04-20 14:47:29 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.43947819297199" STUDIES="1" TAU2="0.0" TOTAL_1="101" TOTAL_2="102" WEIGHT="100.0" Z="0.7730746774845054">
<NAME>technique 1 vs technique 2</NAME>
<CONT_DATA CI_END="0.21493978243920348" CI_START="-0.4949397824392037" EFFECT_SIZE="-0.14000000000000012" ESTIMABLE="YES" MEAN_1="3.17" MEAN_2="3.31" MODIFIED="2010-04-20 14:45:47 +0100" MODIFIED_BY="[Empty name]" ORDER="83" SD_1="1.3" SD_2="1.28" SE="0.18109505339839063" STUDY_ID="STD-Casey-2003" TOTAL_1="101" TOTAL_2="102" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.3608899426587498" CI_START="-0.3408899426587502" DF="0" EFFECT_SIZE="0.009999999999999787" ESTIMABLE="YES" I2="0.0" ID="CMP-003.02.02" MODIFIED="2010-04-20 14:47:35 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.9554557710284886" STUDIES="1" TAU2="0.0" TOTAL_1="101" TOTAL_2="102" WEIGHT="100.0" Z="0.05585694390922257">
<NAME>technique 1 vs technique 3</NAME>
<CONT_DATA CI_END="0.3608899426587498" CI_START="-0.3408899426587502" EFFECT_SIZE="0.009999999999999787" ESTIMABLE="YES" MEAN_1="3.17" MEAN_2="3.16" MODIFIED="2010-04-20 14:36:52 +0100" MODIFIED_BY="[Empty name]" ORDER="71" SD_1="1.3" SD_2="1.25" SE="0.17902877064401443" STUDY_ID="STD-Casey-2003" TOTAL_1="101" TOTAL_2="102" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.4972034711576481" CI_START="-0.1972034711576483" DF="0" EFFECT_SIZE="0.1499999999999999" ESTIMABLE="YES" I2="0.0" ID="CMP-003.02.03" MODIFIED="2010-04-20 14:40:47 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Z="0.3971343974657169" STUDIES="1" TAU2="0.0" TOTAL_1="102" TOTAL_2="102" WEIGHT="100.0" Z="0.8467501684265112">
<NAME>technique 2 vs technique 3</NAME>
<CONT_DATA CI_END="0.4972034711576481" CI_START="-0.1972034711576483" EFFECT_SIZE="0.1499999999999999" ESTIMABLE="YES" MEAN_1="3.31" MEAN_2="3.16" MODIFIED="2010-04-20 14:37:33 +0100" MODIFIED_BY="[Empty name]" ORDER="73" SD_1="1.28" SD_2="1.25" SE="0.17714788327558306" STUDY_ID="STD-Casey-2003" TOTAL_1="102" TOTAL_2="102" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.2936405416577242" CI_END="0.09276411511804122" CI_START="-0.1484540763175409" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.027844980599749845" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-003.03" MODIFIED="2010-10-29 05:56:47 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.8634491627402606" P_Q="0.8634491627402606" P_Z="0.6509115498315846" Q="0.2936405416577242" RANDOM="NO" SCALE="0.31" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="304" TOTAL_2="306" UNITS="" WEIGHT="300.0" Z="0.4524962134980656">
<NAME>Global state: 1b. Average change (CGI-S, decline = good)</NAME>
<GROUP_LABEL_1>Experimental</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.14948193770823368" CI_START="-0.2694819377082337" DF="0" EFFECT_SIZE="-0.06" ESTIMABLE="YES" I2="0.0" ID="CMP-003.03.01" MODIFIED="2010-04-26 15:34:34 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.5745421980263425" STUDIES="1" TAU2="0.0" TOTAL_1="101" TOTAL_2="102" WEIGHT="100.0" Z="0.561374600402033">
<NAME>technique 1 vs technique 2</NAME>
<CONT_DATA CI_END="0.14948193770823368" CI_START="-0.2694819377082337" EFFECT_SIZE="-0.06" ESTIMABLE="YES" MEAN_1="-0.43" MEAN_2="-0.37" MODIFIED="2010-04-20 14:39:28 +0100" MODIFIED_BY="[Empty name]" ORDER="76" SD_1="0.71" SD_2="0.81" SE="0.10688050360139291" STUDY_ID="STD-Casey-2003" TOTAL_1="101" TOTAL_2="102" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.16230241073329132" CI_START="-0.24230241073329128" DF="0" EFFECT_SIZE="-0.03999999999999998" ESTIMABLE="YES" I2="0.0" ID="CMP-003.03.02" MODIFIED="2010-04-26 15:34:34 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.6983627605938153" STUDIES="1" TAU2="0.0" TOTAL_1="101" TOTAL_2="102" WEIGHT="99.99999999999999" Z="0.3875315133291227">
<NAME>technique 1 vs technique 3</NAME>
<CONT_DATA CI_END="0.16230241073329132" CI_START="-0.24230241073329128" EFFECT_SIZE="-0.03999999999999998" ESTIMABLE="YES" MEAN_1="-0.43" MEAN_2="-0.39" MODIFIED="2010-04-20 14:39:28 +0100" MODIFIED_BY="[Empty name]" ORDER="78" SD_1="0.71" SD_2="0.76" SE="0.10321741232442376" STUDY_ID="STD-Casey-2003" TOTAL_1="101" TOTAL_2="102" WEIGHT="99.99999999999999"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.23555236266370486" CI_START="-0.19555236266370482" DF="0" EFFECT_SIZE="0.020000000000000018" ESTIMABLE="YES" I2="0.0" ID="CMP-003.03.03" MODIFIED="2010-04-26 15:34:34 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Z="0.8556965030186133" STUDIES="1" TAU2="0.0" TOTAL_1="102" TOTAL_2="102" WEIGHT="100.0" Z="0.18185502216905913">
<NAME>technique 2 vs technique 3</NAME>
<CONT_DATA CI_END="0.23555236266370486" CI_START="-0.19555236266370482" EFFECT_SIZE="0.020000000000000018" ESTIMABLE="YES" MEAN_1="-0.37" MEAN_2="-0.39" MODIFIED="2010-04-20 14:39:28 +0100" MODIFIED_BY="[Empty name]" ORDER="80" SD_1="0.81" SD_2="0.76" SE="0.10997771610292555" STUDY_ID="STD-Casey-2003" TOTAL_1="102" TOTAL_2="102" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.2985895727115816" CI_END="4.515152852383779" CI_START="-1.0760458264573272" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="MD" EFFECT_SIZE="1.719553512963226" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-003.04" MODIFIED="2010-10-29 05:57:06 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.8613151870446476" P_Q="0.8613151870446476" P_Z="0.22798718256081396" Q="0.2985895727115816" RANDOM="NO" SCALE="6.72" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="294" TOTAL_2="302" UNITS="" WEIGHT="300.0" Z="1.2055600770015242">
<NAME>Mental state: Average change (PANSS, high decline = good)</NAME>
<GROUP_LABEL_1>Experimental</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="5.693825598989353" CI_START="-4.513825598989353" DF="0" EFFECT_SIZE="0.5899999999999999" ESTIMABLE="YES" I2="0.0" ID="CMP-003.04.01" MODIFIED="2010-04-26 17:03:21 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.8207573628141738" STUDIES="1" TAU2="0.0" TOTAL_1="97" TOTAL_2="100" WEIGHT="100.0" Z="0.22657097670179308">
<NAME>technique 1 vs technique 2</NAME>
<CONT_DATA CI_END="5.693825598989353" CI_START="-4.513825598989353" EFFECT_SIZE="0.5899999999999999" ESTIMABLE="YES" MEAN_1="-7.59" MEAN_2="-8.18" MODIFIED="2010-04-20 14:46:26 +0100" MODIFIED_BY="[Empty name]" ORDER="87" SD_1="19.23" SD_2="17.23" SE="2.6040405024009" STUDY_ID="STD-Casey-2003" TOTAL_1="97" TOTAL_2="100" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="7.425882045446487" CI_START="-2.385882045446488" DF="0" EFFECT_SIZE="2.5199999999999996" ESTIMABLE="YES" I2="0.0" ID="CMP-003.04.02" MODIFIED="2010-04-26 17:03:21 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.31404391969671597" STUDIES="1" TAU2="0.0" TOTAL_1="97" TOTAL_2="101" WEIGHT="99.99999999999999" Z="1.0067729299821404">
<NAME>technique 1 vs technique 3</NAME>
<CONT_DATA CI_END="7.425882045446487" CI_START="-2.385882045446488" EFFECT_SIZE="2.5199999999999996" ESTIMABLE="YES" MEAN_1="-7.59" MEAN_2="-10.11" MODIFIED="2010-04-20 14:46:29 +0100" MODIFIED_BY="[Empty name]" ORDER="88" SD_1="19.23" SD_2="15.74" SE="2.5030470376718443" STUDY_ID="STD-Casey-2003" TOTAL_1="97" TOTAL_2="101" WEIGHT="99.99999999999999"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="9.093832019489261E-33" CI_END="6.4936765119294" CI_START="-2.6336765119294006" DF="0" EFFECT_SIZE="1.93" ESTIMABLE="YES" I2="100.0" ID="CMP-003.04.03" MODIFIED="2010-04-20 14:46:33 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.0" P_Z="0.40717352402891405" STUDIES="1" TAU2="0.0" TOTAL_1="100" TOTAL_2="101" WEIGHT="100.0" Z="0.8288778751680336">
<NAME>technique 2 vs technique 3</NAME>
<CONT_DATA CI_END="6.4936765119294" CI_START="-2.6336765119294006" EFFECT_SIZE="1.9299999999999997" ESTIMABLE="YES" MEAN_1="-8.18" MEAN_2="-10.11" MODIFIED="2010-04-20 14:46:33 +0100" MODIFIED_BY="[Empty name]" ORDER="89" SD_1="17.23" SD_2="15.74" SE="2.328449169437346" STUDY_ID="STD-Casey-2003" TOTAL_1="100" TOTAL_2="101" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="3.8191627383918085" CI_END="0.9935637255301838" CI_START="0.81599335312215" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9004117924238388" ESTIMABLE="YES" EVENTS_1="213" EVENTS_2="235" I2="47.63250123135183" I2_Q="47.23624645595273" ID="CMP-003.05" LOG_CI_END="-0.002804272732765767" LOG_CI_START="-0.08831337888600314" LOG_EFFECT_SIZE="-0.04555882580938445" METHOD="MH" MODIFIED="2010-04-20 14:59:24 +0100" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.148142514062084" P_Q="0.1502823088145443" P_Z="0.036751124823976654" Q="3.7904808996016497" RANDOM="NO" SCALE="2.179580176838078" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="312" TOTAL_2="310" WEIGHT="300.0" Z="2.0885180954717937">
<NAME>Loss to follow up: 1a. Any reason</NAME>
<GROUP_LABEL_1>Experimental</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.2586631368514691" CI_START="0.8650820454082019" DF="0" EFFECT_SIZE="1.0434782608695652" ESTIMABLE="YES" EVENTS_1="72" EVENTS_2="69" I2="0.0" ID="CMP-003.05.01" LOG_CI_END="0.09990951296562847" LOG_CI_START="-0.06294270157760216" LOG_EFFECT_SIZE="0.018483405694013133" MODIFIED="2010-04-20 14:52:59 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.6563890564608188" STUDIES="1" TAU2="0.0" TOTAL_1="104" TOTAL_2="104" WEIGHT="100.0" Z="0.44490410613718206">
<NAME>technique 1 vs technique 2</NAME>
<DICH_DATA CI_END="1.2586631368514691" CI_START="0.8650820454082019" EFFECT_SIZE="1.0434782608695652" ESTIMABLE="YES" EVENTS_1="72" EVENTS_2="69" LOG_CI_END="0.09990951296562847" LOG_CI_START="-0.06294270157760216" LOG_EFFECT_SIZE="0.018483405694013133" MODIFIED="2010-04-20 14:52:59 +0100" MODIFIED_BY="[Empty name]" ORDER="95" O_E="0.0" SE="0.09566019695415677" STUDY_ID="STD-Casey-2003" TOTAL_1="104" TOTAL_2="104" VAR="0.009150873281308064" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="2.9123572243771683E-30" CI_END="1.007576632268617" CI_START="0.7325520569293213" DF="0" EFFECT_SIZE="0.8591288229842448" ESTIMABLE="YES" EVENTS_1="72" EVENTS_2="83" I2="100.0" ID="CMP-003.05.02" LOG_CI_END="0.003278086779156893" LOG_CI_START="-0.13516150785598394" LOG_EFFECT_SIZE="-0.06594171053841355" MODIFIED="2010-04-20 14:53:13 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Z="0.06188138355322587" STUDIES="1" TAU2="0.0" TOTAL_1="104" TOTAL_2="103" WEIGHT="100.0" Z="1.8671447005443538">
<NAME>technique 1 vs technique 3</NAME>
<DICH_DATA CI_END="1.0075766322686168" CI_START="0.7325520569293211" EFFECT_SIZE="0.8591288229842446" ESTIMABLE="YES" EVENTS_1="72" EVENTS_2="83" LOG_CI_END="0.003278086779156797" LOG_CI_START="-0.13516150785598408" LOG_EFFECT_SIZE="-0.0659417105384136" MODIFIED="2010-04-20 14:53:13 +0100" MODIFIED_BY="[Empty name]" ORDER="94" O_E="0.0" SE="0.08132010317572735" STUDY_ID="STD-Casey-2003" TOTAL_1="104" TOTAL_2="103" VAR="0.006612959180510941" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="2.6686669470136552E-30" CI_END="0.9724920621572678" CI_START="0.6970496322294681" DF="0" EFFECT_SIZE="0.8233317886932343" ESTIMABLE="YES" EVENTS_1="69" EVENTS_2="83" I2="100.0" ID="CMP-003.05.03" LOG_CI_END="-0.012113934861242927" LOG_CI_START="-0.15673629760361074" LOG_EFFECT_SIZE="-0.08442511623242682" MODIFIED="2010-04-20 14:53:25 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.0" P_Z="0.022119645376024965" STUDIES="1" TAU2="0.0" TOTAL_1="104" TOTAL_2="103" WEIGHT="100.0" Z="2.288307064944518">
<NAME>technique 2 vs technique 3</NAME>
<DICH_DATA CI_END="0.9724920621572679" CI_START="0.6970496322294684" EFFECT_SIZE="0.8233317886932344" ESTIMABLE="YES" EVENTS_1="69" EVENTS_2="83" LOG_CI_END="-0.012113934861242877" LOG_CI_START="-0.1567362976036106" LOG_EFFECT_SIZE="-0.08442511623242677" MODIFIED="2010-04-20 14:53:25 +0100" MODIFIED_BY="[Empty name]" ORDER="93" O_E="0.0" SE="0.08495189176710814" STUDY_ID="STD-Casey-2003" TOTAL_1="104" TOTAL_2="103" VAR="0.007216823914810457" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="17.54635063405833" CI_END="1.7548068588241539" CI_START="0.9813842456547291" CI_STUDY="95" CI_TOTAL="95" DF="14" EFFECT_MEASURE="RR" EFFECT_SIZE="1.3123032444587215" ESTIMABLE="YES" EVENTS_1="99" EVENTS_2="75" I2="20.211328885532982" I2_Q="17.945282613029157" ID="CMP-003.06" LOG_CI_END="0.24422932321618826" LOG_CI_START="-0.008160918109877102" LOG_EFFECT_SIZE="0.11803420255315555" METHOD="MH" MODIFIED="2010-10-29 05:58:30 +0100" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="0.22822952113911021" P_Q="0.2529003494877441" P_Z="0.06677060662025924" Q="17.061785654535697" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="1560" TOTAL_2="1550" WEIGHT="1500.0" Z="1.8332149827395003">
<NAME>Loss to follow-up: 1b. Various specific reasons</NAME>
<GROUP_LABEL_1>Experimental</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.5906104403409704" CI_START="0.22632820134314519" DF="0" EFFECT_SIZE="0.6" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="10" I2="0.0" ID="CMP-003.06.01" LOG_CI_END="0.20156382871876902" LOG_CI_START="-0.6452613279514817" LOG_EFFECT_SIZE="-0.2218487496163564" MODIFIED="2010-04-20 14:59:56 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.30445290707882033" STUDIES="1" TAU2="0.0" TOTAL_1="104" TOTAL_2="104" WEIGHT="100.0" Z="1.0269311341033236">
<NAME>technique 1 vs technique 2 - adverse events</NAME>
<DICH_DATA CI_END="1.5906104403409702" CI_START="0.22632820134314519" EFFECT_SIZE="0.6" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="10" LOG_CI_END="0.20156382871876896" LOG_CI_START="-0.6452613279514817" LOG_EFFECT_SIZE="-0.2218487496163564" MODIFIED="2009-08-18 20:25:35 +0100" MODIFIED_BY="[Empty name]" ORDER="41" O_E="0.0" SE="0.49742928888023613" STUDY_ID="STD-Casey-2003" TOTAL_1="104" TOTAL_2="104" VAR="0.24743589743589742" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.30093876910252" CI_START="0.4346052200207177" DF="0" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="10" I2="0.0" ID="CMP-003.06.02" LOG_CI_END="0.3619050616957094" LOG_CI_START="-0.3619050616957094" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-04-20 15:00:11 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="1.0" STUDIES="1" TAU2="0.0" TOTAL_1="104" TOTAL_2="104" WEIGHT="100.0" Z="0.0">
<NAME>technique 1 vs technique 2 - worsening illness</NAME>
<DICH_DATA CI_END="2.30093876910252" CI_START="0.43460522002071766" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="10" LOG_CI_END="0.3619050616957094" LOG_CI_START="-0.36190506169570946" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-08-18 20:31:41 +0100" MODIFIED_BY="[Empty name]" ORDER="42" O_E="0.0" SE="0.42516964939801477" STUDY_ID="STD-Casey-2003" TOTAL_1="104" TOTAL_2="104" VAR="0.1807692307692308" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.422828045757967" CI_START="0.23915593932259432" DF="0" EFFECT_SIZE="0.5833333333333334" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="12" I2="0.0" ID="CMP-003.06.03" LOG_CI_END="0.1531524170970167" LOG_CI_START="-0.6213188291637527" LOG_EFFECT_SIZE="-0.23408320603336796" MODIFIED="2010-04-26 17:13:35 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Z="0.23609871175341401" STUDIES="1" TAU2="0.0" TOTAL_1="104" TOTAL_2="104" WEIGHT="100.0" Z="1.184794543183315">
<NAME>technique 1 vs technique 2 - withdrew consent</NAME>
<DICH_DATA CI_END="1.422828045757967" CI_START="0.23915593932259432" EFFECT_SIZE="0.5833333333333334" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="12" LOG_CI_END="0.1531524170970167" LOG_CI_START="-0.6213188291637527" LOG_EFFECT_SIZE="-0.23408320603336796" MODIFIED="2009-08-18 20:34:07 +0100" MODIFIED_BY="[Empty name]" ORDER="43" O_E="0.0" SE="0.4549282437480739" STUDY_ID="STD-Casey-2003" TOTAL_1="104" TOTAL_2="104" VAR="0.20695970695970695" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="35.187087212843885" CI_START="0.4547122614388988" DF="0" EFFECT_SIZE="4.0" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="1" I2="0.0" ID="CMP-003.06.04" LOG_CI_END="1.5463833174249595" LOG_CI_START="-0.34226333476903464" LOG_EFFECT_SIZE="0.6020599913279624" MODIFIED="2010-04-26 17:13:35 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="1.0" P_Z="0.21144980235099287" STUDIES="1" TAU2="0.0" TOTAL_1="104" TOTAL_2="104" WEIGHT="100.0" Z="1.2495888504760893">
<NAME>technique 1 vs technique 2 - non-compliance</NAME>
<DICH_DATA CI_END="35.187087212843885" CI_START="0.4547122614388988" EFFECT_SIZE="4.0" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="1" LOG_CI_END="1.5463833174249595" LOG_CI_START="-0.34226333476903464" LOG_EFFECT_SIZE="0.6020599913279624" MODIFIED="2009-08-18 20:34:52 +0100" MODIFIED_BY="[Empty name]" ORDER="50" O_E="0.0" SE="1.1094003924504583" STUDY_ID="STD-Casey-2003" TOTAL_1="104" TOTAL_2="104" VAR="1.2307692307692308" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="12.596668012924528" CI_START="0.49616295305927965" DF="0" EFFECT_SIZE="2.5" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="2" I2="0.0" ID="CMP-003.06.05" LOG_CI_END="1.100255683612197" LOG_CI_START="-0.30437566626812157" LOG_EFFECT_SIZE="0.3979400086720376" MODIFIED="2010-10-29 05:57:50 +0100" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="1.0" P_Z="0.26676737862309585" STUDIES="1" TAU2="0.0" TOTAL_1="104" TOTAL_2="104" WEIGHT="100.0" Z="1.1105377721652105">
<NAME>technique 1 vs technique 2 - other (lost to follow-up, protocol violation and patient met withdrawal criteria)</NAME>
<DICH_DATA CI_END="12.596668012924528" CI_START="0.49616295305927965" EFFECT_SIZE="2.5" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="2" LOG_CI_END="1.100255683612197" LOG_CI_START="-0.30437566626812157" LOG_EFFECT_SIZE="0.3979400086720376" MODIFIED="2009-08-18 20:35:14 +0100" MODIFIED_BY="[Empty name]" ORDER="51" O_E="0.0" SE="0.8250874079570181" STUDY_ID="STD-Casey-2003" TOTAL_1="104" TOTAL_2="104" VAR="0.6807692307692308" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="4.0489725966702883E-32" CI_END="2.9702133724508024" CI_START="0.3302327352937602" DF="0" EFFECT_SIZE="0.9903846153846155" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="6" I2="100.0" ID="CMP-003.06.06" LOG_CI_END="0.47278764903082643" LOG_CI_START="-0.48117987821804276" LOG_EFFECT_SIZE="-0.004196114593608086" MODIFIED="2010-04-20 15:02:02 +0100" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="0.0" P_Z="0.9862434231637702" STUDIES="1" TAU2="0.0" TOTAL_1="104" TOTAL_2="103" WEIGHT="99.99999999999999" Z="0.017242166517328954">
<NAME>technique 1 vs technique 3 - adverse events</NAME>
<DICH_DATA CI_END="2.9702133724508024" CI_START="0.3302327352937602" EFFECT_SIZE="0.9903846153846154" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="6" LOG_CI_END="0.47278764903082643" LOG_CI_START="-0.48117987821804276" LOG_EFFECT_SIZE="-0.004196114593608135" MODIFIED="2010-04-20 15:02:02 +0100" MODIFIED_BY="[Empty name]" ORDER="167" O_E="0.0" SE="0.5603652477214045" STUDY_ID="STD-Casey-2003" TOTAL_1="104" TOTAL_2="103" VAR="0.314009210853871" WEIGHT="99.99999999999999"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="3.0112484343965" CI_START="0.5089571380025848" DF="0" EFFECT_SIZE="1.2379807692307692" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="8" I2="0.0" ID="CMP-003.06.07" LOG_CI_END="0.4787465872087617" LOG_CI_START="-0.29331879037986525" LOG_EFFECT_SIZE="0.09271389841444824" MODIFIED="2010-04-20 15:02:02 +0100" MODIFIED_BY="[Empty name]" NO="7" P_CHI2="1.0" P_Z="0.6378359016107693" STUDIES="1" TAU2="0.0" TOTAL_1="104" TOTAL_2="103" WEIGHT="100.0" Z="0.4707267209058711">
<NAME>technique 1 vs technique 3 - worsening illness</NAME>
<DICH_DATA CI_END="3.0112484343965003" CI_START="0.5089571380025848" EFFECT_SIZE="1.2379807692307692" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="8" LOG_CI_END="0.47874658720876173" LOG_CI_START="-0.29331879037986525" LOG_EFFECT_SIZE="0.09271389841444824" MODIFIED="2010-04-20 15:02:02 +0100" MODIFIED_BY="[Empty name]" ORDER="168" O_E="0.0" SE="0.45351502458081555" STUDY_ID="STD-Casey-2003" TOTAL_1="104" TOTAL_2="103" VAR="0.20567587752053773" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="55.353956463085176" CI_START="0.8682707741981937" DF="0" EFFECT_SIZE="6.9326923076923075" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="1" I2="0.0" ID="CMP-003.06.08" LOG_CI_END="1.7431486678285988" LOG_CI_START="-0.06134481698730173" LOG_EFFECT_SIZE="0.8409019254206487" MODIFIED="2010-04-20 15:02:02 +0100" MODIFIED_BY="[Empty name]" NO="8" P_CHI2="1.0" P_Z="0.06774432737184091" STUDIES="1" TAU2="0.0" TOTAL_1="104" TOTAL_2="103" WEIGHT="100.0" Z="1.826703728468164">
<NAME>technique 1 vs technique 3 - withdrew consent</NAME>
<DICH_DATA CI_END="55.353956463085176" CI_START="0.8682707741981937" EFFECT_SIZE="6.9326923076923075" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="1" LOG_CI_END="1.7431486678285988" LOG_CI_START="-0.06134481698730173" LOG_EFFECT_SIZE="0.8409019254206487" MODIFIED="2010-04-20 15:02:02 +0100" MODIFIED_BY="[Empty name]" ORDER="169" O_E="0.0" SE="1.0599684053676697" STUDY_ID="STD-Casey-2003" TOTAL_1="104" TOTAL_2="103" VAR="1.1235330203776805" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="34.84587616676647" CI_START="0.45037716678842304" DF="0" EFFECT_SIZE="3.9615384615384617" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="1" I2="0.0" ID="CMP-003.06.09" LOG_CI_END="1.542151388919284" LOG_CI_START="-0.3464236354505754" LOG_EFFECT_SIZE="0.5978638767343543" MODIFIED="2010-04-20 15:02:02 +0100" MODIFIED_BY="[Empty name]" NO="9" P_CHI2="1.0" P_Z="0.21463282093348324" STUDIES="1" TAU2="0.0" TOTAL_1="104" TOTAL_2="103" WEIGHT="100.0" Z="1.2409267844128227">
<NAME>technique 1 vs technique 3 - non-compliance</NAME>
<DICH_DATA CI_END="34.84587616676647" CI_START="0.45037716678842304" EFFECT_SIZE="3.9615384615384617" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="1" LOG_CI_END="1.542151388919284" LOG_CI_START="-0.3464236354505754" LOG_EFFECT_SIZE="0.5978638767343543" MODIFIED="2010-04-20 15:02:02 +0100" MODIFIED_BY="[Empty name]" ORDER="170" O_E="0.0" SE="1.1093583179119981" STUDY_ID="STD-Casey-2003" TOTAL_1="104" TOTAL_2="103" VAR="1.2306758775205378" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="4.480459681208256" CI_START="0.3420623092342856" DF="0" EFFECT_SIZE="1.2379807692307692" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="4" I2="0.0" ID="CMP-003.06.10" LOG_CI_END="0.6513225735451891" LOG_CI_START="-0.4658947767162926" LOG_EFFECT_SIZE="0.09271389841444824" MODIFIED="2010-10-29 05:58:10 +0100" MODIFIED_BY="[Empty name]" NO="10" P_CHI2="1.0" P_Z="0.7449533543791466" STUDIES="1" TAU2="0.0" TOTAL_1="104" TOTAL_2="103" WEIGHT="100.0" Z="0.32530089461301986">
<NAME>technique 1 vs technique 3 - other (lost to follow-up, protocol violation, patient met withdrawal criteria)</NAME>
<DICH_DATA CI_END="4.480459681208256" CI_START="0.3420623092342856" EFFECT_SIZE="1.2379807692307692" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="4" LOG_CI_END="0.6513225735451891" LOG_CI_START="-0.4658947767162926" LOG_EFFECT_SIZE="0.09271389841444824" MODIFIED="2010-04-20 15:02:02 +0100" MODIFIED_BY="[Empty name]" ORDER="171" O_E="0.0" SE="0.6562590018586699" STUDY_ID="STD-Casey-2003" TOTAL_1="104" TOTAL_2="103" VAR="0.4306758775205377" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="4.375073291345675" CI_START="0.6227588920438922" DF="0" EFFECT_SIZE="1.6506410256410255" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="6" I2="0.0" ID="CMP-003.06.11" LOG_CI_END="0.640985332732135" LOG_CI_START="-0.20568006268663844" LOG_EFFECT_SIZE="0.2176526350227482" MODIFIED="2010-04-20 15:03:14 +0100" MODIFIED_BY="[Empty name]" NO="11" P_CHI2="1.0" P_Z="0.3135996912833515" STUDIES="1" TAU2="0.0" TOTAL_1="104" TOTAL_2="103" WEIGHT="99.99999999999999" Z="1.0076975581925827">
<NAME>technique 2 vs technique 3 - adverse events</NAME>
<DICH_DATA CI_END="4.375073291345675" CI_START="0.6227588920438922" EFFECT_SIZE="1.6506410256410255" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="6" LOG_CI_END="0.640985332732135" LOG_CI_START="-0.20568006268663844" LOG_EFFECT_SIZE="0.2176526350227482" MODIFIED="2010-04-20 15:03:14 +0100" MODIFIED_BY="[Empty name]" ORDER="172" O_E="0.0" SE="0.49733544433028737" STUDY_ID="STD-Casey-2003" TOTAL_1="104" TOTAL_2="103" VAR="0.24734254418720436" WEIGHT="99.99999999999999"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="3.0112484343965" CI_START="0.5089571380025848" DF="0" EFFECT_SIZE="1.2379807692307692" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="8" I2="0.0" ID="CMP-003.06.12" LOG_CI_END="0.4787465872087617" LOG_CI_START="-0.29331879037986525" LOG_EFFECT_SIZE="0.09271389841444824" MODIFIED="2010-04-20 15:03:14 +0100" MODIFIED_BY="[Empty name]" NO="12" P_CHI2="1.0" P_Z="0.6378359016107693" STUDIES="1" TAU2="0.0" TOTAL_1="104" TOTAL_2="103" WEIGHT="100.0" Z="0.4707267209058711">
<NAME>technique 2 vs technique 3 - worsening illness</NAME>
<DICH_DATA CI_END="3.0112484343965003" CI_START="0.5089571380025848" EFFECT_SIZE="1.2379807692307692" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="8" LOG_CI_END="0.47874658720876173" LOG_CI_START="-0.29331879037986525" LOG_EFFECT_SIZE="0.09271389841444824" MODIFIED="2010-04-20 15:03:14 +0100" MODIFIED_BY="[Empty name]" ORDER="173" O_E="0.0" SE="0.45351502458081555" STUDY_ID="STD-Casey-2003" TOTAL_1="104" TOTAL_2="103" VAR="0.20567587752053773" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="89.7442270389147" CI_START="1.5738514609857928" DF="0" EFFECT_SIZE="11.884615384615385" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="1" I2="0.0" ID="CMP-003.06.13" LOG_CI_END="1.9530065213642192" LOG_CI_START="0.19696374154381383" LOG_EFFECT_SIZE="1.0749851314540166" MODIFIED="2010-04-20 15:03:14 +0100" MODIFIED_BY="[Empty name]" NO="13" P_CHI2="1.0" P_Z="0.016411361483130497" STUDIES="1" TAU2="0.0" TOTAL_1="104" TOTAL_2="103" WEIGHT="100.0" Z="2.399636461910579">
<NAME>technique 2 vs technique 3 - withdrew consent</NAME>
<DICH_DATA CI_END="89.7442270389147" CI_START="1.5738514609857928" EFFECT_SIZE="11.884615384615385" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="1" LOG_CI_END="1.9530065213642192" LOG_CI_START="0.19696374154381383" LOG_EFFECT_SIZE="1.0749851314540166" MODIFIED="2010-04-20 15:03:14 +0100" MODIFIED_BY="[Empty name]" ORDER="174" O_E="0.0" SE="1.031508221418458" STUDY_ID="STD-Casey-2003" TOTAL_1="104" TOTAL_2="103" VAR="1.064009210853871" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="15.622661923686403" CI_START="0.06278454281234827" DF="0" EFFECT_SIZE="0.9903846153846154" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" I2="0.0" ID="CMP-003.06.14" LOG_CI_END="1.1937550346804002" LOG_CI_START="-1.2021472638676167" LOG_EFFECT_SIZE="-0.004196114593608135" MODIFIED="2010-04-20 15:03:14 +0100" MODIFIED_BY="[Empty name]" NO="14" P_CHI2="1.0" P_Z="0.9945223664790337" STUDIES="1" TAU2="0.0" TOTAL_1="104" TOTAL_2="103" WEIGHT="100.0" Z="0.00686524945817614">
<NAME>technique 2 vs technique 3 - non-compliance</NAME>
<DICH_DATA CI_END="15.622661923686403" CI_START="0.06278454281234827" EFFECT_SIZE="0.9903846153846154" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.1937550346804002" LOG_CI_START="-1.2021472638676167" LOG_EFFECT_SIZE="-0.004196114593608135" MODIFIED="2010-04-20 15:03:14 +0100" MODIFIED_BY="[Empty name]" ORDER="175" O_E="0.0" SE="1.407364870074757" STUDY_ID="STD-Casey-2003" TOTAL_1="104" TOTAL_2="103" VAR="1.9806758775205378" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.6447060134464944" CI_START="0.09271934965583434" DF="0" EFFECT_SIZE="0.4951923076923077" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="4" I2="0.0" ID="CMP-003.06.15" LOG_CI_END="0.4223774027099659" LOG_CI_START="-1.0328296232251444" LOG_EFFECT_SIZE="-0.30522611025758933" MODIFIED="2010-10-29 05:58:30 +0100" MODIFIED_BY="[Empty name]" NO="15" P_CHI2="1.0" P_Z="0.4109657652880676" STUDIES="1" TAU2="0.0" TOTAL_1="104" TOTAL_2="103" WEIGHT="100.0" Z="0.8221952926068441">
<NAME>technique 2 vs technique 3 - other (lost to follow-up, protocol violation, patient met withdrawal criteria)</NAME>
<DICH_DATA CI_END="2.6447060134464944" CI_START="0.09271934965583434" EFFECT_SIZE="0.4951923076923077" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="4" LOG_CI_END="0.4223774027099659" LOG_CI_START="-1.0328296232251444" LOG_EFFECT_SIZE="-0.30522611025758933" MODIFIED="2010-04-20 15:03:14 +0100" MODIFIED_BY="[Empty name]" ORDER="176" O_E="0.0" SE="0.854795810425237" STUDY_ID="STD-Casey-2003" TOTAL_1="104" TOTAL_2="103" VAR="0.7306758775205378" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="2.8410199208563807" CI_END="1.1387892705198226" CI_START="1.0047359721417743" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0696646880122556" ESTIMABLE="YES" EVENTS_1="277" EVENTS_2="259" I2="29.6027463476169" I2_Q="27.45443285869969" ID="CMP-003.07" LOG_CI_END="0.05644336664493298" LOG_CI_START="0.002051951401570239" LOG_EFFECT_SIZE="0.02924765902325161" METHOD="MH" MODIFIED="2010-04-20 15:03:21 +0100" MODIFIED_BY="[Empty name]" NO="7" P_CHI2="0.24159110953696994" P_Q="0.2519705632650283" P_Z="0.03504432900527545" Q="2.7568879516849165" RANDOM="NO" SCALE="2.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="310" TOTAL_2="310" WEIGHT="300.0" Z="2.1078458084311866">
<NAME>Adverse events: Any event</NAME>
<GROUP_LABEL_1>Technique A</GROUP_LABEL_1>
<GROUP_LABEL_2>Technique B</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Technique A</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Technique B</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.0972525401586086" CI_START="0.9092752957995199" DF="0" EFFECT_SIZE="0.9988516546612382" ESTIMABLE="YES" EVENTS_1="92" EVENTS_2="93" I2="0.0" ID="CMP-003.07.01" LOG_CI_END="0.040306594917411835" LOG_CI_START="-0.041304608146955156" LOG_EFFECT_SIZE="-4.990066147716858E-4" MODIFIED="2010-04-20 14:58:15 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.9808780098256779" STUDIES="1" TAU2="0.0" TOTAL_1="103" TOTAL_2="104" WEIGHT="100.00000000000001" Z="0.02396815525996789">
<NAME>technique 1 vs technique 2</NAME>
<DICH_DATA CI_END="1.0972525401586086" CI_START="0.9092752957995198" EFFECT_SIZE="0.9988516546612382" ESTIMABLE="YES" EVENTS_1="92" EVENTS_2="93" LOG_CI_END="0.040306594917411835" LOG_CI_START="-0.041304608146955205" LOG_EFFECT_SIZE="-4.990066147716858E-4" MODIFIED="2010-04-20 14:58:15 +0100" MODIFIED_BY="[Empty name]" ORDER="164" O_E="0.0" SE="0.04793882466197968" STUDY_ID="STD-Casey-2003" TOTAL_1="103" TOTAL_2="104" VAR="0.0022981309099720307" WEIGHT="100.00000000000001"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.2306740266592215" CI_START="0.9790442680706671" DF="0" EFFECT_SIZE="1.0976722423675285" ESTIMABLE="YES" EVENTS_1="92" EVENTS_2="83" I2="0.0" ID="CMP-003.07.02" LOG_CI_END="0.09014303492126138" LOG_CI_START="-0.009197670868807831" LOG_EFFECT_SIZE="0.04047268202622677" MODIFIED="2010-04-20 14:58:17 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.11025922007936319" STUDIES="1" TAU2="0.0" TOTAL_1="103" TOTAL_2="102" WEIGHT="100.0" Z="1.5970291029898431">
<NAME>technique 1 vs technique 3</NAME>
<DICH_DATA CI_END="1.2306740266592215" CI_START="0.9790442680706671" EFFECT_SIZE="1.0976722423675285" ESTIMABLE="YES" EVENTS_1="92" EVENTS_2="83" LOG_CI_END="0.09014303492126138" LOG_CI_START="-0.009197670868807831" LOG_EFFECT_SIZE="0.04047268202622677" MODIFIED="2010-04-20 14:58:17 +0100" MODIFIED_BY="[Empty name]" ORDER="165" O_E="0.0" SE="0.05835322232551106" STUDY_ID="STD-Casey-2003" TOTAL_1="103" TOTAL_2="102" VAR="0.003405098555770522" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.2596923702774738" CI_START="0.9966558343526855" DF="0" EFFECT_SIZE="1.1204819277108433" ESTIMABLE="YES" EVENTS_1="93" EVENTS_2="83" I2="0.0" ID="CMP-003.07.03" LOG_CI_END="0.10026449892462097" LOG_CI_START="-0.00145478656889854" LOG_EFFECT_SIZE="0.04940485617786119" MODIFIED="2010-04-20 14:58:20 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Z="0.0569230427898075" STUDIES="1" TAU2="0.0" TOTAL_1="104" TOTAL_2="104" WEIGHT="100.00000000000001" Z="1.9039012769345152">
<NAME>technique 2 vs technique 3</NAME>
<DICH_DATA CI_END="1.2596923702774738" CI_START="0.9966558343526855" EFFECT_SIZE="1.1204819277108433" ESTIMABLE="YES" EVENTS_1="93" EVENTS_2="83" LOG_CI_END="0.10026449892462097" LOG_CI_START="-0.00145478656889854" LOG_EFFECT_SIZE="0.04940485617786119" MODIFIED="2010-04-20 14:58:20 +0100" MODIFIED_BY="[Empty name]" ORDER="166" O_E="0.0" SE="0.059750411817477186" STUDY_ID="STD-Casey-2003" TOTAL_1="104" TOTAL_2="104" VAR="0.0035701117123581178" WEIGHT="100.00000000000001"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES MODIFIED="2010-10-29 05:16:56 +0100" MODIFIED_BY="[Empty name]">
<FIGURE FILENAME="Risk of bias summary.png" FILE_TYPE="PNG" ID="FIG-01" MODIFIED="2010-10-29 05:16:56 +0100" MODIFIED_BY="[Empty name]" NO="1" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_TABLE_PLOT">
<CAPTION/>
<FILE>iVBORw0KGgoAAAANSUhEUgAAASgAAAGSCAIAAADfNMtdAAASE0lEQVR42u3dP48cRRPH8ZWQEMEF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</FILE>
</FIGURE>
<FIGURE FILENAME="Risk of bias graph.png" FILE_TYPE="PNG" ID="FIG-02" MODIFIED="2010-10-29 05:16:56 +0100" MODIFIED_BY="[Empty name]" NO="2" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_GRAPH_PLOT">
<CAPTION/>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAiMAAADnCAMAAAD7EqYIAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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==
</FILE>
</FIGURE>
</FIGURES>
<FEEDBACK/>
<APPENDICES MODIFIED="2010-09-27 13:47:18 +0100" MODIFIED_BY="[Empty name]">
<APPENDIX ID="APP-01" MODIFIED="2010-09-27 13:47:18 +0100" MODIFIED_BY="[Empty name]" NO="1">
<TITLE MODIFIED="2010-09-27 13:47:18 +0100" MODIFIED_BY="[Empty name]">Previous search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2010-09-27 13:45:33 +0100" MODIFIED_BY="[Empty name]">
<P>Search for original interventions for weight gain Cochrane review (<LINK REF="REF-Faulkner-2007" TYPE="REFERENCE">Faulkner 2007</LINK>).<BR/>Cochrane Schizophrenia Group's Register (January 2005) was searched using a subject/text-word search strategy with schizophrenia, antipsychotic medication, exercise, intervention, cognitive therapy, behavioural therapy, diet, weight loss, weight gain, weight change, weight, physical therapy as the main search terms.</P>
<P>MEDLINE (1966-1/2005) CINAHL (1982-1/2005), UMI ProQuest Digital Dissertations (1861 to 1/2005), HealthSTAR (1990-1/2005), Sports Discus (1975-1/2005), EMBASE (1974-1/2005), PsycINFO (1872 to 1/2005), and registers of ongoing clinical trials were also searched (see Cochrane Schizophrenia Group Module for full details).</P>
</APPENDIX_BODY>
</APPENDIX>
</APPENDICES>
<EXTENSIONS/>
</COCHRANE_REVIEW>